<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15342129</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>368</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>36</EndPage><MedlinePgn>33-6</MedlinePgn></Pagination><Abstract><AbstractText>It has been suggested that genetic influences unmasked during neurodevelopment to produce schizophrenia may appear throughout neurodegeneration to produce AD plus psychosis. Risk of schizophrenia and psychosis in Alzheimer's disease (AD) has been linked to polymorphic variation at the dopamine receptor DRD3 gene implying similar causative mechanisms. We tested this association in a large cohort of Alzheimer's disease patients with a diagnosis of probable AD of 3 years or more duration from the relatively genetically homogenous Northern Irish population. We assessed relationships between genotypes/alleles of the DRD3 BalI polymorphism and the presence or absence of psychotic symptoms (delusions, hallucinations) in AD patients during the month prior to interview and at any stage during the dementia. No significant associations were found when delusions and hallucinations were cross-tabulated against S and G alleles and SS, SG and GG genotypes. Logistic regression failed to detect any influence of APOE, gender, family history or prior psychiatric history. In conclusion, we were unable to confirm previously reported associations between the DRD3 BalI polymorphism and psychotic symptoms in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Queen's University of Belfast, 97 Lisburn Road, Belfast BT97BL, Northern Ireland, UK. david.craig@qub.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Dominic J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Robyn</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McIlroy</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>A Peter</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493593">DRD3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15342129</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2004.06.052</ArticleId><ArticleId IdType="pii">S0304-3940(04)00792-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15336465</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0149-2918</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2004</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>980</StartPage><EndPage>990</EndPage><MedlinePgn>980-90</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The presence of certain behavioral and psychological symptoms (eg, paranoia, hallucinations, aggression, activity disturbances) in Alzheimer's disease (AD) may predict faster cognitive and functional decline; therefore, such symptoms represent an important treatment target. Behavioral and psychological symptoms of dementia (BPSD) may be caused at least in part by cholinergic deficits. Regulatory studies of rivastigmine in AD were not designed to evaluate effects on BPSD, but further investigation of rivastigmine in AD was prompted by later studies demonstrating behavioral benefits in other types of dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The primary aim of this article was to review available data on the behavioral benefits of rivastigmine in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relevant data were identified through a MEDLINE search for studies published in peer-reviewed journals through January 2004. The search terms were Alzheimer, behavior, psychosis, and rivastigmine. Data presented at international scientific congresses were also reviewed to ensure that the most recent data were considered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A meta-analysis of three 6-month, placebo-controlled trials of rivastigmine in mild to moderate AD indicated that rivastigmine 6 to 12 mg/d may improve or prevent disruptive BPSD (P &lt; 0.05 vs placebo). In patients with more advanced AD, 2 open-label studies of up to 12 months' duration found that improvements in BPSD were accompanied by a decrease in the use of psychotropic medications. Rivastigmine demonstrated behavioral benefits in patients with dementia with Lewy bodies (DLB) in a double-blind, placebo-controlled study (P &lt; 0.05). In open-label extension studies, rivastigmine provided sustained effects (up to 2 years) in patients with mild to moderate AD or DLB.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The available dats suggest that rivastigmine may be a well-tolerated treatment option for improving or preventing psychotic and nonpsychotic symptoms associated with AD. Prospective, double-blind studies are needed to evaluate these preliminary findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finkel</LastName><ForeName>Sanford I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Chicago Medical School, Chicago, Illinois, USA. sandy.finkel@cje.net</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="Y">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>61</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15336465</ArticleId><ArticleId IdType="doi">10.1016/s0149-2918(04)90172-5</ArticleId><ArticleId IdType="pii">S0149291804901725</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15322245</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0026-895X</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular pharmacology</Title><ISOAbbreviation>Mol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.</ArticleTitle><Pagination><StartPage>538</StartPage><EndPage>544</EndPage><MedlinePgn>538-44</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is a neurodegenerative disorder associated with a decline in cognitive abilities. Patients also frequently have noncognitive symptoms, such as anxiety, depression, apathy, and psychosis, that impair daily living. The most commonly prescribed treatments for Alzheimer's disease are acetylcholinesterase inhibitors, such as donepezil and galantamine. Enhanced cholinergic functions caused by these compounds are believed to underlie improvements in learning, memory, and attention. The noncognitive aspects of dementia, however, are usually linked to serotonin and dopamine rather than acetylcholine because those neurotransmitter systems most directly influence mood, emotional balance, and psychosis. Fast-scan cyclic voltammetry applied to mouse striatal brain slices was used to measure the real-time release of dopamine arising from spontaneous activity or from single electrical stimulations. At concentrations that include their prescribed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) increase action potential-dependent dopamine release. Consistent with previous literature, the data support slightly different modes of action for donepezil and galantamine. The ability of these commonly prescribed drugs to alter catecholamine release may underlie their influence over noncognitive symptoms of dementia. Furthermore, these results suggest that acting via nicotinic receptors, these drugs may serve presently untapped therapeutic roles by altering dopamine release in other disorders involving dopaminergic systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lifen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Baylor College of Medicine, Houston, TX 77030-3498, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fu-Ming</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS021229</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharmacol</MedlineTA><NlmUniqueID>0035623</NlmUniqueID><ISSNLinking>0026-895X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15322245</ArticleId><ArticleId IdType="doi">10.1124/mol.104.000299</ArticleId><ArticleId IdType="pii">mol.104.000299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15313842</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1249</StartPage><EndPage>1253</EndPage><MedlinePgn>1249-53</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Serotonin has been linked to neuropsychiatric symptoms in Alzheimer disease, mainly agitation/aggression, depression, and psychosis. Neuropsychiatric symptoms have been associated with polymorphisms of the promoter region (5-HTTPR ) and intron 2 of the serotonin transporter gene (5-HTTVNTR) or the 5-HT2A and 5-HT2C receptor genes in some but not all studies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association of the serotonin promoter, transporter, and receptor genes with neuropsychiatric symptoms in patients with Alzheimer disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample included 96 patients with Alzheimer disease from the outpatient clinic of the University of California Los Angeles Alzheimer's Disease Research Center, Los Angeles. The Neuropsychiatric Inventory was used to measure neuropsychiatric symptoms, and blood samples were available for genetic analysis. Based on the literature, we hypothesized that the 5-HT2A and 5-HT2C receptor polymorphisms would be associated with agitation/aggression and psychosis and the 5-HTTPR or 5-HTTVNTR polymorphisms, with agitation/aggression or depression and anxiety. One-way analyses of variance were performed with age, ethnicity, sex, or education as covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 102T genotype of the 5-HT2A receptor was significantly associated with delusions (P =.045) and agitation/aggression (P =.002). We did not replicate previous associations of the 5-HT2C receptor polymorphism with psychosis or of the 5-HTTPR polymorphism with agitation/aggression, psychosis, or depression. We did not find any associations with the 5-HTTVNTR polymorphism and agitation/aggression, depression, or anxiety.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The 5-HT2A receptor polymorphism may contribute to the expression of psychosis and agitation/aggression in patients with Alzheimer disease. Absence of other positive associations may be due to the relatively small sample size and/or potentially small effect size of the polymorphisms and requires further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assal</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, Calif., USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarc&#xf3;n</LastName><ForeName>Maricela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Esther C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Masterman</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="Y">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId><ArticleId IdType="doi">10.1001/archneur.61.8.1249</ArticleId><ArticleId IdType="pii">61/8/1249</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15311344</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-5354</ISSN><JournalIssue CitedMedium="Print"><Volume>251</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>688</StartPage><EndPage>695</EndPage><MedlinePgn>688-95</MedlinePgn></Pagination><Abstract><AbstractText>Clinical expressions of cognition and behaviour in Alzheimer's disease (AD) patients are heterogeneous. Therefore, assessing the entire range of selective cognitive and behavioural characteristics of dementia in minute detail is extremely important. However, considering that groups of different symptoms may respond to the same pharmacological agent, it is also evident that a correct evaluation of the behaviour requires the grouping of symptoms in fewer syndromes. Thus, the authors have analysed various connections between selective cognitive domains and behavioural symptoms (BPSD) in probable AD outpatients. Two hundred and forty four patients with diagnosis of probable AD, according to DSM-IV and NINCDS-ADRDA criteria were enrolled. The evaluation included the Mini Mental State Examination, the Mental Deterioration Battery, and the Neuropsychiatric Inventory. Treatment with low doses of neuroleptic drugs only was allowed. Principal component analysis condensed the 18 cognitive/behavioural variables in 7 factors namely general-cognitive, constructional abilities, hyperactivity, psychosis, anxiety, mood-excitement and mood-depression/apathy. None of the cognitive domains were included in the behavioural factors and vice-versa. Furthermore, the only BPSD which impaired continuously with progression of disease severity was apathy which was also the most severe symptom. In conclusion, many cognitive and behavioural syndromes exist in patients with AD. However, the results of this study suggest that cognition and behaviour are independent dimensions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Tor Vergata, Rome, Italy. g.spalletta@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldinetti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Buccione</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Perri</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Scalmana</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15311344</ArticleId><ArticleId IdType="doi">10.1007/s00415-004-0403-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15307296</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[The clinical relevance of memantine use].</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>330</EndPage><MedlinePgn>321-30</MedlinePgn></Pagination><Abstract><AbstractText>Memantine is an NMDA receptor antagonist with moderate affinity, which results in neuroprotective potential due to reducing overstimulation caused by glutamate (excitotoxicity) and simultaneous lack of adverse events (especially psychosis) typical for an antagonist with higher affinity like phencyclidine. In randomized, controlled studies it has been shown that memantine is beneficial in the treatment of moderate to severe dementia of Alzheimer's type and it became the very first compound to be registered for this purpose both in Europe (including Poland) and in the United States. Further investigation require usefulness of memantine in less advanced stages of Alzheimer's disease as well as other types of dementia especially vascular; promising results are shown in dual therapy: memantine + cholinesterase inhibitor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Z Kliniki Psychiatrii Wieku Podesz&#x142;ego i Zaburze&#x144; Psychotycznych UM w Lodzi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Kliniczne w&#x142;a&#x15b;ciwo&#x15b;ci memantyny.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15307296</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">15279761</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8480</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current treatment options in neurology</Title><ISOAbbreviation>Curr Treat Options Neurol</ISOAbbreviation></Journal><ArticleTitle>Poststroke Neuropsychiatric Illness: An Integrated Approach to Diagnosis and Management.</ArticleTitle><Pagination><StartPage>403</StartPage><EndPage>420</EndPage><MedlinePgn>403-420</MedlinePgn></Pagination><Abstract><AbstractText>Patients who have had stroke are at significant risk for various neuropsychiatric illnesses. The most common and important of these are poststroke depression and poststroke dementia (attributable to vascular dementia, Alzheimer's dementia, or a combination of mechanisms). Poststroke neuropathology may lead some patients to experience concurrent and "overlapping" mood and cognitive symptoms. Less frequently, poststroke anxiety disorders, psychosis, isolated pathologic expressions of emotions, and apathy or fatigue may be encountered. The authors review the current literature on poststroke neuropsychiatry and offer an integrated approach to pathophysiologic concepts and clinical surveillance, screening, diagnosis, and evidence-based pharmacologic and nonpharmacologic intervention for these clinical problems on the clinical boundary between neurology and psychiatry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>James A.</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences Rehabilitation, University of California, Davis Medical Center, 2230 Stockton Boulevard, Sacramento, CA 95817, USA. james.bour geois@ucdmc.ucdavis.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilty</LastName><ForeName>Donald M.</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Celia H.</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Wineinger</LastName><ForeName>Mark A.</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Servis</LastName><ForeName>Mark E.</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Neurol</MedlineTA><NlmUniqueID>9815940</NlmUniqueID><ISSNLinking>1092-8480</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15279761</ArticleId><ArticleId IdType="doi">10.1007/s11940-996-0031-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Neurol. 1986 Aug;43(8):763-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3729755</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):26-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9547463</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Feb;12(2):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9097215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Spring;11(2):176-89</Citation><ArticleIdList><ArticleId IdType="pubmed">10333990</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Med. 2001 May;62(5):268-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11385885</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2002 May;17(5):486-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11994939</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1997 Nov;28(11):2321</Citation><ArticleIdList><ArticleId IdType="pubmed">9368583</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1991 Winter;3(1):23-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7580168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ital J Neurol Sci. 1995 May;16(4):209-16</Citation><ArticleIdList><ArticleId IdType="pubmed">7591672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Spring;11(2):268-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10333999</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1999 Mar;30(3):691-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10066874</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2002 Feb;15(1):85-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11796955</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Mar;157(3):351-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10698809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 Apr 24;336(17):1216-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Jul;51(1 Suppl 1):S45-52; discussion S65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9674762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Jan-Mar;57(1-3):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10708811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2002 May;190(5):296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12011609</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1996 Mar 11;156(5):553-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8604962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1984 Feb 11;1(8372):297-300</Citation><ArticleIdList><ArticleId IdType="pubmed">6141377</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 10:9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9720476</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2001;61(1):81-110</Citation><ArticleIdList><ArticleId IdType="pubmed">11217873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Sep 9;40(1-2):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8882915</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2000;12 Suppl 1:63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11098416</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Apr;154(4):562-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9090349</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaska Med. 1990 Jan-Mar;32(1):20-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2353741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1989 Jul;50 Suppl:18-23; discussion 24-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2661548</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1996 Jul;27(7):1211-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8685930</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1994 Jun;25(6):1099-104</Citation><ArticleIdList><ArticleId IdType="pubmed">8202964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1992 Jan;14(1):69-76</Citation><ArticleIdList><ArticleId IdType="pubmed">1730403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):490-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10201422</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 1997 Jun;78(6):658-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9196475</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Geriatr Med. 1999 Nov;15(4):765-83</Citation><ArticleIdList><ArticleId IdType="pubmed">10499934</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rehabil. 1998 Feb;12(1):73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9549028</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Feb;43(2):250-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">2136055</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jan 25;54(2):447-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10668712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1996 Fall;8(4):453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9116485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 1999 Sep;80(9):985-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10488996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 1997 Jun;19(3):340-56</Citation><ArticleIdList><ArticleId IdType="pubmed">9268809</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Mar 14;54(5):1124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10720286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):258-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11459907</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rehabil. 1997 May;11(2):114-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9199863</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Apr;154(4):497-501</Citation><ArticleIdList><ArticleId IdType="pubmed">9090336</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 May;15(5):419-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10822241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):276-85</Citation><ArticleIdList><ArticleId IdType="pubmed">1821244</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2002 Feb;17(2):194-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11813286</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 Feb;145(2):172-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3341462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2001 Sep;189(9):623-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11580007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1994 Aug;182(8):425-31</Citation><ArticleIdList><ArticleId IdType="pubmed">8040651</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1998 Oct;29(10):2080-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9756586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1988 Apr;49(4):151-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3356672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 9:38-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9720486</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 1994 Apr;75(4):403-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8172499</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 1997;48:217-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9046957</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2000 Aug;31(8):1829-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10926942</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2000 Mar;7(2):159-69</Citation><ArticleIdList><ArticleId IdType="pubmed">10809936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1996 Mar;8(1):35-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8743648</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1998 Nov;43(9):921-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9825164</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1997 Summer;5(3):229-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9209565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebrovasc Dis. 2001 Aug;12(2):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11490100</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1991 Jan 15;29(2):149-58</Citation><ArticleIdList><ArticleId IdType="pubmed">1995084</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1995 May;26(5):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7740579</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1998 Feb;29(2):368-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9472876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1999 Fall;12(3):128-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10593701</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 1999 May;80(5 Suppl 1):S8-16</Citation><ArticleIdList><ArticleId IdType="pubmed">10326898</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1995 Apr;91(4):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7625207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 May;48(5):1317-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9153465</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1995 Oct;7(4):298-309</Citation><ArticleIdList><ArticleId IdType="pubmed">8535057</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 2000 Jan-Feb;41(1):5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10665263</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):371-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9527152</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1997 Jul;28(7):1464-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9227702</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1994 Feb;114(1):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">7846193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1990 Jul;51 Suppl:26-31; discussion 32-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2195010</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9749682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15264967</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65 Suppl 11</Volume><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>22</EndPage><MedlinePgn>16-22</MedlinePgn></Pagination><Abstract><AbstractText>Lewy body dementia, also referred to as dementia with Lewy bodies (DLB), is a neurodegenerative disorder now considered to be the second most common cause of dementia after Alzheimer's disease. Postmortem findings suggest that DLB accounts for 20% to 34% of all dementia cases and is often underdiagnosed. Salient features of DLB include fluctuations in cognition, perceptual abnormalities (e.g., visual hallucinations), and mild parkinsonism. Other symptoms include frequent falls, nighttime agitation, and depression. DLB symptomatology can be partly explained by the extensive destruction of dopaminergic and acetylcholinergic pathways caused by neurodegeneration. For this reason, DLB patients are especially vulnerable to the antidopaminergic and anticholinergic actions of most conventional antipsychotics, which makes treatment of the psychotic symptoms of DLB extremely difficult. Patients are particularly sensitive to developing extrapyramidal symptoms (EPS) and also to the potentially fatal complication of neuroleptic sensitivity, which affects approximately 50% of DLB patients. Therefore, a need exists for antipsychotic drugs with less propensity to induce EPS and reduced affinity for dopamine and acetylcholine receptors. Here we review studies evaluating the efficacy and tolerability of atypical antipsychotics for the treatment of psychoses associated with DLB. Olanzapine appears to be poorly tolerated, and risperidone has been associated with high risk of neuroleptic malignant syndrome. Clozapine use remains controversial because of its potent anticholinergic action and risk of agranulocytosis. Quetiapine has been shown to reduce psychiatric manifestations of DLB without causing neuroleptic sensitivity or increasing EPS. Hence, quetiapine is an attractive candidate for the treatment of psychoses in DLB and other dementias.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baskys</LastName><ForeName>Andrius</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, University of California at Irvine, USA. andrius.baskys@med.va.gov</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>53</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15264967</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15264966</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65 Suppl 11</Volume><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Efficacy of atypical antipsychotics in elderly patients with dementia.</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>15</EndPage><MedlinePgn>11-5</MedlinePgn></Pagination><Abstract><AbstractText>Pharmacotherapy in patients with dementia aims to improve distressing behavioral and psychological signs of dementia after nonpharmacologic interventions fail, without causing unacceptable side effects or exacerbating underlying cognitive impairment. We review data describing risperidone (3 published placebo-controlled trials), olanzapine (1 abstract regarding a placebo-controlled trial and a published placebo-controlled trial), quetiapine (1 published open-label trial and an abstract regarding a placebo-controlled trial), and aripiprazole (1 abstract regarding a placebo-controlled trial). For example, a 12-week study of risperidone in patients with Alzheimer's disease showed a dose-related improvement in psychosis and agitation. The frequency of extrapyramidal symptoms (EPS) was also significantly greater in patients receiving the highest doses. A 6-week study of olanzapine showed greater improvement than placebo in agitation/aggression and psychosis with doses of 5 and 10 mg/day, but not 15 mg/day, with side effects including gait disturbance and sedation at all doses. A 52-week, open-label trial of quetiapine (median dose = 138 mg/day) in elderly patients with psychosis suggested good tolerability with apparent behavioral benefit; EPS improved or remained unchanged in most patients. Limited data describing aripiprazole have shown inconclusive evidence regarding relief of psychosis in elderly patients with Alzheimer's disease-related dementia, with apparently good tolerability over the short term. It appears that, in the aggregate, atypical antipsychotics are efficacious for treatment of agitation in dementia, with less clear impact on psychosis, but their tolerability profiles clearly differ. The National Institute of Mental Health-funded Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease project will provide the first head-to-head comparisons of atypicals in dementia and will examine possible drug-drug differences between efficacy and effectiveness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurobehavioral Therapeutics, Monroe Community Hospital, University of Rochester Medical Center, Rochester, NY 14620, USA. pierre_tariot@urmc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Profenno</LastName><ForeName>Louis A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>17</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15264966</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15236409</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>124</EndPage><MedlinePgn>121-4</MedlinePgn></Pagination><Abstract><AbstractText>The explanation for why some patients develop psychotic change in Alzheimer's disease (AD) is unclear. "Psychosis-modifier genes" may act in the setting of neurodegeneration to produce AD plus psychosis in a similar way to how genetic modulation during neurodevelopment leads to schizophrenia. Because there is increasing interest in the common disruption of cytokine pathways seen in both AD and schizophrenia, we tested the association between the functional interleukin-1beta -511 promoter polymorphism with delusions and hallucinations in AD. Significant associations between psychotic symptoms and the CC genotype (p = 0.001 - p = 0.043) and C allele (p = 0.014 vs p = 0.048) were found, thus confirming the previously noted increased risk in schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Queen's University of Belfast, Belfast BT9 7BL, United Kingdom. david.craig@qub.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Dominic J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>McCool</LastName><ForeName>Keira</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>McIlroy</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>A Peter</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15236409</ArticleId><ArticleId IdType="doi">10.1002/ana.20120</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15219708</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0166-4328</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Behavioural brain research</Title><ISOAbbreviation>Behav Brain Res</ISOAbbreviation></Journal><ArticleTitle>Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>76</EndPage><MedlinePgn>69-76</MedlinePgn></Pagination><Abstract><AbstractText>Histamine H3 receptor antagonists/inverse agonists have been proposed as potential therapeutic agents for the treatment of a number of neurological disorders ranging from attention deficit hyperactivity disorder and Alzheimer's disease to narcolepsy and schizophrenia. With respect to the latter, schizophrenic patients typically exhibit impaired prepulse inhibition (PPI) of startle, a reflex that can be modeled in many animal species. Certain strains of mice naturally display poor PPI and it was recently suggested that these mice might offer a new way to screen for novel antipsychotic compounds. To examine whether H3 receptor antagonists might enhance PPI in mice with naturally occurring deficits, DBA/2 and C57BL/6 were tested in a startle paradigm with three prepulse intensities: 5, 10 and 15 dB above background. Both thioperamide and ciproxifan enhanced PPI in the DBA/2 strain; thioperamide also showed a trend towards enhancing PPI in C57BL/6. Risperidone, an atypical antipsychotic, enhanced PPI in both the DBA/2 and the C57BL/6 strain. These data confirm previous reports describing a natural deficit in PPI in some mouse strains that is amenable to enhancement with known antipsychotics. Further, these data suggest that H3 receptor antagonists/inverse agonists have anti-psychotic potential for disorders such as schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Browman</LastName><ForeName>Kaitlin E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Neuroscience Research, Abbott Laboratories, AP9A, 100 Abbott Park, Abbott Park, IL 60064-6115, USA. kaitlin.e.browman@abbott.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komater</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>Curzon</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rueter</LastName><ForeName>Lynne E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Hancock</LastName><ForeName>Arthur A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Gerard B</ForeName><Initials>GB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Brain Res</MedlineTA><NlmUniqueID>8004872</NlmUniqueID><ISSNLinking>0166-4328</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018100">Receptors, Histamine H3</NameOfSubstance></Chemical><Chemical><RegistryNumber>5EVQ7IRG99</RegistryNumber><NameOfSubstance UI="C115705">ciproxifan</NameOfSubstance></Chemical><Chemical><RegistryNumber>II4319BWUI</RegistryNumber><NameOfSubstance UI="C052075">thioperamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004307" MajorTopicYN="N">Dose-Response Relationship, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="Y">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018100" MajorTopicYN="N">Receptors, Histamine H3</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15219708</ArticleId><ArticleId IdType="doi">10.1016/j.bbr.2003.11.001</ArticleId><ArticleId IdType="pii">S0166432803004224</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">15213777</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-5998</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Primary care companion to the Journal of clinical psychiatry</Title><ISOAbbreviation>Prim Care Companion J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Measures to Assess the Noncognitive Symptoms of Dementia in the Primary Care Setting.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>163</EndPage><MedlinePgn>158-163</MedlinePgn></Pagination><Abstract><AbstractText>Noncognitive symptoms associated with Alzheimer's disease and related dementias include psychosis, mood disturbances, personality changes, agitation, aggression, pacing, wandering, altered sexual behavior, changed sleep patterns, and appetite disturbances. These noncognitive symptoms of dementia are common, disabling to both the patient and the caregiver, and costly. Primary care physicians will often play a major role in diagnosing and treating dementia and related disorders in the community. Accurate recognition and treatment of noncognitive symptoms is vital. A brief, user-friendly assessment tool would aid in the clinical management of noncognitive symptoms of dementia. Accordingly, we reviewed the available measures for their relevance in a primary care setting. Among these instruments, the Neuropsychiatric Inventory-Questionnaire seems most appropriate for use in primary care and worthy of further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forester</LastName><ForeName>Brent P.</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, N.H.; and McLean Hospital, Belmont, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oxman</LastName><ForeName>Thomas E.</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion J Clin Psychiatry</MedlineTA><NlmUniqueID>100887410</NlmUniqueID><ISSNLinking>1523-5998</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15213777</ArticleId><ArticleId IdType="pmc">PMC419385</ArticleId><ArticleId IdType="doi">10.4088/pcc.v05n0403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL, Masterman DL. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. J Clin Psychiatry. 1998&#xa0;59suppl 13. 23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C, Steinberg M, and Tschanz JT. et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000&#xa0;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Deimling GT, Bass DM.. Symptoms of mental impairment among elderly adults and their effects on caregivers. J Gerontol. 1986;41:778&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">3772056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Mace NL, Lucas MJ.. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C, Rovner B, and Chase GA. et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990&#xa0;147:1049&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Assessment of disruptive behavior/agitation in the elderly: function, methods and difficulties. J Geriatr Psychiatry Neurol. 1995&#xa0;8suppl 1. 52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7710649</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson BE, Barry PP, and Renick N. et al. Physician confidence and interest in learning more about common geriatric topics. J Am Geriatr Soc. 2001&#xa0;49:963&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527489</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR.. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL.. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Franssen E.. Stage specific incidence of potentially remediable behavioral symptoms in aging and AD: a study of 120 patients using the BEHAVE-AD. Bull of Clinical Neuroscience. 1989;54:95&#x2013;112.</Citation></Reference><Reference><Citation>Reisberg B, Borenstein J, and Salob SP. et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987&#xa0;48suppl 5. 9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, and Patterson MB. et al. The behavioral rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. Am J Psychiatry. 1995&#xa0;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Lawlor B, and Craig S. Assessment Scales in Old Age Psychiatry. London, England: Martin Dunitz Ltd. 1999</Citation></Reference><Reference><Citation>Cohen-Mansfield. Agitated behaviors in the elderly. 2: preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">3760436</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS.. A description of agitation in a nursing home. J Gerontol. 1989;44:M77&#x2013;M84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, and Gray K. et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994&#xa0;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer D, Cummings JL, and Ketchel P. et al. Validation of NPI-Q: a brief clinical form of the NPI. J Neuropsychiatry Clin Neurosci. 2000&#xa0;12:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Cummings JL, and Fiorello T. et al. The spectrum of behavior changes in Alzheimer's disease. Neurology. 1996&#xa0;46:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen J, Burgio L, and Kollar M. et al. The Pittsburgh Agitation Scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry. 1994&#xa0;2:60&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson IM, Graham-White J.. Psychogeriatric Dependency Rating Scale (PGDRS): a method of assessment for use by nurses. Br J Psychiatry. 1980;137:558&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">6452189</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegel B, Carlson B, and Kopp Z. et al. Effect of standardized nurse case-management telephone interventions on resource use in patients with chronic heart failure. Arch Intern Med. 2002&#xa0;162:707&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">11911726</ArticleId></ArticleIdList></Reference><Reference><Citation>Unutzer J, Katon W, and Williams JW Jr. et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care. 2001&#xa0;39:785&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">11468498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15207448</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-7947</ISSN><JournalIssue CitedMedium="Print"><Issue>9</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Archives of gerontology and geriatrics. Supplement</Title><ISOAbbreviation>Arch Gerontol Geriatr Suppl</ISOAbbreviation></Journal><ArticleTitle>The management of psychogeriatric patient.</ArticleTitle><Pagination><StartPage>465</StartPage><EndPage>470</EndPage><MedlinePgn>465-70</MedlinePgn></Pagination><Abstract><AbstractText>The exponential growth in the prevalence of cognitive impairment of old patients leads the physicians to deal with a larger incidence of behavioral disorders (such as excitement,aggressiveness), and psychotic symptoms (such as delirium and visual hallucinations). The presence of psychotic troubles in dementia causes a remarkable distress to caregivers and involves higher difficulties in the patient management. The estimates of such troubles range between 15 and 75 %. Geriatric assessment and the management of behavioral troubles require a prompt evaluation of all their possible causes. As a matter of fact, their appearance often reveals a physical disturbance (pain, fever, etc.), or adverse environmental conditions, or it could also be a consequence of a multiple drug therapy. For this reason,the use of antipsychotics should always be preceded by an accurate clinical diagnosis.Anxiolytic, anti-depressive, anti-convulsive and anti-psychotic drugs are among the therapeutic strategies for the management of the psychogeriatric patient. Atypical antipsychotics seem to be able to decrease the psychotic symptoms, with low levels of therapeutic failure. They also reduce extrapyramidal effects and the growth of prolactine hormone, which is quite useful when dealing with very old patients. Risperidone and olanzapine are two atypical anti-psychotics, which already proved to be adequate and well tolerated during the treatment of schizophrenia and of acute maniacal disorders. Our experience, with a population of patients followed by our Alzheimer Evaluation Unit (AEU), confirms that a low dose of olanzapine (5mg/day) and risperidone (0.5-1.0 mg/day) are effective in lowering behavioral disturbances, and psychotic symptoms due to dementia. Even in the long run,low doses of these drugs are still well tolerated. Higher levels of risperidone (&gt; 1 mg/die)often caused extra-pyramidal symptoms such as rigidity and dyskinesia, whereas higher levels of olanzapine (&gt; 5 mg/day) lead to an exceeding sedation. The management of behavioral disturbances is one of the most important goals in the global treatment of patients affected by dementia, to the extent of improving the quality of life. Atypical antipsychotics are preferable compared to old-generation drugs, therefore, they are the key therapeutic strategy we cannot renounce.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zannino</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Aging Science, Policlinico Umberto I, University La Sapienza, I- 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargiulo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lamenza</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Marotta</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Barzotti</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ettorre</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Marigliano</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Arch Gerontol Geriatr Suppl</MedlineTA><NlmUniqueID>8911786</NlmUniqueID><ISSNLinking>0924-7947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15207448</ArticleId><ArticleId IdType="doi">10.1016/j.archger.2004.04.058</ArticleId><ArticleId IdType="pii">S0167494304000962</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15207435</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-7947</ISSN><JournalIssue CitedMedium="Print"><Issue>9</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Archives of gerontology and geriatrics. Supplement</Title><ISOAbbreviation>Arch Gerontol Geriatr Suppl</ISOAbbreviation></Journal><ArticleTitle>Behavior in degenerative dementias: mood disorders, psychotic symptoms and predictive value of neuropsychological deficits.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>378</EndPage><MedlinePgn>365-78</MedlinePgn></Pagination><Abstract><AbstractText>We studied mood disorders (MD) and psychotic symptoms (PS) in patients with fronto -temporal dementia (FTD) and Alzheimer's disease (AD) by means of different diagnostic instruments. These were: a subjective scale (subsets of survey psychiatric assessment schedule: SPAS), an objective scale (subsets of neuropsychiatric inventory: NPI) and a projective task (Wartegg completion task: WCT). A general tendency of NPI to over estimate the presence of symptoms compared to SPAS was observed, but distribution and severity of symptoms were quite homogeneous in the two dementia-groups, independently of the diagnostic scales. At variance with the scales, the WCT showed a more severe impairment in FTD than in AD. The regression analysis selected neuropsychological models able to predict behavioral disorders only in FTD, in particular, a planning deficit predicted PS. These data confirm the hypothesis that a damage in the frontal areas constitutes the neurobiological basis of PS in degenerative brain diseases. Furthermore, they suggest that mostly in FTD, behavioral disorders, as well as cognitive deficits, should be considered a direct expression of neural damage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silveri</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Gerontology and Physiatrics-Memory Clinic, I-00168 Rome, Italy. silveri@rm.unicatt.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvigni</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Jenner</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Colamonico</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Arch Gerontol Geriatr Suppl</MedlineTA><NlmUniqueID>8911786</NlmUniqueID><ISSNLinking>0924-7947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15207435</ArticleId><ArticleId IdType="doi">10.1016/j.archger.2004.04.047</ArticleId><ArticleId IdType="pii">S0167494304000834</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15206674</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Treatment of psychotic symptoms with lamotrigine in Alzheimer disease.</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>233</EndPage><MedlinePgn>232-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Le&#xf3;n</LastName><ForeName>Ovidio A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15206674</ArticleId><ArticleId IdType="doi">10.1097/01.jcp.0000117431.83724.b0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15195459</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0893-0341</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>21</EndPage><MedlinePgn>17-21</MedlinePgn></Pagination><Abstract><AbstractText>Mild cognitive impairment (MCI) has emerged as an identifiable condition and in many cases is a transitional state preceding diagnosable Alzheimer disease (AD). Neurobiological and neuroimaging characteristics of amnestic-type MCI have been investigated, but few comprehensive neuropsychiatric studies have been reported. The aim of this preliminary study was to define the neuropsychiatric features of the amnestic-type MCI and compare them with those of mild AD and normal controls. The Neuropsychiatric Inventory (NPI) was used to assess the neuropsychiatric symptoms in three age and education comparable groups, i.e., 28 MCI, 124 mild AD, and 50 normal subjects. Individual subscores of the 10 NPI symptoms and total NPI scores were compared between the MCI patients and the other 2 groups. The results of this preliminary investigation showed that MCI patients frequently manifested neuropsychiatric symptoms. The most common symptoms in the MCI group were dysphoria (39%), apathy (39%), irritability (29%), and anxiety (25%). There were significant differences in apathy, dysphoria, irritability, anxiety, agitation, and aberrant motor behavior between the MCI and control groups; in contrast, only delusions were significantly less common in MCI compared with mild AD. There was a significant difference between the MCI and control groups on total NPI scores (p = 0.001), but not between the MCI and mild AD groups (p = 0.304). Amnestic MCI is associated with significant neuropsychiatric symptoms, especially mood disturbances and apathy. Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Tzung J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masterman</LastName><ForeName>Donna L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Freddy</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fairbanks</LastName><ForeName>Lynn A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15195459</ArticleId><ArticleId IdType="doi">10.1097/00002093-200401000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15190680</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1400</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Acta neurobiologiae experimentalis</Title><ISOAbbreviation>Acta Neurobiol Exp (Wars)</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>70</EndPage><MedlinePgn>53-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55782/ane-2004-1491</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1491</ELocationID><Abstract><AbstractText>With the development of new therapeutic strategies, and the concept of mild cognitive impairment (MCI) as an early stage of Alzheimer's disease (AD), there is an increasing need for an early and accurate diagnosis of sporadic AD. Therefore, biological markers allowing a positive diagnosis early in the course of the disease are highly desirable. The most extensively evaluated markers of sporadic AD are amyloid-beta proteins and levels of both total and phosphorylated microtubule-associated protein tau. In this study, we review the currently available data on the aforementioned markers assessed in the cerebrospinal fluid or plasma, alone and in combinations, focusing on their clinical applicability including sensitivity in the diagnosis of AD and mild cognitive impairment, specificity in discriminating AD from other dementias and correlations with the disease progression and apolipoprotein E genotype. We also analyze advantages and potential drawbacks of using biomarkers in the laboratory diagnosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, 8/10 Czechoslowacka St., 92-216 Lodz, Poland. tmsobow@csk.am.lodz.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142; Piotr</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Acta Neurobiol Exp (Wars)</MedlineTA><NlmUniqueID>1246675</NlmUniqueID><ISSNLinking>0065-1400</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>141</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15190680</ArticleId><ArticleId IdType="doi">10.55782/ane-2004-1491</ArticleId><ArticleId IdType="pii">1491</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15175977</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>10</Issue><PubDate><MedlineDate>2004 May 16-31</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Donepezil therapy in patients with vascular and post-traumatic cognitive impairment: some clinical observations].</ArticleTitle><Pagination><StartPage>938</StartPage><EndPage>943</EndPage><MedlinePgn>938-43</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Donepezil is a procholinergic drug that slows down cognitive and functional impairment in patients with Alzheimer's disease. Little research has been carried out to study its effect in other types of neurobehavioural disorders.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The purpose of this study was to describe the response to donepezil therapy in patients with neurobehavioural disorders due to vascular and post-traumatic causes.</AbstractText><AbstractText Label="CASE REPORTS" NlmCategory="METHODS">Donepezil was administered to four patients with mild cognitive impairment due to vascular causes, to two patients with vascular dementia and to two patients with post-traumatic dementia. Following an average time of four months, the effects exerted on the cognitive, functional and behavioural areas were evaluated. One patient did not tolerate the drug and another suffered an episode of congestive heart failure that gave rise to a moderate neurobehavioural exacerbation. Two patients underwent a moderate improvement, three patients showed a slight improvement and no changes were observed in one patient. In general, memory, attention, depression, apathy and psychotic traits tended to improve. Aggressiveness/irritability tended to get worse. The functional repercussions of these changes were negligible or inexistent.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with donepezil improved cognition and conduct in patients with neurobehavioural disorders due to vascular or post-traumatic causes. These results will have to be confirmed and expanded by means of controlled studies, and research must continue into the characteristics of responding patients and the relevance of their responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olazar&#xe1;n-Rodr&#xed;guez</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Consulta de Neurolog&#xed;a, CEP Hermanos Sangro, Area 1 Atenci&#xf3;n Especializada del INSALUD, Madrid, Spain. javier@mariawolff.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Ordu&#xf1;a</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Mart&#xed;n</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento con donepecilo en pacientes con deterioro cognitivo vascular y postraum&#xe1;tico: observaciones cl&#xed;nicas.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15175977</ArticleId><ArticleId IdType="pii">rn2003573</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15121649</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>161</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies.</ArticleTitle><Pagination><StartPage>843</StartPage><EndPage>849</EndPage><MedlinePgn>843-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This investigation was undertaken to clarify the neuropathological substrates of key psychiatric symptoms in dementia with Lewy bodies.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors studied 112 autopsy-confirmed cases of dementia with Lewy bodies in patients who had had annual standardized clinical evaluations until their death. The relationships of persistent psychiatric symptoms (visual hallucinations, delusions, depression) to plaques (Consortium to Establish a Registry for Alzheimer's Disease protocol), tangles (Braak staging), and Lewy bodies (consensus Lewy body staging) were evaluated. In addition, symptom frequency and persistent symptoms were compared in the patients with Lewy body dementia and 90 patients with autopsy-confirmed Alzheimer's disease studied prospectively during life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main neuropathological correlate of persistent visual hallucinations was the presence of less severe tangle pathology, but there was no significant association between tangle pathology and persistent delusions. Lewy body staging was associated with the presence of persistent visual hallucinations and persistent delusions. All baseline psychiatric features were significantly more frequent in dementia with Lewy bodies than in Alzheimer's disease, as were persistent visual hallucinations, but patients who had dementia with Lewy bodies and severe tangle pathology had a clinical symptom profile more similar to that of Alzheimer's disease patients and were less likely to have neocortical Lewy bodies.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The modest proportion of patients with Lewy body dementia and more severe tangle pathology resembled Alzheimer's disease patients clinically. Unlike Alzheimer's disease, dementia with Lewy bodies showed a significant inverse association between tangle burden and psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK. c.g.ballard@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacoby</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Del Ser</LastName><ForeName>Teodoro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>M Nadeem</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Zsuzanna</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Elaine K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Joachim</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jaros</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2005 Apr;162(4):817. doi: 10.1176/appi.ajp.162.4.817</RefSource><PMID Version="1">15800176</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15121649</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.161.5.843</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15112090</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-1855</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Zeitschrift fur Rheumatologie</Title><ISOAbbreviation>Z Rheumatol</ISOAbbreviation></Journal><ArticleTitle>[Psychiatric disorders in rheumatic diseases, as exemplified by systemic lupus erythematosus (SLE)].</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>130</EndPage><MedlinePgn>122-30</MedlinePgn></Pagination><Abstract><AbstractText>Among the rheumatic diseases, systemic lupus erythematosus (SLE) reveals the highest frequency of central nervous symptoms. Psychiatric abnormalities are present in over 90% of the patients, if very mild cognitive impairment is included. The psychiatric syndromes listed by the American College of Rheumatologists encompass cognitive syndromes, including the acute confusional state, anxiety disorders, depressive symptomatology and psychosis. Associations between cognitive impairment and demographic and disease variables, i. e. disease severity, have not been clearly identified so far. The same holds true for the evolution of depressive symptoms. Reactive depression in coping with a chronic disease is, however, a psychologically plausible factor in addition to specific cerebral lesions. Therapeutic interventions in SLE should consist of a combined pharmacological and nonpharmacological treatment. Corticosteroid drugs, however, may be effective in alleviating mild psychiatric symptoms as well.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuro-Centrum D&#xfc;sseldorf, Lehrpraxis der Klinik und Poliklinik f&#xfc;r Psychiatrie und Psychotherapie der Heinrich-Heine-Universit&#xe4;t, Hohenzollernstr. 1-5, 40211 D&#xfc;sseldorf, Germany. m.haupt@alzheimer-praxis-duesseldorf.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Psychische St&#xf6;rungen bei rheumatischen Erkrankungen am Beispiel des Systemischen Lupus Erythematodes (SLE).</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Rheumatol</MedlineTA><NlmUniqueID>0414162</NlmUniqueID><ISSNLinking>0340-1855</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15112090</ArticleId><ArticleId IdType="doi">10.1007/s00393-004-0618-z</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15108180</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>127B</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation.</ArticleTitle><Pagination><StartPage>51</StartPage><EndPage>59</EndPage><MedlinePgn>51-9</MedlinePgn></Pagination><Abstract><AbstractText>Fine-tuning of neuronal connections during development is regulated through environmental interactions. Some fine-tuning occurs through changes in gene expression and/or epigenetic gene-specific DNA methylation states. DNA methylation occurs by transfer of a methyl group from S-adenosyl methionine to cytosine residues in the dinucleotide sequence CpG. Although CpG sequences spread throughout the genome are usually heavily methylated, those occurring in CpG islands in the promoter regions of genes are less methylated. In most cases, the extent of DNA methylation correlates with the extent of gene inactivation. Other known epigenetic mechanisms include histone deacetylation and chromatin remodeling, RNA inhibition, RNA modification, and DNA rearrangement. Exposure memory expressed as epigenetic DNA modifications allows genomic plasticity and short-term adaptation of each generation to their environment. Environmental factors that affect DNA methylation include diet, proteins, drugs, and hormones. Induced methylation changes may produce altered gene response upon subsequent hormonal stimulation. The gene-specific DNA methylation state may be preserved upon transmission through mitosis and meiosis. An increasing amount of data implicates a role for DNA methylation in multi-factorial psychiatric disorders. For example, L-methionine treatment can exacerbate psychosis; while valproate, a drug producing hypomethylated DNA, reduces such symptoms. Hypermethylation of the promoter region of the RELN gene correlates with reduced gene expression. This gene's protein Reelin, which is necessary for neuronal migration and synaptogenesis, is reduced in schizophrenia and bipolar disorder, suggesting hypermethylation of the promoter region in these disorders. Some evidence implicates methylation of the promoter regions of the DRD2 and HTR2A genes in schizophrenia and mood disorders as well. DNA methylation usually increases with age, although hypomethylation of the promoter region of the amyloid A4 precursor gene during aging may play a role in Alzheimer's disease. More studies are needed to define the role of methylomics and other epigenetic phenomena in the nervous system.</AbstractText><CopyrightInformation>Copyright 2003 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdolmaleky</LastName><ForeName>Hamid Mostafavi</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School at Massachusetts Mental Health Center, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Cassandra L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>Stephen V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Shafa</LastName><ForeName>Rahim</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Glatt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Ming T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25MH60485</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018899" MajorTopicYN="N">CpG Islands</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15108180</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.20142</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15096405</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Executive dysfunction in Alzheimer disease.</ArticleTitle><Pagination><StartPage>556</StartPage><EndPage>560</EndPage><MedlinePgn>556-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Executive dysfunction (EDF) is common in Alzheimer disease (AD); however, its relationship to other symptoms is difficult to assess in patients with AD.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the prevalence of EDF and study its relationship to cognitive, functional, and neuropsychiatric symptoms in patients with AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">A retrospective analysis of data from participants in the English Instruments Protocol of the Alzheimer's Disease Cooperative Study. Subjects were drawn from a sample of patients evaluated at tertiary referral centers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 64% of AD patients were classified as having EDF. Patients with EDF performed worse on tests of cognition (P &lt;.001), dementia severity (P &lt;.001), and activities of daily living (P =.01) and had more frequent symptoms of psychosis (P =.03) with greater emergence during the 12-month interval (P =.03) compared with patients with normal executive function. Less than 30% of the variance in executive function performance was explained by cognitive measures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings support the assessment of executive function in persons with AD and the importance of frontal lobe dysfunction in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swanberg</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tractenberg</LastName><ForeName>Rochelle E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Mohs</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-U01 AG-10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="N">Discrimination Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15096405</ArticleId><ArticleId IdType="mid">NIHMS683800</ArticleId><ArticleId IdType="pmc">PMC4419376</ArticleId><ArticleId IdType="doi">10.1001/archneur.61.4.556</ArticleId><ArticleId IdType="pii">61/4/556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287:2335&#x2013;2338.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988038</ArticleId></ArticleIdList></Reference><Reference><Citation>Collette F, Van der Linden M, Salmon E. Executive dysfunction in Alzheimer&#x2019;s disease. Cortex. 1999;35:57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgaramella TM, Borgo F, Mondini S, et al. Executive deficits appearing in the initial stage of Alzheimer&#x2019;s disease. Brain Cogn. 2001;46:264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527345</ArticleId></ArticleIdList></Reference><Reference><Citation>Binetti G, Magni E, Padovani A, et al. Executive dysfunction in early Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1996;60:91&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486198</ArticleId><ArticleId IdType="pubmed">8558161</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56:1233&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520939</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Fairbanks LA, O&#x2019;Connor S, et al. Activities of daily living in Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2001;9:81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156757</ArticleId></ArticleIdList></Reference><Reference><Citation>Skurla R, Rogers JC, Sunderland T. Direct assessment of activities of daily living in Alzheimer&#x2019;s disease: a controlled study. J Am Geriatr Soc. 1988;36:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">3339225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Mahler M, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1995;7:476&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">8555751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann UM, Mohr E, Gearing M, et al. Heterogeneity in Alzheimer&#x2019;s disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry. 1992;55:956&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1015199</ArticleId><ArticleId IdType="pubmed">1431960</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6:358&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7841807</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50:873&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">8352676</ArticleId></ArticleIdList></Reference><Reference><Citation>Adcock RA, Constable RT, Gore JC, Goldman-Rakic PS. Functional neuro-anatomy of executive processes involved in dual-task performance. Proc Natl Acad Sci U S A. 2000;97:3567&#x2013;3572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16280</ArticleId><ArticleId IdType="pubmed">10725387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2000;69:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737034</ArticleId><ArticleId IdType="pubmed">10896687</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer SR, Sclan SG, Yaffee RA, et al. The neglected half of Alzheimer&#x2019;s disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc. 1994;42:1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">7983290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ST, Sultzer DL, Hinkin CH, et al. Executive dysfunction in Alzheimer&#x2019;s disease: association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci. 1998;10:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813788</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643&#x2013;663.</Citation></Reference><Reference><Citation>Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976;12:313&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">1009768</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL, de Hamsher KS, editors. Multilingual Aphasia Examination. Iowa City: University of Iowa; 1976.</Citation></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris SF, Mackell JM, Mohs R. A multicenter evaluation of new treatment efficacy instruments for Alzheimer&#x2019;s disease clinical trials: overview and general results. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S1&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236947</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Logsdon RG, Peskind E, et al. Alzheimer&#x2019;s Disease Cooperative Study Group. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087767</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44:M77&#x2013;M84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, et al. The Behavioral Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens J. Applied Multivariate Statistics for the Social Sciences. 3. Mahwah, NJ: Lawrence Erlbaum; 1996.</Citation></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Pfeffer RI, Kurosaki MS, Harrah CH, Jr, et al. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Freels S, Cohen D, Eisdorfer C, et al. Functional status and clinical findings in patients with Alzheimer&#x2019;s disease. J Gerontol. 1992;47:M177&#x2013;M182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1430852</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer&#x2019;s disease with and without delusions. Am J Psychiatry. 1992;149:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL, Duara R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2000;15:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Gilley DW, Bennett DA, et al. Hallucinations, delusions, and cognitive decline in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2000;69:172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737043</ArticleId><ArticleId IdType="pubmed">10896689</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Ready RE, Stout JC, et al. Neurobehaviors and psychotic symptoms in Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2000;6:815&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105471</ArticleId></ArticleIdList></Reference><Reference><Citation>Neisser U. Visual search. Sci Am. 1964;210:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14183749</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn FG, Cummings JL, Gornbein J. Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci. 1991;3:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821254</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen KJ, Mutchup KS, Norstrom S, et al. A cognitive battery for dementia: development and measurement characteristics. Psychol Assess. 1991;3:168&#x2013;174.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15086685</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.</ArticleTitle><Pagination><StartPage>852</StartPage><EndPage>853</EndPage><MedlinePgn>852-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Akiko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Turkoz</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Gharabawi</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15086685</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52230_12.x</ArticleId><ArticleId IdType="pii">JGS52230_12</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15085219</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>55</Issue><PubDate><Year>2004</Year><Season>Mar-May</Season></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Neuropsychiatric symptoms in patients with Alzheimer disease].</ArticleTitle><Pagination><StartPage>5</StartPage><EndPage>9</EndPage><MedlinePgn>5-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the past decade neuropsychiatric symptoms are not recognized until moderate and late stages of Alzheimer Disease (AD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify the neuropsychiatric symptoms in different stage of the disease.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">72 patients with probable AD (NINCDS ADRDA criteria) and 19 control subjects underwent an extensive neurologic, neuropsychologic, and neuropsychiatric evaluation including the brief questionnaire form of the Neuropsychiatric Inventory (NPI-Q).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">87,5% developed neuropsychiatric symptoms, being apathy and irritability the most frequent. In those with CDR 0,5 such findings were already present in 66,6%. Patients with mild dementia (MMSE 21-30) showed more affective symptoms, those with moderate (MMSE 11-20) more psychotic symptoms and patients with severe impairment (MMSE 0-11) showed more expression of frontal deterioration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neuropsychiatric symptoms are frequent manifestations of AD, and must be recognized and treated properly even in the early stages of the disease because they contribute to caregiver burden and often precipitate institutionalization in nursing home.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollero</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Dr. Teodoro Alvarez (GCBA). andreapollero@hotmail.com.ar</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gim&#xe9;nez</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Taragano</LastName><ForeName>Fernando E</ForeName><Initials>FE</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Trastornos neuropsiqui&#xe1;tricos en pacientes con Enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15085219</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15045036</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1699-3993</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Drugs of today (Barcelona, Spain : 1998)</Title><ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation></Journal><ArticleTitle>The benefits of microarrays as tools for studying neuropsychiatric disorders.</ArticleTitle><Pagination><StartPage>147</StartPage><EndPage>156</EndPage><MedlinePgn>147-56</MedlinePgn></Pagination><Abstract><AbstractText>DNA microarray technology is currently an area of great interest. These microarray or "gene chip" technologies, which arose out of the development of large-scale sequencing approaches, are now coming increasingly into use, generating a far greater volume of data than the data representing the sequences themselves. This technology is a powerful tool for the analysis of the organization and regulation of the brain in both diseased and healthy subjects. It can provide new insights into gene function, disease pathophysiology, disease classification and drug development. In this review, the basic theory of microarray technology and its analysis methods are presented, and technical problems are discussed. Additionally, some current results from microarray technology conducted in neuropsychiatry are presented.</AbstractText><CopyrightInformation>(c) 2004 Prous Science. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gr&#xfc;nblatt</LastName><ForeName>Edna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bayerische Julius-Maximilians-University of W&#xfc;rzburg, Clinic for Psychiatry and Psychotherapy, Neurochemical Laboratory, Germany. edna.gruenblatt@mail.uni-wuerzburg.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Drugs Today (Barc)</MedlineTA><NlmUniqueID>101160518</NlmUniqueID><ISSNLinking>1699-3993</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>62</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15045036</ArticleId><ArticleId IdType="pii">799426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15041028</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2004</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0952-3278</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Prostaglandins, leukotrienes, and essential fatty acids</Title><ISOAbbreviation>Prostaglandins Leukot Essent Fatty Acids</ISOAbbreviation></Journal><ArticleTitle>Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function.</ArticleTitle><Pagination><StartPage>361</StartPage><EndPage>372</EndPage><MedlinePgn>361-72</MedlinePgn></Pagination><Abstract><AbstractText>The central nervous system has the second highest concentration of lipids after adipose tissue. Long chain fatty acids, particularly arachidonic acid and docosahexaenoic acid, are integral components of neural membrane phospholipids. Alterations in neural membrane phospholipid components cannot only influence crucial intracellular and intercellular signaling but also alter many membrane physical properties such as fluidity, phase transition temperature, bilayer thickness, and lateral domains. A deficiency of docosahexaenoic acid markedly affects neurotransmission, membrane-bound enzyme and ion channel activities, gene expression, intensity of inflammation, and immunity and synaptic plasticity. Docosahexaenoic acid deficiency is associated with normal aging, Alzheimer disease, hyperactivity, schizophrenia, and peroxisomal disorders. Although the molecular mechanism of docosahexaenoic acid involvement in the disorders remains unknown, the supplementation of docosahexaenoic acid in the diet restores gene expression and modulates neurotransmission. Also, improvements are seen in signal transduction processes associated with behavioral deficits, learning activity, peroxisomal disorders, and psychotic changes in schizophrenia, depression, hyperactivity, stroke, and Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horrocks</LastName><ForeName>Lloyd A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA. horrocks.2@osu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farooqui</LastName><ForeName>Akhlaq A</ForeName><Initials>AA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>Prostaglandins Leukot Essent Fatty Acids</MedlineTA><NlmUniqueID>8802730</NlmUniqueID><ISSNLinking>0952-3278</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>25167-62-8</RegistryNumber><NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>130</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15041028</ArticleId><ArticleId IdType="doi">10.1016/j.plefa.2003.12.011</ArticleId><ArticleId IdType="pii">S0952327804000079</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">15034499</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2002</Year><Month>Oct</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response.</ArticleTitle><Pagination><StartPage>742</StartPage><EndPage>750</EndPage><MedlinePgn>742-50</MedlinePgn></Pagination><Abstract><AbstractText>Historically, drugs that increase central cholinergic transmission have primarily been investigated for relieving cognitive symptoms in mild-to-moderate Alzheimer's disease. These efforts have led to the somewhat unexpected findings that cholinergic therapy has a beneficial effect on selected neuropsychiatric symptoms in AD across disease stages. In Parkinson's disease with dementia and dementia with Lewy bodies, cholinergic deficits are more severe than in AD, and there is emerging evidence that cholinesterase inhibitors are efficacious in treating core symptoms of attentional disturbance and psychosis. Recent data also suggest a rational basis for cholinergic therapy in vascular dementia. The cognitive and neuropsychiatric effects of cholinergic therapy observed in AD and other dementias form the crux of an integrative model of cholinergic therapeutic efficacy that encompasses the diverse central nervous system actions of acetylcholine and its complementary interactions with central monoamine transmitters. This heuristic framework highlights the broader therapeutic potential of cholinergic therapy for symptom-based indications in other neuropsychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. dkaufer@pitt.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>23</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15034499</ArticleId><ArticleId IdType="doi">10.1017/s1092852900008737</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15018690</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>8</EndPage><MedlinePgn>3-8</MedlinePgn></Pagination><Abstract><AbstractText>Although many older adults with serious psychiatric illnesses share common concerns, such as medical comorbidity, personal loss, greater propensity for adverse medication effects, and greater dependence on others for basic needs such as transportation, individualized treatment needs must be differentiated by underlying psychiatric disorders. This retrospective study evaluated clinical characteristics and resource use among 137 older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia who were discharged from an urban, academic medical center's inpatient geropsychiatric unit. The authors found women to be significantly overrepresented among individuals with schizophrenia or schizoaffective disorder compared to those with bipolar disorder, depression, and dementia (P=.034). Among those with bipolar disorder, anticonvulsant medications were predominantly used as mood stabilizers, with only the rare use of lithium. Individuals with schizophrenia or schizoaffective disorder were the youngest group of patients; individuals with dementia were the oldest group (P&lt;.001). This shows significant differences in clinical characteristics among hospitalized older adults with serious mental illnesses. Additional studies are needed on outcomes of serious chronic psychiatric illnesses in later life to optimize care environments for older adult psychiatric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA. martha.sajatovic@uhhs.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Susan Hatters</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Sabharwal</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bingham</LastName><ForeName>C Raymond</ForeName><Initials>CR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000046" MajorTopicYN="N">Academic Medical Centers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009820" MajorTopicYN="N">Ohio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="N">Psychiatric Department, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014600" MajorTopicYN="N">Utilization Review</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15018690</ArticleId><ArticleId IdType="doi">10.1177/0891988703258821</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15006016</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-7995</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Focus on aripiprazole.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>213</EndPage><MedlinePgn>207-13</MedlinePgn></Pagination><Abstract><AbstractText>This paper is an overview of recently published research concerning the neuroleptic drug aripiprazole. Aripiprazole is an antipsychotic drug with high affinity for D(2)- and D(3)-receptors and the dopamine autoreceptor. It also has serotonin 5-HT(1A)-receptor partial agonist and 5-HT(2A)-receptor antagonist properties. It is prescribed in the treatment of schizophrenia and is under the treatment of schizophrenia and schizoaffective investigation for treatment of bipolar disorder. The drug is given by mouth in an initial dose of 10 or 15 mg once daily. The dose may be adjusted at intervals of not less than 2 weeks up to a maximum of 30 mg daily. It appears to be useful in disorder and has a better side-effect profile than haloperidol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cheadle Royal Hospital, and Honorary Senior Lecturer, University of Liverpool, UK. drbengreen@hotmail.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15006016</ArticleId><ArticleId IdType="doi">10.1185/030079903125002919</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15000807</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1090-6576</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Genetic testing</Title><ISOAbbreviation>Genet Test</ISOAbbreviation></Journal><ArticleTitle>Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>309</StartPage><EndPage>314</EndPage><MedlinePgn>309-14</MedlinePgn></Pagination><Abstract><AbstractText>Patients with Alzheimer disease (AD) often exhibit psychotic symptoms associated with cognitive impairment. A few association studies have been carried out to determine if the serotonin transporter and receptor genes are potential risk factors for AD and/or associated psychopathology. The aim of this study was to investigate the association of a serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the 5-HT2A receptor T102C polymorphism with the risk of developing dementia and/or psychotic symptoms in a group of sporadic AD patients from Italy. No significant differences in the distribution of allele and genotype frequencies of 5-HTTLPR and 5-HT2A T102C were found between patient and control groups. However, a significant association between the C102/C102 5-HT2A genotype and psychotic symptoms (p &lt; 0.001) was observed. Our data strongly confirm results from previous studies suggesting that the C102 allele of the 5-HT2A receptor is associated with the occurrence of psychotic symptoms in AD. On the contrary, the serotonin transporter does not appear to be a major susceptibility factor in the pathophysiology of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience - Neurological Clinics, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micheli</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ceravolo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Tognoni</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Test</MedlineTA><NlmUniqueID>9802546</NlmUniqueID><ISSNLinking>1090-6576</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="Y">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15000807</ArticleId><ArticleId IdType="doi">10.1089/109065703322783662</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14999455</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0933-7954</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Social psychiatry and psychiatric epidemiology</Title><ISOAbbreviation>Soc Psychiatry Psychiatr Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Resource utilisation for neuropsychiatric disorders in developing countries: a multinational Delphi consensus study.</ArticleTitle><Pagination><StartPage>218</StartPage><EndPage>227</EndPage><MedlinePgn>218-27</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Substantial information is now available at a global and regional level relating to the burden of mental disorders, yet hardly any international data are available on the resources that are needed to respond to this global burden.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of this study was to develop consensus-driven estimates of resource utilisation, coverage and adherence for key mental health care interventions capable of reducing leading neuropsychiatric causes of disease burden.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A resource utilisation questionnaire was developed for a series of mental health care interventions for schizophrenia, affective and anxiety disorders, alcohol misuse, epilepsy and Alzheimer's disease. Expert opinion surveys using a Delphi approach were conducted in seven countries (Brazil, China, Egypt, Ghana, India, Mexico and Thailand). Initial results were fed back to participants in order to elicit a second, final set of consensus estimates. Mean and median values were calculated, together with measures of dispersion and agreement.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-seven psychiatrists took part in the first Delphi round and 60 completed the seven consensus panels in the second Delphi round. Expected resource use was highest for acute psychosis, mania, severe depression and severe dementia (at least monthly outpatient visits, and over 25% of cases admitted to hospital with an average length of stay one month). Aggregated estimates for current treatment coverage ranged from below 20% for Alzheimer's disease to 60% for epilepsy. Coverage and adherence levels for affective disorders were both below 50%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Delphi technique proved to be a feasible and efficient method for data collection and consensus generation concerning mental health care resource utilisation. Results provide a set of range estimates for mental health resource planning and evaluation in a variety of developing regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Cleusa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Epidemiology, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chisholm</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Van Ommeren</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Soc Psychiatry Psychiatr Epidemiol</MedlineTA><NlmUniqueID>8804358</NlmUniqueID><ISSNLinking>0933-7954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14999455</ArticleId><ArticleId IdType="doi">10.1007/s00127-004-0729-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14758577</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>115</StartPage><EndPage>126</EndPage><MedlinePgn>115-26</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Psychotic symptoms and behavioral disturbances are a concern in the care of elderly patients with Alzheimer's dementia (AD). This study was conducted to compare the efficacy of olanzapine versus placebo in patients with psychotic symptoms associated with AD in long-term or continuing-care settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients (n = 652) with AD and delusions or hallucinations were randomly assigned to 10 weeks of double-blind treatment with placebo or fixed-dose olanzapine (1.0, 2.5, 5.0, 7.5 mg/day).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age was 76.6+/-10.4 years. Repeated-measures analysis showed significant improvement from baseline in NPI/NH Psychosis Total scores (sum of Delusions, Hallucinations items-primary efficacy measure) in all five treatment groups (p&lt;0.001), but no pairwise treatment differences were seen at the 10-week endpoint. However, under LOCF analysis, improvement in the 7.5 mg olanzapine group (-6.2 +/- 4.9) was significantly greater than with placebo (-5.0 +/- 6.1, p = 0.008), while endpoint CGI-C scores showed the greatest improvement in the Olz 2.5 olanzapine group (2.8 +/- 1.4, p = 0.030) relative to placebo (3.2 +/- 1.4). There were significant overall treatment-group differences in increased weight, anorexia, and urinary incontinence, with olanzapine showing numerically higher incidences. However, neither the incidence of any other individual events, including extrapyramidal symptoms, nor of total adverse events occurred with significantly higher frequency in any olanzapine group relative to placebo. No clinically relevant significant changes were seen across groups in cognition or any other vital sign or laboratory measure, including glucose, triglyceride, and cholesterol.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While 1.0 mg olanzapine did not show significant differences from placebo, the 2.5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated.</AbstractText><CopyrightInformation>Copyright 2004 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Middelheim Hospital, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasco</LastName><ForeName>Manuel Mart&#xed;n</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Deberdt</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jeandel</LastName><ForeName>Claude</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hay</LastName><ForeName>Donald P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Carrie A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId><ArticleId IdType="doi">10.1002/gps.1032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14756158</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The meaning of words.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>222</EndPage><MedlinePgn>219-22</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014149">Tranquilizing Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001242" MajorTopicYN="N">Assertiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040541" MajorTopicYN="N">Marketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="Y">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014149" MajorTopicYN="N">Tranquilizing Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014705" MajorTopicYN="Y">Verbal Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14756158</ArticleId><ArticleId IdType="doi">10.1017/s1041610203009487</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14690773</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer's disease: clinical characteristics and history.</ArticleTitle><Pagination><StartPage>105</StartPage><EndPage>111</EndPage><MedlinePgn>105-11</MedlinePgn></Pagination><Abstract><AbstractText>The concept of psychosis of Alzheimer's disease and dementia is developed with respect to prevalence, incidence, clinical characteristics, clinical course, and potential response to treatment. Psychosis frequently occurs subsequent to the onset of dementia. Published prevalence estimates of psychosis in patients with AD range from 10 to 73% with an overall median of 34% within clinic populations, and from 7 to 20% in community and clinical trials populations depending on definitions used. Among people with AD who have no psychotic symptoms there appears to be an annualized incidence of psychosis of about 20% in outpatients, and a much higher rate in nursing home patients. Female gender, somewhat greater cognitive impairment among outpatients, somewhat lesser cognitive impairment among nursing home patients, and physical aggression are more associated with psychotic signs and symptoms than not. Right frontal hypometabolism and greater frontal neuropsychological deficits occur in AD patients with psychosis in comparison to those without. Among nursing home patients with dementia who have clinically significant agitation, the substantial majority have delusions or hallucinations. Among patients in nursing homes with dementia and psychosis, nearly two-thirds have persistent symptoms over at least 12 weeks, and among outpatient studies, hallucinations and delusions may persist in approximately 40-50% over periods of 3 months to one year. There is some evidence that psychotic symptoms improve modestly with antipsychotic medication treatment. There is sufficient descriptive and empirical research to support the validity of a syndrome of psychosis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and the Behavioral Sciences, University of Southern California, Keck School of Medicine, 1975 Zonal Avenue, KAM 400, Los Angeles, CA 90033, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5P50 AG05142-19</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>43</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14690773</ArticleId><ArticleId IdType="doi">10.1016/s0022-3956(03)00092-x</ArticleId><ArticleId IdType="pii">S002239560300092X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14674953</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Psychiatric epidemiology of old age: the H70 study--the NAPE lecture 2003.</ArticleTitle><Pagination><StartPage>4</StartPage><EndPage>18</EndPage><MedlinePgn>4-18</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe methodological issues and possibilities in the epidemiology of old age psychiatry using data from the H70 study in G&#xf6;teborg, Sweden.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A representative sample born during 1901-02 was examined at 70, 75, 79, 81, 83, 85, 87, 90, 92, 95, 97, 99 and 100 years of age, another during 1906-07 was examined at 70 and 79 years of age, and samples born between 1922 and 1930 were examined at 70 years of age. The study includes psychiatric examinations and key informant interviews performed by psychiatrists, physical examinations performed by geriatricians, psychometric testings, blood sampling, computerized tomographies of the brain, cerebrospinal fluid analyses, anthropometric measurements, and psychosocial background factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mental disorders are found in approximately 30% of the elderly, but is seldom detected or properly treated. Incidence of depression and dementia increases with age. The relationship between blood pressure and Alzheimer's disease is an example of how cross-sectional and longitudinal studies yield completely different results. Brain imaging is an important tool in epidemiologic studies of the elderly to detect silent cerebrovascular disease and other structural brain changes. The high prevalence of psychotic symptoms is an example of the importance to use several sources of information to detect these symptoms. Dementia should be diagnosed in all types of studies in the elderly, as it influences several outcomes such as mortality, blood pressure, and rates of depression. Suicidal feelings are rare in the elderly and are strongly related to mental disorders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Modern epidemiologic studies in population samples should be longitudinal and include assessments of psychosocial risk factors as well as comprehensive sets of biologic markers, such as brain imaging, neurochemical analyses, and genetic information to maximize the contribution that epidemiology can provide to increase our knowledge about the etiology of mental disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sahlgrenska University Hospital, G&#xf6;teborg, Sweden. ingmar.skoog@neuro.gu.se</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019531">Lecture</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14674953</ArticleId><ArticleId IdType="doi">10.1046/j.1600-0447.2003.00260.x</ArticleId><ArticleId IdType="pii">260</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14653431</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Cultural aspects of psychosis in the elderly.</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>231</EndPage><MedlinePgn>225-31</MedlinePgn></Pagination><Abstract><AbstractText>The elderly population is rapidly growing and increasing in diversity. Furthermore, mental disorders are common in this population. Elderly patients are at increased risk for developing psychotic symptoms. Consequently, clinicians must increase their awareness of culture and its effect on psychosis in the elderly. This article briefly reviews the components of cultural assessments, cultural issues pertaining to diagnosis and treatment, and culture-bound syndromes. Some studies have demonstrated ethnic differences in the presention, assessment, diagnosis, and treatment of psychotic disorders in the elderly. These differences may be explained by factors including clinicians' bias, cultural distance between patients and clinicians, culturally biased diagnostic instruments, stereotypes of psychopathology, and biological and other environmental factors. However, some studies have not documented ethnic differences in diagnosing and treating psychotic disorders. Appropriate assessments and diagnoses include patients' and clinicians' ethnic and cultural contexts. Rigorous methodological research is needed to further evaluate the prevalence and treatment of psychotic disorders in ethnic minority elders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faison</LastName><ForeName>Warachal Eileen</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Alzheimer's Research and Clinical Programs, Medical University of South Carolina, North Charleston 29406, USA. faison@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Dena</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 P30 AG021677-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 R01 AG15922-05S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="Y">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>87</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14653431</ArticleId><ArticleId IdType="doi">10.1177/0891988703258668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14653430</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Nonpharmacologic interventions for psychotic symptoms in dementia.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>224</EndPage><MedlinePgn>219-24</MedlinePgn></Pagination><Abstract><AbstractText>This article proposes an initial nomenclature and systematic approach for the nonpharmacologic understanding and treatment of psychotic symptoms in dementia. An analysis of delusions and hallucinations must examine alternative etiologies, including misdiagnosis and misunderstanding, the misinterpretation of reality because of cognitive losses, sensory deprivation and vision loss, ambiguous sensations, and delirium and medical causes. Nonpharmacologic treatments frequently follow directly from etiology, such as improving sensory function via hearing aids or eyeglasses, providing stimulation, changing antecedents prone to misinterpretation (eg, reflections in windows), or circumventing misinterpretations (eg, ensuring that an equivalent object is available so there is no sense of loss or theft). Given the differences between psychotic symptoms in Alzheimer's disease and those in other diseases, the term psychosis should be abandoned for most dementia patients, and assessments of etiology should be developed. Future research should clarify what proportion of symptoms currently identified as psychotic are attributable to related etiologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen-Mansfield</LastName><ForeName>Jiska</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The George Washington University and the Research Institute on Aging, Hebrew Home of Greater Washington, Rockville, Maryland 20852, USA. cohen-mansfield@hebrew-home.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="N">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012678" MajorTopicYN="N">Sensation Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012683" MajorTopicYN="N">Sensory Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14653430</ArticleId><ArticleId IdType="doi">10.1177/0891988703258665</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14653429</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic management of psychosis in the elderly: a critical review.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>218</EndPage><MedlinePgn>213-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Psychotic symptoms are seen in numerous psychiatric illnesses afflicting the elderly. This article reviews the efficacy of the pharmacologic management of psychotic symptoms in primary psychotic disorders, affective disorders, and neurodegenerative disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A comprehensive literature review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Evidence to support the use of pharmacologic interventions to manage psychotic symptoms in elderly patients afflicted with primary psychotic disorders and affective disorders is limited by the absence of randomized, placebo-controlled trials (RCTs). The use of low-dose clozapine is supported by RCTs in Parkinson's disease. The efficacy of risperidone and olanzapine for the treatment of psychotic symptoms has been demonstrated by large RCTs in Alzheimer's disease.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is evidence of the efficacy of antipsychotic medications to manage psychotic symptoms in elderly patients. However, the absence of published evidence from RCTs in primary psychotic and affective disorders, and the limited evidence in the neurodegenerative illnesses, is notable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoeh</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia 19104, USA. nickhoeh@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gyulai</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Streim</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14653429</ArticleId><ArticleId IdType="doi">10.1177/0891988703258663</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14653428</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>The biology of psychosis in older people.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>212</EndPage><MedlinePgn>207-12</MedlinePgn></Pagination><Abstract><AbstractText>The nosology, classification, and biological basis of psychosis in the elderly have been much debated. Psychotic features are seen in schizophrenia, affective illness, and dementia in the elderly. This article reviews evidence for the biological basis of psychosis in older people. In schizophrenia, there is evidence of gender differences in brain volume loss and dopamine receptor numbers, possibly linked to estrogen loss in women. Neuroimaging evidence of ventricular brain changes and more dopamine receptors have also been documented. In Alzheimer's disease, genetic factors such as PS1 and ApoE4 have been associated with psychotic symptoms, and histopathological studies have revealed differences in neuronal pathology. Radiological studies have shown right and left hemisphere differences in size, blood flow, and glucose metabolism between psychotic and nonpsychotic patients. In affective illnesses, there is evidence of structural brain changes in psychotic depression. Ample evidence suggests that biological substrates underlie many psychotic symptoms. More research will identify causal links between brain changes, symptom appearance, and the effects of psychosocial factors in their genesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Manchester, Wythenshawe Hospital, Education and Research Centre, Manchester, United Kingdom. SKarim@fs1.with.man.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14653428</ArticleId><ArticleId IdType="doi">10.1177/0891988703258661</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14653427</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Psychosis in elderly patients: classification and pharmacotherapy.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>206</EndPage><MedlinePgn>199-206</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis in elderly patients is a growing clinical concern because psychotic symptoms most frequently occur as noncognitive manifestations of Alzheimer's disease, as side effects of drug therapy for Parkinson's disease, or as the primary abnormalities in schizophrenia, and the clinical characteristics of psychosis are distinct for each. In planning antipsychotic pharmacotherapy for elderly patients, age-related pharmacokinetic changes, polypharmacy for comorbid diseases, and concerns about the underlying conditions responsible for the psychotic symptoms must be considered. Traditional antipsychotic agents bind to dopamine receptors and effectively relieve positive schizophrenic symptoms but frequently cause tardive dyskinesia and other extrapyramidal symptoms, a problem for elderly patients, particularly for those with Parkinson's disease. Atypical antipsychotics bind to dopamine and serotonin receptors, relieving both positive and negative symptoms, and are less likely to cause extrapyramidal symptoms. The authors review common diagnostics associated with psychosis in the elderly and clinical guidelines to selecting antipsychotic pharmacotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical University of South Carolina, Institute of Psychiatry, Charleston 29406, USA. mintzerj@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Targum</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="N">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14653427</ArticleId><ArticleId IdType="doi">10.1177/0891988703258658</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14645660</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0026-895X</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Molecular pharmacology</Title><ISOAbbreviation>Mol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.</ArticleTitle><Pagination><StartPage>1309</StartPage><EndPage>1316</EndPage><MedlinePgn>1309-16</MedlinePgn></Pagination><Abstract><AbstractText>Cholinesterase inhibitors are commonly used to improve cognition and treat psychosis and other behavioral symptoms in Alzheimer's disease, Parkinson's disease, and other neuropsychiatric conditions. However, mechanisms may exist that down-regulate the synaptic response to altered cholinergic transmission, thus limiting the efficacy of cholinomimetics in treating disease. Acetylcholinesterase knockout (AChE-/-) mice were used to investigate the neuronal adaptations to diminished synaptic acetylcholine (ACh) metabolism. The striatum of AChE-/- mice showed no changes in choline acetyltransferase activity or levels of the vesicular ACh transporter but showed striking 60% increases in the levels of the highaffinity choline transporter. This transporter takes choline from the synapse into the neuron for resynthesis of ACh. In addition, the striata of AChE-/- mice showed dramatic reductions in levels of the M1, M2, and M4 muscarinic ACh receptors (mAChRs), but no alterations in dopamine receptors or the beta2 subunit of nicotinic receptors. M1, M2, and M4 also showed decreased dendritic and cell surface distributions and enhanced intracellular localizations in striatal neurons of AChE-/- mice. mAChR antagonist treatment reversed the shifts in mAChR distribution, indicating that internalized receptors in AChE-/- mice can recover to basal distributions. Finally, AChE-/- mice showed increased sensitivity to mAChR antagonist-induced increases in locomotor activity, demonstrating functional mAChR down-regulation. mAChR downregulation in AChE-/- mice has important implications for the long-term use of cholinesterase inhibitors and other cholinomimetics in treating disorders characterized by perturbed cholinergic function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volpicelli-Daley</LastName><ForeName>Laura A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Whitehead Biomedical Research Building, 615 Michael St., 5th Floor, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabovska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Duysen</LastName><ForeName>Ellen G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Shawn M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Blakely</LastName><ForeName>Randy D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Lockridge</LastName><ForeName>Oksana</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-NS30454</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharmacol</MedlineTA><NlmUniqueID>0035623</NlmUniqueID><ISSNLinking>0026-895X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C065637">choline transporter</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14645660</ArticleId><ArticleId IdType="doi">10.1124/mol.64.6.1309</ArticleId><ArticleId IdType="pii">64/6/1309</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14620077</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Prediction of mortality in nursing home residents: impact of passive self-harm behaviors.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>196</EndPage><MedlinePgn>187-96</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to determine whether indirect self-destructive behaviors predict mortality in nursing home residents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This cross-sectional study with follow-up after 2 years and 3 months surveyed 593 residents in 10 nursing homes in the eastern suburbs of Sydney, Australia. The following instruments were used: Harmful Behaviors Scale (HBS), Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Functional Assessment Staging Scale, Resident Classification Index, Cumulative Illness Rating Scale, Even Briefer Assessment Scales for Depression, and the suicide item from the Structured Hamilton Depression Rating Scale. Diagnoses of depression, dementia, and psychosis were obtained from nursing home records. Mortality data were obtained in August 1999.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At follow-up, 297 (50.1%) residents were still alive with a mean survival time of 565.4 days. Survival analyses found that mortality was predicted by older age, male gender, lower level of functioning, lower levels of behavioral disturbance on the BEHAVE-AD, and higher scores on the HBS "passive self-harm" factor-based subscale, which includes refusal to eat, drink, or take medication.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">These results suggest that passive self-harm behaviors predict mortality in nursing home residents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, Australia. b.draper@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Lee-Fay</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Vicki</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009517" MajorTopicYN="N" Type="Geographic">New South Wales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016312" MajorTopicYN="N">Treatment Refusal</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14620077</ArticleId><ArticleId IdType="doi">10.1017/s1041610203008871</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14620075</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Associations between psychotic symptoms and dependence in activities of daily living among older adults with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>179</EndPage><MedlinePgn>171-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is associated with dependence in activities of daily living (ADL). In addition to the cognitive impairment resulting from AD, the presence of psychotic symptoms may further increase this dependence. The objective of this study was to quantify the additional contribution of psychotic symptoms to dependence in ADL.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We analyzed data from 558 individuals with AD referred to a memory clinic. Information on ADL, psychotic symptoms, depression symptoms, and cognition was collected with standardized instruments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of psychotic symptoms was correlated with dependence in ADL (r = -.44, p &lt; .001). The independent contribution of psychotic symptoms to ADL (basic and instrumental) after consideration for cognitive impairment and depression symptoms was assessed with hierarchical regression models. Twenty-five percent of basic ADL variance was explained by cognition; psychotic symptoms accounted for an additional 7% of the variance (b = -0.12, p &lt; .001). Cognitive impairment explained 31% of instrumental ADL variance; psychotic symptoms accounted for an additional 6% (b = -0.21, p &lt; .001).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Psychotic symptoms are associated with dependence in ADL after controlling for cognitive impairment and depression symptoms. Future research should investigate possible causal linkages between psychotic symptoms and dependence in ADL. This may have implications regarding interventions to maintain independent living in people with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Mun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Lakehead University, Thunder Bay, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;dard</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Molloy</LastName><ForeName>D William</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Sacha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lever</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14620075</ArticleId><ArticleId IdType="doi">10.1017/s1041610203008858</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14620074</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease ethics--informed consent and related issues in clinical trials: results of a survey among the members of the Research Ethics Committees in Sweden.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>170</EndPage><MedlinePgn>157-70</MedlinePgn></Pagination><Abstract><AbstractText>The rapid advances in biomedical sciences have induced special moral and ethical attitudes, which ought to be taken into account. One of the most essential issues is the principles for participation in research of subjects with reduced decision-making capacity. We conducted a questionnaire survey among members of the research ethics committees in Sweden to find out their attitudes to a range of ethical issues related to research on subjects with Alzheimer's disease. One hundred thirty-six of those approached responded (66%), and 117 of the responses (56%) were considered substantially complete. There were 16 questions with fixed reply alternatives. Some central questions concerned the informed consent process. With a few exceptions, there were no significant differences in attitudes between the experts and laypersons, between persons of different ages, and between men and women. However, women and laypersons were in general keener to preserve the patient's integrity and the experts were more willing than the laypersons to allow participation of subjects with dementia in placebo-controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Gunbrith</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen-Cilag AB, Sollentuna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="Y">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017041" MajorTopicYN="Y">Ethics Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004992" MajorTopicYN="Y">Ethics, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032984" MajorTopicYN="Y">Ethics, Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007258" MajorTopicYN="N">Informed Consent</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007872" MajorTopicYN="N">Legal Guardians</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="N">Mental Competency</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="KIE">123054</OtherID><OtherID Source="NRCBL">VF 18.5.6</OtherID><KeywordList Owner="KIE"><Keyword MajorTopicYN="N">Biomedical and Behavioral Research</Keyword><Keyword MajorTopicYN="N">Empirical Approach</Keyword></KeywordList><GeneralNote Owner="KIE">21 refs.</GeneralNote><GeneralNote Owner="KIE">KIE Bib: human experimentation/ethics committees; human experimentation/foreign countries; human experimentation/informed consent; human experimentation/special populations</GeneralNote></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14620074</ArticleId><ArticleId IdType="doi">10.1017/s1041610203008846</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14596656</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-6566</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>11</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy of dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>2027</StartPage><EndPage>2037</EndPage><MedlinePgn>2027-37</MedlinePgn></Pagination><Abstract><AbstractText>The syndrome of dementia with Lewy bodies (DLB) is characterised by the clinical triad of fluctuating cognitive impairment, recurrent visual hallucinations and spontaneous motor features of Parkinsonism. In an attempt to define DLB as a distinct clinical syndrome separate from Alzheimer's disease (AD) and Parkinson's disease (PD) with dementia, a consensus workshop in 1995 established a new set of diagnostic criteria. Dementia that precedes or accompanies the onset of spontaneous (i.e., not neuroleptic-induced) Parkinsonism is termed DLB. In addition, fluctuations in alertness, cognition and function and visual hallucinations are emphasised and included as core features of DLB. The degree to which an individual patient exhibits cognitive impairment, behavioural problems and Parkinsonian features is variable. Therefore, treatment must be individualised. Although there are no officially approved drugs for DLB, limited experience from clinical trials, as well as past experience with the treatment of AD and PD patients, provide some basis for making drug choices. The cholinergic deficit seen in DLB makes cholinesterase inhibitor drugs the mainstay of treatment for cognitive impairment. This class of drugs has also shown therapeutic benefit in reducing hallucinations and other neuropsychiatric symptoms of the disease. Because of their relatively greater therapeutic window, cholinesterase inhibitors are also used as first-line therapy for the treatment of psychosis in DLB. Patients with DLB are extremely sensitive to the extrapyramidal side effects of neuroleptic medications. Thus, only atypical antipsychotic agents such as quetiapine, should be considered as alternative treatment for psychosis. Anxiety and depression are best treated with selective serotonin re-uptake inhibitors, whereas REM sleep behaviour disorder may be treated with low dose clonazepam. Parkinsonism responds to dopaminergic agents; however, precipitation or aggravation of hallucinosis may occur. Levodopa is preferred over dopamine agonists due to its lower propensity to cause hallucinations and somnolence. As the diagnostic criteria for DLB become more refined and validated by postmortem studies, it is hoped that rigorous, well-designed trials will be performed, aimed at alleviating the primary target symptoms of dementia, psychosis and Parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA. fernandez@neurology.ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>93</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14596656</ArticleId><ArticleId IdType="doi">10.1517/14656566.4.11.2027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14572623</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>121</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies to serotonin in serum of patients with psychiatric disorders.</ArticleTitle><Pagination><StartPage>51</StartPage><EndPage>57</EndPage><MedlinePgn>51-7</MedlinePgn></Pagination><Abstract><AbstractText>Antibodies to serotonin in serum were investigated by ELISA in patients with paranoid schizophrenia (N=27), schizoaffective psychosis (N=38), depression (N=67), Alzheimer's disease (N=21), chronic alcoholism (N=43), rheumatoid arthritis (N=25), and multiple sclerosis (N=16), and in healthy volunteers (N=60). Increased antibody reactivity to serotonin was found in schizoaffective psychosis, chronic alcoholism, and rheumatoid arthritis. Decreased antibody reactivity to serotonin was found in multiple sclerosis and depression. These anti-serotonin antibodies belong to the class of so-called natural autoantibodies. Alterations of these natural autoantibodies could indicate a disturbance to the immune system. It is possible that these antibodies could also influence receptor function. Autoantibodies to neurotransmitters in a wide spectrum of psychiatric disorders have not previously been reported.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, Osianderstr. 24, D-72076, T&#xfc;bingen, Federal Republic of Germany. klaus.schott@med.uni-tuebingen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Jacques-Emmanuel</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Richartz</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Batra</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Eusterschulte</LastName><ForeName>Beate</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Reinhild</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Peter Alfred</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Buchkremer</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14572623</ArticleId><ArticleId IdType="doi">10.1016/s0165-1781(03)00137-9</ArticleId><ArticleId IdType="pii">S0165178103001379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14566100</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1-2</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives.</ArticleTitle><Pagination><StartPage>78</StartPage><EndPage>90</EndPage><MedlinePgn>78-90</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis is common in patients with Alzheimer's disease (AD) and contributes substantially to patient morbidity and caregiver distress. Antipsychotic medications are used to treat psychosis and other psychiatric or behavioral symptoms in AD, although optimal treatment guidelines have been elusive. Choosing the most advantageous medication for an individual patient is challenging. This article provides an overview of clinical management principles and medication treatment strategies for patients with AD and psychosis. Effects of individual medications are also described. Medications in the conventional neuroleptic, atypical antipsychotic, cholinesterase inhibitor, and serotonergic classes have been shown to ameliorate psychosis and behavioral symptoms in patients with AD, although the evidence is not conclusive for many medications. Side effects vary substantially across medication classes and modestly among individual patients. Improvement in agitation, aggression, or other behaviors with antipsychotic medication treatment may not depend on distinct antipsychotic effects. In contrast, there is preliminary evidence that delusions and hallucinations may respond to treatment with medications outside the antipsychotic class. Many important clinical questions warrant further research study. In particular, studies to compare how individual symptoms respond to different medications, and to examine how to best manage overlapping symptoms or incomplete treatment response are needed.</AbstractText><CopyrightInformation>Copyright 2004 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, and Gero/Neuropsychiatry Division, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. dsultzer@ucla.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH56031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>88</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14566100</ArticleId><ArticleId IdType="doi">10.1159/000074279</ArticleId><ArticleId IdType="pii">74279</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14564129</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1-2</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>100</StartPage><EndPage>108</EndPage><MedlinePgn>100-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric symptoms (NPS) of Alzheimer's disease (AD) occur throughout the course of AD. Behaviors include mood alterations, psychosis, agitation, and apathy. These symptoms are a major cause of diminished quality of life for both patients and caregivers. Evidence suggests that a cholinergic deficit resulting from a loss of cholinergic neurons is the biological basis of some NPS in AD and related dementias. The basal forebrain nuclei, the primary source of cholinergic projections to the cortex, become atrophied in AD. Cholinesterase inhibitors (ChE-Is) enhance neuronal transmission by increasing the availability of acetylcholine at the receptors. This effect is believed to be beneficial in improving or stabilizing many behavioral symptoms of AD. Preliminary studies of ChE-Is have shown mixed results; however, the results of more recent studies have been favorable.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To review major trials of ChE-Is and summarize effects on behavioral symptoms. Agents reviewed include donepezil, galantamine, rivastigmine, tacrine, and metrifonate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The review of the studies favors a benefit of the ChE-Is in reducing NPS. Of the three agents in current use, studies of all showed significant benefit in AD. Most studies showed a positive trend toward reduction of NPS on a scaled measuring tool in the treatment group even if statistical significance was not reached. In some studies, specific behavioral symptoms, particularly apathy and hallucinations, were reduced.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Evidence suggests that ChE-Is have psychotropic effects and may be of value in managing neuropsychiatric behavioral symptoms in AD. Further studies will be necessary to fully understand the potential of these agents.</AbstractText><CopyrightInformation>Copyright 2004 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wynn</LastName><ForeName>Zakiya J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>70</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14564129</ArticleId><ArticleId IdType="doi">10.1159/000074281</ArticleId><ArticleId IdType="pii">74281</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14557567</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Neuromotor abnormalities and risk for psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>954</StartPage><EndPage>958</EndPage><MedlinePgn>954-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cross-sectional studies in Alzheimer's disease (AD) show a strong relationship between extrapyramidal motor signs and presence of psychosis, yet it remains unclear whether neuromotor abnormalities precede and therefore can predict development of psychosis in AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify cognitive and motor risk factors for the development of psychosis in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Baseline clinical motor ratings and instrumental measures of neuromuscular function were obtained from 54 nonpsychotic patients with AD who were evaluated annually for 2 years for the development of psychosis. Survival analyses were performed to identify incidence and risks associated with psychosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of new onset psychosis in our sample was 32.5% in 2 years. Patients with abnormal agonist muscle burst amplitudes during rapid alternating movements of the hand were more likely to develop psychosis than those without (OR = 4.31; p = 0.007). Women with AD also had a higher risk of developing psychosis within 2 years than men (OR = 1.33; p = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using simple noninvasive instrumental procedures for assessing neuromotor function, it may be possible to identify an individual's level of risk for developing psychosis during the course of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caligiuri</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, and the UCSD Alzheimer's Disease Research Center, La Jolla, CA 92093, USA. mcaligiuri@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peavy</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AGO-5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG12963</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG14291</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14557567</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000086823.08213.de</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14557526</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>10</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Staff members' emotional reactions to aggressive and suicidal behavior of inpatients.</ArticleTitle><Pagination><StartPage>1388</StartPage><EndPage>1394</EndPage><MedlinePgn>1388-94</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study examined the relationship between the characteristics of inpatients and staff members' emotional reactions to the patients, particularly the extent to which the reactions were related to patients' aggressive or suicidal behavior.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Feeling Word Checklist-58 was used to measure staff members' feelings. Two positive and five negative feeling dimensions were examined: important, confident, rejected, on guard, bored, overwhelmed, and inadequate. A total of 253 staff members from a wide variety of psychiatric wards at a university-affiliated hospital in Oslo, Norway, completed a total of 2473 checklists about their emotional reactions to 207 patients. For each patient, a member of the research team used information from ward staff who knew the patient to complete a Social Dysfunction and Aggression Scale measuring whether the patient had been aggressive (outward aggression) or suicidal (inward aggression).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Staff reported positive feelings about patients much more frequently than negative feelings. Multiple regression analysis revealed that patient characteristics explained much more of the variance in negative feelings than in positive feelings. Outward aggression explained an average of 22 percent of the variance in scores on the five negative dimensions. Inward aggression explained an average of 12 percent more of the variance in scores on the five negative dimensions. Gender, age, amount of medication, and diagnosis (psychotic or not psychotic) explained only a small proportion of the variance in feeling scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even though the level of negative feelings toward patients was low, patients' aggressive and suicidal behavior explained a large proportion of the variance in negative feelings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossberg</LastName><ForeName>Jan I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Research and Education, University Hospital, Oslo, Norway. j.i.rxssberg@psykiatri.uio.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friis</LastName><ForeName>Svein</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="Y">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="N">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="N">Psychiatric Department, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14557526</ArticleId><ArticleId IdType="doi">10.1176/appi.ps.54.10.1388</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">12973385</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1699-3993</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Drugs of today (Barcelona, Spain : 1998)</Title><ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation></Journal><ArticleTitle>Quetiapine fumarate (Seroquel): a new atypical antipsychotic.</ArticleTitle><Pagination><StartPage>193</StartPage><EndPage>210</EndPage><MedlinePgn>193-210</MedlinePgn></Pagination><Abstract><AbstractText>The goal of antipsychotic drug development efforts over the past 10 years has been to develop agents with increased efficacy and safety and fewer of the side effects commonly associated with the older antipsychotic medications. The newer agents, often called atypical antipsychotics, are effective in treating both the positive and negative symptoms of schizophrenia and are associated with fewer neurological- and endocrine-related side effects compared to the older agents. As a result, patients are likely to remain on therapy longer, preventing relapses and costly hospitalizations. Quetiapine fumarate (Seroquel) is the most recently introduced atypical antipsychotic and is indicated for the management of the manifestations of psychotic disorders and schizophrenia. Quetiapine, like clozapine (the archetypal atypical antipsychotic), interacts with a broad range of neurotransmitter receptors and has a higher affinity for serotonin (5-HT(2A)) receptors relative to dopamine (D(2)) receptors in the brain. Further, quetiapine's pharmacological effects appear selective for the mesolimbic and mesocortical dopamine systems, which are believed to be the areas of the brain responsible for the therapeutic effects of antipsychotics. In contrast to most standard antipsychotics and some atypical antipsychotics, quetiapine's effects on the nigrostriatal dopamine system, which is responsible for the extrapyramidal (or motor) side effects, are minimal. Quetiapine also has minimal activity on dopamine receptors in the tuberoinfundibular dopamine system, thereby avoiding the problem of hyperprolactinemia, common with the standard antipsychotics and some atypical antipsychotics. Because of these properties, quetiapine is an effective antipsychotic agent with a relatively benign side effect profile. Several large, placebo- and active-controlled, multicenter trials have shown quetiapine to be effective against both positive (e.g., hallucinations, delusions) and negative symptoms (e.g., emotional withdrawal, apathy) and to have benefits in reducing hostility, aggression and affective symptoms. Patients on long-term treatment report high compliance, good satisfaction, increased ability to function and improvements consistent with a better quality of life. Because of quetiapine's excellent tolerability profile, its use is particularly appropriate in patients especially sensitive to adverse effects, e.g., elderly patients with psychotic symptoms and other neurological disorders such as Parkinson's and Alzheimer's disease.</AbstractText><CopyrightInformation>(c) 1999 Prous Science. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Clinical Medicine Group, Zeneca Pharmaceuticals, Wilmington, Delaware 19850, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Drugs Today (Barc)</MedlineTA><NlmUniqueID>101160518</NlmUniqueID><ISSNLinking>1699-3993</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12973385</ArticleId><ArticleId IdType="doi">10.1358/dot.1999.35.3.533849</ArticleId><ArticleId IdType="pii">533849</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12961833</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-867X</ISSN><JournalIssue CitedMedium="Print"><Volume>58 Suppl 1</Volume><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Geriatrics</Title><ISOAbbreviation>Geriatrics</ISOAbbreviation></Journal><ArticleTitle>Choosing treatment for Alzheimer's patients and their caregivers.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>22</EndPage><MedlinePgn>3-18, 23; quiz 19-22</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Peskin</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatrics</MedlineTA><NlmUniqueID>2985102R</NlmUniqueID><ISSNLinking>0016-867X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="Y">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020441" MajorTopicYN="N">Ginkgo biloba</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011368" MajorTopicYN="N">Professional-Family Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>120</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12961833</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12960744</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-8829</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Psychiatric genetics in Australia.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>141</EndPage><MedlinePgn>131-41</MedlinePgn></Pagination><Abstract><AbstractText>Australian research in psychiatric genetics covers molecular genetic studies of depression, anxiety, alcohol dependence, Alzheimer's disease, bipolar disorder, schizophrenia, autism, and attention deficit hyperactivity disorder. For each disorder, a variety of clinical cohorts have been recruited including affected sib pair families, trios, case/controls, and twins from a large population-based twin registry. These studies are taking place both independently and in collaboration with international groups. Microarray studies now complement DNA investigations, while animal models are in development. An Australian government genome facility provides a high throughput genotyping and mutation detection service to the Australian scientific community, enhancing the contribution of Australian psychiatric genetics groups to gene discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mowry</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Queensland Centre for Schizophrenia Research, University of Queensland, The Park, Centre for Mental Health, Wacol, Queensland 4076, Australia. bryan_mowry@qcsr.uq,edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>116</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12960744</ArticleId><ArticleId IdType="doi">10.1097/00041444-200309000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12940326</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-4348</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Southern medical journal</Title><ISOAbbreviation>South Med J</ISOAbbreviation></Journal><ArticleTitle>Exacerbation of psychosis by misinterpretation of physical symptoms.</ArticleTitle><Pagination><StartPage>702</StartPage><EndPage>704</EndPage><MedlinePgn>702-4</MedlinePgn></Pagination><Abstract><AbstractText>Impaired processing of perceptual information is often a prominent aspect of psychotic disorders. Physical symptoms such as pain or discomfort may be either incorrectly perceived or misinterpreted by psychotic patients. Presented here is a series of cases in which somatic symptoms occurred in psychotic patients and worsened their psychotic states but only later were recognized as physical problems. Psychotic patients may be unable to comprehend or describe their physical symptoms adequately. Physical disorders of psychotic patients may be overlooked if clinicians are not vigilant and thorough in assessing the patients' complaints, especially if such complaints sound delusional or bizarre.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Roy R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, G.V. (Sonny) Montgomery VA Medical Center Jackson, MS 39216, USA. roy.reeves@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Rafael A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>South Med J</MedlineTA><NlmUniqueID>0404522</NlmUniqueID><ISSNLinking>0038-4348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010468" MajorTopicYN="N">Perceptual Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010469" MajorTopicYN="Y">Perceptual Distortion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012803" MajorTopicYN="Y">Sick Role</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12940326</ArticleId><ArticleId IdType="doi">10.1097/01.SMJ.0000078686.34109.11</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12940325</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-4348</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Southern medical journal</Title><ISOAbbreviation>South Med J</ISOAbbreviation></Journal><ArticleTitle>Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.</ArticleTitle><Pagination><StartPage>699</StartPage><EndPage>701</EndPage><MedlinePgn>699-701</MedlinePgn></Pagination><Abstract><AbstractText>Orally disintegrating olanzapine is a recently marketed form of olanzapine that dissolves rapidly on contact with saliva. We describe six demented patients resistant to treatment with common oral antipsychotic medications who were successfully treated with the formulation. The importance of these case reports is to make physicians aware that orally disintegrating olanzapine may be useful for the management of psychobehavioral disturbances in demented patients who resist or have difficulty taking standard oral medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Roy R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Mississippi School of Medicine, Jackson, MS, USA. roy.reeves@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Rafael A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>South Med J</MedlineTA><NlmUniqueID>0404522</NlmUniqueID><ISSNLinking>0038-4348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020208" MajorTopicYN="N">Brain Injury, Chronic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12940325</ArticleId><ArticleId IdType="doi">10.1097/01.SMJ.0000051066.55838.0A</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12938075</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><MedlineDate>2003 Jul 16-31</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Factors that modify the natural course of Alzheimer's disease].</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>155</EndPage><MedlinePgn>149-55</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer s disease (AD) is an insidious, and progressive disorder of the nervous system that typically occurs after age 65, with incidence rising with chronological age. The disorder is characterized by a pronounced memory loss, due to neuropathological changes in the mesial temporal lobes; as the pathology spreads throughout the cerebral cortex. However, it is still unknown why some areas are more affected than others, with the subsequent clinical heterogeneity (or phenotypes), and variability in the clinical course. The most salient neurobehavioral syndromes that can affect the clinical course are extrapyramidal signs, as well as a wide variety of psychiatric syndromes (e.g., psychotic symptoms, depression, aggression). Similarly, medication use (e.g., antipsychotics, sedatives) have shown to have a detrimental effect in the course of the disease. Current palliative treatments for AD may alter the natural history of the disease by extending the time that affected patients may live at home.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>O L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. lopezol@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author></AuthorList><Language>spa</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-MH01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Factores que modifican el curso natural de la enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>101</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12938075</ArticleId><ArticleId IdType="pii">rn2002447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12934967</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64 Suppl 9</Volume><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>6</EndPage><MedlinePgn>3-6</MedlinePgn></Pagination><Abstract><AbstractText>The defining characteristic of Alzheimer's disease is cognitive impairment, but commonly this impairment is accompanied by mood and behavioral symptoms such as depression, anxiety, irritability, inappropriate behavior, sleep disturbance, psychosis, and agitation. The symptoms of Alzheimer's disease are not normative to the aging process. Diagnosis of Alzheimer's disease in the majority of cases can be made with confidence through office-based clinical assessment and informant interview. Alzheimer's disease is the most common of the dementing disorders and is exponentially increasing in incidence, projected to affect 8.64 million people in the United States by the year 2047. At present, no treatment can prevent or cure Alzheimer's disease, and the fact that Alzheimer's affects a geriatric population makes treatment all the more challenging. Therapies that could delay onset of symptoms even briefly would have a major impact on public health. As the prevalence of Alzheimer's disease increases, researchers are examining the efficacy of treatment options beyond the realm of the established cholinesterase inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grossberg</LastName><ForeName>George T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, St. Louis University School of Medicine, St. Louis, MO 63104, USA. grossbgt@slu.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>13</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12934967</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12928511</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease.</ArticleTitle><Pagination><StartPage>346</StartPage><EndPage>353</EndPage><MedlinePgn>346-53</MedlinePgn></Pagination><Abstract><AbstractText>This cross-sectional study examines relationships among the constellation of psychiatric syndromes in Alzheimer's disease (AD) as a function of dementia severity in 1155 patients with probable AD. The frequency of major depression decreased in severe stages, while agitation, aggression, and psychosis were more frequent in late stages. Major depression was associated with anhedonia, sleep disorders, depressed mood, low self-esteem, anxiety, and hopelessness in mild/moderate and severe stages. Agitation was associated with aggression and psychosis in mild/moderate stages, and psychosis was associated with aggression in moderate/severe stages. In addition, there was a constellation of psychiatric symptoms (e.g., anxiety, wandering, irritability, inappropriate behavior, uncooperativeness, emotional lability) associated with agitation, aggression, and psychosis, which varied according to the severity of the dementia, suggesting a progressive deterioration of frontal-temporal limbic structures. Education and race were independently associated with psychosis. However, while education was associated with psychosis in mild/moderate stages, race was associated with psychosis in moderate/severe stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. lopezol@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Habeych</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-MH01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId><ArticleId IdType="doi">10.1176/jnp.15.3.346</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12921516</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1060-0280</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Annals of pharmacotherapy</Title><ISOAbbreviation>Ann Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1321</StartPage><EndPage>1324</EndPage><MedlinePgn>1321-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">MEDLINE (1966-January 2003) and Science Citation Index searches were performed. Key search terms included olanzapine, Alzheimer(s), and dementia.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Four trials of olanzapine and subsequent post hoc analyses were reviewed. Three trials found a benefit associated with olanzapine use, but a fourth trial did not.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Olanzapine appears to be effective in treating psychotic and behavioral disturbances associated with Alzheimer disease. However, the most appropriate dose remains to be determined. The benefit of olanzapine therapy must be weighed against the adverse effect profiles of olanzapine and alternative treatment options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schatz</LastName><ForeName>Robin A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>College of Pharmacy, The University of Toledo, Toledo, OH, USA. robinschatz@msn.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Pharmacother</MedlineTA><NlmUniqueID>9203131</NlmUniqueID><ISSNLinking>1060-0280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>16</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12921516</ArticleId><ArticleId IdType="doi">10.1345/aph.1D050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12921503</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1060-0280</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Annals of pharmacotherapy</Title><ISOAbbreviation>Ann Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Seizures associated with quetiapine treatment.</ArticleTitle><Pagination><StartPage>1224</StartPage><EndPage>1227</EndPage><MedlinePgn>1224-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report a case of seizures in a patient with Alzheimer disease, who was receiving quetiapine for psychoses.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 75-year-old white man with Alzheimer disease was observed to have seizures while receiving quetiapine 500 mg/d and carbamazepine 200 mg/d. He had been taking quetiapine for 18 months prior to the event. No other toxic, metabolic, or anatomic abnormalities were identified to explain the seizures. After cessation of quetiapine treatment, the patient remained seizure free. An objective causality assessment revealed that the adverse drug reaction was possible.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The patient was taking a relatively high dose of quetiapine. An increased risk of seizures has been associated with Alzheimer disease. Using a relatively high dose of quetiapine may have resulted in seizures in our patient with Alzheimer disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As with other antipsychotics, quetiapine should be used cautiously in elderly patients with conditions that can lower the seizure threshold, and special monitoring should be performed for this serious adverse effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dogu</LastName><ForeName>Okan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey. okandogu@mersin.edu.tr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevim</LastName><ForeName>Serhan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kaleagasi</LastName><ForeName>Hakan S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Pharmacother</MedlineTA><NlmUniqueID>9203131</NlmUniqueID><ISSNLinking>1060-0280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12921503</ArticleId><ArticleId IdType="doi">10.1345/aph.1C516</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12908661</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>72</EndPage><MedlinePgn>57-72</MedlinePgn></Pagination><Abstract><AbstractText>This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Olin</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McManus</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="Y">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId><ArticleId IdType="doi">10.1093/oxfordjournals.schbul.a006991</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12893111</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prevalence, etiology, and treatment of depression in Parkinson's disease.</ArticleTitle><Pagination><StartPage>363</StartPage><EndPage>375</EndPage><MedlinePgn>363-75</MedlinePgn></Pagination><Abstract><AbstractText>Parkinson's disease (PD) is primarily a disease of elderly individuals with a peak age at onset of 55 to 66 years. It is characterized by bradykinesia, rigidity, tremor, and postural instability; and affects approximately 1 million individuals in the US and is the second most common neurodegenerative disease next to Alzheimer's disease. The motor symptoms of PD are the focus of pharmacotherapy, yet the nonmotor symptoms (e.g., dementia, psychosis, anxiety, insomnia, autonomic dysfunction, and mood disturbances) can be the most disturbing, disabling, and misunderstood aspects of the disease. Depressive symptoms occur in approximately half of PD patients and are a significant cause of functional impairment for PD patients. There is accumulating evidence suggesting that depression in PD is secondary to the underlying neuroanatomical degeneration, rather than simply a reaction to the psychosocial stress and disability. The incidence of depression is correlated with changes in central serotonergic function and neurodegeneration of specific cortical and subcortical pathways. Understanding comorbid depression in PD may therefore add to the understanding of the neuroanatomical basis of melancholia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>William M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>DeLong</LastName><ForeName>Mahlon R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>133</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12893111</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(03)00530-4</ArticleId><ArticleId IdType="pii">S0006322303005304</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12857363</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1525-8610</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>4 Suppl</Issue><PubDate><Year>2003</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Journal of the American Medical Directors Association</Title><ISOAbbreviation>J Am Med Dir Assoc</ISOAbbreviation></Journal><ArticleTitle>Challenges in the management of psychotic symptoms in long-term care.</ArticleTitle><Pagination><StartPage>H17</StartPage><EndPage>H20</EndPage><MedlinePgn>H17-20</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gravenstein</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Beier</LastName><ForeName>Manju</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Dir Assoc</MedlineTA><NlmUniqueID>100893243</NlmUniqueID><ISSNLinking>1525-8610</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>13</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12857363</ArticleId><ArticleId IdType="doi">10.1097/01.JAM.0000078012.86972.F0</ArticleId><ArticleId IdType="pii">S1525-8610(04)70361-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12856535</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>16</Issue><PubDate><Year>2003</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Delirious states in elderly persons. Therapeutic modalities].</ArticleTitle><Pagination><StartPage>750</StartPage><EndPage>755</EndPage><MedlinePgn>750-5</MedlinePgn></Pagination><Abstract><AbstractText>THE MAJOR THERAPEUTIC TRENDS: The treatment of psychosis in late life depends on the etiology of the delusion but also on its behavioral consequences (agitation, aggressiveness). We distinguish between the treatment of long term old psychosis and delusions occurring late in life (after the age of 60). FOR THE OLD PSYCHOSES: The reduction in the symptomatology often permits a reduction in the doses and the relay to atypical neuroleptics with improved tolerance. FOR DELUSIONS OCCURRING LATE IN LIFE: The treatment will be adjusted to the etiology of the delusion: delirious states associated with dementia, thymus delusion, schizophrenic or non-schizophrenic psychosis, delusion related to cerebral-vascular disorders or to sensorial dysafferentation. One should note that emotional and delusional disorders are often concomitant in the elderly. THE TWO TREATMENT AXES: The first therapeutic element is non-pharmacological: reassurance or even brief psychotherapy, family counseling and prevention of enhancing, notably environmental, factors. The pharmacological element preferably includes atypical anti-psychotics, antidepressants in some cases together with anti-epileptics in cases of concomitant rebellious aggressiveness. In cases of dementia with cholinergic deficiency (Alzheimer, Lewy body dementia, mixed dementia) cholinesterase inhibitors have demonstrated their efficacy on the hallucinations. Advice for a pertinent strategy of action should be provided.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pancrazi</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de m&#xe9;decine et de g&#xe9;rontologie, CH de Courbevoie-Neuilly, 30, av. Kilford, 92401 Courbevoie. mp.pancrazi@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;tais</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les &#xe9;tats d&#xe9;lirants du sujet &#xe2;g&#xe9;. Modalit&#xe9;s th&#xe9;rapeutiques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="Y">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011614" MajorTopicYN="N">Psychotherapy, Brief</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12856535</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12849265</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Vascular cognitive impairment.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>98</EndPage><MedlinePgn>89-98</MedlinePgn></Pagination><Abstract><AbstractText>Cerebrovascular disease is the second most common cause of acquired cognitive impairment and dementia and contributes to cognitive decline in the neurodegenerative dementias. The current narrow definitions of vascular dementia should be broadened to recognise the important part cerebrovascular disease plays in several cognitive disorders, including the hereditary vascular dementias, multi-infarct dementia, post-stroke dementia, subcortical ischaemic vascular disease and dementia, mild cognitive impairment, and degenerative dementias (including Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies). Here we review the current state of scientific knowledge on the subject of vascular brain burden. Important non-cognitive features include depression, apathy, and psychosis. We propose use of the term vascular cognitive impairment, which is characterised by a specific cognitive profile involving preserved memory with impairments in attentional and executive functioning. Diagnostic criteria have been proposed for some subtypes of vascular cognitive impairment, and there is a pressing need to validate and further refine these. Clinical trials in vascular cognitive impairment are in their infancy but support the value of therapeutic interventions for symptomatic treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Institute for Aging and Health, Newcastle General Hospital, Newcastle upon Tyne, UK. j.t.obrien@ncl.ac.uk &lt;j.t.obrien@ncl.ac.uk&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erkinjuntti</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sawada</LastName><ForeName>Tohru</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pantoni</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bowler</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gorelick</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Rockwood</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>107</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12849265</ArticleId><ArticleId IdType="doi">10.1016/s1474-4422(03)00305-3</ArticleId><ArticleId IdType="pii">S1474442203003053</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12847557</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-563X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Season>Summer</Season></PubDate></JournalIssue><Title>CNS drug reviews</Title><ISOAbbreviation>CNS Drug Rev</ISOAbbreviation></Journal><ArticleTitle>Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.</ArticleTitle><Pagination><StartPage>159</StartPage><EndPage>186</EndPage><MedlinePgn>159-86</MedlinePgn></Pagination><Abstract><AbstractText>Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M(1) receptor agonist, and a potential new treatment for Alzheimer's disease. However, later in vitro and in vivo functional studies suggest that this compound is probably better described as a subtype selective M(1)/M(4) muscarinic receptor agonist. This subtype selectivity profile has been claimed to explain the limited classical cholinomimetic side effects, particularly gastrointestinal, seen with xanomeline in animals. However, in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline and in the patient population this led to a &gt;50% discontinuation rate. Clearly, the preclinical studies have not been able to predict this adverse profile of xanomeline, and this suggests that either xanomeline is not as subtype selective as predicted from preclinical research or that there are differences between humans and animals with regard to muscarinic receptors. Nevertheless, in Alzheimer's patients xanomeline dose-dependently improves aspects of behavioral disturbance and social behavior including a reduction in hallucinations, agitation, delusions, vocal outbursts and suspiciousness. The effects on cognition are not as robust and mainly seen at the highest doses tested. These effects in Alzheimer's patients have given impetus to the suggestion that muscarinic agonists have potential antipsychotic effects. The current review assesses the antipsychotic profile of xanomeline within the framework of the limited clinical studies with cholinergic agents in man, and the preclinical research on xanomeline using various models commonly used for the assessment of new antipsychotic drugs. In general, xanomeline has an antipsychotic-like profile in various dopamine models of psychosis and this agrees with the known interactions between the cholinergic and dopaminergic systems in the brain. Moreover, current data suggests that the actions of xanomeline at the M(4) muscarinic receptor subtype might mediate its antidopaminergic effects. Particularly intriguing are studies showing that xanomeline, even after acute administration, selectively inhibits the firing of mesolimbic dopamine cells relative to dopamine cell bodies projecting to the striatum. This data suggest that xanomeline would have a faster onset of action compared to current antipsychotics and would not induce extrapyramidal side effects. The preclinical data on the whole are promising for an antipsychotic-like profile. If in a new formulation (i.e., transdermal) xanomeline has less adverse effects, this drug may be valuable in the treatment of patients with psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>Naheed R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, NeuroSearch A/S, 93 Pederstrupvej, Ballerup, Denmark. max@neurosearch.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Robin G</ForeName><Initials>RG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Drug Rev</MedlineTA><NlmUniqueID>9514898</NlmUniqueID><ISSNLinking>1080-563X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9ORI6L73CJ</RegistryNumber><NameOfSubstance UI="C075257">xanomeline</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013830" MajorTopicYN="N">Thiadiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12847557</ArticleId><ArticleId IdType="pmc">PMC6741650</ArticleId><ArticleId IdType="doi">10.1111/j.1527-3458.2003.tb00247.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol 1995;65:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">7872138</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 1997;11:450&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolomeo AC, Morris H, Buccafusco JJ, et al. The preclinical pharmacological profile of WAY&#x2010;132983, a potent M1 preferring agonist. J Pharmacol Exp Ther 2000;292:584&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">10640295</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsall NJM, Nathanson NM, Schwartz, RD. Muscarinic receptors: It's a knockout. Trends Pharmacol Sci 2001;22:215&#x2013;219.</Citation></Reference><Reference><Citation>Blaha CD, Winn P. Modulation of dopamine efflux in the striatum following cholinergic stimulation of the substantia nigra in intact and pedunculopontine tegmental nucleus&#x2010;lesioned rats. J Neurosci 1993;13:1035&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576613</ArticleId><ArticleId IdType="pubmed">8441002</ArticleId></ArticleIdList></Reference><Reference><Citation>Blandini F, Greenamyre JT, Nappi G. The role of glutamate in the pathophysiology of Parkinson's disease. Funct Neurol 1996;11:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8936453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Offen WW, Shannon HE, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11 (Suppl 4): S16&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations. Ann Neurol 1980;7:329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7377758</ArticleId></ArticleIdList></Reference><Reference><Citation>Borda T, Perez RR, Joensen L, Gomez RM, Sterin&#x2010;Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: Molecular interaction. J Immunol 2002;168:3667&#x2013;3674.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907133</ArticleId></ArticleIdList></Reference><Reference><Citation>Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">693742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48 (Suppl6): S10&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Butkerait P, Friedman E. Scopolamine modulates apomorphine&#x2010;induced behavior in rats treated with haloperidol or SCH 23390. Eur J Pharmacol 1988;148:269&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897925</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet; 2002;359:1283&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11965273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Carter PA, Peters SC, et al. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 1998;795:179&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Calligaro DO, Falcone JF. Arachidonic acid release in cell lines transfected with muscarinic receptors: A simple functional assay to determine response of agonists. Cell Signal 1999;11:405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Shannon HE, Rasmussen K, et al. Potential role of muscarinic receptors in schizophrenia. Life Sci 1999;64:527&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">10069519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, Whitesitt CA, Shannon HE, et al. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997;40:158&#x2013;170.</Citation></Reference><Reference><Citation>Calabresi P, Lacey MG, North RA. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording. Br J Pharmacol 1989;98:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854679</ArticleId><ArticleId IdType="pubmed">2804543</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 1994;380 (Suppl): 14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman CA, Yeomans JS, Blaha CD, Blackburn JR. Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience 1997;76:177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8971770</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564520</ArticleId><ArticleId IdType="pubmed">6135762</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopoulos A, El Fakahany EE. Novel persistent activation of muscarinic M1 receptors by xanomeline. Eur J Pharmacol 1997;334:R3&#x2013;R4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9346340</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopoulos A, Pierce TL, Sorman JL, El Fakahany EE. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol Pharmacol 1998;53:1120&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9614217</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopoulos A, Parsons AM, El Fakahany EE. Pharmacological analysis of the novel mode of interaction between xanomeline and the muscarinic acetylcholine receptor. J Pharmacol Exp Ther 1999;289:1220&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornpropst J, Occolowitz T, Shipley L. Metabolism of xanomeline, a candidate drug in the treatment of Alzheimer's disease, in rat and monkey. ISSX Proceedings of 5th N. American Meeting 1993;4:256.</Citation></Reference><Reference><Citation>Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H]AF&#x2010;DX 384 is reduced in the caudate&#x2010;putamen of subjects with schizophrenia. Life Sci 1999;64:1761&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">10353630</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook JM, Tomaskovic&#x2010;Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry 2000;48:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978721</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook JM, Tomaskovic&#x2010;Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001;158:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Behavioral and psychiatric symptoms associated with Huntington's disease. Adv Neurol 1995;65:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">7872139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: The bridging study. Eur J Clin Pharmacol 1995;48:421&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">8582458</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL and Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">146524</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M. Animal models of anxiety based on classical conditioning: The conditioned emotional response (CER) and the fear&#x2010;potentiated startle effect. Pharmacol Ther 1990;47:147&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2203068</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Muscarinic1 and 2 receptor mRNA in the human caudate&#x2010;putamen: No change in m1 mRNA in schizophrenia. Mol Psychiatry 2000;5:203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulnard R, Cotman C, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 2000;283:1007&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">10697060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 1991;256:727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">1994002</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver DL. Physostigmine and lithium response in the schizophrenia's. Am J Psychiatry 1981;138:1078&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">7258385</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001;22:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11479003</ArticleId></ArticleIdList></Reference><Reference><Citation>Farde L, Suhara T, Halldin C, et al. PET study of the M1&#x2010;agonists [11C]xanomeline and [11C]butylthio&#x2010;TZTP in monkey and man. Dementia 1996;7:187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835881</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster GL, Blaha CD. Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 2000;12:3596&#x2013;3604.</Citation><ArticleIdList><ArticleId IdType="pubmed">11029630</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894570</ArticleId></ArticleIdList></Reference><Reference><Citation>Futami T, Takakusaki K, Kitai ST. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci Res 1995;21:331&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">7777224</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Rill E, Biedermann JA, Chambers T, et al. Mesopontine neurons in schizophrenia. Neuroscience 1995;66:321&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477875</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor&#x2010;deficient mice. Proc Natl Acad Sci USA 2001;98:15312&#x2013;15317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65026</ArticleId><ArticleId IdType="pubmed">11752469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlcah J, Casey DE. Drug treatment of schizophrenia: Myths and realities. Curr Opin Psychiatry 1994;7:65&#x2013;70.</Citation></Reference><Reference><Citation>Gillespie T, Bonate P, Cornpropst J, DeLong A, Shipley L. Electrospray MS and MS/MS for the metabolite identification in various animal and human biotransformation studies. Presentation af 41st ASMS Conf on MS , San Francisco , CA ;1994.</Citation></Reference><Reference><Citation>Gomeza J, Zhang L, Kostenis E, et al. Enhancement of D1 dopamine receptor&#x2010;mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999;96:10483&#x2013;10488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17915</ArticleId><ArticleId IdType="pubmed">10468635</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999;96:1692&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15563</ArticleId><ArticleId IdType="pubmed">9990086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronier B, Perry KW, Rasmussen K. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology (Berl) 2000;147:347&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan JJ, Tonnaer JA, Rijk H, Broekkamp CL, van Delft AM. Facilitation of amphetamine&#x2010;induced rotation by muscarinic antagonists is correlated with M2 receptor affinity. Brain Res 1987;410:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3580900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmo ME, Bower JM. Acetylcholine and memory. Trends Neurosci 1993;16:218&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">7688162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann N, Lanct&#xf4;t KL, Naranjo, CA. Behavioral disorders in demented elderly patients. CNS Drugs 1996;6 (4): 280&#x2013;300.</Citation></Reference><Reference><Citation>Hernandez&#x2010;Lopez S, Gongora&#x2010;Alfaro JL, Martinez&#x2010;Fong D, Rosales MG, Aceves J. Cholinergic stimulation of rostral and caudal substantia nigra pars compacta produces opposite effects on circling behavior and striatal dopamine release measured by brain microdialysis. Neuroscience 1994;62:441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">7830890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 1995;120:128&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">7480543</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt DJ, Herman MM, Hyde TM, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999;94:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10613493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486563</ArticleId><ArticleId IdType="pubmed">8795611</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowsky DS, El&#x2010;Yousef MK, Davis JM, Sekerke HJ. Antagonists effects of physostigmine and methylphenidate in man. Am J Psychiatry 1973;130:1370&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">4754682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Shannon HE. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 2000;294:1017&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">10945854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment&#x2010;resistant schizophrenics. Psychopharmacol Bull 1988;24:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">3290950</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczmar AG, Richardson DL. Cholinergic mechanisms, schizophrenia and neuropsychiatric adaptive dysfunctions In: Singh MM, Warburton DM, Lal H, Eds. Central cholinergic mechanisms and adaptive dysfunctions. New York : Plenum Press, 1984:193&#x2013;221.</Citation></Reference><Reference><Citation>Karoum F, Egan MF. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: A comparison of acute clozapine and haloperidol. Br J Pharmacol 1992;105:703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1908433</ArticleId><ArticleId IdType="pubmed">1628156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer D. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9 (Suppl 2): 8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9718229</ArticleId></ArticleIdList></Reference><Reference><Citation>Kofman O, McGlynn SM, Olmstead MC, Yeomans JS. Differential effects of atropine, procaine and dopamine in the rat ventral tegmentum on lateral hypothalamic rewarding brain stimulation. Behav Brain Res 1990;38:55&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">2346616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey MG, Calabresi P, North RA. Muscarine depolarizes rat substantia nigra zona compacta and ventral tegmental neurons in vitro through M1&#x2010;like receptors. J Pharmacol Exp Ther 1990;253:395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">2329522</ArticleId></ArticleIdList></Reference><Reference><Citation>Laruelle M, Abi&#x2010;Dargham A. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 1999;13:358&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667612</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AI. Immunological localization of m1&#x2010;m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993;52:441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">8441326</ArticleId></ArticleIdList></Reference><Reference><Citation>Loudon JM, Bromidge SM, Brown F, et al. SB 202026: A novel muscarinic partial agonist with functional selectivity for M 1 receptors. J Pharmacol Exp Ther 1997;283:1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas R, Heaton J, Carter G, Satterwhite J. Single and multiple dose safety, pharmacodynamics and pharmacokinetics of xanomeline, a novel muscarinic M1 agonist, in healthy male subjects. Neuropsychopharmacology 1994;10 (Suppl 3, Part 2): 117&#x2013;114.</Citation></Reference><Reference><Citation>Luebke JI, McCarley RW, Greene RW. Inhibitory action of muscarinic agonists on neurons in the rat laterodorsal tegmental nucleus in vitro. J Neurophysiol 1993;70:2128&#x2013;2135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8294974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur A, Shandarin A, LaViolette SR, Parker J, Yeomans JS. Locomotion and stereotypy induced by scopolamine: Contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Res 1997;775:144&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9439838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD. Tremulous jaw movements produced by acute tacrine administration: Possible relation to parkinsonian side effects. Pharmacol Biochem Behav 1997;56:273&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">9050085</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina A, Bodick N, Goldberger AL, Mac MM, Lipsitz LA. Effects of central muscarinic&#x2010;1 receptor stimulation on blood pressure regulation. Hypertension 1997;29:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052903</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus&#x2010;dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001;21:5239&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore H, Fadel J, Sarter M, Bruno JP. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 1999;88:811&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">10363819</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224268</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller JL. Love potions and the ointment of witches: Historical aspects of the nightshade alkaloids. J Toxicol Clin Toxicol 1998;36:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">9776969</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AT, Kasper SC, Gillespie TA, DeLong AF. Determination of xanomeline and active metabolite, N&#x2010;desmethylxanomeline, in human plasma by liquid chromatography&#x2010; atmospheric pressure chemical ion&#x2010;izationmass spectrometry. J Chromatogr B Biomed Appl 1995;668:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">7581862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CL, Sarter M, Bruno JP. Repeated pretreatment with amphetamine sensitizes increases in cortical acetylcholine release. Psychopharmacology (Berl) 2000;151:406&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">11026747</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer H, Sundland DM and Gershon S. Sernyl, ditran, and their antagonists: Succinate and THA. Int J Neuropsych 1966;2:216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">5336046</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer H, Sundland D and Gershon S. Ditran and its antagonists in a mixed psychiatric population. J Nerv Ment Dis 1966;142:256&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">5936310</ArticleId></ArticleIdList></Reference><Reference><Citation>Parada, MA , Parada MP, Hernandez L, Garcia F, Murzi E and Contreras Q. Clozapine&#x2010;induced acetylcholine release in the rat prefrontal cortex, nucleus accumbens and striatum does not develop tolerance. Prog Neuro-Psychopharmacol Biol Psychiat 1998;22:1379&#x2013;1397.</Citation></Reference><Reference><Citation>Parker GC, Rugg EL, Winn P. Cholinergic stimulation of substantia nigra: Abolition of carbachol&#x2010;induced eating by unilateral 6&#x2010;hydroxydopamine lesion of nigrostriatal dopamine neurones. Exp Brain Res 1991;87:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">1723691</ArticleId></ArticleIdList></Reference><Reference><Citation>Periyasamy S, Messer WS, Jr. , Roknich S, Sauerberg P, Hoss W. 1,2,5&#x2013;Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover. Brain Res 1995;693:118&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">8653399</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Perry RH. Acetylcholine and hallucinations: disease&#x2010;related compared to drug&#x2010;induced alterations in human consciousness. Brain Cogn 1995;28:240&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">8546852</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 2001;49:716&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer CA and Jenney EH. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 1957;66:753&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">13425257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard GT, Howard JL. Effects of drugs on punished behavior: Pre&#x2010;clinical test for anxiolytics. Pharmacol Ther 1990;45:403&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">1967842</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J Clin Psychiatry 1999;60:318&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen T, Sauerberg P, Nielsen EB, et al. Muscarinic receptor agonists decrease cocaine self&#x2010;administration rates in drug&#x2010;naive mice. Eur J Pharmacol 2000;402:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reever CM, Ferrari&#x2010;DiLeo G, Flynn DD. The M5 (m5) receptor subtype: fact or fiction Life Sci 1997;60:1105&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">9121354</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos&#x2010;like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">7965768</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson GS, Fibiger HC. Effects of olanzapine on regional C&#x2010;Fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">8822533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 1997;20:757&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">9406329</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: A model of parkinsonian tremor. Prog Neurobiol 1998;56:591&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9871939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarter M, Bruno JP. Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends Neurosci 1999;22:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 2000;95:933&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">10682701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerberg P, Larsen JJ, Falch E, Krogsgaard&#x2010;Larsen P. A novel class of conformationally restricted heterocyclic muscarinic agonists. J Med Chem 1986;29:1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">3712371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerberg P, Olesen PH, Nielsen S, et al. Novel functional M1 selective muscarinic agonists. Synthesis and structure&#x2010;activity relationships of 3&#x2010;(1,2,5&#x2010;thiadiazolyl)&#x2010;1,2,5,6&#x2010;tetrahydro&#x2010;1&#x2010;methylpyridines. J Med Chem 1992;35:2274&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pubmed">1613751</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerberg P, Jeppesen L, Olesen PH, et al. Muscarinic agonists with antipsychotic&#x2010;like activity: Structure&#x2010;activity relationships of 1,2,5&#x2010;thiadiazole analogues with functional dopamine antagonist activity. J Med Chem 1998;41:4378&#x2013;4384.</Citation><ArticleIdList><ArticleId IdType="pubmed">9784113</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerberg P, Jeppesen L, Olesen PH, et al. Identification of side chains on 1,2,5&#x2010;thiadiazole&#x2010;azacycles optimal for muscarinic m1 receptor activation. Bioorg Med Chem Lett 1998;8:2897&#x2013;2902.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873644</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheel&#x2010;Kr&#xfc;ger J. New aspects on the functional role of acetylcholine in the basal ganglia system. Interactions with other neurotransmitters In: Singh MM, Warburton DM, Lal H, Eds. Central cholinergic mechanisms and adaptive dysfunctions. New York : Plenum Press, 1984:105&#x2013;139.</Citation></Reference><Reference><Citation>Shannon HE, Bymaster FP, Calligaro DO, et al. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M 1 receptors. J Pharmacol Exp Ther 1994;269:271&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon HE, Hart JC, Bymaster FP, et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 1999;290:901&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411607</ArticleId></ArticleIdList></Reference><Reference><Citation>Magyar K, Szende B, Lengyel J, et al. The neuroprotective and neuronal rescue effects of (&#x2010;)&#x2010;deprenyl. J Neural Transm 1998;52 (Suppl): 109&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9564614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheardown MJ, Shannon HE, Swedberg MD, et al. M1 receptor agonist activity is not a requirement for muscarinic antinociception. J Pharmacol Exp Ther 1997;281:868&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152396</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipley L, Brown T, Cornpropst J. Plasma pharmacokinetics and balance excretion of 14C&#x2013;3&#x2010;(3&#x2010;hexyloxy&#x2010;1,2,5&#x2010;thiadiazol&#x2010;4&#x2010;yl)&#x2010;1,2,5,6&#x2010;tetrahydro&#x2010;1&#x2013;methyl&#x2010;pyridine in rats and rhesus monkeys. ISSX Proceedings, 4th N. American Meeting 1992;4:186.</Citation></Reference><Reference><Citation>Shipley L, Cornpropst J, Skaggs T, Brown T, Lindsay T, Gillespie T. Differences in the metabolism of xanomeline, a candidate drug in the treatment of Alzheimer's disease, in rat and monkey via oral and subcutaneous administration. 4th Int ISSX Meeting 1995;Abst. 271.</Citation></Reference><Reference><Citation>Singh MM, Kay SR. Pharmacology of central cholinergic mechanisms and schizophrenic disorders In: Singh MM, Warburton DM, Lal H, Eds. Central cholinergic mechanisms and adaptive dysfunctions. New York : Plenum Press, 1984:247&#x2013;308.</Citation></Reference><Reference><Citation>Sramek JJ, Cutler NR, Hurley DJ, Seifert RD. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7535938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995;35:800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">8522637</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanhope KJ, Mirza NR, Bickerdike MJ, et al. The muscarinic receptor agonist xanomeline has an antipsychotic&#x2010;like profile in the rat. J Pharmacol Exp Ther 2001;299:782&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602695</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel PW, Cohen ML. Low&#x2010;affinity M(2) receptor binding state mediates mouse atrial bradycardia: Comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. J Pharmacol Exp Ther 2001;296:818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181912</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: The role of newer antipsychotics. Drugs Aging 1999;14:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10069407</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J, Tamura R, Kadam D, Sanger T, Gannon KS and Tollefson GD. Olanzapine in the treatment of psychiatric disturbances associated with Alzheimer's disease 1999; Poster presented at the Annual meeting of the American Academy of Neurology, Toronto, Canada.</Citation></Reference><Reference><Citation>Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8297213</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow NR, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine&#x2010;treated rats: Similarities to clozapine. Psychopharmacology (Berl) 1994;114:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">7855231</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow NR, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine&#x2010;treated rats: Similarities to clozapine. Psychopharmacology (Berl) 1994;114:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">7855231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry 1999;Suppl:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double&#x2010;blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">9611669</ArticleId></ArticleIdList></Reference><Reference><Citation>Varty GB, Higgins GA. Examination of drug&#x2010;induced and isolation&#x2010;induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 1995;122:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">8711060</ArticleId></ArticleIdList></Reference><Reference><Citation>Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998;12:304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">9876958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JQ, McGinty JF. Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine&#x2010;treated rats. Neuroscience 1996;75:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JQ, McGinty JF. Intrastriatal injection of a muscarinic receptor agonist and antagonist regulates striatal neuropeptide mRNA expression in normal and amphetamine&#x2010;treated rats. Brain Res 1997;748:62&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9067445</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5&#x2010;HT1 and 5&#x2010;HT2 receptors. Br J Pharmacol 1998;125:1413&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565721</ArticleId><ArticleId IdType="pubmed">9884068</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson JM, Hunter AJ, Brown AM, Middlemiss DN. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. Eur J Pharmacol 1999;370:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10323282</ArticleId></ArticleIdList></Reference><Reference><Citation>White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221:1054&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">6136093</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn P. Cholinergic stimulation of substantia nigra: effects on feeding, drinking and sexual behaviour in the male rat. Psychopharmacology (Berl) 1991;104:208&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1876665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood MD, Murkitt KL, Ho M, et al. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol 1999;126:1620&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565933</ArticleId><ArticleId IdType="pubmed">10323594</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991;37:475&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Lamping KG, Duttaroy A, et al. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 2001;98:14096&#x2013;14101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61174</ArticleId><ArticleId IdType="pubmed">11707605</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001;410:207&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242080</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995;12:3&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7766284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeomans JS, Takeuchi J, Baptista M, et al. Brain&#x2010;stimulation reward thresholds raised by an antisense oligonucleotide for the M5 muscarinic receptor infused near dopamine cells. J Neurosci 2000;20:8861&#x2013;8867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773088</ArticleId><ArticleId IdType="pubmed">11102495</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeomans J, Forster G, Blaha C. M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci 2001;68:2449&#x2013;2456.</Citation><ArticleIdList><ArticleId IdType="pubmed">11392612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborszky L, Cullinan WE. Projections from the nucleus accumbens to cholinergic neurons of the ventral pallidum: A correlated light and electron microscopic double&#x2010;immunolabeling study in rat. Brain Res 1992;570:92&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">1617433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int Clin Psychopharmacol 1996;11:199&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng XP, Le F, Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997;321:349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9085047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knockout mice. J Neurosci 2002;22:1709&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758851</ArticleId><ArticleId IdType="pubmed">11880500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994;269:R1&#x2013;R2.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12837678</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Gatifloxacin precipitation of psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>470</StartPage><EndPage>471</EndPage><MedlinePgn>470-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Roy R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>L4618BD7KJ</RegistryNumber><NameOfSubstance UI="D000077734">Gatifloxacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001991" MajorTopicYN="N">Bronchitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="Y">Fluoroquinolones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077734" MajorTopicYN="N">Gatifloxacin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12837678</ArticleId><ArticleId IdType="pii">S1064-7481(12)61308-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12837670</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer disease: validity of the construct and response to risperidone.</ArticleTitle><Pagination><StartPage>414</StartPage><EndPage>425</EndPage><MedlinePgn>414-25</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors evaluated the efficacy of risperidone in reducing psychotic and aggressive symptoms in a subgroup of patients who fulfilled operationalized criteria for psychosis of dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Authors conducted a subgroup analysis of patients in the risperidone database arising from a previous double-blind, randomized, placebo-controlled study. In the primary study, patients age 55 or older, with a DSM-IV diagnosis of Alzheimer disease and/or vascular dementia were randomized to placebo or 0.5 mg, 1.0 mg, or 2.0 mg/day of risperidone. For this analysis, patients were selected who fulfilled operationalized criteria for psychosis of dementia. These criteria were then validated. The primary outcome measures were the newly developed Psychosis and Aggression Severity Indices, derived from Parts 1 and 2 of the BEHAVE-AD rating scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At Week 12 and endpoint, patients with psychosis of dementia receiving 1 mg or 2 mg/day of risperidone showed significantly more improvement on the Psychosis Severity and Aggressiveness Severity Indices than those receiving placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The construct of psychosis of dementia was validated, and the severity of both psychosis and aggressiveness was reduced with risperidone treatment in a robust and dose-related way, with a continuing response over the 12-week trial period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Southern California, Keck School of Medicine, Department of Psychiatry, Los Angeles, CA 90033, USA. sazen@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Ira R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sohee</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Napolitano</LastName><ForeName>Judy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Rick A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Azen</LastName><ForeName>Stanley P</ForeName><Initials>SP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 P50 AG5142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12837670</ArticleId><ArticleId IdType="pii">S1064-7481(12)61297-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12837669</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in Alzheimer disease: evidence for subtypes.</ArticleTitle><Pagination><StartPage>406</StartPage><EndPage>413</EndPage><MedlinePgn>406-13</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Psychotic symptoms in Alzheimer disease (AD) identify a phenotype with distinct neurobiology and genetic architecture. The authors investigated whether AD with psychosis is homogeneous or is a composite of subtypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Authors performed factor and cluster analyses of the psychotic-symptom items of the CERAD Behavioral Rating Scale in 188 probable and possible AD subjects who have displayed at least one psychotic symptom.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Exploratory factor analysis resulted in a one-factor solution that comprised misidentification delusions, auditory and visual hallucinations, and the misidentification of people. Persecutory delusions were also frequently present and were independent of the misidentification/hallucination factor. Cluster analysis yielded similar results.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Misidentification/hallucinations and persecutory delusions may identify two subtypes of psychosis in AD. Longitudinal study is needed to determine whether these proposed subtypes remain stable and independent over time or merge into a single group over the course of illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bacanu</LastName><ForeName>Silviu-Alin</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Perez-Madri&#xf1;an</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>Vishwajit L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12837669</ArticleId><ArticleId IdType="pii">S1064-7481(12)61296-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12837138</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1525-8610</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Journal of the American Medical Directors Association</Title><ISOAbbreviation>J Am Med Dir Assoc</ISOAbbreviation></Journal><ArticleTitle>Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.</ArticleTitle><Pagination><StartPage>183</StartPage><EndPage>188</EndPage><MedlinePgn>183-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the adverse events associated with the appropriate use of oral risperidone and oral olanzapine in long-term care patients with behavioral and psychotic disturbances associated with dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Observational analysis.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Analysis was performed at five consulting pharmacist sites across the United States. Participants were recruited at 89 skilled nursing facilities by consultant pharmacists who provided services at each site.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 730 men and women with dementia who had been residents of a skilled nursing facility for at least 90 days were included in the study. Alzheimer's disease was the primary diagnosis in 47% of patients.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were treated with risperidone &lt; or =2 mg/day or olanzapine &lt; or =10 mg/day for at least 90 days.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Targets for antipsychotic use included nonaggressive symptoms of psychosis and verbally and physically aggressive behaviors. The effects of risperidone and olanzapine were determined from progress notes, psychotropic monitoring forms, and physicians' order forms after 91 days of treatment. Adverse events of particular significance in the elderly population, including agitation/anxiety, laxative use, dry eyes, and falls, were collected from audited medical records. The evaluation period extended from 3 months before to 3 months after initiation of treatment with risperidone or olanzapine.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 474 patients in the risperidone group and 256 patients in the olanzapine group. Mean dosages of risperidone at Days 1 and 91 (0.7 +/- 0.3 mg/day and 1.0 +/- 0.5 mg/day, respectively) and olanzapine (3.3 +/- 1.4 mg/day and 4.7 +/- 2.1 mg/day, respectively) were at least 50% lower than the maximum dosages recommended by the Center for Medicare and Medicaid Services for elderly patients with psychosis or behavioral symptoms of dementia. The need for eye lubrication was minimal in both groups and did not differ significantly between them. Anxiolytic use decreased in the risperidone group and remained constant in the olanzapine group, with no significant difference between groups. In the olanzapine and risperidone groups, the number of patients with orders for laxatives increased 10.2% and 1.8%, respectively (P = 0.003), the mean number of days of laxative administration increased 19.1% and 4.3%, respectively (P &lt; 0.001), and the mean number of doses of laxative administered increased 14.2% and 4.1%, respectively (P = 0.001). Among patients qualifying for analysis, falls were recorded for 17.9% of patients receiving olanzapine and 6.9% receiving risperidone (P = 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among long-term care residents with dementia who received low doses of risperidone or olanzapine, the incidence of adverse events was low. When considering adverse events of particular concern in the elderly, specifically falls and laxative use, risperidone may be preferred over olanzapine in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Harlan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Creative Care Consulting, Clark, New Jersey 07066, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slyk</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Deymann</LastName><ForeName>Sheila</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cornacchione</LastName><ForeName>Mario J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Dir Assoc</MedlineTA><NlmUniqueID>100893243</NlmUniqueID><ISSNLinking>1525-8610</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Am Med Dir Assoc. 2003 Sep-Oct;4(5):290</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="Y">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008485" MajorTopicYN="N">Medical Audit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="Y">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012866" MajorTopicYN="N">Skilled Nursing Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014985" MajorTopicYN="N">Xerophthalmia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12837138</ArticleId><ArticleId IdType="doi">10.1097/01.JAM.0000073958.38462.60</ArticleId><ArticleId IdType="pii">S1525-8610(04)70343-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12817671</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0333-7308</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>The Israel journal of psychiatry and related sciences</Title><ISOAbbreviation>Isr J Psychiatry Relat Sci</ISOAbbreviation></Journal><ArticleTitle>Urethral masturbation and sexual disinhibition in dementia: a case report.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>72</EndPage><MedlinePgn>67-72</MedlinePgn></Pagination><Abstract><AbstractText>Urethral masturbation and sexual disinhibition as manifestations of behavioral and psychological symptoms of dementia (BPSD) are described in a 90-year-old patient who repeatedly self-inserted foreign bodies into his urethra. A diagnosis was made of late onset sexual disinhibition and hypersexuality in a patient with Dementia of the Alzheimer Type. Significant reduction of his sexual behavior was achieved with low doses of haloperidol. Similar symptoms are noted in Pick's disease, other fronto-temporal lesions, mania and following a seizure or treatment of Parkinson's disease, and have been described as Kluver-Busy-type. Clinicians should consider this diagnosis when investigating dysuria, cystitis, haematuria and urinary tract infections even in the very old.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Geriatric Medical Center, Shmuel Harofe Hospital, Beer-Yaakov, Tel Aviv University, Israel. mikiyoav@netvision.net.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkman</LastName><ForeName>Pinhas</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Shapira</LastName><ForeName>Adi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Israel</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Abramovitz</LastName><ForeName>Jancu</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Israel</Country><MedlineTA>Isr J Psychiatry Relat Sci</MedlineTA><NlmUniqueID>8108287</NlmUniqueID><ISSNLinking>0333-7308</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005547" MajorTopicYN="Y">Foreign Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="Y">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008418" MajorTopicYN="N">Masturbation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014521" MajorTopicYN="Y">Urethra</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12817671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12810496</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Dementia with Lewy bodies and the neurobehavioral decline of Mervyn Peake.</ArticleTitle><Pagination><StartPage>889</StartPage><EndPage>892</EndPage><MedlinePgn>889-92</MedlinePgn></Pagination><Abstract><AbstractText>Mervyn Peake (1911-1968) was an accomplished British artist, poet, novelist, and playwright. He was a prolific and talented illustrator and wrote hundreds of poems, 4 novels, and several plays. His exceptional career was prematurely ended by a neurodegenerative illness variously ascribed to Alzheimer disease, Parkinson disease, or postencephalitic parkinsonism. However, a detailed review of biographical accounts produces substantial evidence in support of a probable diagnosis of dementia with Lewy bodies, a clinical entity remaining undiagnosed outside specialty dementia clinics. Peake developed signs of parkinsonism and insidious cognitive decline during his fifth decade. A breakdown in his writing style has frequently been cited as reflecting his encroaching dementia. Visual hallucinations are portrayed in sketches, and together with paranoid delusions are apparent in poetry composed during his illness. His deterioration was progressive and punctuated by well-described episodes of confusion and psychosis. His occasional preservation of insight is poignantly captured in drawings of figures with dunce caps or pointed heads, often with expressions of fear and apprehension etched with an economy of strokes. Peake spent his final years in various psychiatric institutions but continued to exhibit lucid intervals even late into his illness. His tragic deterioration remained undiagnosed at the time, but in retrospect, his progressive dementia with parkinsonism, visual hallucinations, and marked cognitive fluctuations likely represents one of the earliest recognized historical cases of dementia with Lewy bodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahlas</LastName><ForeName>Demetrios J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Sunnybrook and Women's College Health Sciences Centre, Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada. dj.sahlas@sw.ca</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001154" MajorTopicYN="N">Art</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005197" MajorTopicYN="Y">Famous Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Peake</LastName><ForeName>Mervyn</ForeName><Initials>M</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12810496</ArticleId><ArticleId IdType="doi">10.1001/archneur.60.6.889</ArticleId><ArticleId IdType="pii">60/6/889</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12810495</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia.</ArticleTitle><Pagination><StartPage>884</StartPage><EndPage>888</EndPage><MedlinePgn>884-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer disease (AD) is characterized by memory and visuospatial deficits with relative sparing of personality. Mutations in 3 genes (presenilin 1 and 2 and amyloid precursor protein) are associated with presenile AD. Presenilin 1 gene mutations have not been described in African Americans.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied an African American family with autosomal dominant rapidly progressive dementia and psychosis occurring early in the fifth decade of life. We performed neurologic evaluations, psychometrics, and neuroimaging. We sequenced the amyloid precursor protein gene, presenilin 1 and 2, and tau in affected and unaffected family members. One patient underwent a brain biopsy and subsequent autopsy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Personality change, auditory and visual hallucinations, delusions, memory impairment, word-finding difficulties, and subsequent rigidity, dystonia, myoclonus, and mutism developed in 2 brothers. Neuropsychometric testing in one was consistent with frontotemporal dementia or atypical AD. Neuroimaging studies showed diffuse cortical involvement. A clinical diagnosis of familial non-Alzheimer dementia was made. However, results of temporal lobe biopsy in one revealed amyloid neuritic plaques, and autopsy results confirmed the diagnosis of AD. Gene sequencing revealed a presenilin 1 point mutation (M139V) cosegregating with the disease. A tau polymorphism in exon 7 (A178T) was found in an affected brother and unaffected relatives.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report the first documented presenilin mutation in African American patients presenting with early personality change, psychosis, and memory loss with preserved praxis. The M139V mutation can present differently between kindreds, with some features suggestive of a frontal lobe syndrome. The M139V mutation can lead to atypical AD, and genetic background may have a role in determining the phenotype of genetically defined AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rippon</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS01966-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2004 May;61(5):801. doi: 10.1001/archneur.61.5.801-a</RefSource><PMID Version="1">15148163</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12810495</ArticleId><ArticleId IdType="doi">10.1001/archneur.60.6.884</ArticleId><ArticleId IdType="pii">60/6/884</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12801159</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>99</EndPage><MedlinePgn>94-9</MedlinePgn></Pagination><Abstract><AbstractText>In this post hoc analysis of baseline responses to the CERAD Behavior Rating Scale for Dementia in a clinical trial of interventions for agitation in Alzheimer's disease (AD), the authors investigated the distribution of, and relationships between, agitation, depression, and psychosis in 148 individuals with AD. Prevalence of depressive symptoms was highest (78.4%), followed by agitation (77.6%) and psychotic symptoms (69.3%); 51.1% of the sample had symptoms in all 3 domains. Cross-sectionally, psychotic symptoms were most closely associated with Mini-Mental State Examination (MMSE) scores, while agitation was less so. Depressive symptoms were relatively consistently prevalent across MMSE levels. After controlling for the presence of agitated symptoms, psychosis and depression were significantly associated, but neither symptoms of psychosis nor of depression were associated with agitation when depression or psychosis, respectively, was controlled for. Significant psychopathological comorbidity should be considered in the design of clinical trials targeting particular psychopathology in this disease population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tractenberg</LastName><ForeName>Rochelle E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Center for Population and Health, Georgetown University, Washington, DC 20057-1197, USA. ret7@georgetown.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Marian B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Teri</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003155" MajorTopicYN="Y">Community Mental Health Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12801159</ArticleId><ArticleId IdType="mid">NIHMS683804</ArticleId><ArticleId IdType="pmc">PMC4418652</ArticleId><ArticleId IdType="doi">10.1177/0891988703016002006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers and caregivers. J Clin Psychiatry. 2001;62(suppl 21):3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Koss E, Wild KV, et al. Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer&#x2019;s Disease and Associated Disorders. 1996;10(1):20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8919493</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP. The interrelations between psychosis, behavioral disturbance, and depression in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Disease and Associated Disorders. 1999;13(suppl 2):S3&#x2013;S8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10622673</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1996;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Rozzini L, Gozzetti A, et al. Behavioral syndromes in Alzheimer&#x2019;s disease: description and correlates. Dement Geriatr Cogn Disord. 1999;10:130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard J-ME, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer&#x2019;s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tan MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin DB, Green CR, Schmeidler J, et al. Noncognitive disturbances in Alzheimer&#x2019;s disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc. 1997;45:1331&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack JL, Patterson MB, Tariot PN. The Behavior Rating Scale for Dementia (BRSD): development of test scales and presentation of data for 555 individuals with Alzheimer&#x2019;s disease. J Geriatr Psychiatry Neurol. 1999;12:211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616870</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Koss E, Patterson M, et al. A comparison of the Cohen-Mansfield Agitation Inventory with CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer&#x2019;s disease. J Psych Res. 1998;32:347&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">9844950</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in Alzheimer&#x2019;s disease patients: as randomized placebo controlled clinical trial. Neurology. 2000;55:1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, et al. The CERAD Behavioral Rating Scale for Dementia. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack JL, Patterson MB. Manual: CERAD behavior rating scale for dementia. 2. Durham, NC: Consortium to Establish a Registry for Alzheimer&#x2019;s Disease; 1996.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris SH, Mackell JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer&#x2019;s disease clinical trials: overview and general results. Alzheimer&#x2019;s Disease and Associated Disorders. 1997;11(suppl 2):S1&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236947</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI) Rockville, MD: Research Institute of the Hebrew Home of Greater Washington; 1991.</Citation></Reference><Reference><Citation>Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation and behavioral disturbance in community-dwelling persons with Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2002;14:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11884649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunik ME, Snow-Turek AL, Iqbal N, et al. Contribution of psychosis and depression to behavioral disturbances in geropsychiatric inpatients with dementia. J Gerontology Medical Sciences. 1999;54A:M157&#x2013;M161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10191845</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz AG, Teri L. Depression, cognition, and functional ability in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc. 1994;42(2):186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tractenberg RE, Gamst A, Weiner MF, et al. Frequency of behavioral symptoms characterizes agitation in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2001;16:886&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373072</ArticleId><ArticleId IdType="pubmed">11571769</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF. Clinical diagnosis of cognitive function and dementing illness. In: Weiner MF, Lipton AM, editors. The dementias: diagnosis, treatment and research. 3. Washington, DC: American Psychiatric Publishers; 2003. pp. 49&#x2013;76.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12800962</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-838X</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2003</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>American family physician</Title><ISOAbbreviation>Am Fam Physician</ISOAbbreviation></Journal><ArticleTitle>Use of atypical antipsychotic drugs in patients with dementia.</ArticleTitle><Pagination><StartPage>2335</StartPage><EndPage>2340</EndPage><MedlinePgn>2335-40</MedlinePgn></Pagination><Abstract><AbstractText>Increasingly, atypical antipsychotic drugs are prescribed for elderly patients with symptoms of psychosis and behavioral disturbances. These symptoms often occur in patients with Alzheimer's disease, other dementias, or Parkinson's disease. As the average age of Americans increases, the prevalence of Alzheimer's disease and Parkinson's disease will rise accordingly. Although nonpharmacologic treatments for behavioral disturbances should be tried first, medications often are needed to enable the patient to be adequately cared for. Current guidelines recommend using risperidone and olanzapine to treat psychosis in patients with Alzheimer's dementia. Quetiapine and clozapine are recommended for treatment of psychosis in patients with Parkinson's disease. Additional research is needed for a recently approved agent, ziprasidone. To minimize side effects, these medications should be started at low dosages that are increased incrementally. Drug interactions, especially those involving the cytochrome P450 system, must be considered. Clozapine's potentially lethal side effects limit its use in the primary care setting. Informed use of atypical antipsychotic drugs allows family physicians to greatly improve quality of life in elderly patients with dementia and behavior disturbances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Motsinger</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Andrews Air Force Base, Maryland, USA. charles.motsinger@osan.af.mil</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perron</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Lacy</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Fam Physician</MedlineTA><NlmUniqueID>1272646</NlmUniqueID><ISSNLinking>0002-838X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am Fam Physician. 2004 Aug 1;70(3):447-8.</RefSource><PMID Version="1">15317432</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12800962</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12766913</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Visuospatial impairment in dementia with Lewy bodies and Alzheimer's disease: a process analysis approach.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>391</EndPage><MedlinePgn>387-91</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reports of differential impairments on visual-construction tasks in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are sometimes controversial, whereas visual-perceptual data are lacking. The existence of different clinical sub-groups of DLB has been hypothesized to explain the discrepancies among the cognitive results. The goal of this study was to compare the visual-perceptual performance of subjects with DLB with predominant psychosis, DLB with predominant parkinsonian features and AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a cross-sectional neuropsychological study with between diagnostic group comparisons. The Benton Judgement Line Orientation (BJLO) test was administered to four DLB patients with predominant psychosis (DLB-psy), four DLB subjects with predominant parkinsonian features (DLB-PD), and 13 patients with AD. An analysis of error types was applied to the results of the BJLO with QO1, QO2, QO3, QO4 (visual attention) errors, as well as VH, IQO, IQOV, and IQOH (visual-spatial perception) errors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A MANOVA showed significant differences between the DLB, and AD groups on the number of VH (F = 6.049, df = 1,19, p = 0.024), IQOH (F = 4.645, df = 1,19, p = 0.044) and QO1 (F = 4.491, df = 1,19, p = 0.047) errors, but no difference on the total score of the BJLO. Another MANOVA and post hoc Student-Newman-Keuls analyses demonstrated that the DLB-psy sub-group made significantly more VH and IQOH errors than AD and the DLB-PD subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subjects with DLB and psychosis have more severe visual-perception (VH errors) impairments than subjects with DLB and predominant parkinsonian features, and AD subjects.</AbstractText><CopyrightInformation>Copyright 2003 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Program, Centre for Addiction and Mental Health, Toronto, Canada. Martine_Simard@camh.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Reekum</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Myran</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000377" MajorTopicYN="N">Agnosia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007600" MajorTopicYN="N">Judgment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12766913</ArticleId><ArticleId IdType="doi">10.1002/gps.839</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12764897</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0032-5481</ISSN><JournalIssue CitedMedium="Print"><Volume>113</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>Postgraduate medicine</Title><ISOAbbreviation>Postgrad Med</ISOAbbreviation></Journal><ArticleTitle>Defining diffuse Lewy body disease. Tetrad of symptoms distinguishes illness from other dementias.</ArticleTitle><Pagination><StartPage>71</StartPage><EndPage>3</EndPage><MedlinePgn>71-5; quiz 3</MedlinePgn></Pagination><Abstract><AbstractText>It is an ageless principle in medicine that physicians cannot diagnose and treat an illness they do not recognize. In the past two decades, we have come to recognize the classic clinical picture of diffuse Lewy body disease. Once primary care physicians understand this challenging disorder, they are in an ideal position to identify and manage it. As with many dementing illnesses and other medical conditions, diffuse Lewy body disease is not curable, but much can be done to improve the quality of life of patients and their family.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Jonathan T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>University of South Florida College of Medicine, Tampa, USA. jonathan.stewart@med.va.gov</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Postgrad Med</MedlineTA><NlmUniqueID>0401147</NlmUniqueID><ISSNLinking>0032-5481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075202" MajorTopicYN="N">Contraindications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>20</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12764897</ArticleId><ArticleId IdType="doi">10.3810/pgm.2003.05.1408</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12740595</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-4184</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>392</EndPage><MedlinePgn>383-92</MedlinePgn></Pagination><Abstract><AbstractText>Though efforts to identify the genetic etiology of Alzheimer disease (AD) have made substantial progress, to date only some of the genes contributing to AD risk have been identified. Utilization of more etiologically homogeneous subphenotypes represents one strategy to facilitate the identification of novel risk genes in complex disorders. In this review, we evaluate the hypothesis that psychotic symptoms, such as delusions and hallucinations, define a suitable subphenotype in AD patients for gene-mapping efforts. Psychotic symptoms occur in 40-60% of patients with AD and are associated with more severe cognitive deficits and a more rapidly deteriorating course. The presence of psychotic symptoms in AD confers increased risk of similar symptoms to affected siblings. Candidate gene association analyses and initial linkage analysis have yielded significant results. We discuss possible genetic models of psychotic symptoms in AD, and suggest strategies for further investigation. Identification of such genetic factors may facilitate gene-mapping studies for both AD and idiopathic psychoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15231, USA. sweetra@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-43693</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-49671</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>184</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId><ArticleId IdType="doi">10.1038/sj.mp.4001262</ArticleId><ArticleId IdType="pii">4001262</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12727688</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>857</StartPage><EndPage>866</EndPage><MedlinePgn>857-66</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This report provides a description of the prevalence and clinical features of the major depressive syndrome of Alzheimer's disease using data derived from structured diagnostic assessments of 243 patients with probable Alzheimer's disease and 151 nondemented elderly comparison subjects.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects were characterized by a consortium of four Alzheimer's disease research centers and the Geriatric Psychiatry Branch of the National Institute of Mental Health. All sites administered the Clinical Assessment of Depression in Dementia, a structured, anchored diagnostic interview that was developed to reliably diagnose and characterize major depressive episodes in this population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Despite the use of a common, reliable methodology for the assessment and diagnosis of major depressive episodes, the prevalence of major depression in Alzheimer's disease ranged widely from 22.5% to 54.4% across the recruitment sites. The prevalence of major depressive episodes among Alzheimer's disease patients in the aggregate sample exceeded that for elderly comparison subjects and reached nearly 50% among the most severely demented patients. Alzheimer's disease patients with a current major depressive episode had earlier mean ages at onset, a higher mean Hamilton Depression Rating Scale score, and were more likely to be experiencing psychotic symptoms than those who had not developed a major depressive episode. Although the major depressive episodes of Alzheimer's disease patients and nondemented elderly comparison subjects included similar numbers of depressive symptoms, patients with Alzheimer's disease were more likely to report a diminished ability to concentrate or indecisiveness and less likely to experience sleep disturbances and feelings of worthlessness or excessive guilt during their major depressive episodes. None of the clinical features of major depression differed significantly in frequency among depressed Alzheimer's disease patients with mild, moderate, or severe dementia. Concurrent psychotic symptoms progressively increased with dementia severity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The high rate of major depressive episodes that occur after the onset of cognitive impairment among patients with Alzheimer's disease (the majority of whom had no premorbid history of major depression), common emergence in the early stages of dementia when symptoms of cognitive impairment are least likely to contribute to the syndromal diagnosis of major depression, and differences in the clinical presentations of the major depressive episodes of Alzheimer's disease patients and nondemented elderly comparison subjects, all support the validity of the major depressive syndrome of Alzheimer's disease. Our findings suggest that the major depressive syndrome of Alzheimer's disease may be among the most common mood disorders of older adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zubenko</LastName><ForeName>George S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Room E1230, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. zubenkog@pitt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zubenko</LastName><ForeName>Wendy N</ForeName><Initials>WN</Initials></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Spoor</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Deborah B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Glenn E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Sunderland</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 00540</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH/AG 47346</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2003 May;160(5):811-4. doi: 10.1176/appi.ajp.160.5.811</RefSource><PMID Version="1">12727680</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12727688</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.160.5.857</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12716263</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>242</EndPage><MedlinePgn>235-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In vivo proton magnetic resonance spectroscopy is a safe and noninvasive tool that can be used to study aspects of brain chemistry and metabolism. This study was designed to evaluate its role in routine application to reveal the diagnostic reasons for cognitive impairment.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">37 Alzheimer's disease patients (NINCDS-ADRDA criteria), 31 patients with subcortical ischemic vascular dementia (Chui et al. criteria), and 13 subjects with subjective cognitive impairment (DSM-IV criteria) were included in this retrospective study. Magnetic resonance images were used for atrophy rating; additionally, proton magnetic resonance spectroscopy was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly reduced N-acetylaspartate levels (p &lt;.05) were found in both patients with Alzheimer's disease and patients with subcortical ischemic vascular dementia compared to the group with subjective memory complaints. The ratios of N-acetylaspartate/creatine and N-acetylaspartate/myo-inositol were significantly lower in Alzheimer's disease patients compared to patients with vascular dementia (p =.012) or patients with subjective memory impairment (p =.002). N-acetylaspartate/creatine and N-acetylaspartate/myo-inositol ratios were positively correlated to the degree of cerebral atrophy. Disoriented patients displayed a low N-acetylaspartate/creatine ratio. In contrast, we were not able to relate concurrent psychotic or behavioral symptoms to any spectroscopic parameter.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study indicates that proton magnetic resonance spectroscopy parameters could provide additional information in differentiating between Alzheimer's disease, subcortical ischemic vascular dementia, and subjective cognitive impairment. Therefore, this method can contribute to the routine diagnosis of dementia. Psychiatric and behavioral symptoms associated with dementia or due to a major psychiatric disorder cannot be related to changes in the measured proton magnetic resonance spectroscopy parameters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacher</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vonbank</LastName><ForeName>Herbert</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kemmler</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lingg</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marksteiner</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>MU72812GK0</RegistryNumber><NameOfSubstance UI="D003401">Creatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003401" MajorTopicYN="N">Creatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12716263</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0303</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12700711</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0893-133X</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.</ArticleTitle><Pagination><StartPage>1168</StartPage><EndPage>1175</EndPage><MedlinePgn>1168-75</MedlinePgn></Pagination><Abstract><AbstractText>Xanomeline is a muscarinic M(1)/M(4) preferring receptor agonist with little or no affinity for dopamine receptors. The compound reduces psychotic-like symptoms in patients with Alzheimer's disease and exhibits an antipsychotic-like profile in rodents without inducing extrapyramidal side effects (EPS) at therapeutically relevant doses. In the present study, we examined whether the xanomeline-induced functional dopamine antagonism found in rodent studies could also be observed in nonhuman primates. In addition, we studied whether the lack of EPS observed in rodents also applies to primates. To this end, we investigated the effects of xanomeline on the behavior induced by D-amphetamine and (-)-apomorphine in drug-naive Cebus apella monkeys. Antipsychotic compounds antagonize amphetamine-induced motor unrest and stereotypies in this species. Xanomeline inhibited D-amphetamine-induced motor unrest, stereotypies and arousal as well as apomorphine-induced stereotypies and arousal in drug-naive Cebus apella monkeys. Xanomeline did not induce EPS but vomiting occurred in some monkeys at high doses, in accordance with emetic events observed in Alzheimer patients following xanomeline administration. Even when xanomeline was tested in EPS-sensitized Cebus apella monkeys, EPS were not observed at the dose range of xanomeline used in the D-amphetamine-apomorphine combination study (0.5-3 mg/kg). However, when xanomeline was tested at 4 mg/kg, moderate dystonia was seen in two out of three monkeys. It is concluded that xanomeline inhibits D-amphetamine- and (-)-apomorphine-induced behavior in Cebus apella monkeys at doses that do not cause EPS. These data further substantiate that muscarinic receptor agonists may be useful in the pharmacological treatment of psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Maibritt B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Research Institute of Biological Psychiatry, Sct. Hans Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink-Jensen</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Peacock</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gerlach</LastName><ForeName>Jes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lundbaek</LastName><ForeName>Jens August</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Werge</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043588">Receptor, Muscarinic M4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9ORI6L73CJ</RegistryNumber><NameOfSubstance UI="C075257">xanomeline</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002428" MajorTopicYN="N">Cebus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043588" MajorTopicYN="N">Receptor, Muscarinic M4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013830" MajorTopicYN="N">Thiadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12700711</ArticleId><ArticleId IdType="doi">10.1038/sj.npp.1300151</ArticleId><ArticleId IdType="pii">1300151</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12677553</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0720-4299</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>204</EndPage><MedlinePgn>199-204</MedlinePgn></Pagination><Abstract><AbstractText>The course of behavioural and psychotic features of patients with Alzheimer's disease treated with an inhibitor of the acetylcholinesterase (rivastigmine), and their association to cognitive impairment is presented in the study. Standardized examination of global functional deterioration (GDS), cognitive impairment (MMSE) and behavioural or psychotic symptoms (Behave-AD) were performed over two years. We could analyse the complete data from 44 of initially 91 patients with mild to moderate Alzheimer's disease. The cognitive component (measured by MMSE, ADAS-cog) and the functional assessment (GDS) showed a continuous decline after a one year period of stabilization, in contrast with behavioural and psychotic symptoms, especially delusions, which still improved after treatment of two years. While cognitive items in correlation with functional aspects formed a homogeneous factor over the two-year period, psychotic features displayed more variability over time evaluated by factor analysis. Nevertheless mood and anxiety disorder in combination with aggressive behaviour as well as hallucinations formed an independent factor in the course of Alzheimer's disease. In addition to other studies of the course of Alzheimer's disease we could demonstrate that distinct behavioural and psychotic symptoms may also present as independent factors in Alzheimer patients under constant treatment conditions with an inhibitor of the acetylcholinesterase (rivastigmine).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wobrock</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Arbeitsgruppe Gerontopsychiatrie, Universit&#xe4;ts-Nervenklinik und Poliklinik - Psychiatrie und Psychotherapie, Universit&#xe4;tskliniken des Saarlandes, Homburg/Saar. thomas.wobrock@uniklinik-saarland.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Retz-Junginger</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Retz</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Supprian</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>R&#xf6;sler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Auspr&#xe4;gung, Stabilit&#xe4;t und Muster kognitiver und nicht kognitiver Symptome bei Patienten mit Alzheimer-Demenz. Verlaufsbeobachtungen &#xfc;ber zwei Jahre unter konstanten Behandlungsbedingungen mit Rivastigmin.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="Y">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12677553</ArticleId><ArticleId IdType="doi">10.1055/s-2003-38509</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12647432</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>6 Suppl</Issue><PubDate><Year>2002</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Acetylcholinesterase inhibitors--beyond Alzheimer's disease].</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>141</EndPage><MedlinePgn>133-41</MedlinePgn></Pagination><Abstract><AbstractText>Based on a literature review, the application of Acetylcholinesterase inhibitors, IAchE (donepezil, rivastigmine, galantanine) in the treatment of various illnesses which have cholinergic system disability and dementia in their course--(dementia with Lewy bodies, vascular dementia, Parkinson's disease, Multiple Sclerosis, Down Syndrome), delirium symptoms (e.g. Korsakoff psychosis), hyperkinesis, attention and memory disorders--is presented. Promising results in the treatment of late dyskinesias, in schizophrenia with impaired cognitive function, as well as in the additional treatment of various psychotic states are noted. It should be stressed that in Poland, the IAchE have been approved only in the treatment of slight to moderate dementia in the course of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>I Klinika Psychiatryczna Katedry Psychiatrii AM w &#x141;odzi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Inhibitory acetylocholinesterazy--nie tylko w chorobie Alzheimera.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020915" MajorTopicYN="N">Korsakoff Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="Y">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>37</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>22</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>22</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12647432</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12636179</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>14 Suppl 1</Volume><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The ABC of Alzheimer's disease: behavioral symptoms and their treatment.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>49</EndPage><MedlinePgn>27-49</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) are a common manifestation of Alzheimer's disease (AD) and other dementia syndromes. Patients experience prominent and multiple symptoms, which are both distressing and a source of considerable social, health, and economic cost. Development of symptoms is in part related to progressive neurodegeneration and cholinergic deficiency in brain regions important in the regulation of behavioral and emotional responses including the cortex, hippocampus, and limbic system. Cholinesterase (ChE) inhibitors offer a mechanism-based approach to therapy to enhance endogenous cholinergic neurotransmission. Studies using ChE inhibitors have demonstrated their clear potential to improve or stabilize existing BPSD. Differences have been noted between selective acetylcholinesterase (AChE) inhibitors (donepezil and galantamine) and dual ChE inhibitors (rivastigmine) in terms of treatment response. While donepezil has shown efficacy in moderate to severe noninstitutionalized AD patients, conflicting results have been obtained in mild to moderate patients and in nursing home patients. Galantamine has been shown to delay the onset of BPSD during a five-month study but has been otherwise poorly studied to-date. Both donepezil and galantamine have not as yet demonstrated efficacy in reducing psychotic symptoms or in reducing levels of concomitant psychotropic medication use. Studies with the dual ChE inhibitor rivastigmine in mild to moderately severe AD and in Lewy body dementia (LBD) have shown improvements in behavioral symptoms including psychosis. Improvements have been maintained over a period of up to two years. In addition, institutionalized patients with severe AD have shown symptomatic benefits with a reduction in the requirement for additional psychotropic drugs following treatment with rivastigmine. The psychotropic properties associated with rivastigmine may in part be mediated through effects on butyrylcholinesterase. Current treatment options are limited for patients with dementia syndromes other than AD. However, data concerning rivastigmine in patients with LBD and preliminary studies in Parkinson's disease dementia and vascular dementia suggest a role for ChE inhibitors across the spectrum of dementia syndromes. Finally, studies that incorporated a delayed start design demonstrate that ChE inhibitors may delay the progression of BPSD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grossberg</LastName><ForeName>George T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Saint Louis University School of Medicine, St. Louis, Missouri 63104, USA. grossbgt@slu.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>130</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>15</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>15</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12636179</ArticleId><ArticleId IdType="doi">10.1017/s1041610203008652</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12633121</PMID><DateCompleted><Year>2003</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>143</EndPage><MedlinePgn>134-43</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Elderly patients with a DSM-IV diagnosis of dementia of the Alzheimer's type, vascular dementia, or a combination of the 2 (i.e., mixed dementia) and significant aggressive behaviors were randomized to receive, for a period of 12 weeks, a flexible dose of either placebo or risperidone solution up to a maximum of 2 mg/day. Outcome measures were the Cohen-Mansfield Agitation Inventory (CMAI), the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) rating scale, and the Clinical Global Impression of Severity (CGI-S) and of Change (CGI-C) scales.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 345 patients were randomized to treatment with risperidone or placebo, and 337 patients received at least one dose of study drug. The trial was completed by 67% of patients in the placebo group and 73% of patients in the risperidone group. The mean +/- SE dose of risperidone was 0.95 +/- 0.03 mg/day. The primary endpoint of the study, the difference from baseline to endpoint in CMAI total aggression score, showed a significant reduction in aggressive behavior for risperidone versus placebo (p &lt;.001). A similar improvement was also seen for the CMAI total non-aggression subscale (p &lt;.002) and for the BEHAVE-AD total (p &lt;.001) and psychotic symptoms subscale (p =.004). At endpoint, the CGI-S and the CGI-C scores indicated a significantly greater improvement with risperidone compared with placebo (p &lt;.001). Overall, 94% and 92% of the risperidone and placebo groups, respectively, reported at least 1 adverse event. Somnolence and urinary tract infection were more common with risperidone treatment, whereas agitation was more common with placebo. There was no significant difference in the number of patients who reported extrapyramidal symptoms between the risperidone (23%) and placebo (16%) groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with low-dose (mean = 0.95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Academic Department for Old Age Psychiatry, School of Psychiatry, University of New South Wales, Sydney, Australia. h.brodaty@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Clarnette</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0205</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12630656</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The influence of cognitive impairment and psychiatric symptoms on daily functioning in nursing facilities: a longitudinal study.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>213</EndPage><MedlinePgn>209-13</MedlinePgn></Pagination><Abstract><AbstractText>The influence of psychiatric symptoms and cognitive status on daily living skills was explored among persons with dementia residing in skilled nursing facilities. Psychiatric symptoms were examined in three domains: 1) depression, 2) psychosis, and 3) behavioral disturbances. Twenty-eight subjects were followed for a 1-year duration in rural nursing facilities. The relationship between psychiatric symptoms, cognition, and daily living skills was assessed using correlation and regression analyses. Over a one-year period, cognitive and functional impairment progressed significantly. In contrast, psychiatric symptoms across all three domains did not necessarily persist or increase. Deterioration in cognitive function was significantly correlated with reduced functional status both cross-sectionally and longitudinally. Among psychiatric symptoms, only behavioral disturbances were significantly associated with functional impairment cross-sectionally. Cognitive decline and loss of social functioning may constitute the greatest source of disability among persons in nursing facilities. Furthermore, both impairments increase over time in contrast to psychiatric symptoms, which appear to have a more variable course. These findings may have implications for treatment interventions that seek to enhance functioning in the skilled nursing setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Iowa College of Medicine, 500 Newton Road, Iowa City, Iowa 52242-1000, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellingrod</LastName><ForeName>Vicki L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Kutschner</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Turvey</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Arndt</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 MH01633-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007484" MajorTopicYN="N" Type="Geographic">Iowa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012424" MajorTopicYN="Y">Rural Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12630656</ArticleId><ArticleId IdType="doi">10.1023/a:1021964900323</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12621314</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0893-0341</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Psychiatric symptomatology and prodromal Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to determine the prevalence of psychiatric symptoms among nondemented individuals with memory changes and whether such symptoms predict progression of functional decline or diagnosis of Alzheimer disease (AD). A semi-structured interview was administered at baseline to controls (n = 32) and to nondemented subjects with memory changes (n = 112) and to each subject's collateral source. The interview assessed the impact of cognition on functional abilities in daily life and a variety of psychiatric symptoms, including symptoms of psychosis, depression, and personality change. Participants were followed annually for 3 years to determine who had progressive functional decline and who progressed to meet clinical criteria for AD. Those diagnosed with AD on follow-up had more symptoms of personality change, such as agitation and passivity, at baseline than those who did not progress to meet clinical criteria for AD. Mild depressive symptoms were also more common among individuals at baseline who subsequently 'converted' to AD. Symptoms of personality change were associated with a more rapid increase in functional difficulty over time, whereas depressive symptoms were not. Changes in personality are more common among subjects with memory changes who go on to develop AD. Particular types of personality change, such as agitation and passivity, are related to progression of functional difficulty over time. Depressive symptoms, although common in prodromal AD, are not associated with a more rapid functional decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Copeland</LastName><ForeName>Maura P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, USA. mcopeland@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Ella</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hines</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Mastromauro</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zaitchik</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gunther</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>7</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>7</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12621314</ArticleId><ArticleId IdType="doi">10.1097/00002093-200301000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12611748</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol.</ArticleTitle><Pagination><StartPage>186</StartPage><EndPage>193</EndPage><MedlinePgn>186-93</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study investigated whether measurement of plasma levels may be useful in monitoring clinical efficacy and side effects during oral haloperidol (HL) treatment of psychosis and behavioral dyscontrol in patients with Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">After a single-blind placebo period of 1 week, 71 outpatients with AD were randomized to a 6-week, double-blind, placebo-controlled trial of HL 2 mg-3 mg/day (standard dose), HL 0.5 mg-0.75 mg/day (low dose), or placebo, with plasma levels for HL drawn at the end of 6 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 40 patients who received active HL for 6 weeks, 35 had plasma levels drawn. Plasma levels were all below the lower limit of the postulated therapeutic range in schizophrenia. Nonetheless, HL plasma level significantly correlated with clinical efficacy as measured by reduction in Brief Psychiatric Rating Scale Total score, Psychosis factor, and Hostile-Suspiciousness factor, the Behavioral Syndromes Scale for Dementia Psychomotor Agitation scale, and with the severity of extrapyramidal side effects (EPS). Oral dose did not significantly correlate with any of these efficacy or side-effect measures. Plasma levels significantly correlated with HL dose. When both HL dose and HL plasma level were included as independent variables in linear-regression analyses, only HL plasma level was a significant predictor of efficacy and EPS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Measurement of HL plasma levels may have potential usefulness as an adjunct in monitoring treatment response to oral HL in AD patients with psychosis or disruptive behavior.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA. ghp4@Columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>Devangere P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Marston</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinhua</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH55735</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="Y">Monitoring, Physiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>4</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>4</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12611748</ArticleId><ArticleId IdType="pii">S1064-7481(12)61261-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22034255</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1294-8322</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Dialogues in clinical neuroscience</Title><ISOAbbreviation>Dialogues Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Behavioral disturbances in dementia.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>59</EndPage><MedlinePgn>49-59</MedlinePgn></Pagination><Abstract><AbstractText>Psychological symptoms and behavioral abnormalities are common and prominent characteristics of dementia. They include symptoms such as depression, anxiety psychosis, agitation, aggression, disinhibition, and sleep disturbances. Approximately 30% to 90% of patients with dementia suffer from such behavioral disorders. There are complex interactions between cognitive deficits, psychological symptoms, and behavioral abnormalities. A large number of standardized, reliable, and well-validated instruments for assessing the behavioral and psychological symptoms of dementia have been developed in order to evaluate the efficacy of treatment. Neurodegenerative processes in various brain areas, particularly in the frontotemporal cortex and limbic regions, leading to cholinergic, serotonergic, and noradrenergic neurotransmitter dysfunctions constitute the biological matrix of behavioral symptoms, whereas psychological factors and personality traits play a modifying role. A large number of pharmacological, psychoeducational, psychotherapeutic, and social strategies have been developed to improve the quality of life of patients and their caregivers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xfc;ller-Spahn</LastName><ForeName>Franz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Psychiatric Hospital of the University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dialogues Clin Neurosci</MedlineTA><NlmUniqueID>101238198</NlmUniqueID><ISSNLinking>1294-8322</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Los s&#xed;ntomas psicol&#xf3;gicos y los trastornos de conducta son caracter&#xed;sticas comunes y prominentes de la demencia. Ellos incluyen s&#xed;ntomas como depresi&#xf3;n, ansiedad, psicosis, agitaci&#xf3;n, agresividad, desinhibici&#xf3;n y trastornos del sue&#xf1;o. Aproximadainente un 80% a 30% de los pacientes con demencia sufren de tales trastornos de conducta. Existen interacciones complejas entre los d&#xe9;ficits cognitivos, los s&#xed;ntomas psicologicos y los trastornos de conducta. Se ha desarrollado un gran n&#xfa;mero de instrumentes estandarizados, confiables y bien validados para cuantificar los s&#xed;ntomas conductuales y psicol&#xf3;gicos de la demencia, y as&#xed; poder evaluar la eficacia del tratamiento. Los procesos neurodegenerativos que ocurren en diversas &#xe1;reas cerebrales, especialmente en la corteza fronto-temporal y en las regiones l&#xed;mbicas, llevan a disfunciones de los neurotransmisores colin&#xe9;rgicos, serotonin&#xe9;rgicos y noradren&#xe9;rgicos, y de ese modo constituyen la base biol&#xf3;gica de los s&#xed;ntomas conductuales; en cambio, los factores psicol&#xf3;gicos y los rasgos de personalidad tienen un roi modification. Se ha desarrollado un gran n&#xfa;mero de estrategias farmacol&#xf3;gicas, pscoeducacionales, psicoterap&#xe9;uticas y sociales para mejorar la calidad de vida de los pacientes y de sus cuidadores.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Les sympt&#xf4;mes psychologiques et les anomalies comportementales constituent des caract&#xe9;ristiques &#xe0; la fois courantes et importantes de la d&#xe9;mence. Ils incluent des sympt&#xf4;mes tels que la d&#xe9;pression, l'anxi&#xe9;t&#xe9;, la psychose, l'agitation, l'agressivit&#xe9;, la d&#xe9;sinhibition et les troubles du sommeil. Environ 30 &#xe0; 30 % des patients atteints de d&#xe9;mence souffrent de tels troubles comportementaux. Des interactions complexes existent entre les d&#xe9;ficits cognitifs, les sympt&#xf4;mes psychologiques et les anomalies du comportement. Un grand nombre d'outils standardis&#xe9;s, fiables, et bien valid&#xe9;s pour explorer les sympt&#xf4;mes comportementaux et psychologiques de la d&#xe9;mence ont &#xe9;t&#xe9; d&#xe9;velopp&#xe9;s afin d'&#xe9;valuer l'efficacit&#xe9; du traitement. Les processus neurod&#xe9;g&#xe9;n&#xe9;ratifs dans diff&#xe9;rentes aires du cerveau, particuli&#xe8;rement dans le cortex frontotemporal et les r&#xe9;gions limbiques, entra&#xee;nant des dysfonctionnements des neurotransmetteurs cholinergiques, s&#xe9;rotoninergiques et noradr&#xe9;nergiques, forment la base biologique des sympt&#xf4;mes comportementaux, alors que les facteurs psychologiques et les traits de personnalit&#xe9; jouent un r&#xf4;le modificateur. Un grand nombre de strat&#xe9;gies pharmacologiques, psycho&#xe9;ducationnelles, psychoth&#xe9;rapeutiques et sociales ont &#xe9;t&#xe9; d&#xe9;velopp&#xe9;es pour am&#xe9;liorer la qualit&#xe9; de vie des patients et de leurs soignants.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">aggression</Keyword><Keyword MajorTopicYN="N">agitation</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">disinhibition</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22034255</ArticleId><ArticleId IdType="pmc">PMC3181717</ArticleId><ArticleId IdType="doi">10.31887/DCNS.2003.5.1/fmuellerspahn</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Honig LS., Mayeux R. Natural history of Alzheimer's disease. Aging Clin Exp Res. 2001;13:171&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442300</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch LH., Bylsma FW., Rovner B., Steele C., Folstein M. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry. 1991;148:1159&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">1882992</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N., Lanct&#xf4;t K., Naranjo C. Behavioral disorders in demented elderly patients. Current issues in pharmacotherapy. CNS Drugs. 1996;6:280&#x2013;300.</Citation></Reference><Reference><Citation>Zaudig M. Assessing behavioral symptoms of dementia of the Alzheimer type: categorical and quantitative approaches. Int Psychogeriatr. 1996;8(suppl2):183&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051447</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins P., Mace M., Lucas M. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne J., Lyketsos C., Baker L., et al. The relationship of cognitive and functional impairment to depressive features in Alzheimer's disease and other dementias. J Neuropsychiatry Clin Neurosci. 1998;10:440&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813790</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega M., Cummings J., Fiorello T., Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastwood R., Reisberg B. Mood and behaviours. In: Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. London, UK: Martin Dunitz; 1996;XX:175&#x2013;190.</Citation></Reference><Reference><Citation>Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood. Br J Psychiatry. 1990;157:81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397367</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease. I. Disorders of thought content. Br J Psychiatry. 1990;157:72&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397365</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease. II. Disorders of perception. Br J Psychiatry. 1990;157:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397366</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease. IV. Disorders of behaviour. Br J Psychiatry. 1990;157:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C., Steinberg M., Tschanz J., et al. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L., Borson S., Kiyak A., et al. Behavioural disturbance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc. 1989;37:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">2783433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pick A. On the relationship between aphasia and senile atrophy of the brain. In: Rottenberg D, Hochberg F, eds. Neurological Classics in Modern Translation. New York, NY: Hafner Press; 1977;XX:35&#x2013;40.</Citation></Reference><Reference><Citation>Mychack P., Kramer J., Boone K., Miller B. The influence of right frontotemporal dysfunction on social behavior in frontotemporal dementia. Neurology. 2001;56(suppl 4):S11&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402144</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards-Lee T., Miller B., Benson D., et al. The temporal lobe variant of frontotemporal dementia. Brain. 1997;120:1027&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">9217686</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-Spahn F., Hock C. Behavioral disturbances in old age. In: Lader M, Naber D, eds. Difficult Clinical Problems in Psychiatry. London, UK: Martin Dunitz; 1999;XX:181&#x2013;198.</Citation></Reference><Reference><Citation>Sandman O. Influence of the patient's environment on the progression of Alzheimer's disease. Neurobiol Aging. 1995;16:871&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">8622775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins P. Behavioral disturbances of dementia: practical and conceptual issues. Int Psychogeriatr. 1996;8(suppl 3):281&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154576</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood D., Barker W., Ownby R., Duara R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. Int J Geriatr Psychiatry. 2000;15:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C., Steele C., Galik E., et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66&#x2013;71 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9892299</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf4;ller HJ., Graeber M. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci. 1998;248:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">9728729</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel S., Burns A., Cohen G. Overview. XX. Int Psychogeriatr. 2000;12(suppl 1):13&#x2013;18.</Citation></Reference><Reference><Citation>Zaudig M. Behavioral and psychological symptoms of dementia in the International Classification of Diseases (ICD-10) and beyond (ICD-11). Int Psychogeriatr. 2000;12(suppl 1):29&#x2013;40.</Citation></Reference><Reference><Citation>Reisberg B., Borenstein J., Salob S., et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(5, suppl):9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">3760436</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J., Marx M., Rosenthal A. A description of agitation in a nursing home. J Gerontol. 1989;44:M77&#x2013;M84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J., Mega M., Gray K., et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P., Mack J., Patterson M., et al. Behavioral Pathology Committee of the Consortium to Establish a &#x201c;Registry for Alzheimer's Disease.&#x201d; The behavior rating scale of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B., Franssen E., Sclan S., et al. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci. 1989;54:95&#x2013;112.</Citation></Reference><Reference><Citation>Raskind M., Peskind E. Neurobiologie bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer's Dis Assoc Disord. 1994;8(suppl 3):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W. Neuropathology of psychotic symptoms in Alzheimer's disease. Int Psychogeriatr. 1996;8(suppl 3):233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. Organic delusions: phenomenology, anatomical correlations, and review. Br J Psychiatry. 1985;146:184&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">3156653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko G. Etiology: clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia. Int Psychogeriatr. 1996;8(suppl3):219&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154567</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstl H., Burns A., Levy R., et al. Neuropathological correlates of behavioral disturbance in confirmed Alzheimer's disease. Br J Psychiatry. 1993;163:364&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401967</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer A., Stratmann G., Procter A., et al. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol. 1988;23:616&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">2457353</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M., Cummings J., Fairbanks L., et al. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry. 1996;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley D., Wilson R., Beckett L., et al. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J Am Geriatr Soc. 1997;45:1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste D., Finkel S. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg R., Jeste D. Overview of depression and psychosis in Alzheimer's disease. Ami J Psychiatry. 1989;146:577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchter A., Spar J. The late-onset psychoses. J Nerv Ment Dis. 1985;173:488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">2862222</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS., Salmon DP., Thai LJ., et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste D., Wragg R., Salomon D., et al. Cognitive deficits of patients with Alzheimer's disease with and without delusions. Ami J Psychiatry. 1992;149:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y., Albert M., Brandt J., et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300&#x2013;2307.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko G., Moossy J., Martinez A., et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez O., Becker J., Brenner R., et al. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographs correlates. Neurology. 1991;41:906&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">2046938</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M., Folstein S., McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowles C. XX. Nursing Home Statistical Yearbook. Anacortes, Wash: Cowles Research Group; 1997;XX:XX&#x2013;XX.</Citation></Reference><Reference><Citation>Schneider L., Pollock V., Lyness S. A meta-analysis of controlled trials of neuroleptic treatment in dementia, J Am Geriatr Soc. 1990;38:553&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand D., Marder K., Michaels K., et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I., Jeste D., Mintzer J., et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J., Clark S., Gannon K., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry. 2000;57:968&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus D., Arvanitis L., Kowalcyk B., and the Seroquel Trial Study Group Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry. 1999;60:292&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362435</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman C., Vaccaro B., Lieff J., et al. Clozapine in older patients with psychosis and behavioral disturbances. Am J Geriatr Psychiatry . 1995;3:26&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">28530955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunik M., Puryear L., Orengo C., et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriat Psychiatry. 1998;13:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489578</ArticleId></ArticleIdList></Reference><Reference><Citation>Neugroschl J. Agitation. How to manage behavior disturbances in the older patient with dementia. Geriatrics. 2002;57:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11974389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins P., Mave N., Lucas M. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryden M. Aggressive behaviour in persons with dementia who live in the community. Alzheimer's Dis Assoc Disord. 1988;2:342&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">3196468</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastley R., Wilcock G. Prevalence and correlates of aggressive behaviors occurring in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:484&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">9178055</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel M., Gold D., Andres D., et al. Predictors and consequences of aggressive behavior by community-based dementia patients. Gerontologist. 1990;30:206&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">2347502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai S., Hwang J., Yang C., Liu K. Physical aggression and associated factors in probable Alzheimer's disease. Alzheimer Dis Assoc Disord. 1996;10:82&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8727169</ArticleId></ArticleIdList></Reference><Reference><Citation>Paveza G., Cohen D., Eisdorfer C., et al. Severe family violence and Alzheimer's disease: prevalence and risk factors. Gerontologist. 1992;32:493&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">1427252</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack BG., Mulsant BH., Rosen J., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Ami J Psychiatry. 2002;159:460&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P., Erb R., Podgorski C., et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9433339</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson A., Tariot P., Erb R., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C., Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry. 2002;52:243&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182930</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand D., Sano M., Tang M., et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry. 1996;53:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8629893</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkin S., Mahendra N. Insight in Alzheimer's patients: results of a longitudinal study using three assessment methods. Am J Alzheimers Dis Other Dement. 2001;16:211&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833994</ArticleId><ArticleId IdType="pubmed">11501343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott B., Lafleche G., Whelihan W., et al. Impaired awareness of deficits in Alzheimer's disease. Alzheimers Dis Assoc Disord. 1996;10:68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8727167</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko G., Moossy J., Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol. 1990;47:209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1689144</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos G., Silver J., Frances A., Carpenter D. Pharmacotherapy of depressive disorder in older adults. Postgrad Med Expert Consensus Guidelines, 2001. Special Report. New York, NY: McGraw-Hill; 2001;XX:XX&#x2013;XX.</Citation></Reference><Reference><Citation>MQIIer-Spahn F., Hock C. Risk factors and differential diagnosis of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 3):37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard R., Rossor M. Typical clinical features. In: Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. London, UK: Martin Dunitz; 1996;XX:35&#x2013;50.</Citation></Reference><Reference><Citation>Small G., Rabins P., Barry P., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343469</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller-Spahn F., Hock C. The role of antidepressants in the treatment of dementia. Eur Neuropsychopharmacol. 1997;7(suppl 25:133&#x2013;134.</Citation></Reference><Reference><Citation>Montgomery SA., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol. 1995;9(suppl 4):33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7622822</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyth A., Gottfries C. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1705151</ArticleId></ArticleIdList></Reference><Reference><Citation>Magai C., Kennedy G., Cohen C., Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000;8:66&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12590626</PMID><DateCompleted><Year>2003</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>72</EndPage><MedlinePgn>63-72</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the outcomes of 3 interventions for the management of dementia complicated by depression or psychosis: psychogeriatric case management, general practitioners with specialist psychogeriatric consultation, and standard care for nursing home residents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The sample for this 12-week randomized controlled trial consisted of 86 subjects with dementia from 11 Sydney, Australia, nursing homes, of whom 34 had depression, 33 had depression and psychosis, and 19 had psychosis. All participants received full psychiatric assessments and physical examinations. Information was obtained from the residents' families and nursing home staff. Depression measures included the Even Briefer Assessment Scale for Depression, Hamilton Rating Scale for Depression, Cornell Scale for Depression in Dementia, and Geriatric Depression Scale. Psychosis measures included the Behavioral Pathology in Alzheimer's Disease Rating Scale, Neuropsychiatric Inventory, and Scale for the Assessment of Positive Symptoms. Data were obtained from nursing home records on prescription of psychotropic medication and demographic information. Management plans were formulated by a multidisciplinary team before random assignment to interventions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All 3 groups improved from pretreatment to posttreatment on depression scales for depression groups and psychosis scales for psychosis groups. Mode of management appeared to make no difference in rate or amount of improvement; neither of the treatment group-by-time interactions were significant. Neither use of antidepressants nor use of antipsychotics predicted depression or psychosis outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Participation in the study was associated with improvement in depression and psychosis, perhaps because of the presence of a psychogeriatric team, the increased attention focused on residents, or the generalization of active intervention techniques to control subjects. A formula-driven psychogeriatric team case management approach was not significantly more effective than a consultative approach or standard care. This study demonstrates the difficulties and feasibility of conducting service-oriented research in nursing homes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales and the Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Millar</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Lee-Fay</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sharah</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Paton</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019090" MajorTopicYN="N">Case Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005194" MajorTopicYN="N">Family Practice</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005852" MajorTopicYN="N">Geriatric Psychiatry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>2</Month><Day>20</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>6</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>2</Month><Day>20</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12590626</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0113</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12566926</PMID><DateCompleted><Year>2003</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1424-862X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Neuro-Signals</Title><ISOAbbreviation>Neurosignals</ISOAbbreviation></Journal><ArticleTitle>GSK3beta signalling: casting a wide net in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>261</EndPage><MedlinePgn>251-61</MedlinePgn></Pagination><Abstract><AbstractText>Glycogen synthase kinase-3beta (GSK3beta) is a kinase that plays a pivotal role in numerous cellular functions from modulation of microtubule dynamics and cell death. It also affects higher functions such as cognition and mood. Deregulation of GSK3beta activity in the adult brain is implicated in several CNS disorders, such as affective disorders, schizophrenia, stroke and neurodegenerative diseases, such as Alzheimer's disease (AD). In AD, GSK3beta has a major role in microtubule stability by its ability to phosphorylate the microtubule associated protein tau. The present review focuses on recent developments in the understanding of GSK3beta with an emphasis on events likely to be critical to the pathophysiology of AD.</AbstractText><CopyrightInformation>Copyright 2003 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Ratan V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>AstraZeneca R&amp;D, SE-151 85 S&#xf6;dert&#xe4;lje, Sweden. Ratan.Bhat@Astrazeneca.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budd</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurosignals</MedlineTA><NlmUniqueID>101134359</NlmUniqueID><ISSNLinking>1424-862X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>110</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>2</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>2</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12566926</ArticleId><ArticleId IdType="doi">10.1159/000067423</ArticleId><ArticleId IdType="pii">67423</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12562143</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63 Suppl 13</Volume><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Use of quetiapine in elderly patients.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>26</EndPage><MedlinePgn>21-6</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral problems associated with psychosis in the elderly have a significant negative impact on patients' quality of life and can lead to placement in a nursing home. Because of their decreased propensity to produce extrapyramidal symptoms, atypical antipsychotics such as quetiapine hold promise in the treatment of these vulnerable patients. Quetiapine may, in theory, be particularly advantageous in this regard because of its lack of anticholinergic activity and its relatively loose binding to dopamine receptors. This article reviews the somewhat limited number of clinical studies of the use of quetiapine in treating older patients with schizophrenia and other psychotic disorders, patients with psychosis associated with Alzheimer's disease or dementia with Lewy bodies, and patients with Parkinson's disease and drug-induced psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Rochester School of Medicine, Monroe Community Hospital, Rochester, NY 14620, USA. pierre_tariot@urmc.rochester.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>2</Month><Day>4</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>2</Month><Day>4</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12562143</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12556570</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Are late-onset schizophrenia spectrum disorders neurodegenerative conditions? Annual rates of change on two dementia measures.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>52</EndPage><MedlinePgn>45-52</MedlinePgn></Pagination><Abstract><AbstractText>Some investigators assert that emergence of schizophrenia spectrum disorders in mid- to late life (LOSD, i.e., onset after age 45) reflects neurodegenerative processes. The authors examined 1- and 2-year changes among 37 outpatients with LOSDs on the Mini-Mental State Examination (MMSE) and Mattis Dementia Rating Scale, compared with 69 patients having earlier-onset schizophrenia spectrum disorders (EOSD), 67 having Alzheimer's disease (AD) with psychosis, 72 having AD with baseline MMSE scores &gt;/=24, and 56 normal comparison subjects (NCs). Cognitive changes among LOSD patients were similar to those in EOSD patients and NCs, whereas the AD groups had greater declines. Results support viewing LOSDs as static encephalopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Barton W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, USA. bpalmer@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondi</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Twamley</LastName><ForeName>Elizabeth W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Golshan</LastName><ForeName>Shahrokh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12674</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01452</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43693</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH49671</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12556570</ArticleId><ArticleId IdType="doi">10.1176/jnp.15.1.45</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12543269</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0531-5565</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>1-2</Issue><PubDate><Year>2003</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Experimental gerontology</Title><ISOAbbreviation>Exp Gerontol</ISOAbbreviation></Journal><ArticleTitle>Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>128</EndPage><MedlinePgn>119-28</MedlinePgn></Pagination><Abstract><AbstractText>Neurodegenerative disorders such as Alzheimer's disease, Lewy-Body dementia, Parkinson's disease and cerebrovascular dementia result in an insidious cognitive and behavioural decline culminating in the development of severe dementia. Based on current population projections it has been estimated that by 2050 the number of individuals over 65 will increase to 1.1 billion worldwide and as a consequence, the number of cases of dementia to 37 million. Faced with such an enormous public health and socio-economic burden it is evident that the importance of therapeutic intervention aimed at either finding a cure or preventing disease progression cannot be overstated. The aim of the present paper is to present an overview, in the context of a brain aging continuum, at what stage cognition enhancing and/or neuroprotective intervention strategies aimed at stabilising and/or preventing neurodegenerative disease could demonstrate potential clinical benefit. In particular, the clinical identification of patients with mild cognitive impairment and age-associated memory impairment which may represent a 'transition' state between normal aging and dementia is discussed as a potential clinical population cohort targeted for early intervention in dementia. Considering the wide spectrum of cognitive and psychotic effects in dementia juxtaposed with the neuropathological evolution of the disease, it is clear that a variety of therapeutic intervention(s) will be required in order, to at the least, stabilise disease progression. Evidently, since Alzheimer's disease is by far the most prevalent form of dementia, and will undoubtedly serve as the benchmark for any future treatment of dementia, an update of current symptomatic and disease-modifying therapeutic approaches (cholinergic, glutamatergic, nootropics, beta-amyloid cascade inhibitors) will be reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lockhart</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Servier, Division of Cerebral Pathology, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France. brian.lockhart@fr.netgrs.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lestage</LastName><ForeName>Pierre J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Gerontol</MedlineTA><NlmUniqueID>0047061</NlmUniqueID><ISSNLinking>0531-5565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>25</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>25</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12543269</ArticleId><ArticleId IdType="doi">10.1016/s0531-5565(02)00163-8</ArticleId><ArticleId IdType="pii">S0531556502001638</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12527543</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The epidemiology of psychosis in dementia.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>91</EndPage><MedlinePgn>83-91</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Authors compared delusions, hallucinations, and misidentification delusions in Alzheimer disease (AD) and vascular dementia (VaD) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors report data on the prevalence, severity, clinical, and demographic associations of these symptoms in a population sample of 260 persons with dementia, examined with the Neuropsychiatric Inventory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary finding was that there was no difference in psychosis as a whole, or in delusions and hallucinations, between AD and VaD. Also, in AD, female gender appeared to be a risk factor for delusions; subjects in an earlier stage of dementia showed fewer delusions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The profile of delusions and hallucinations seen is different from that seen in schizophrenia, further supporting the hypothesis that AD-associated psychosis is a distinct phenomenological syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leroi</LastName><ForeName>Iracema</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Service, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voulgari</LastName><ForeName>Argyro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John C S</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>16</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>16</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12527543</ArticleId><ArticleId IdType="pii">S1064-7481(12)61243-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12523876</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.</ArticleTitle><Pagination><StartPage>1156</StartPage><EndPage>1163</EndPage><MedlinePgn>1156-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment of psychotic symptoms in patients with mood disorders is a complex challenge. Antipsychotic medications in these individuals may be associated with extrapyramidal symptoms (EPS), worsening of depression, and functional impairment. Atypical antipsychotics such as quetiapine and risperidone are associated with a decreased incidence of adverse events such as EPS. The objective of this study was to compare the efficacy and tolerability of quetiapine and risperidone for the treatment of depressive symptoms in outpatients with psychosis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In this 4-month, multicenter, open-label trial, patients were randomly assigned in a 3:1 ratio of quetiapine to risperidone, and both drugs were flexibly dosed. Eligible patients had psychoses and demonstrated 1 of several DSM-IV diagnoses, including schizoaffective disorder, bipolar I disorder, major depressive disorder, delusional disorder, Alzheimer's dementia, schizophreniform disorder, vascular dementia, and substance abuse dementia. Patients were classified as mood disordered if they had bipolar disorder, major depressive disorder, or schizoaffective disorder. Efficacy was assessed using the Positive and Negative Syndrome Scale and the Clinical Global Impressions scale. The Hamilton Rating Scale for Depression (HAM-D) was used to assess the level of depressive symptoms. The primary tolerability assessment was presence or absence of substantial EPS, defined as EPS severe enough to require an alteration in treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 554 patients were randomly assigned to quetiapine and 175 to risperidone. Mean doses at 16 weeks were 318 mg for quetiapine and 4.4 mg for risperidone. Although both agents produced improvements in mean HAM-D scores, quetiapine produced a greater improvement than risperidone in all patients (p =.0015). Within the mood-diagnosed population, incidences of both substantial EPS (p =.001) and at least moderate EPS (p =.0373) occurred significantly less frequently among patients taking quetiapine. For patients with non-mood diagnoses, incidences of substantial EPS were fewer for patients taking quetiapine than for those taking risperidone (p =.062); however, this was not statistically significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest that quetiapine may be a useful agent in the management of depressive symptoms in patients with psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA. sajatovic@juno.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullen</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Sweitzer</LastName><ForeName>Dennis E</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>6</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12523876</ArticleId><ArticleId IdType="doi">10.4088/jcp.v63n1211</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12436383</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>9</Issue><PubDate><MedlineDate>2002 Nov 1-15</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Treatment of neuropsychiatric symptoms in Alzheimer's disease].</ArticleTitle><Pagination><StartPage>846</StartPage><EndPage>850</EndPage><MedlinePgn>846-50</MedlinePgn></Pagination><Abstract><AbstractText>The overall goal of all therapeutic interventions in Alzheimer s disease (AD) is the optimisation of the adaptive functions and quality of life of these patients. The general strategy for the use of pharmacological interventions in the treatment of neuropsychiatric manifestations of AD includes the following: 1) An exhaustive evaluation of the psychiatric symptomatology; 2) Establish a hierachy of the simptoms to treat based on their severity of symptoms and on their impact on the caregiver; 3) The identification of an adequate agent based on the type of symptoms and subject s characteristics; 4) The initial use of low doses with gradual titration, and 5) Changing one drug at a time. Regarding psychotic symptons, the introduction of new agents (e.g., risperidone) has replaced the use of traditional treatments (e.g., thioridazine) in patients with AD. The presence of psychomotor agitation and aggression can be treated with great variety of drugs, such as antipsychotics, anticonvulsants, antidepressants, and sedatives. Selective serotonine re uptake inhibitors are the treatment of choice for depressive symptomatology. The cholinesterase inhibitors have shown to be useful in the treatment of hallucinations, anxiety and apathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Nuerolog&#xed;a. Escuela de Medicina de la Universidad de Pittsburg, Pennsyvania, EE.UU. dcaufer@pitt.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento de los s&#xed;ntomas neuropsiqui&#xe1;tricos en la enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>19</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>19</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12436383</ArticleId><ArticleId IdType="pii">rn2002003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12422480</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>33</Issue><PubDate><Year>2002</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Psychosis revealing a silent celiac disease in a young women with trisomy 21].</ArticleTitle><Pagination><StartPage>1551</StartPage><EndPage>1553</EndPage><MedlinePgn>1551-3</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Down's syndrome is characterized by an abnormal frequency of coeliac disease and by the frequent occurrence of neurological disorders such as Alzheimer-type dementia of early onset. However, psychosis is rare in Down's syndrome.</AbstractText><AbstractText Label="OBSERVATION" NlmCategory="METHODS">We report the case of a 41-year-old woman, who presented with Down's syndrome. She was living with her parents and had a normal social life. She suddenly experienced some esthesic hallucinations, depression, anorexia, affective flattening and autistic behavior. Biological evaluation revealed macrocytosis, polyclonal IgA and IgG hypergammaglobulinemia and strong positivity for anti-gliadin antibodies of IgG and IgA isotypes. Brain CTscan was normal. Since digestive specimen biopsies did not evidence villous atrophy, we concluded in a silent coeliac disease. After 12 months of gluten-free diet a spectacular and lasting improvement of both psychotic and depressive symptoms was obtained.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The effects of abnormal interaction between the immune system and gluten can be expressed not only in the gut (coeliac disease) but also in the brain (psychosis) in genetically predisposed patients, such as those suffering from Down's syndrome. There was evidence for brain disorder related to coeliac disease in our patient.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our case report shows that, before concluding in Alzheimer-type dementia in Down's syndrome, a biological search for coeliac disease is useful since a gluten-free diet may improve the psychiatric symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serratrice</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de m&#xe9;decine interne, H&#xf4;pital de la Timone Marseille.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disdier</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Granel</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean Michel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Laugier</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Berenguer</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Weiller</LastName><ForeName>Pierre Jean</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Psychose r&#xe9;v&#xe9;lant une maladie coeliaque silencieuse chez une jeune femme ayant une trisomie 21.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8002-80-0</RegistryNumber><NameOfSubstance UI="D005983">Glutens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002446" MajorTopicYN="N">Celiac Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005983" MajorTopicYN="N">Glutens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>9</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>9</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12422480</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12404019</PMID><DateCompleted><Year>2003</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>49</Issue><PubDate><Year>2002</Year><Season>Sep-Nov</Season></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Dementia and cognitive impairment in Parkinson disease].</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>188</EndPage><MedlinePgn>184-8</MedlinePgn></Pagination><Abstract><AbstractText>Changes in cognitive function and disturbances in behavior are commonly seen in parkinsonian patients and they are inherent features of the disease. Estimates on the prevalence of dementia in this disorder are quite variable, ranging from 15 to 25%. Advanced age, depression, severity of akinesia, and the presence of dopaminomimetic psychosis, are considered as risk factors in the development of cognitive deterioration within this patient population. Cognitive dysfunction may manifest as relatively circumscribed deficits or overt dementia. The finding of mild cognitive deficits is common in Parkinson's disease, such as reduced flexibility, psychomotor slowing, reduction in learning capacity and information retrieval, and disturbances in visuospatial tasks. The most prevalent cognitive disturbance is an impairment in visuospatial tasks, not necessarily related to the degree of motor disability. Dementia, when present early on in the course of the disease may suggest alternative diagnoses (Diffuse Lewy body dementia, Alzheimer's disease with extrapyramidal features, Fronto-temporal dementia, etc.), while in those cases in whom the dementing disorder develops at a later stage, it is assumed to be an integral part of the disease, albeit corresponding to variable pathogenetic mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gershanik</LastName><ForeName>Oscar S</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad de Buenos Aires, Argentina. gersh@movi.com.ar</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Demencia y deterioro cognitivo en la enfermedad de Parkinson.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>15</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>23</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12404019</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">12354372</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8480</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current treatment options in neurology</Title><ISOAbbreviation>Curr Treat Options Neurol</ISOAbbreviation></Journal><ArticleTitle>Suicide in Neurologic Illness.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>468</EndPage><MedlinePgn>457-468</MedlinePgn></Pagination><Abstract><AbstractText>The risk of attempted or completed suicide is increased in patients with migraine with aura, epilepsy, stroke, multiple sclerosis, traumatic brain injury, and Huntington's disease. Contrary to the general perception that the risk of suicide among patients with Alzheimer's disease and other dementing conditions is low, several reports suggest that the risk of suicide in these patients increases relative to the general population. Some patients at risk for neurologic disorders are also at increased risk for suicide; in particular, the risk of suicide is increased among persons at risk for Huntington's disease, independent of the presence or absence of the Huntington's gene mutation. The risk of attempted or completed suicide in neurologic illness is strongly associated with depression, feelings of hopelessness or helplessness, and social isolation. Additional suicide risk factors in persons with neurologic illness include cognitive impairment, relatively younger age (under 60 years), moderate physical disability, recent onset or change in illness, a lack of future plans or perceived meaning in life, recent losses (personal, occupational, or financial), and prior history of psychiatric illness or suicidal behavior. Substance dependence, psychotic disorders, anxiety disorders, and some personality disorders (eg, borderline personality disorder) may also contribute to increased risk of suicide among persons with neurologic illnesses. Identification and aggressive treatment of psychiatric problems, especially depression, as well as reduction of modifiable suicide risk factors among patients with neurologic illness is needed to reduce the risk of attempted and completed suicide in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arciniegas</LastName><ForeName>David B.</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>*Neuropsychiatry Service, Departments of Psychiatry and Neurology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C268-68, Denver, CO 80262, USA. David.Arciniegas@UCHSC.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>C. Alan</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Neurol</MedlineTA><NlmUniqueID>9815940</NlmUniqueID><ISSNLinking>1092-8480</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12354372</ArticleId><ArticleId IdType="doi">10.1007/s11940-002-0013-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 1992 Jan;24(1):17-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1347545</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Winter;11(1):32-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9990553</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Orthopsychiatry. 1987 Apr;57(2):212-219</Citation><ArticleIdList><ArticleId IdType="pubmed">2954468</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 1996 Mar-Apr;65(2):86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8711087</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 1993 Apr;30(4):293-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8487273</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1992 Feb;42(2):392-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1736172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):542-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1640228</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1998 Apr 18;316(7139):1206</Citation><ArticleIdList><ArticleId IdType="pubmed">9583928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1627975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1992 Dec;43(12):1189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1360938</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1993;9(3):217-219</Citation><ArticleIdList><ArticleId IdType="pubmed">11941216</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1991 Sep;81(9):1198-200</Citation><ArticleIdList><ArticleId IdType="pubmed">1951834</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Health. 1999 Jul;48(1):7-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10485160</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 1992 Dec;29(12):911-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1479606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1984 Dec;47(12):1283-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6239910</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Med. 1992;22(3):231-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1487386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):209-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9081559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):140-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1627974</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2001 Spring;14 (1):37-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11281315</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Jan 15;49(2):137-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11164760</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2002;43 Suppl 2:8-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11903476</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2):180-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9581214</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 Apr;37(1):11-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1862159</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2000 Jul;31(7):1482-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10884441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1987 Dec;80(6):909-17</Citation><ArticleIdList><ArticleId IdType="pubmed">3684404</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1998 Jul;27(4):503-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9884008</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1986 Feb;16(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2938203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2001 Sep;189(9):623-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11580007</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 2001 Sep-Oct;42(5):382-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11739904</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jul;90(1):70-2</Citation><ArticleIdList><ArticleId IdType="pubmed">7976453</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1992 Dec;49(12):1296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">1449409</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1998 Aug 5;280(5):471-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9701087</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2000 Dec;16(4):415-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11314880</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Mar;12(3):337-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9152718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1980 Feb;43(2):168-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7359153</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Jan;150(1):108-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8417551</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1993 Dec 15;48(4):231-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8135306</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Aug;41(8):1193-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1866003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1996 May;184(5):274-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8627272</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1997 Jun;95(6):551-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9242852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cephalalgia. 1985 May;5 Suppl 2:225-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3893738</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2002 Jun;43(6):644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12060025</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Soc Med. 1988;16(3):149-53</Citation><ArticleIdList><ArticleId IdType="pubmed">3194726</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1987 Oct;76(4):339-45</Citation><ArticleIdList><ArticleId IdType="pubmed">3321920</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Mar;157(3):351-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10698809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2001 Dec;55(12):863-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11707478</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1985 Jun;8(2):183-201</Citation><ArticleIdList><ArticleId IdType="pubmed">3895187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2002 Spring;15(1):38-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11936242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1994 Spring;6(2):154-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8044037</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1986 May;47(5):258-60</Citation><ArticleIdList><ArticleId IdType="pubmed">3700345</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 May;64(5):1293-304</Citation><ArticleIdList><ArticleId IdType="pubmed">10205260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 2000 May;6 Suppl 2:S186-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10871811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9608407</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 Sep 25;337(13):910-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9302306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 1986 Sep;42(5):699-702</Citation><ArticleIdList><ArticleId IdType="pubmed">3760198</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Inj. 2001 Nov;15(11):935-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11689092</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2000 Oct;2(5):427-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11122992</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Aug;15(8):729-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10960885</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):436-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11561024</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1986 Jun;24(2):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2940862</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 1998 Spring;28(1):1-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9560163</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Nov;147(11):1493-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2221162</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 2000 Sep;102(3):150-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10987374</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2001 Aug;14(4):465-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11470962</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2001 Fall;14(3):120-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11563434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1983 Oct;44(10):385-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6643400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebrovasc Dis. 2001;12(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11435675</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2001 Dec;69(6):942-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11777121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12230086</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Atypical antipsychotics in Parkinson-sensitive populations.</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>170</EndPage><MedlinePgn>156-70</MedlinePgn></Pagination><Abstract><AbstractText>Drug-induced iatrogenic hallucinations and psychosis occur in about 30% of Parkinson's disease (PD) patients and are the single most important precipitant for nursing home placement, which carries a grave prognosis. In addition, parkinsonism is a frequent accompaniment to the more common dementing syndromes, Alzheimer's disease (AD), vascular dementia, and dementia with Lewy bodies (DLB). The five most recent antipsychotic drugs approved by the Food and Drug Administration in the United States have been marketed as "atypical" antipsychotics (AA) due to their relative freedom from extrapyramidal symptoms when used in schizophrenia patients. The use of these newer antipsychotic drugs in PD and other parkinson-sensitive populations represents the most stringent test to their freedom from motor side effects. To date, clozapine, risperidone, olanzapine, and quetiapine have been studied in parkinson-vulnerable populations. This article reviews the data and highlights the differences that these four drugs have on motor function. It also emphasizes the challenges in evaluating the available data on the motor effects of AA, especially on the non-PD elderly and cognitively impaired population. Suggestions are made for future research to improve the interpretability of these studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="N">Iatrogenic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>171</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12230086</ArticleId><ArticleId IdType="doi">10.1177/089198870201500307</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12215881</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>9</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Presenile dementia in polycystic lipomembranous osteodysplasia].</ArticleTitle><Pagination><StartPage>879</StartPage><EndPage>882</EndPage><MedlinePgn>879-82</MedlinePgn></Pagination><Abstract><AbstractText>We present a 36-year-old woman with a 3-year history of cognitive decline followed by development of a small stepped gait and urinary and fecal incontinence. Workup revealed multiple bone cysts documented by X-ray and idiopathic hyperprolactinoma. An MRI confirmed the CT finding of massive bilateral basal ganglia calcification. This is the first case of polycystic lipomembranous osteodysplasia described in Germany. We conclude that patients with presenile dementia, psychosis, or early-onset Parkinsonism associated with basal ganglia calcification should undergo X-rays of hand and feet to rule out polycystic lipomembranous osteodysplasia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Psychiatrische Klinik Sonnenhalde, CH-Riehen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kl&#xfc;nemann</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Ibach</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Putzhammer</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Trender-Gerhard</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Schuierer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>H E</ForeName><Initials>HE</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pr&#xe4;senile Demenz bei polyzystischer lipomembran&#xf6;ser Osteodysplasie.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001845" MajorTopicYN="N">Bone Cysts</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002114" MajorTopicYN="N">Calcinosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="Y">Chromosome Aberrations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005808" MajorTopicYN="Y">Genes, Recessive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008060" MajorTopicYN="N">Lipodystrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>20</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12215881</ArticleId><ArticleId IdType="doi">10.1007/s00115-002-1289-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12211120</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Factor structure of the Cornell Scale for Depression in Dementia among Japanese poststroke patients.</ArticleTitle><Pagination><StartPage>715</StartPage><EndPage>722</EndPage><MedlinePgn>715-22</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">the present study reports on the first translation and use of the Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos, Abrams, Young, &amp; Shamoian, 1988) among poststroke patients (n = 101) in Japan.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">the study had three main purposes: 1. To examine the factor structure of the CSDD among Japanese poststroke patients; 2. To compare this with the factor structure identified for Anglo-American Alzheimer's (AD) patients; and 3. To examine the prevalence and covariates of depressive symptoms among the Japanese stroke survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">poststroke patients and their caregivers (n = 202), at a random sample of neurological hospitals in western Japan, were interviewed using the study instruments. Data was also collected from patient charts. All subjects at each site who met the study criteria participated in the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">the four-factor solution for poststroke subjects was analogous to that found among AD patients with 2 main exceptions. In contrast to AD patients: 1. Physical complaints were unrelated to depressed mood in stroke patients; and 2. Agitation and psychosis loaded with depressed mood in stroke patients rather than as a separate unique factor as in AD patients. However, in the exploratory 5-factor model, agitation and suicidal ideation comprised a unique factor. Using standard cutoff scores for the CSDD, 58.2% of poststroke patients had scores suggesting possible depression. CSDD scores were not related to functional ability, or stroke characteristics such as aphasia or right or left-sided paralysis. However, scores were significantly higher among subjects &lt; or = 2 years poststroke. Feelings of irritability, anxiety, sadness, and sleep problems were most prevalent.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">despite the prevalence of depressive symptoms, none of the subjects were currently receiving any mental health treatment. Findings suggest that symptoms differ by poststroke duration, which may necessitate different treatment approaches.</AbstractText><CopyrightInformation>Copyright 2002 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schreiner</LastName><ForeName>Andrea S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Hiroshima International University, Faculty of Health Sciences, Hiroshima, Japan. a-streit@jrckicn.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12211120</ArticleId><ArticleId IdType="doi">10.1002/gps.684</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19810981</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy of agitation and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>655</StartPage><EndPage>664</EndPage><MedlinePgn>655-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/14737175.2.5.655</ELocationID><Abstract><AbstractText>Behavioral disorders, such as agitation and psychosis, are the main reasons for nursing home placement of Alzheimer's disease patients. This review article discusses the efficacy and adverse effects rates of antipsychotics, the most effective and widely-used medications for psychosis in elderly patients and the most commonly prescribed class of psychotropic medicines in long-term care institutions. In addition, the efficacy of selective serotonin reuptake inhibitors is discussed. Recommendations are provided regarding these existing and potential new clinical strategies. A future perspective is provided, taking into consideration prospective developments in preventative treatments of Alzheimer's disease over the next 5 years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verhoeff</LastName><ForeName>Nicolaas P L G</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Kunin-Lunenfeld Applied Research Unit, Posluns Building, 7th Floor, Room 762, Baycrest Centre for Geriatric Care, 3560 Bathurst Street, Toronto, ON M6A 2E1, Canada. pverhoeff@klaru-baycrest.on.ca</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19810981</ArticleId><ArticleId IdType="doi">10.1586/14737175.2.5.655</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12192617</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-4184</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity.</ArticleTitle><Pagination><StartPage>726</StartPage><EndPage>733</EndPage><MedlinePgn>726-33</MedlinePgn></Pagination><Abstract><AbstractText>N-methyl-D-aspartate (NMDA) glutamate receptor antagonists are used in clinical anesthesia and are being developed as therapeutic agents for preventing neurodegeneration in stroke, epilepsy, and brain trauma. However, the ability of these agents to produce neurotoxicity in adult rats and psychosis in adult humans compromises their clinical usefulness. In addition, an NMDA receptor hypofunction (NRHypo) state might play a role in neurodegenerative and psychotic disorders, like Alzheimer's disease, bipolar disorder and schizophrenia. Thus, developing pharmacological means of preventing these NRHypo-induced effects could have significant clinically relevant benefits. NRHypo neurotoxicity appears to be mediated by a complex disinhibition mechanism that results in the excessive stimulation of certain vulnerable neurons. Here we report our findings that five agents (phenytoin, carbamazepine, valproic acid, lamotrigine, and riluzole), thought to possess anticonvulsant activity because they inhibit voltage-gated sodium channels, prevent NRHypo neurotoxicity. The ability of tetrodotoxin, a highly selective inhibitor of voltage-gated sodium channels, to prevent the same neurotoxicity suggests that inhibition of this ion channel is the likely mechanism of action of these five agents. We also found that three other anticonvulsants (felbamate, gabapentin and ethosuximide), whose mechanism is less clear, also prevent NRHypo neurotoxicity, suggesting that inhibition of voltage-gated sodium channels is not the only mechanism via which anticonvulsants can act to prevent NRHypo neurotoxicity. Several of these agents have been found to be of clinical use in bipolar disorder. It would be of interest to determine whether these agents might have therapeutic benefits for conditions in which a NRHypo state may exist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>N B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St Louis, MO 63110-1093, USA. fabern@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>X-P</ForeName><Initials>XP</Initials></Author><Author ValidYN="Y"><LastName>Heinkel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nemmers</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6158TKW0C5</RegistryNumber><NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010672" MajorTopicYN="N">Phenytoin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015222" MajorTopicYN="N">Sodium Channels</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2002</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2002</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>8</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>8</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12192617</ArticleId><ArticleId IdType="doi">10.1038/sj.mp.4001087</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12151841</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1350-7540</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current opinion in neurology</Title><ISOAbbreviation>Curr Opin Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in the dementias.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>450</EndPage><MedlinePgn>445-50</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Neuropsychiatric, or non-cognitive symptoms are increasingly recognized as manifestations of dementias.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">In Alzheimer's disease, recent advances have included the identification of behavioral profiles, differentiation of apathy and depression, characterization of risk factors for psychosis and its links to agitation and aggression, and an analysis of depressive symptoms in the absence of major depression. Functional neuroimaging data mainly supported the role of the anterior cingulate in apathy. The orbitofrontal and anterior cingulate tangle burden were associated with agitation, and increased orbitofrontal and mid-temporal muscarinic M2 receptors with psychosis and hallucinations. Selected genetic polymorphisms of dopamine and serotonin receptors or transporters were linked with aggression, hallucinations or psychosis. When compared with other dementias, individuals with frontotemporal dementia disclosed, as expected, different behaviors and particularly aberrant social behavior. The frequency of delusions and visual hallucinations was increased in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies, suggesting common mechanisms such as Lewy body pathology and cholinergic deficiency. The latter was supported by an improvement of these symptoms by cholinesterase inhibitors.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Future research directions include both clinical and basic neuroscience investigations. The detection of early neuropsychiatric symptoms might be a marker for dementia, and the possible existence of a mild neuropsychiatric impairment syndrome should be explored. More longitudinal studies with pathological confirmation will facilitate correlations with neuropsychiatric symptoms. Functional neuroimaging and behavioral neurogenetics will permit in-vivo correlations and consequently help patient management and care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assal</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>UCLA School of Medicine, Los Angeles, CA 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurol</MedlineTA><NlmUniqueID>9319162</NlmUniqueID><ISSNLinking>1350-7540</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12151841</ArticleId><ArticleId IdType="doi">10.1097/00019052-200208000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12145451</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Progressive aphasia with Lewy bodies.</ArticleTitle><Pagination><StartPage>55</StartPage><EndPage>58</EndPage><MedlinePgn>55-8</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies (DLB) may include both Alzheimer and Lewy body pathology, but has never been reported to cause primary progressive aphasia. We report a 69-year-old woman who died 11 years after presenting with the syndrome of progressive aphasia. Six years after aphasia onset she developed visual hallucinations, and subsequently parkinsonism. Autopsy examination revealed Alzheimer's disease (AD), cortical Lewy bodies, and depigmentation and Lewy bodies in the substantia nigra and locus ceruleus. The aphasia most likely reflected the initial onset of AD, and the psychosis and parkinsonism most likely reflected the subsequent onset of Lewy body pathology. This first reported case of progressive aphasia occurring within the context of AD and Lewy body pathology uniquely illustrates the clinical and pathological nosological relationships between these two disease processes, and demonstrates a limitation of the general term, 'DLB'.</AbstractText><CopyrightInformation>Copyright 2002 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, AZ 85259, USA. Caselli.Richard@Mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Sue</LastName><ForeName>Lucia I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 P30 AG19610-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 R01 MH57899-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001037" MajorTopicYN="N">Aphasia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12145451</ArticleId><ArticleId IdType="doi">10.1159/000064925</ArticleId><ArticleId IdType="pii">64925</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12131944</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>2-B</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>[Reliability of volumetric measures of mesial temporal structures].</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>428</EndPage><MedlinePgn>420-8</MedlinePgn></Pagination><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">The development of reliable techniques for volumetric measurement of mesial temporal structures (amygdala, hippocampus and parahippocampal gyrus) on magnetic resonance imaging (MRI) can provide data for the study of neuropsychiatric disorders, mainly temporal lobe epilepsy, Alzheimer's disease and schizophrenia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We investigated these techniques performing intraobserver and interobserver reliability study concerning normal controls, epilepsy and Alzheimer's disease patients using the intra-class correlation coefficient.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Intra-observer reliability of evaluated structures ranged from 0.93 to 0.99 (p&lt;0.001). Inter-observer reliability ranged from 0.70 to 0.95 (p &lt; or = 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results suggest that the technique of MRI morphometry of mesial temporal regions can be considered a reliable tool which may help in the investigation of neuropsychiatric disorders, since used by adequately trained clinicians and researchers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Renato L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Instituto de Psiquiatria, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo. rlmarche@dialdata.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottino</LastName><ForeName>C&#xe1;ssio M C</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Dion&#xed;sio</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>Suely K Nagahashi</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>de Castro</LastName><ForeName>Cl&#xe1;udio C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Confiabilidade de medidas volum&#xe9;tricas de estruturas temporais mesiais.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004833" MajorTopicYN="N">Epilepsy, Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020534" MajorTopicYN="N">Parahippocampal Gyrus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>35</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12131944</ArticleId><ArticleId IdType="pii">S0004-282X2002000300016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12105318</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Linkage analysis of Alzheimer disease with psychosis.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>120</EndPage><MedlinePgn>118-20</MedlinePgn></Pagination><Abstract><AbstractText>Although a portion of risk for late-onset AD (LOAD) is attributable to APOE, the search for other loci is ongoing. The authors hypothesize that psychotic symptoms with LOAD (LOAD+P) identify a potentially more etiologically homogeneous form of AD. Linkage analysis of families with LOAD+P identified one significant and several suggestive novel linkage signals, which bolsters the conjecture of greater etiologic homogeneity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bacanu</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, School of Medicine, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chowdari</LastName><ForeName>K V</ForeName><Initials>KV</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01489</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH53459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH57881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2002 Jul 9;59(1):11-2. doi: 10.1212/wnl.59.1.11</RefSource><PMID Version="1">12105301</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="Y">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12105318</ArticleId><ArticleId IdType="doi">10.1212/wnl.59.1.118</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12105301</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Psychotic genes or forgetful ones?</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>12</EndPage><MedlinePgn>11-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2002 Jul 9;59(1):118-20. doi: 10.1212/wnl.59.1.118</RefSource><PMID Version="1">12105318</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12105301</ArticleId><ArticleId IdType="doi">10.1212/wnl.59.1.11</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12099667</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1521-6934</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Best practice &amp; research. Clinical obstetrics &amp; gynaecology</Title><ISOAbbreviation>Best Pract Res Clin Obstet Gynaecol</ISOAbbreviation></Journal><ArticleTitle>Mood, cognition and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>370</EndPage><MedlinePgn>357-70</MedlinePgn></Pagination><Abstract><AbstractText>There is good evidence for sex differences in brain disease, and that oestrogen modulates brain development and ageing. For example, females are significantly more likely to suffer from Alzheimer's disease, depression and late-onset psychosis than are men. Moreover, hormone replacement therapy may reduce the rate of cognitive decline in post-menopausal women and reduce their risk of developing Alzheimer's disease (as compared to post-menopausal women who do not take hormone replacement therapy). The neurobiological basis of these differences in brain disease and ageing was unknown until relatively recently. In this chapter we discuss results of studies demonstrating that sex steroids (i) are crucial for development and ageing of brain regions affected in Alzheimer's disease; (ii) interact with neuronal networks and chemical systems at many different levels in brain, and (iii) affect mood and cognitive function in elderly women without Alzheimer's disease. The current literature supports the hypothesis that sex steroids can modulate brain ageing and provides a number of potential neurobiological explanations for the cognitive effects of hormone replacement therapy. There is only limited evidence that hormone replacement therapy is effective in women already suffering from Alzheimer's disease. Nonetheless, recent work may lead to new prevention strategies for age-related cognitive decline and brain diseases such as Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright 2002 Elsevier Science Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Compton</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Amelsvoort</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Declan</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Best Pract Res Clin Obstet Gynaecol</MedlineTA><NlmUniqueID>101121582</NlmUniqueID><ISSNLinking>1521-6934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012739">Gonadal Steroid Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="N">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012739" MajorTopicYN="N">Gonadal Steroid Hormones</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="Y">Postmenopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012723" MajorTopicYN="N">Sex</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12099667</ArticleId><ArticleId IdType="doi">10.1053/beog.2002.0285</ArticleId><ArticleId IdType="pii">S1521693402902853</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12080488</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>8</Issue><PubDate><MedlineDate>2002 Apr 16-30</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Dementia with frontal lobe atrophy: clinical study from 18 patients with cognitive impairment and frontal lobe involvement detected by structural and functional neuroimaging].</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>714</EndPage><MedlinePgn>709-14</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize clinically patients with cognitive impairment and frontal lobe degeneration at neuroimaging.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients diagnosed of dementia or mild neurocognitive impairment by DSM IV criteria and neuropsychological tests with frontal lobe atrophy and hipoperfusion detected by computed tomography and single photon emission computed tomography.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">18 patients, 5:1 on behalf of women; mean age at onset, 74 years; hereditary for dementia, 38%; mean duration of illness at first testing, 2 years; the most common initial symptoms, memory loss. At initial examination, psychotic or behavioral impairment was found in 61% and parkinsonism in 38%, the commonest cognitive troubles at this moment was the executive function, language and anterograde memory dysfunctions at the same rate. Frontal lobe atrophy and hypoperfusion was found in 100%, temporal in 88% and parietal in 38%. Electroencephalogram was pathological in 33%. The course of the disease was progressive but with fluctuation in 27%. Frontotemporal dementia clinical criteria in 13 patients, 4 of them clinical criteria of dementia with Lewy bodies too, and clinical criteria of Alzheimer s disease in 5.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uterga</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Neurolog&#xed;a; Hospital de Basurto, Bilbao, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Iriarte</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Garc&#xed;a</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Taramundi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Alvaro</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Cortina</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Demencia con atrofia frontal: estudio cl&#xed;nico de 18 pacientes con deterioro intelectual y degeneraci&#xf3;n de los l&#xf3;bulos frontales seg&#xfa;n la neuroimagen.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12080488</ArticleId><ArticleId IdType="pii">rn2001452</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12077953</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0029-6570</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>38</Issue><PubDate><MedlineDate>2002 Jun 5-11</MedlineDate></PubDate></JournalIssue><Title>Nursing standard (Royal College of Nursing (Great Britain) : 1987)</Title><ISOAbbreviation>Nurs Stand</ISOAbbreviation></Journal><ArticleTitle>Religious beliefs and practices in acute mental health patients.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>36</EndPage><MedlinePgn>33-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Holistic practice involves caring for the physical, psychological, social and spiritual needs of patients. Spiritual assessment is an important part of the patient's overall assessment. Religion is a component of spirituality and is supported by a recognisable formal system of beliefs. Religious beliefs might help patients in their search for meaning in life, especially in difficult circumstances such as during an episode of illness. A small, retrospective anonymous audit of patients' notes (n = 23) was undertaken to assess the recording of patients' religious affiliations, beliefs and practices in an acute mental health unit for older people.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">All individuals had a religious affiliation documented in their notes, but there was a lack of recorded information about their beliefs and practices. The findings showed that religious beliefs were only discussed with patients who had psychotic symptoms that had a religious content. Therefore, it would seem that patients on this unit are not having their spiritual and religious needs met. Staff training on religious awareness might help to address these issues.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hilton</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mental Health Service for Older People, Central and North West London Mental Health NHS Trust, Northwick Park Hospital, Harrow, Middlesex. claire.hilton@hhh-tr.nthames.nhs.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaznavi</LastName><ForeName>Farina</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zuberi</LastName><ForeName>Tahira</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nurs Stand</MedlineTA><NlmUniqueID>9012906</NlmUniqueID><ISSNLinking>0029-6570</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006694" MajorTopicYN="Y">Holistic Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012068" MajorTopicYN="Y">Religion and Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029181" MajorTopicYN="N">Spirituality</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12077953</ArticleId><ArticleId IdType="doi">10.7748/ns2002.06.16.38.33.c3204</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12040309</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0893-0341</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive and behavioral effects of quetiapine in Alzheimer disease patients.</ArticleTitle><Pagination><StartPage>128</StartPage><EndPage>130</EndPage><MedlinePgn>128-30</MedlinePgn></Pagination><Abstract><AbstractText>In a prospective, open-label, 12-week pilot study in outpatients with probable Alzheimer disease (AD) with psychosis or aggressive behaviors, we used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) to evaluate the cognitive and behavioral effects of quetiapine. After receiving doses ranging from 50 to 150 mg, patients given quetiapine showed a significant decrease of delusions, aggression, and overall behaviors based on NPI scores at 6 and 12 weeks. ADAS-cog scores did not show a significant change over 12 weeks. This study provides initial evidence that quetiapine does not significantly worsen cognition in AD outpatients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Division of Cognitive Neurology, Department of Neurology, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Shu-Ing</ForeName><Initials>SI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12040309</ArticleId><ArticleId IdType="doi">10.1097/00002093-200204000-00011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12015112</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-6450</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</Title><ISOAbbreviation>Zhonghua Liu Xing Bing Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[A case-control study on family history of Alzheimer's disease].</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>56</EndPage><MedlinePgn>54-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the relationship between Alzheimer's disease and its family history of the patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Stratified analyses and logistic regression analysis were used to examine the association between Alzheimer's disease and its family history exposure in 127 cases and 254 matched controls from a population-based case-control study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The risk of Alzheimer's disease was significantly higher in those who had at least one first-degree relative with dementia or major psychosis as compared to those who had no dementia or major relatives with psychosis (OR = 6.25; 8.33). Adjusted for age and level of education, family history of dementia was still associated with Alzheimer's disease positively (OR = 2.07).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study provides evidence that familial aggregation of Alzheimer's disease might exist among people living Beijing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jiahong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Institute of Basic Medical Sciences, CAMS &amp; PUMC, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhenxin</ForeName><Initials>Z</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Liu Xing Bing Xue Za Zhi</MedlineTA><NlmUniqueID>8208604</NlmUniqueID><ISSNLinking>0254-6450</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12015112</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12009504</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology.</ArticleTitle><Pagination><StartPage>547</StartPage><EndPage>553</EndPage><MedlinePgn>547-53</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The presence of psychotic symptoms in Alzheimer Disease subjects (AD+psychosis, AD+P) is a marker for a phenotype characterized by more severe cognitive impairment and a more rapidly deteriorating course. Although AD+P has been inconsistently associated with more severe neuropathology, no prior studies have examined measures of neuronal and synaptic integrity.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether AD+P is associated with evidence of disrupted neuronal and synaptic integrity, as indicated by magnetic resonance spectroscopy (MRS) measurement of N-acetyl-L-aspartate and the membrane breakdown products, glycerophosphocholine and glycerophosphoethanolamine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">31P and 1H MRS studies of perchloric acid extract from postmortem brain of AD subjects with and without a history of psychotic symptoms. All subjects were characterized for the presence of comorbid cortical Lewy body pathology and for history of neuroleptic use. Brain tissue from dorsolateral prefrontal, superior temporal, inferior parietal, and occipital cortex, amygdala, and cerebellum were examined in all subjects. Statistical analysis accounted for correlated observations across brain regions within-subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AD+P subjects demonstrated significant elevations of glycerophosphoethanolamine and significant reductions of N-acetyl-L-aspartate. Between group differences were greatest in neocortical brain regions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Excess impairment of neocortical neuronal and synaptic integrity may provide the structural substrate underlying AD+P. Confirmation of these findings using in vivo MRS measures is indicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Geriatrics, Neuropsychiatry, University of Pittsburgh School of Medicine, PA, USA. SweetRA@MSX.UPMC.EDU</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panchalingam</LastName><ForeName>Kanagasabai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pettegrew</LastName><ForeName>Jay W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>McClure</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08974</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH53310</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(02)00009-x</ArticleId><ArticleId IdType="pii">S019745800200009X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12003247</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>409</EndPage><MedlinePgn>401-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms in subjects with Alzheimer disease (AD+psychosis, AD+P) are a marker for a distinct phenotype characterized by more rapid cognitive and functional decline and a liability to aggressive behaviors. We recently found that AD subjects homozygous for long alleles (l) of an insertion/deletion polymorphism in the promoter region of the serotonin transporter (5-HTTPR) had elevated rates of aggressive behavior.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the 5-HTTPR ll genotype confers an increased risk of AD+P, and of the combined AD+P/aggressive phenotype.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The 5-HTTPR genotype was determined in 332 subjects diagnosed with possible or probable AD. All subjects received structured psychiatric assessments and were categorized with regard to their history of aggressive behaviors and psychotic symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistent with other reports, AD+P was associated with a significant increased risk for aggressive behavior. AD+P and aggression were both significantly associated with 5-HTTPR ll genotype and with an increased l allele frequency. Subjects with the combined behavioral phenotype (AD+P and aggressive behavior) had the highest rate of ll genotype and highest l allele frequency.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 5-HTTPR l allele appears to confer risk for the combined AD+P/aggressive phenotype. Confirmation of this association in a similar behaviorally well-characterized independent sample is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Pittsburgh, Pennsylvania, USA. sweetra@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>B G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Sukonick</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Kastango</LastName><ForeName>K B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Ferrell</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01613</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52247</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59666</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12003247</ArticleId><ArticleId IdType="doi">10.1017/s1041610201007827</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11994888</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>346</EndPage><MedlinePgn>343-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The majority of patients with Alzheimer's disease (AD) or vascular dementia display, in addition to cognitive impairment, various degrees of behavioral disturbances. As the use of cholinesterase inhibitors for the treatment of cognitive impairment in dementia becomes widespread, many of these patients will be treated concomitantly with cholinesterase inhibitors and with anti-psychotic drugs to ameliorate behavioral disturbances. Despite the widespread use of this combination in clinical practice, the safety and tolerability of such combination therapy has not been evaluated in controlled clinical trials. This pilot study examined the effects of addition of risperidone 0.5-2 mg/day to patients on rivastigmine 3-12 mg/day, and vice versa.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks. Adverse events caused by co-administration were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No clinically relevant adverse interactions were observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These preliminary results indicate that rivastigmine and risperidone can be safely co-administered. Confirmation of these results in large clinical trials studies is warranted.</AbstractText><CopyrightInformation>Copyright 2002 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiser</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sheba Medical Center, Tel Hashomer, Israel. mweiser@netvision.net.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotmensch</LastName><ForeName>Heschi H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Korczyn</LastName><ForeName>Amos D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cicin-Sain</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>Rivastigmine-Risperidone Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="Y">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11994888</ArticleId><ArticleId IdType="doi">10.1002/gps.599</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11981238</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease.</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>110</EndPage><MedlinePgn>107-10</MedlinePgn></Pagination><Abstract><AbstractText>The risk of psychosis among patients with Parkinson's disease (PD) is high, and the management of these patients remains a substantial problem for physicians. Atypical antipsychotics, despite their advantages over conventional antipsychotics, can cause different side effects and deterioration of PD. Several reports have suggested that donepezil can be helpful in the treatment of psychotic conditions in patients with dementia with Lewy bodies and Alzheimer's disease. This report presents the results of preliminary study of six patients (four women, two men; age range, 60-75 years) with PD (range of duration, 3-7 years) and dementia complicated by psychosis. All patients were treated with antiparkinsonian therapy, and donepezil was added to their regular treatment. The severity of the psychotic symptoms was assessed using the Scale for the Assessment of Positive Symptoms, and extrapyramidal symptoms were assessed using the Simpson-Angus Scale. With the addition of donepezil (as much as 10 mg/day) to their constant antiparkinsonian treatment, five patients had clinically significant (more than 53%) improvement on the assessment scale, and one patient had minimal (24%) improvement after 6 weeks of the treatment. None of the patients had side effects or deterioration of parkinsonian symptoms. The results suggest that donepezil may ameliorate psychotic symptoms in patients with PD, but this will need to be tested further in controlled, double-blind trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bergman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mental Health Center Tirat Carmel, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11981238</ArticleId><ArticleId IdType="doi">10.1097/00002826-200203000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11961984</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2008</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0029-2001</ISSN><JournalIssue CitedMedium="Print"><Volume>122</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</Title><ISOAbbreviation>Tidsskr Nor Laegeforen</ISOAbbreviation></Journal><ArticleTitle>[Dementia with Lewy bodies].</ArticleTitle><Pagination><StartPage>525</StartPage><EndPage>529</EndPage><MedlinePgn>525-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some 10%-15% of patients with dementia are diagnosed as dementia with Lewy bodies (DLB), a disorder characterised by the presence of Lewy bodies in the brainstem and cortex.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Review of pathology, clinical symptoms, pharmacological and nonpharmacological treatment, based on the literature and on personal experience.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neurochemical findings are marked cortical reduction of acetylcholine and nigrostriatal dopamine deficiency. Key features of the clinical syndrome are dementia, fluctuating consciousness, visual hallucinations and parkinsonism. There are pathological and clinical overlaps between DLB and Alzheimer's disease on the one hand, and between DLB and Parkinson's disease on the other; the relationship between these diseases awaits further elucidation. Clinical consensus criteria for DLB have been published and shown to have high sensitivity and specificity. Fluctuating consciousness may be difficult to detect, but diagnostic instruments exist that may help in the evaluation. Drug treatment of DLB is difficult. Cholinesterase inhibitors have been shown to improve cognition and psychiatric symptoms. Atypical antipsychotics may improve psychosis, but some patients develop severe sensitivity reactions. The effect of antiparkinson agents is unknown.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Alderspsykiatrisk seksjon Rogaland psykiatriske sjukehus Postboks 1163 Hillev&#xe5;g 4095 Stavanger. daa@post.rps.no</Affiliation></AffiliationInfo></Author></AuthorList><Language>nor</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Demens med Lewy-legemer.</VernacularTitle></Article><MedlineJournalInfo><Country>Norway</Country><MedlineTA>Tidsskr Nor Laegeforen</MedlineTA><NlmUniqueID>0413423</NlmUniqueID><ISSNLinking>0029-2001</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>39</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11961984</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11936242</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>"Life is not worth living": hopelessness in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>43</EndPage><MedlinePgn>38-43</MedlinePgn></Pagination><Abstract><AbstractText>This study investigated the prevalence and clinical correlates of hopelessness among 91 patients diagnosed with probable Alzheimer's disease (AD) according to National Institute of Neurological Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria. Hopeless ideation was measured with Item 3 on the Hamilton Depression Rating Scale (Suicide), which inquires specifically whether the patient thinks "life is not worth living." The results showed that hopelessness was present in 10% (n = 9) of the sample. Patients with these cognitions evidenced greater psychological symptoms of mood disturbance and more insight into their cognitive and functional impairments. Unrelated factors included age, education, Mini-Mental State Examination score, neurovegetative signs of depression, affective expressions of depression, agitation/disinhibition, and psychosis. Although indifference is frequent in AD, these results indicate that thoughts of hopelessness are also a common phenomenon, occurring in approximately 10% of our probable AD cohort. These thoughts appear to be related to the subjective expressions of depression and anxiety rather than the neurovegetative or affective signs and are more prominent among patients with greater deficit awareness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>Dylan G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Mental Health Services, VA Greater Los Angeles Healthcare System, California 90073, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH00910</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH56031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11936242</ArticleId><ArticleId IdType="doi">10.1177/089198870201500108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11936240</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>30</EndPage><MedlinePgn>24-30</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms occurring in Alzheimer's disease (AD + psychosis, AD + P) are a marker for a more rapidly deteriorating phenotype. We have developed a polygenic model of AD + P risk, conditioned on the presence of AD. Whether risk genes for AD itself contribute to AD + P risk is not established, although our model predicts they will not. The most important identified genetic determinant of sporadic, late-onset AD is the apolipoprotein E epsilon 4 allele (APOE4). The effect of APOE4 on AD phenotype is to reduce the age of onset of AD. Prior studies examining the association of APOE4 with AD + P have reported conflicting results. However, no prior studies have examined if APOE4 reduces time to onset of psychosis in AD. The objective of this study was to examine the effect of APOE4 and alpha1-antichymotrypsin/AA (ACT/AA) genotypes on time to psychosis onset in subjects with AD. A longitudinal study of psychosis incidence in 316 subjects with AD with no history of current or prior psychotic symptoms at entry was undertaken. APOE and ACT genotyping was conducted per established protocols. Data were analyzed by survival analysis and Cox proportional hazards models. There were no significant associations of APOE or ACT genotypes with time to psychosis onset and no significant interaction of these genotypes with time to psychosis onset. There remained no significant associations after covarying for age, age of AD onset, degree of cognitive impairment, gender, race, and education. This is the first study to examine the genetic prediction of psychosis onset in AD. The findings support the hypothesis that these two genetic determinants of AD risk do not contribute to the risk of development of psychotic symptoms in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000514">alpha 1-Antichymotrypsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000514" MajorTopicYN="N">alpha 1-Antichymotrypsin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11936240</ArticleId><ArticleId IdType="doi">10.1177/089198870201500106</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11917507</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1340-2544</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology</Title><ISOAbbreviation>Nihon Shinkei Seishin Yakurigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>13</EndPage><MedlinePgn>3-13</MedlinePgn></Pagination><Abstract><AbstractText>N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) and ketamine have been known to cause schizophrenia-like psychosis (positive symptoms, negative symptoms, cognitive dysfunction) in humans. A dysfunction of glutamatergic neurotransmission may play an important role in the pathophysiology of schizophrenia. In this review, the glutamate hypothesis of schizophrenia, especially the mechanism of neurotoxicity of NMDA receptor antagonist in the posterior cingulate cortex and retrosplenial cortex of the brain, is summarized. Furthermore, the roles of the posterior cingulate cortex and the retrosplenial cortex in the pathophysiology of schizophrenia and Alzheimer's disease are also discussed. Moreover, the glycine site of the NMDA receptor, metabotropic glutamate receptor, AMPA receptor, and antioxidant glutathione as novel potential targets for the treatment of schizophrenia are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chiba, 260-8670 Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyo</LastName><ForeName>Masaomi</ForeName><Initials>M</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Shinkei Seishin Yakurigaku Zasshi</MedlineTA><NlmUniqueID>9509023</NlmUniqueID><ISSNLinking>1340-2544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005971">Glutamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical><Chemical><RegistryNumber>J1DOI7UV76</RegistryNumber><NameOfSubstance UI="D010622">Phencyclidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005971" MajorTopicYN="N">Glutamates</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010622" MajorTopicYN="N">Phencyclidine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>111</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11917507</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11914406</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Increased familial risk of the psychotic phenotype of Alzheimer disease.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>911</EndPage><MedlinePgn>907-11</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms in patients with AD (AD with psychosis [AD+P]) define a phenotype characterized by more rapid cognitive and functional decline and a liability to aggressive behaviors.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if AD+P aggregates within families.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Case-control study of AD+P frequency in 461 siblings of 371 probands diagnosed with AD. All siblings were ascertained as part of a genetic investigation and also were diagnosed with AD. Statistical analysis used Generalized Estimating Equations to adjust for clustering within families.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AD+P in probands was associated with a significantly increased risk for AD+P in family members (OR, 2.41; 95% CI 1.46-4.0; p = 0.0006). The correlation among siblings for AD+P status was modest: 0.16.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AD+P demonstrates familial aggregation. Further studies are required to investigate a possible genetic basis of AD+P.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Neuropsychiatry, School of Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. SweetRA@MSX.UPMC.EDU</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01489</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH53459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH57881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46290</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH46373</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId><ArticleId IdType="doi">10.1212/wnl.58.6.907</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11904750</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Disentangling the pathology of schizophrenia and paraphrenia.</ArticleTitle><Pagination><StartPage>313</StartPage><EndPage>320</EndPage><MedlinePgn>313-20</MedlinePgn></Pagination><Abstract><AbstractText>With increasing longevity, the number of older schizophrenic patients is growing. Previous criteria used the age of symptom onset to differentiate between the late manifestations of early-onset schizophrenia and late-onset schizophreniform disorders. Current DSM-IV or ICD 10 nomenclatures do not differentiate between early- and late-onset schizophrenia. Many decades of repeated failures to provide for distinguishing neuropathological findings have prompted narrower definition criteria. Since psychotic or schizophreniform symptoms in old age may be a manifestation of Alzheimer's disease, we attempted to base a distinction between both early- and late-onset schizophrenia on the presence of degenerative changes. This study examined the brains of 64 schizophrenic patients and 18 controls immunocytochemically for tau and amyloid staining. We divided patients according to their ages at the onset of symptoms: &lt;40, &gt;40. Using Braak's classification, we assessed the presence of neurofibrillary pathology. Stages III and IV were observed in 11.1% (2/18) of controls, 36.7% (11/30) of early-onset schizophrenics (&lt;40) and 58.8% (20/34) of late-onset (&gt;40) schizophrenics (chi2=11.39, P =0.003). Stages V and VI (definite Alzheimer's disease) did not significantly differ among groups (chi2=3.6, P =0.165). Astrocytes, subependymal and fibroblastic, also exhibited tau-positive tangles. Chi-square analysis of the data revealed a significant association between tau-positive glial tangles and Braak staging ( P =0.002). Amyloid deposits were sparse in comparison to tau-related changes. The restricted limbic tauopathy not only affected a majority of patients with late-onset schizophrenia (19 female: 1 male among positive cases) ( P =0.048) but also appeared in one-third of those elderly schizophrenic patients whose symptom onset occurred before 40 years of age (8 female: 3 male among positive cases) ( P =0.048). The resultant changes define a type of neuronal cytoskeletal disruption that alters the flow of information through the hippocampus and provides a useful clinico-pathological correlate to a group of patients until recently diagnosed as schizophrenic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casanova</LastName><ForeName>Manuel F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, Medical College of Georgia, Downtown VA Medical Center, 1 Freedom Way, 26 Psychiatry Service, 3B-121, Augusta, GA 30910, USA. casanova@np2.mcg.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Janice R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Royston</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bruton</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2001</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2000</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11904750</ArticleId><ArticleId IdType="doi">10.1007/s00401-001-0468-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11890487</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>10</Issue><PubDate><Year>2001</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?</ArticleTitle><Pagination><StartPage>1294</StartPage><EndPage>1300</EndPage><MedlinePgn>1294-300</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Several previous studies have examined the effects of pharmacological interventions for agitated behavior in patients with dementia. However, the choice of medication in clinical practice continues to be directed largely by local pharmacotherapy culture rather than empirical treatment guidelines. We examined the relationship between behavioral improvement and co-occurring delusions and mood symptoms in patients with dementia who were treated with haloperidol, an antipsychotic medication, or trazodone, a serotonergic antidepressant.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, double-blind, parallel-group, 9-week treatment trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Inpatient geropsychiatry unit.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Twenty-eight patients with dementia and agitated or aggressive behaviors.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Haloperidol 1 to 5 mg/day or trazodone 50 to 250 mg/day.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Cohen-Mansfield Agitation Inventory (CMAI), Hamilton Depression Rating Scale (Ham-D), and delusional thoughts subscale and hallucinations subscale of the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CMAI scores improved in each treatment group over the 9 weeks of treatment (P &lt; .001 in each group). Within the haloperidol treatment group, CMAI improvement was not associated with baseline delusional thoughts score or with change in delusional thoughts score over the course of treatment. Within the trazodone treatment group, CMAI improvement was associated with baseline score on total Ham-D (r = -0.60, P = .02), Ham-D items measuring subjective mood symptoms (r = -0.50, P = .07), and Ham-D items measuring neurovegetative signs (r = -0.49, P = .08). CMAI improvement was also associated with improvement in Ham-D total score over the course of treatment (r = 0.62, P = .02).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mild depressive symptoms in patients with dementia and agitated behavior are associated with greater behavioral improvement by trazodone-treated patients. In contrast, the presence of delusions in concert with behavioral disturbance does not necessarily predict greater behavioral improvement with haloperidol treatment than in subjects without signs of psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>D L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, and VA Greater Los Angeles Healthcare System, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>K F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Gunay</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH00910</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH56031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>YBK48BXK30</RegistryNumber><NameOfSubstance UI="D014196">Trazodone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014196" MajorTopicYN="N">Trazodone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>16</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11890487</ArticleId><ArticleId IdType="doi">10.1046/j.1532-5415.2001.49256.x</ArticleId><ArticleId IdType="pii">49256</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11844887</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>73</EndPage><MedlinePgn>67-73</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a post hoc analysis of a subgroup of patients with DLB included in a larger double-blind, placebo-controlled, randomized parallel group trial of olanzapine for the treatment of psychosis in patients with Alzheimer's disease. Patients meeting the consensus criteria for DLB and exhibiting parkinsonism and visual hallucinations were selected from the initial study. Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). Extrapyramidal symptoms were evaluated with the Simpson-Angus scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-nine patients met the criteria for DLB; 10 were randomized to placebo, 5 received 5 mg of olanzapine, 7 received 10 mg of olanzapine and 7 received 15 mg of olanzapine. Patients with DLB treated with 5 mg of olanzapine showed significant reductions in delusions and hallucinations. Patients treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of olanzapine. There was no significant exacerbation of parkinsonian symptoms in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic toxicity did not differ among treatment groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This preliminary analysis suggests that olanzapine (5 or 10 mg) reduces psychosis in patients with DLB without worsening parkinsonism.</AbstractText><CopyrightInformation>Copyright 2002 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCLA School of Medicine, Los Angeles, Calif., USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Street</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Masterman</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>W Scott</ForeName><Initials>WS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11844887</ArticleId><ArticleId IdType="doi">10.1159/000048636</ArticleId><ArticleId IdType="pii">48636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11838627</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>58</EndPage><MedlinePgn>54-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vitamin B6, or pyridoxine, plays an intrinsic role in the synthesis of certain neurotransmitters that take part in development of psychotic states. Several reports indicate that vitamin B6 may be a factor in a number of psychiatric disorders and related conditions, such as autism, Alzheimer's disease, hyperactivity, learning disability, anxiety disorder, and depression. Moreover, there are anecdotal reports of a reduction in psychotic symptoms after vitamin B6 supplementation of psychopharmacologic treatment of patients suffering from schizophrenia or organic mental disorder. The aim of this study was to examine whether vitamin B6 therapy influences psychotic symptoms in patients suffering from schizophrenia and schizoaffective disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The effects of the supplementation of vitamin B6 to antipsychotic treatment on positive and negative symptoms in 15 schizophrenic and schizoaffective patients (DSM-IV criteria) were examined in a double-blind, placebo-controlled, crossover study spanning 9 weeks. All patients had stable psychopathology for at least 1 month before entry into the study and were maintained on treatment with their prestudy psychoactive and antiparkinsonian medications throughout the study. All patients were assessed using the Positive and Negative Syndrome Scale (PANSS) for schizophrenia on a weekly basis. Patients randomly received placebo or vitamin B6, starting at 100 mg/day in the first week and increasing to 400 mg/day in the fourth week by 100-mg increments each week.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further studies with larger populations and shorter duration of illness are needed to clarify the question of the possible efficacy of vitamin B6 in treatment of psychotic symptoms in schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel. lernervld@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miodownik</LastName><ForeName>Chanoch</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kaptsan</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Hagit</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Loewenthal</LastName><ForeName>Uri</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Kotler</LastName><ForeName>Moshe</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>8059-24-3</RegistryNumber><NameOfSubstance UI="D025101">Vitamin B 6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025101" MajorTopicYN="N">Vitamin B 6</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11838627</ArticleId><ArticleId IdType="doi">10.4088/jcp.v63n0111</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11803444</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-4184</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>43</EndPage><MedlinePgn>32-43</MedlinePgn></Pagination><Abstract><AbstractText>NMDA glutamate receptor antagonists are used in clinical anesthesia, and are being developed as therapeutic agents for preventing neurodegeneration in stroke, epilepsy, and brain trauma. However, the ability of these agents to produce neurotoxicity in adult rats and psychosis in adult humans compromises their clinical usefulness. In addition, an NMDA receptor hypofunction (NRHypo) state might play a role in neurodegenerative and psychotic disorders, like Alzheimer's disease and schizophrenia. Thus, understanding the mechanism underlying NRHypo-induced neurotoxicity and psychosis could have significant clinically relevant benefits. NRHypo neurotoxicity can be prevented by several classes of agents (e.g. antimuscarinics, non-NMDA glutamate antagonists, and alpha(2) adrenergic agonists) suggesting that the mechanism of neurotoxicity is complex. In the present study a series of experiments was undertaken to more definitively define the receptors and complex neural circuitry underlying NRHypo neurotoxicity. Injection of either the muscarinic antagonist scopolamine or the non-NMDA antagonist NBQX directly into the cortex prevented NRHypo neurotoxicity. Clonidine, an alpha(2) adrenergic agonist, protected against the neurotoxicity when injected into the basal forebrain. The combined injection of muscarinic and non-NMDA Glu agonists reproduced the neurotoxic reaction. Based on these and other results, we conclude that the mechanism is indirect, and involves a complex network disturbance, whereby blockade of NMDA receptors on inhibitory neurons in multiple subcortical brain regions, disinhibits glutamatergic and cholinergic projections to the cerebral cortex. Simultaneous excitotoxic stimulation of muscarinic (m(3)) and glutamate (AMPA/kainate) receptors on cerebrocortical neurons appears to be the proximal mechanism by which the neurotoxic and psychotomimetic effects of NRHypo are mediated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>N B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St Louis, MO 63110, USA. farbern@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Dikranian</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>X P</ForeName><Initials>XP</Initials></Author><Author ValidYN="Y"><LastName>Heinkel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA00290</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA05072</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical><Chemical><RegistryNumber>118876-58-7</RegistryNumber><NameOfSubstance UI="C062865">2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>7619-35-4</RegistryNumber><NameOfSubstance UI="C012134">SK&amp;F 10047</NameOfSubstance></Chemical><Chemical><RegistryNumber>77521-29-0</RegistryNumber><NameOfSubstance UI="D018350">alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8Y164V895Y</RegistryNumber><NameOfSubstance UI="D002217">Carbachol</NameOfSubstance></Chemical><Chemical><RegistryNumber>C3N1PS8CX1</RegistryNumber><NameOfSubstance UI="C034931">rimcazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>DL48G20X8X</RegistryNumber><NameOfSubstance UI="D012601">Scopolamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J0ND6N0AQC</RegistryNumber><NameOfSubstance UI="D010620">Phenazocine</NameOfSubstance></Chemical><Chemical><RegistryNumber>MN3L5RMN02</RegistryNumber><NameOfSubstance UI="D003000">Clonidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000316" MajorTopicYN="N">Adrenergic alpha-Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002217" MajorTopicYN="N">Carbachol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003000" MajorTopicYN="N">Clonidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010620" MajorTopicYN="N">Phenazocine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="N">Receptors, sigma</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012601" MajorTopicYN="N">Scopolamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018350" MajorTopicYN="N">alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2000</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2001</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2001</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11803444</ArticleId><ArticleId IdType="doi">10.1038/sj.mp.4000912</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11802236</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Addressing the needs of carers of older people: the Islington study.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>86</EndPage><MedlinePgn>85-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Train</LastName><ForeName>Georgina H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Manela</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="Y">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11802236</ArticleId><ArticleId IdType="doi">10.1002/gps.528</ArticleId><ArticleId IdType="pii">10.1002/gps.528</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11782103</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0889-1591</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Brain, behavior, and immunity</Title><ISOAbbreviation>Brain Behav Immun</ISOAbbreviation></Journal><ArticleTitle>T-helper-1 and T-helper-2 responses in psychiatric disorders.</ArticleTitle><Pagination><StartPage>340</StartPage><EndPage>370</EndPage><MedlinePgn>340-70</MedlinePgn></Pagination><Abstract><AbstractText>The expanding field of psychoneuroimmunology has markedly increased knowledge about the interference of the central nervous system and the immune system. Immunological abnormalities in psychiatric patients have been repeatedly described in the last century. Modern concepts of immunology and the growing knowledge of psychoneuroimmunology may help in understanding the distinct immunological mechanisms in psychiatric disorders. One of these concepts regarding the adaptive immune system is the discrimination between Th1-like cell-mediated and Th2-like antibody-related immune responses. This article systematically describes alterations of Th1- or Th2-specific parameters in the major psychiatric disorders schizophrenia, major depression, and Alzheimer's disease. There are several hints of associations of these two distinct arms of immune response with subgroups of schizophrenia and major depression. The immunological research in Alzheimer's disease has already led to a preclinical model of immunotherapy. Categorization of immune parameters may also help to identify a possible immune-related pathophysiology in psychotic and affective disorders, resulting in specific treatment strategies.</AbstractText><CopyrightInformation>Copyright 2001 Elsevier Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Psychiatric Hospital, University of Munich, Nussbaumstr. 7, D-80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ackenheil</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Behav Immun</MedlineTA><NlmUniqueID>8800478</NlmUniqueID><ISSNLinking>0889-1591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="N">Neuroimmunomodulation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>247</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11782103</ArticleId><ArticleId IdType="doi">10.1006/brbi.2001.0647</ArticleId><ArticleId IdType="pii">S0889-1591(01)90647-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11775050</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.</ArticleTitle><Pagination><StartPage>894</StartPage><EndPage>900</EndPage><MedlinePgn>894-900</MedlinePgn></Pagination><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This open-label study examined the efficacy and tolerability of risperidone in the treatment of aggression, agitation, and psychotic symptoms in dementia. The influence of risperidone on cognitive function was also assessed under conditions reflecting normal, daily clinical care.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 34 hospital inpatients and outpatients (mean age = 76 years) with DSM-IV dementia disorders were treated with flexible doses of risperidone (0.5-2 mg/day) for 8 weeks. Assessments, conducted at baseline and after weeks 4 and 8, included the Clinical Global Impressions scale (CGI) and Neuropsychiatric Inventory (NPI) ratings. Cognitive function assessments included the Mini-Mental State Examination (MMSE) and specific measures of cognition (Age Concentration Test [AKT] and Brief Syndrome Test [SKT]). Frequency of extrapyramidal symptoms (EPS) was measured according to the Extrapyramidal Symptom Rating Scale (ESRS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the end of the study, 50% of patients (N = 17) were receiving risperidone, 1 mg/day. 18% (N = 6) were receiving 0.5 mg/day, and 32% (N = 11) received &gt; 1 mg/day (mean dose at endpoint = 1.1 mg/day). An improvement in symptoms, as measured by the CGI-Global Impression of Change scale, was reported for 82% of patients (N = 28) (59% [N = 20] much or very much improved). The frequency and severity of delusions, hallucinations, agitation/aggression, and irritability decreased as measured by the NPI. Multiplication of frequency and severity scores revealed a significant decline during the course of treatment (p &lt; .001, end of study vs. baseline). Caregiver responses on the NPI also showed an improvement, with the mean +/- SD total score decreasing from 24.2 +/- 7.3 at baseline to 21.2 +/- 6.3 at study end (p = .002). MMSE, AKT, and SKT results indicated that there was no decrease in cognitive function during the study. Risperidone treatment was well tolerated, and no clinically relevant changes in EPS. vital signs, or weight were detected.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During treatment with low-dose risperidone, behavioral and psychological symptoms improved overall in 34 patients with dementia, and cognitive function was maintained throughout the treatment period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rainer</LastName><ForeName>M K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Donauspital-Memory Clinic, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masching</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Ertl</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Kraxberger</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Haushofer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11775050</ArticleId><ArticleId IdType="doi">10.4088/jcp.v62n1110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11760691</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Typology of elderly patients hospitalized in psychiatry: evaluation of psychiatric antecedents before age 60].</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>428</EndPage><MedlinePgn>423-8</MedlinePgn></Pagination><Abstract><AbstractText>To take care of elderly patients in psychiatric hospital sets specific problems. It is interesting to know the mode, the frequency, and the reasons of these hospitalizations, to improve the medical care given to these subjects. We made a prospective study with elderly patients hospitalized in a psychiatric institution. The results were completed in discussions with the medical care staff. During the study (January and February 1997), 112 elderly patients, about more than 60 years old, were hospitalized in Villejuif' specialized hospital (inpsychiatric units). Informations about social facts, main psychiatric previous, reasons of the hospitalization, the caring and the evolution of these subjects were collected. The main important reflexion we did observe was the significant difference between elderly patients hospitalized in psychiatric units, with or without psychiatric previous before the age of 60. Those who were hospitalized at the first time in psychiatric units before 60, presented a medium aged population, younger than the other group. They also presented more delusion with psychosis, were more frequently hospitalized longly in psychiatric units, took neuroleptics, and their somatic associate pathologies were less difficult to take care of. In the second group including the elderly patients without psychiatric previous before 60, we did observe very different characteristics: the diagnosis of most of the patients is dementia; these elderly subjects leaved mostly at home, they presented more sadness, aggression, or social inappropriate behaviour. Depression is a more frequent diagnosis. This study of all the elderly patients admitted in a psychiatric hospital confirmed the population's heterogeneity. The existence of an hospitalisation in psychiatric unit before sixty represented a pertinent test to a major and simple approach of these differences. The psychiatric unit which receives more and more elderly patients take care of their differences to the organisation of care needs between the gerontopsychiatric patients types. The patients with a late gerontopsychiatric's disease could need a specific hospitalization in gerontopsychiatric units, especially organised to deliver psychiatric cares and somatic cares, including medical geriatric practicer and medical care staff formed to the dependence need care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pariel-Madjlessi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Interne G&#xe9;riatrique, H&#xf4;pital Ren&#xe9; Muret, 93270 Sevran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madjlessi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fremont</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Belmin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Typologie des patients &#xe2;g&#xe9;s hospitalis&#xe9;s en psychiatrie: importance des ant&#xe9;c&#xe9;dents psychiatriques avant l'&#xe2;ge de 60 ans.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="N">Psychiatric Department, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11760691</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11758666</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.</ArticleTitle><Pagination><StartPage>798</StartPage><EndPage>799</EndPage><MedlinePgn>798-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Eap</LastName><ForeName>C B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Zullino</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>FTA7XXY4EZ</RegistryNumber><NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11758666</ArticleId><ArticleId IdType="doi">10.1097/00005053-200111000-00012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748790</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.</ArticleTitle><Pagination><StartPage>S71</StartPage><EndPage>S77</EndPage><MedlinePgn>S71-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is associated with both cognitive and behavioral symptoms. Agitation, hallucinations, delusions, aggression, irritability, and anxiety are observed in up to 90% of patients with dementia. Although new information has emerged in recent years on the treatment of psychosis and agitation in dementia, very little information is available about the treatment of anxiety symptoms in this population.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the efficacy and tolerability of olanzapine in the treatment of significant anxiety symptoms in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A post hoc analysis of a previously published study was performed. Those post hoc analysis evaluated the response to treatment with olanzapine of a subgroup of AD patients presenting with significant symptoms of anxiety. Patients were considered to have significant symptoms of anxiety if their baseline in the Nursing home version of the Neuropsychiatric Instrument NPI/NH anxiety scores were &gt; or = 2. The analysis included 120 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients receiving olanzapine 5 mg/d were statistically significantly improved on the NPI/NH Anxiety item compared to those receiving placebo (olanzapine, 5 mg/d: -3.72; placebo: -1.67; p = 0.034). In the group of patients with clinically significant anxiety, somnolence was the only treatment-emergent event that was statistically different in any olanzapine treatment group compared with placebo (olanzapine 5 mg/d: 9 patients [25%], p = 0.034; 10 mg/d: 7 [23%], p = 0.054; 15 mg/d: 7 [26%], p = 0.050; placebo: 1 [3.7%]). When controlling for treatment-emergent somnolence, the improvement in anxiety in the olanzapine 5 mg/d group remained statistically significant (p = 0.049).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that olanzapine could be a safe and effective treatment for anxiety in Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical University of South Carolina, Alzheimer's Research and Clinical Programs Charleston, SC 29406-6076, USA. mintzerj@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faison</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Street</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Sutton</LastName><ForeName>V K</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11748790</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200112)16:1+&lt;::aid-gps568&gt;3.0.co;2-m</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200112)16:1+&lt;::AID-GPS568&gt;3.0.CO;2-M</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748789</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>S62</StartPage><EndPage>S70</EndPage><MedlinePgn>S62-70</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms and behavioral disturbances are a leading cause of institutionalization in elderly patients with Alzheimer's disease (AD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Elderly nursing home patients (n=105) with possible or probable AD were entered into a multicenter study to determine the long-term efficacy and safety of olanzapine in treatment of psychotic symptoms and behavioral disturbances due to AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following a double-blind, 6-week exposure to fixed-dose olanzapine (5, 10, or 15 mg/d), patients entered an additional 18-week, open-label, flexible-dose treatment. Baseline was defined from the start of the extension phase.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients improved significantly on the primary efficacy measure, defined a priori, which consisted of the sum of the Agitation/Aggression, Delusions, and Hallucinations items ('Core':) of the NPI/NH. Olanzapine also significantly improved scores for the NPI/NH total and the Core item-associated Occupational Disruptiveness of the NPI/NH, as well as the BPRS total and CGI Severity-of-Alzheimer's scores. Barnes Akathasia scores improved significantly from baseline, while Simpson-Angus and AIMS scores were not significantly changed. Treatment-emergent symptoms included somnolence, accidental injury, and rash. No significant changes were seen in ECGs, including QT(c) interval, nor in weight or vital signs, including orthostasis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low-dose olanzapine appears to be effective and well tolerated for treatment of behavioral disturbances and psychotic symptoms due to AD in elderly patients.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Street</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>W S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Kadam</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Mitan</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Juliar</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11748789</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200112)16:1+&lt;::aid-gps569&gt;3.0.co;2-j</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200112)16:1+&lt;::AID-GPS569&gt;3.0.CO;2-J</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748787</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>S24</StartPage><EndPage>S32</EndPage><MedlinePgn>S24-32</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Double-blind data were compared for placebo and three fixed olanzapine dosages (5 mg/day, 10 mg/day, and 15 mg/day) in 206 nursing home-residing patients with AD for five a priori selected central nervous system anticholinergic-like adverse events: confusion, delirium, delusions, hallucinations, abnormal thinking. Mean change from baseline to endpoint on the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) was measured for a subgroup of 43 patients who had mild to moderate cognitive impairment at baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences in central anticholinergic-like adverse events at any olanzapine dose compared to placebo. Additionally, in the 43-patient subgroup, there were no significant differences in mean change in ADAS-Cog scores between placebo and the three olanzapine dose subgroups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Olanzapine did not differ significantly from placebo for any of the five central nervous system anticholinergic events nor on the ADAS-Cog. Olanzapine's initially reported potent in vitro muscarinic receptor affinity is not consistent with this clinical study of central nervous system anticholinergic-like adverse events in patients with AD.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. jskennedy@LILLY.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagar</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nomikos</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Trzepacz</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Gilmore</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Rotelli</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tollefson</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11748787</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200112)16:1+&lt;::aid-gps570&gt;3.0.co;2-8</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200112)16:1+&lt;::AID-GPS570&gt;3.0.CO;2-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748785</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dementia with Lewy bodies: diagnosis and management.</ArticleTitle><Pagination><StartPage>S12</StartPage><EndPage>S18</EndPage><MedlinePgn>S12-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To summarize the clinical, pathological, imaging and treatment aspects of dementia with Lewy bodies (DLB).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Review of literature (MEDLINE).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DLB is the second most common form of degenerative dementia, accounting for up to 20% of cases in the elderly. It is characterized by fluctuating cognitive impairment, spontaneous parkinsonism and recurrent visual hallucinations. Consensus clinical criteria have been published and have been shown to have high specificity, but they may still lack sensitivity. Pathologically, DLB may be classified as a Lewy body (LB) disorder and/or as an alpha-synucleinopathy. It is probable that a spectrum of LB disorders exists with the clinical features reflecting the distribution and severity of pathology. Although both DLB and Alzheimer's disease (AD) show a reduction in pre-synaptic cholinergic transmission from the basal forebrain, in DLB there are also deficits in cholinergic transmission from brain stem nuclei. Post-synaptic cortical muscarinic receptors are more functionally intact in DLB suggesting potential responsiveness to cholinergic enhancement. Neuroimaging findings indicate a relative preservation of medial temporal lobe structures in DLB but similar distribution of white matter changes on MRI compared with AD. Defects in nigrostriatal dopamine pathways in DLB have been demonstrated with functional neuroimaging using ligands highlighting pre- and post-synaptic dopaminergic systems. Preliminary studies also indicate subtle differences in perfusion patterns on SPECT with a greater degree of occipital hypoperfusion in DLB compared with AD. Accurate diagnosis of DLB is clinically important as the management of psychosis and behavioural disturbances is complicated by sensitivity to neuroleptic medication. There is accumulating evidence to suggest that DLB may be particularly amenable to cholinergic enhancers. The clinical management of DLB is considered using a four step approach: making a diagnosis; identification of problem symptoms; appropriate non-pharmacological interventions; and pharmacological interventions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Consensus criteria for probable DLB have high specificity-a positive clinical diagnosis is likely to be correct. Treatment choices must consider effects upon motor, cognitive and psychiatric symptoms. Non-pharmacological management is an essential first step, as is reduction or withdrawal of drugs with potential adverse effects. Neuroleptic sensitivity reactions appear less likely to occur with the newer atypical antipsychotics. Cholinesterase inhibitors have been shown in open-label studies and one placebo RCT to be well tolerated and effective in treating cognitive and psychiatric symptoms in DLB. They may become first-line treatments.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Health of the Elderly, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK. Robert.Barber@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panikkar</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>49</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11748785</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200112)16:1+&lt;::aid-gps562&gt;3.0.co;2-3</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200112)16:1+&lt;::AID-GPS562&gt;3.0.CO;2-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748783</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions.</ArticleTitle><Pagination><StartPage>S2</StartPage><EndPage>S6</EndPage><MedlinePgn>S2-6</MedlinePgn></Pagination><Abstract><AbstractText>Neuroleptics have a definite role in dementia but the treatment targets need to be more narrowly defined. Symptom clusters that are neuroleptic-responsive (e.g., aggression, psychomotor agitation and psychosis) appear to be emerging but need clearer definition and measurement. A number of these symptom clusters are relatively persistent over time and associated with increased risk of institutionalization, underscoring the need for treatment. The frequency, severity and persistence of the symptom or behaviour, the context in which it occurs and its impact on the carer must be considered before prescribing a neuroleptic. Given the modest effect size for neuroleptic interventions, the safety and tolerability of the agent is also a key factor in determining drug choice. Novel neuroleptics are safer and better tolerated and therefore should be used in preference to conventional agents when neuroleptic treatment is indicated for behavioural and psychological symptoms of dementia.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>St. James's Hospital and Trinity College, Dublin, Ireland. balawlor@indigo.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhriain</LastName><ForeName>S N</ForeName><Initials>SN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>35</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11748783</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200112)16:1+&lt;::aid-gps567&gt;3.0.co;2-p</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200112)16:1+&lt;::AID-GPS567&gt;3.0.CO;2-P</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11746650</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study.</ArticleTitle><Pagination><StartPage>1043</StartPage><EndPage>1053</EndPage><MedlinePgn>1043-53</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We investigated the frequency and inter-relationship of neuropsychiatric disturbances in a population sample of persons suffering from Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Screening 5,092 elderly residents (90% of the population aged 65 and older) of Cache County, Utah, for dementia, we identified 198 persons with AD using a comprehensive neuropsychiatric examination protocol. This examination included the Neuropsychiatric Inventory (NPI), a widely used measure of dementia-associated neuropsychiatric disturbances.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 60% of individuals with AD reported one or more neuropsychiatric symptoms. A latent class analysis revealed that these participants could be classified into three groups (classes) based on their neuropsychiatric symptom profile. The largest class included cases with no neuropsychiatric symptoms (40%) or with a mono-symptomatic disturbance (19%). A second class (28%) exhibited a predominantly affective syndrome, while a third class (13%) had a psychotic syndrome.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Data from this first US population-based study of AD-associated neuropsychiatric disturbances suggest that a significant majority of persons with AD suffer from one or more neuropsychiatric disturbance. Based on phenomenological study, the spectrum of neuropsychiatric symptoms in AD can be empirically classified into three groups: an affective syndrome, a psychotic syndrome and other neuropsychiatric disturbance. The biologic and predictive validity of this classification merits further investigation.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Service, Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, USA. kostas@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheppard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tschanz</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH56511</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Geriatr Psychiatry. 2001 Nov;16(11):1028-9. doi: 10.1002/gps.556</RefSource><PMID Version="1">11746646</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Int J Geriatr Psychiatry. 2001 Nov;16(11):1030-2. doi: 10.1002/gps.557</RefSource><PMID Version="1">11746647</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="N">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId><ArticleId IdType="doi">10.1002/gps.448</ArticleId><ArticleId IdType="pii">10.1002/gps.448</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11746649</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1037</StartPage><EndPage>1042</EndPage><MedlinePgn>1037-42</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Neuropsychiatry and Geriatric Psychiatry Services, School of Medicine, and Department of Mental Hygiene, School of Public Health, The Johns Hopkins University, Baltimore, Maryland, USA. kostas@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>P V</ForeName><Initials>PV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG-11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG98003</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH56511</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Geriatr Psychiatry. 2001 Nov;16(11):1028-9. doi: 10.1002/gps.556</RefSource><PMID Version="1">11746646</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Int J Geriatr Psychiatry. 2001 Nov;16(11):1030-2. doi: 10.1002/gps.557</RefSource><PMID Version="1">11746647</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11746649</ArticleId><ArticleId IdType="doi">10.1002/gps.440</ArticleId><ArticleId IdType="pii">10.1002/gps.440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11739062</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.</ArticleTitle><Pagination><StartPage>346</StartPage><EndPage>360</EndPage><MedlinePgn>346-60</MedlinePgn></Pagination><Abstract><AbstractText>The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>L S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Clinical Antipsychotic Trials of Intervention Effectiveness Program of the National Institute of Mental Health at the University of North Carolina, Chapel Hill, NC, USA. lschneid@usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>P N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>I R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Olin</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>B G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>P V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH 90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>15</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11739062</ArticleId><ArticleId IdType="pii">S1064-7481(12)61450-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11723200</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation.</ArticleTitle><Pagination><StartPage>777</StartPage><EndPage>779</EndPage><MedlinePgn>777-9</MedlinePgn></Pagination><Abstract><AbstractText>This study investigated possible associations between selected polymorphisms in the dopamine receptor genes DRD1 and DRD3 with the presence of psychotic phenomena or aggressive behaviour in a community based cohort of 134 patients with late onset Alzheimer's disease. An association was found between the presence of psychotic symptoms and aggressive behaviour and the DRD1 polymorphism and between the presence of psychosis, but not aggression, and the DRD3 polymorphism. Specifically, carriers of the DRD1 B2 allele were more likely to be aggressive or experience hallucinations whereas homozygous carriers of the DRD3 1 allele were more likely to experience delusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Southampton, Community Clinical Sciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Road, West End, Southampton SO30 3JB, UK. ch4@soton.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ganderton</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Arranz</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collier</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493593">DRD3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):715. doi: 10.1136/jnnp.71.6.715</RefSource><PMID Version="1">11723188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="Y">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11723200</ArticleId><ArticleId IdType="pmc">PMC1737623</ArticleId><ArticleId IdType="doi">10.1136/jnnp.71.6.777</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11697070</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0279-3695</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>10</Issue><PubDate><Year>2001</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of psychosocial nursing and mental health services</Title><ISOAbbreviation>J Psychosoc Nurs Ment Health Serv</ISOAbbreviation></Journal><ArticleTitle>To treat or not to treat? Managing acute symptoms in an elderly patient with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>12</StartPage><EndPage>15</EndPage><MedlinePgn>12-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deegan</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>K P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychosoc Nurs Ment Health Serv</MedlineTA><NlmUniqueID>8200911</NlmUniqueID><ISSNLinking>0279-3695</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11697070</ArticleId><ArticleId IdType="doi">10.3928/0279-3695-20011001-09</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11603264</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>25 Pt 1</Issue><PubDate><MedlineDate>2001 Sep 8-15</MedlineDate></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Cognitive aging in chronic psychotic patients].</ArticleTitle><Pagination><StartPage>1246</StartPage><EndPage>1252</EndPage><MedlinePgn>1246-52</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The cognitive aging of psychotic patients is still poorly apprehended and sometimes wrongly compared with demential or pseudo-demential deterioration. We studied the impact of chronic psychosis on cognitive performance in the elderly.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We estimated cognitive performance in two groups of 15 patients each among persons on old-age pensions or living in geriatric nursing homes. One group included patients who had already showed dissociative or non-dissociative chronic psychosis and the other group persons with no previous psychotic signs. Cognitive estimations were made on the basis of Folstein's Mini Mental State (MMS) score and Signoret's Battery of Cognitive Efficacy (BEC 96). Results obtained in the two groups were compared with the Mann and Whitney non-parametric test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The psychiatric patients showed a significant deficiency compared with the others for memory and executive functions and also a much broader range of scores on the BEC96 that demonstrated deficiency among the psychiatric patients.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Though these findings must be interpreted with caution, they do demonstrate a trend similar to that observed in young schizophrenics and also to that of the cognitive performances observed in older schizophrenics and demented subjects. Patients with dissociated or non-dissociated psychotic disorders show an apparent relative cognitive deficiency irrespective of age. The psychotic elderly appear to exhibit a cognitive clash much more than a simple pseudo-demential deficiency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacus</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Service de g&#xe9;rontologie du Dr Despoisses, GH P. Brousse, Villejuif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ailleret-Jean</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Courcet</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Delmotte-Tsocanakis</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Faraldi</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Hamon-Vilcot</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Heurteux</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Labram</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lutzler</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Planques</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rethore</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Trivalle</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fremont</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Vieillissement cognitif des psychotiques chroniques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11603264</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11603164</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Placement challenges: implications for long-term care of dementia sufferers.</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>288</EndPage><MedlinePgn>285-8</MedlinePgn></Pagination><Abstract><AbstractText>Caregivers and long-term care staff seek appropriate placements for dementia sufferers, but there is little empirical research to guide such decision-making. However, recent national trends in mental health care have emphasized the placement of persons with serious mental illness in privatized, community-based residences. This body of empirical research has indicated that persons with psychosis, substance use disorder, assaultive behavior, and medication noncompliance have shorter tenure in these residential settings. These findings are also important for other, more traditional health care settings, as the patients discharged from community residences may require assistance on occasion from such other settings. This study continues the inquiry into the characteristics of patients with serious mental illness, who have shorter tenure in community residences. Dangerous behaviors, treatment-resistant psychosis, medical illnesses, and social-interpersonal skill deficiencies were common causes for discharge in this study. Since there remains a paucity of published empirical studies on the issue for patients with Alzheimer's disease and other dementias, we present the implications of, and guidelines for, addressing these issues in dementia sufferers in long-term care settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Massachusetts Department of Mental Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>R B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Spillane</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006783" MajorTopicYN="N">Hospitals, State</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="Y">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012112" MajorTopicYN="N">Residential Facilities</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11603164</ArticleId><ArticleId IdType="pmc">PMC10833685</ArticleId><ArticleId IdType="doi">10.1177/153331750101600504</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boruch F (ed.): Behavioral Health Services and Delivery: Models and Methods. Tampa, FL: American College of Physician Executives, 1998.</Citation></Reference><Reference><Citation>Bebout RR , Harris M: In search of pumpkin shells: Residential programming for the homeless mentally ill. In Lamb HR, Backrach LL, Kass FL (eds.): Treating the Homelessly Mentally Ill: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.</Citation></Reference><Reference><Citation>Ridgeway PA , Zipple A: The paradigm shift in residential services: From linear continuum to supported housing approaches. Psychosocial Rehabilitation. 1990; 12: 11-31.</Citation></Reference><Reference><Citation>Carling PJ : Housing and supports for persons with mental illness: Emerging approaches to research and practice. Hospital &amp; Community Psychiatry. 1993; 44: 439-449.</Citation><ArticleIdList><ArticleId IdType="pubmed">8509074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooch C , Leff J: Factors affecting the success of community placements: The TAPS project 26. Psychological Medicine. 1996; 26: 511-520.</Citation><ArticleIdList><ArticleId IdType="pubmed">8733210</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieman N , Smith H, Kendall R, et al.: The TAPS Project 41: Home for life? Residential stability five years after hospital discharge. Community Mental Health Journal. 1998; 34: 401-417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9693869</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfinger SM , Schutt RK, Turner W, et al.: Assessing homeless mentally ill persons for permanent housing: Screening for safety. Community Mental Health Journal. 1996; 32: 275-288.</Citation><ArticleIdList><ArticleId IdType="pubmed">8790969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutbrock LA , Rahav M, Rivera JJ, et al.: Outcomes of homeless mentally ill chemical abusers in community residences and a therapeutic community. Psychiatric Services. 1998; 49: 68-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9444683</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfinger SM , Russell K, Tolomiczerko GS, et al.: Housing placement and subsequent days homeless among formerly homeless adults with mental illness. Psychiatric Services. 1999; 50: 674-679.</Citation><ArticleIdList><ArticleId IdType="pubmed">10332905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton FR , Siegel C, Hannigan A, et al.: Tenure in supportive housing for homeless persons with severe mental illness. Psychiatric Services. 2000; 51: 479-486.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737823</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice B : Who Gets Sick: How Beliefs, Moods, and Thoughts Affect Your Health. Los Angeles, CA: JP Tarcher, 1988.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11584984</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62 Suppl 21</Volume><PubDate><Year>2001</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>25</EndPage><MedlinePgn>23-5</MedlinePgn></Pagination><Abstract><AbstractText>It is well known that serotonergic function is related to aggression. Patients with Alzheimer's disease exhibit aggressive behavior, and alterations in their serotonergic function have been identified. Recent clinical trials involving new antipsychotic agents, such as risperidone, which has both serotonergic and dopaminergic activity, have demonstrated the efficacy and safety of these drugs in treating the psychosis and aggressive behavior associated with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of South Carolina, Charleston, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>15</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>12</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11584984</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11577527</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-5782</ISSN><JournalIssue CitedMedium="Print"><Volume>163</Volume><Issue>38</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Ugeskrift for laeger</Title><ISOAbbreviation>Ugeskr Laeger</ISOAbbreviation></Journal><ArticleTitle>[Receptor mapping in living human beings by means of positron emission tomography].</ArticleTitle><Pagination><StartPage>5199</StartPage><EndPage>5205</EndPage><MedlinePgn>5199-205</MedlinePgn></Pagination><Abstract><AbstractText>PET can map neurotransmitter synthesis, storage, release, binding to receptors, and re-uptake in the brain with tracer concentrations in the picomolar or nanomolar range. Tracers are analogues of naturally occurring precursors or ligands, or are drugs, which bind with varying degrees of specificity to receptor subtypes in the brain. Tracers have been synthesised for many transmitter systems, but dopaminergic and serotonergic neurotransmissions are the main foci of current efforts to selectively trace synthesis, storage, re-uptake, or post-synaptic binding of neurotransmitters. Common measures of the tracer uptake and binding include precursor clearance (k3), a measure of transmitter synthesis and trapping, and binding potential (pB), a measure of the receptor binding per unit of unbound tracer, and hence a measure of the release of the endogenous transmitter, or the occupancy of a drug. Dopamine tracers are used in diseases of the basal ganglia, whereas serotonin, benzodiazepine, and opiate tracers are used in lesions of the cerebral cortex. PET has revealed loss of dopaminergic terminals and dopamine synthetic capacity in Parkinson's disease, MPTP intoxication, and Lesch-Nyhan's syndrome; release of dopamine after administration of cocaine and amphetamine, and in motor activity and cognition; increased synaptic dopamine and release of dopamine, and the 70-90% neuroleptic occupancy of dopamine receptors in the striatum, in patients with schizophrenia; loss of muscarinic and nicotinergic receptors in Alzheimer's disease, and benzodiazepine and opiate receptors in stroke, epilepsy, and Huntington's chorea; altered opiate receptors in chronic pain and drug abuse; and release of opiates in analgesia; but changes in serotonin synthesis, transport, and binding in affective or psychotic disorders remain elusive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gjedde</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arhus Universitetshospital, Arhus Kommunehospital, PET-centret.</Affiliation></AffiliationInfo></Author></AuthorList><Language>dan</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Positron-emissionstomografisk kortlaegning af den levende menneskehjernes receptorer.</VernacularTitle></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Ugeskr Laeger</MedlineTA><NlmUniqueID>0141730</NlmUniqueID><ISSNLinking>0041-5782</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>44</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11577527</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11575062</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1360-7863</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Aging &amp; mental health</Title><ISOAbbreviation>Aging Ment Health</ISOAbbreviation></Journal><ArticleTitle>Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>241</EndPage><MedlinePgn>235-41</MedlinePgn></Pagination><Abstract><AbstractText>The objective was to elicit the prescribing practises of Old Age Psychiatrists in the UK in the treatment of psychotic and behavioural symptoms in patients with dementia. A structured questionnaire was sent to all Old Age Psychiatrists in the United Kingdom. Respondents were questioned regarding their use of both typical and atypical antipsychotics and the most common dosages prescribed. Information was sought about usage of depot medication and dosages; use of alternative or adjunctive medications to antipsychotics and use of parenteral medication for acute management of agitation. The most commonly used antipsychotic to treat psychotic symptoms was haloperidol, and thioridazine to treat behavioural symptoms. A wide range of dosages was used. Use of depot medication was common, with flupenthixol decanoate being the most frequently used. Most respondents use at least one of the atypical antipsychotics, risperidone being most popular. Use of other psychotropic medication used as alternatives to antipsychotics or adjunctives in the treatment of behavioural symptoms was common, the most popular being trazodone. Of the respondents, 62.7% use parenteral medication for the acute management of agitation, the most popular drug being haloperidol. The typical antipsychotics are still the most commonly used despite the reputed better safety profile of the atypicals. There was wide variation in the dosages prescribed. Use of psychotropics other than phenothiazines was common. More research is needed into the use of psychotropic medication for dementia and there is need for consensus in this area. Forming an expert group may be the best way to create uniformity of prescription.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Condren</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>St. Vincent's Hospital,  Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooney</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Ment Health</MedlineTA><NlmUniqueID>9705773</NlmUniqueID><ISSNLinking>1360-7863</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005852" MajorTopicYN="N">Geriatric Psychiatry</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11575062</ArticleId><ArticleId IdType="doi">10.1080/13607860120064961</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11566166</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>472</StartPage><EndPage>475</EndPage><MedlinePgn>472-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study is to analyze the segregation of the 102T/C polymorphism in the serotonin 2A receptor gene in patients affected by sporadic and familial Alzheimer's disease (FAD) with and without psychotic symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The polymorphism was analyzed in 275 subjects. A semistructured interview was used to obtain information about delusions, hallucinations, and other specific behavioral signs occurring during the disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-two percent of AD patients with psychotic symptoms were homozygous for the C102 allele, as compared with 6.9% of AD patients without psychosis. Similarly, the C102/C102 genotype was significantly more frequent in FAD patients with psychosis than in FAD patients without (46.5% vs. 7.8%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data strongly confirm and extend to FAD previous studies suggesting that the genetic variation at this locus is associated with prominent psychotic features in AD and that the 102C allele could play an important role in late-onset AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 85, Florence 50134, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedde</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Forleo</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Piacentini</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Guarnieri</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Bartoli</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ortenzi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Petruzzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Serio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marcon</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Biol Psychiatry 2001 Nov 15;50(10):821</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005784" MajorTopicYN="N">Gene Amplification</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11566166</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(01)01114-3</ArticleId><ArticleId IdType="pii">S0006322301011143</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11562834</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>11</Issue><PubDate><MedlineDate>2001 Jun 1-15</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Strategies for the treatment of Alzheimer's disease. The 'ad continuum' concept].</ArticleTitle><Pagination><StartPage>1074</StartPage><EndPage>1084</EndPage><MedlinePgn>1074-84</MedlinePgn></Pagination><Abstract><AbstractText>The patient with dementia suffers a chronic disorder, with no specific treatment and little therapeutic response, which is accompanied by high co morbidity and additional complications which cause multiple symptoms which limit the patient s autonomy still further, modify the environment and create progressive dependence. Thus, from all angles, approach is very difficult both in seeking the cause and in prevention and also for treatment. The objective of this review is to establish the guidelines for treatment in view of the long term course of the disorder, in accordance with the specific weight and intensity of symptoms from the onset of the illness by means of precise diagnosis of the deficits and control of the commonest disorders which occur over time, such as psycho affective, psychotic, sleep disorders or treatment of a state of confusion and control of the diseases which are most frequent in this population. Finally, we briefly analyze the health care and social requirements of these patients and suggest general recommendations for carers to improve management, classifying the states of dementia into three degrees of severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boada Rovira</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Neurologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain. 7287mbr@comb.es</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Estrategias terap&#xe9;uticas en la enfermedad de Alzheimer: Concepto "ad continuum".</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>28</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11562834</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11562833</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>11</Issue><PubDate><MedlineDate>2001 Jun 1-15</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Dementia in progressive supranuclear paralysis patients].</ArticleTitle><Pagination><StartPage>1071</StartPage><EndPage>1073</EndPage><MedlinePgn>1071-3</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Progressive supranuclear paralysis is difficult to detect in its initial stages. Its symptoms are not specific and often the patients are mistaken as Parkinson s disease patients, or even Alzheimer s ones.</AbstractText><AbstractText Label="DEVELOPMENT" NlmCategory="METHODS">Initial features in progressive supranuclear paralysis are typically a gait disorder with frequent falls, behavioral disorder and often dysarthria. The gaze disorder, showing voluntary conjugate gase paralysis is characteristic, but it can appear late in the course of disease. Other motor signs are axial rigidity, bradykinesia, stiffness, and rarely chorea, ataxia, muscle weakness or myoclonus. Pseudobulbar paralysis is the more remarkable clinical finding. These motor symptoms are accompanied by cognitive disturbances, the typical ones of subcortical dementia, with mind slowness, apathy, depression, and, more often that in other primary dementias, psychotic features and relatively early behavioral disorders. A useful feature to distinguish the mental changes of progressive supranuclear paralysis with other primary subcortical dementias is a more remarkable impairment in visuospatial function, because of the need of a good gaze function to accomplish it. Progressive supranuclear paralysis patients work better in verbal tests that in visuospatial test. We try to describe clinical data and evolutive profile of this entity, whose cognitive disturbances as described by Albert in 1974 strongly stabilized the concept of subcortical dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barquero-Jim&#xe9;nez</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a; Hospital Cl&#xed;nico Universitario San Carlos, Madrid, 28040, Espa&#xf1;a. mbarquero@hcsc.insalud.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez-Salgado</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Demencia en pacientes con par&#xe1;lisis supranuclear progresiva.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020234" MajorTopicYN="N">Gait Ataxia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11562833</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11552008</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>5</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex.</ArticleTitle><Pagination><StartPage>805</StartPage><EndPage>811</EndPage><MedlinePgn>805-11</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Results from recent drug trials suggest a role for the cholinergic system in the manifestation of neuropsychiatric symptoms in AD. To date, the status of muscarinic acetylcholine receptor subtypes in AD in relation to accompanying behavioral disturbances is unknown. This study aimed to measure alterations of muscarinic M(1) and M(2) receptor binding in the frontal and temporal cortex of AD and to correlate the neurochemical findings with clinical features.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The cognitive and behavioral features of 26 patients with AD were assessed prospectively using standardized tests. Together with 14 matched controls, the status of muscarinic M(1) and M(2) receptors in the postmortem frontal and temporal cortex of these patients were measured by radioligand binding assays and were correlated with clinical data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with controls, M(2) receptor density was reduced only in the frontal cortex of AD, whereas M(1) was unaffected. Within the AD group, the neurochemical variables were not affected by demographic factors, disease severity, or cognition. Instead, M(2) receptor density was increased in the frontal and temporal cortex of patients with AD with psychotic symptoms compared with those without these symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests a role for M(2) receptors in the psychosis of AD and may provide the rationale for treatment of behaviorally perturbed patients with AD with cholinomimetics and M(2) antagonists.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>M K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Program, Department of Neurology, Singapore General Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>O F</ForeName><Initials>OF</Initials></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Esiri</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Hope</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043585">Receptor, Muscarinic M2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043585" MajorTopicYN="N">Receptor, Muscarinic M2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11552008</ArticleId><ArticleId IdType="doi">10.1212/wnl.57.5.805</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19811048</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Treatment of behavioral/psychological symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>70</StartPage><EndPage>80</EndPage><MedlinePgn>70-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/1615-9861(200101)1:1&lt;70::AID-PROT70&gt;3.0.CO;2-P</ELocationID><Abstract><AbstractText>This review examines the evidence for the use of drugs as part of the treatment of depressive/psychotic symptoms and behavioral disturbances in persons with Alzheimer's disease. Although conventional antidepressants appear to relieve depressive symptoms in Alzheimer's disease patients, placebo seems equally effective. The use of most medications used to control psychotic symptoms and disturbed/disturbing behaviors in Alzheimer's disease is off-label and not strongly supported by randomized, placebo-controlled trials, especially for so-called agitation. For these reasons, trials of psychotropic drugs in Alzheimer's disease need a placebo condition in addition to active comparators and in the case of nondrug treatments, a sham treatment condition. Cholinesterase inhibiting drugs may reduce behavioral symptoms in addition to slowing cognitive decline. Selective (for brain region) GABA agonists seem to offer the greatest theoretical promise for reducing agitated behaviors not driven by depression or psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>University of Texas, Southwestern Medical Center, Department of Psychiatry, 5323 Harry Hines Blvd., NC6.102, Dallas, Texas 75390-9070, USA. myron.weiner@utsouthwestern.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19811048</ArticleId><ArticleId IdType="doi">10.1002/1615-9861(200101)1:1&lt;70::AID-PROT70&gt;3.0.CO;2-P</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11524787</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-7183</ISSN><JournalIssue CitedMedium="Print"><Volume>114</Volume><Issue>10</Issue><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Duodecim; laaketieteellinen aikakauskirja</Title><ISOAbbreviation>Duodecim</ISOAbbreviation></Journal><ArticleTitle>[What's new in neuropharmacology?].</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1001</EndPage><MedlinePgn>993-1001</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castr&#xe9;n</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Kuopion yliopisto A. I. Virtanen -instituutti PL 1627, 70211 Kuopio. eero.castren@uku.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe4;nnist&#xf6;</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Tiihonen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>fin</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Mit&#xe4; uutta neurofarmakologiasta?</VernacularTitle></Article><MedlineJournalInfo><Country>Finland</Country><MedlineTA>Duodecim</MedlineTA><NlmUniqueID>0373207</NlmUniqueID><ISSNLinking>0012-7183</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065098">Catechol O-Methyltransferase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065098" MajorTopicYN="N">Catechol O-Methyltransferase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009480" MajorTopicYN="N">Neuropharmacology</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11524787</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11520475</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-9338</ISSN><JournalIssue CitedMedium="Print"><Volume>16 Suppl 1</Volume><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Treatment of the agitation of late-life psychosis and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>25s</StartPage><EndPage>28s</EndPage><MedlinePgn>25s-28s</MedlinePgn></Pagination><Abstract><AbstractText>In older as well as younger people, antipsychotic medication is commonly used to treat psychoses. In clinical practice, antipsychotic medication is also used to control severe behavioral disturbances such as agitation, wandering, self-mutilation, as well as assaultiveness. Neuroleptic and non-neuroleptic drug treatments are used to control severe agitation and disruptive behavior. Among typical neuroleptics, very low doses (e.g., 0.25 mg of haloperidol 1-4 times per day) may be effective and limit the development of severe extrapyramidal reactions. Recent experience suggests that the atypical neuroleptics, olanzaine, risperidone, and quetiapine, are also useful for controlling severe agitation in elderly demented nursing home residents. The benzamides are also known for the treatment of behavioral disturbances in Europe, but there is little experience in the U.S.A. Although research studies in this area are virtually nonexistent, growing clinical experience suggests that the following may be quite useful: 1) trazodone; 2) buspirone (Buspar); 3) anticonvulsants (e.g., valproate); and 4) beta-blockers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salzman</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11520475</ArticleId><ArticleId IdType="doi">10.1016/s0924-9338(00)00525-3</ArticleId><ArticleId IdType="pii">S0924933800005253</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11519157</PMID><DateCompleted><Year>2001</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0047-1852</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>8</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nihon rinsho. Japanese journal of clinical medicine</Title><ISOAbbreviation>Nihon Rinsho</ISOAbbreviation></Journal><ArticleTitle>[Depression in late life].</ArticleTitle><Pagination><StartPage>1550</StartPage><EndPage>1554</EndPage><MedlinePgn>1550-4</MedlinePgn></Pagination><Abstract><AbstractText>Depression in the elderly is one of the most important psychotic disorder as well as dementia. In this report, at first we described the relation between brain-organic disorder and depression in late life. It is very interesting that depression in late life has often comorbid process with vascular dementia and dementia of the Alzheimer type. In biological treatments for depression in late life, pharmacotherapy and modified electroconvulsive therapy are useful. We must be aware of the adverse side effects from the use of antidepressant, then SSRIs are selected for clinical depression of late life, because the SSRIs produce fewer side effects. Psychotherapeutic medication, such as cognitive behavioral therapy and reminiscence or life, review is useful for depression in late life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Omori</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dokkyo University School of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Rinsho</MedlineTA><NlmUniqueID>0420546</NlmUniqueID><ISSNLinking>0047-1852</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>13</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11519157</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11514641</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Emergent neuroleptic hypersensitivity as a herald of presenile dementia.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>356</EndPage><MedlinePgn>347-56</MedlinePgn></Pagination><Abstract><AbstractText>Neuroleptic hypersensitivity is characteristic of dementia with Lewy bodies (DLB) but not of other dementias. The authors report 5 patients with psychotic mood disorders and long-standing antipsychotic drug therapy. As they reached 50 to 60 years of age, they unexpectedly developed hypersensitivity to these medications, with rigidity, muteness, or the neuroleptic malignant syndrome. Nearly coincident with this reaction, they developed progressive cognitive deficits consistent with frontotemporal dementia. These patients illustrate emergent neuroleptic hypersensitivity as an early manifestation of other dementias. The predisposition to neuroleptic hypersensitivity could result from depleted nigral dopaminergic neurons suggested by "smudging" of the substantia nigra pars compacta on magnetic resonance imaging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at Los Angeles School of Medicine, Los Angeles 90073, USA. mmendez@ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11514641</ArticleId><ArticleId IdType="doi">10.1176/jnp.13.3.347</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11444257</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0394-9532</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Aging (Milan, Italy)</Title><ISOAbbreviation>Aging (Milano)</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric assessment of Alzheimer's disease and related dementias.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>246</EndPage><MedlinePgn>240-6</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) patients exhibit a variety of behavioral alterations including agitation, apathy, depression, anxiety, delusions, irritability and disinhibition. Most patients with AD exhibit neuropsychiatric symptoms, and behavioral changes become more frequent with advancing disease severity. The NPI is a valid and reliable means of assessing neuropsychiatric symptoms in patients with dementia. The NPI correlates with increasing disability in activities of daily living and increasing cognitive impairment. Physical illness contributes little to behavioral symptoms measured by the NPI. Reduced frontal lobe metabolism and perfusion have been identified in patients with apathy, agitation, psychosis and depression. Patients with elevated agitation scores on the NPI have a higher burden of frontal lobe neurofibrillary tangles than patients without agitation. The NPI is sensitive to behavioral improvements following treatment with cholinesterase inhibitors and psychotropic agents. Neuropsychiatric symptom profiles differ among dementia syndromes, and the NPI provides a means of assessing neuropsychiatric symptoms that may aid in differential diagnosis. Evaluation of neuropsychiatric symptoms is a critical aspect of dementia diagnosis and management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095-1769, USA. cummings@ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 10657</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Aging (Milano)</MedlineTA><NlmUniqueID>9102503</NlmUniqueID><ISSNLinking>0394-9532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>7</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>7</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11444257</ArticleId><ArticleId IdType="doi">10.1007/BF03351482</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">11431075</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-7947</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2001</Year></PubDate></JournalIssue><Title>Archives of gerontology and geriatrics. Supplement</Title><ISOAbbreviation>Arch Gerontol Geriatr Suppl</ISOAbbreviation></Journal><ArticleTitle>Psychosis, serotonin receptor polymorphism and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>283</EndPage><MedlinePgn>279-83</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurological and Psychiatric Sciences, University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedde</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Forleo</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Piacentini</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Latorraca</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Guarnieri</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Ortenzi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bartoli</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Petruzzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Serio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Arch Gerontol Geriatr Suppl</MedlineTA><NlmUniqueID>8911786</NlmUniqueID><ISSNLinking>0924-7947</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>30</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11431075</ArticleId><ArticleId IdType="doi">10.1016/s0167-4943(01)00150-9</ArticleId><ArticleId IdType="pii">S0167494301001509</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11425357</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0039-6257</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Survey of ophthalmology</Title><ISOAbbreviation>Surv Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease: a review for the ophthalmologist.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>524</EndPage><MedlinePgn>516-24</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is the most prevalent dementia. Definitive diagnosis is made only at autopsy, although "probable" diagnoses are made using clinical criteria. Patients with Alzheimer's disease demonstrate severe deficits in memory with cortical features of language difficulty and visuomotor spatial deficits. They also may present with psychotic symptoms of delusions and hallucinations, and personality and behavioral changes. Advancing age, genetics, and environmental risk factors are important in the development of Alzheimer's disease. Visual abnormalities have been described in Alzheimer's disease and may be related to the development of visual hallucinations. Although palliative treatments exist for the cognitive loss and behavioral symptoms, future treatments will focus on both delay of onset and slowing of progression of the disease. Continued research is needed to further understand this devastating disorder, which may in turn lead to more successful treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holroyd</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Virginia Health Sciences Center, Department of Psychiatric Medicine, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KO7-MHO119901A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surv Ophthalmol</MedlineTA><NlmUniqueID>0404551</NlmUniqueID><ISSNLinking>0039-6257</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="Y">Vision Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>82</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11425357</ArticleId><ArticleId IdType="doi">10.1016/s0039-6257(01)00193-x</ArticleId><ArticleId IdType="pii">S003962570100193X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11398563</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Characteristics of assaultive psychiatric inpatients: updated review of findings, 1995-2000.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>156</EndPage><MedlinePgn>153-6</MedlinePgn></Pagination><Abstract><AbstractText>The present paper reviewed the studies of the characteristics of assaultive psychiatric inpatients from 1994 to the present. These studies partially confirmed earlier findings that assaultive patients are older persons with a diagnosis of active psychosis or other neurological abnormality and histories of violence toward others and substance-use disorder. However, the recent studies also document the profile of a second group of assaultive patients: younger females with personality disorders and histories of violence toward others, substance-use disorder, and personal victimization. Since there is a paucity of published empirical research on Alzheimer's and dementia patients for this topic, the implications from the present findings for long-term care and clinical intervention are examined.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>R B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Massachusetts Department of Mental Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11398563</ArticleId><ArticleId IdType="pmc">PMC10833871</ArticleId><ArticleId IdType="doi">10.1177/153331750101600305</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blair DT : Assaultive behavior: Does provocation begin in the front office? Journal of Psychosocial Nursing. 1991; 29:21-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2066912</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S : Violence in psychiatric inpatients: A review. Hospital &amp; Community Psychiatry. 1991; 42:585-590.</Citation><ArticleIdList><ArticleId IdType="pubmed">1864567</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery RB Jr , Hanson MA, Penk WE: Risk factors for psychiatric inpatient assaults on staff. Journal of Mental Health Administration. 1994; 21:24-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10131885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam E , Engelsmann F, Fugere R: Patterns of violent incidents by patients in a general psychiatric facility. Psychiatric Services. 1996; 47:86-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8925353</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen K , Levander S: Individual rather than situational characteristics predict violence in a maximum security hospital. Journal of Interpersonal Violence. 1996; 11:376-390.</Citation></Reference><Reference><Citation>Flannery RB Jr , Hanson MA, Penk WE, et al.: Hospital downsizing and patient assaults on staff. Psychiatric Quarterly. 1997; 68: 67-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9021841</ArticleId></ArticleIdList></Reference><Reference><Citation>Swett C , Mills T: Use of the NOSIE to predict assaults among acute psychiatric inpatients. Psychiatric Services. 1997; 48: 1177-1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb HR : The new state mental hospitals in the community. Psychiatric Services. 1997; 48: 1307-1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323750</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen C , Tarantello C, Jones M, et al.: Repetitively violent patients in psychiatric units. Psychiatric Services. 1998; 49: 1458-1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">9826248</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery RB Jr , Irvin EA, Penk WE: Characteristics of assaultive psychiatric inpatients in an era of managed care. Psychiatric Quarterly. 1999; 70: 247-256.</Citation><ArticleIdList><ArticleId IdType="pubmed">10457549</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery RB Jr , Schuler AP, Farley EM, et al.: Characteristics of assaultive psychiatric patients and the Assaulted Staff Action Program (ASAP): Ten year analysis. Psychiatric Quarterly. 2001. [in press].</Citation><ArticleIdList><ArticleId IdType="pubmed">11780599</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell A , Muncer S, Bibel D: Female-female criminal assault: An evolutionary perspective. Journal of Research in Crime &amp; Delinquency. 1998; 35: 413-429.</Citation></Reference><Reference><Citation>Flannery RB Jr : Violence in the Workplace. New York: Crossroad Publishing, 1995.</Citation></Reference><Reference><Citation>Thienhaus OJ , Piasecki M: Assessment of psychiatric patients' risk of violence toward others. Psychiatric Services. 1998; 49: 1129-1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9735952</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiff K : Unusual diagnoses among violent patients. Psychiatric Clinics of North America. 1998; 21: 567-576.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774796</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasic JR , Fogelman D: Clinician safety. Psychiatric Clinics of North America. 1999; 22: 923-999.</Citation><ArticleIdList><ArticleId IdType="pubmed">10623979</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11392633</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-3205</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>22-23</Issue><PubDate><Year>2001</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Life sciences</Title><ISOAbbreviation>Life Sci</ISOAbbreviation></Journal><ArticleTitle>Elucidating the role of muscarinic receptors in psychosis.</ArticleTitle><Pagination><StartPage>2605</StartPage><EndPage>2613</EndPage><MedlinePgn>2605-13</MedlinePgn></Pagination><Abstract><AbstractText>Muscarinic receptors have been implicated in the regulation of cognition and psychosis based on pharmacological evidence from pre-clinical and clinical studies. Muscarinic agonists have shown promise in the clinic in improving cognition and reducing psychotic episodes in Alzheimer's patients. However, lack of selective muscarinic ligands has limited their use due to troublesome side effects observed at higher doses. Without selective ligands, it has been difficult to assign a specific muscarinic receptor subtype to these high order mental processes. Recent development of muscarinic receptor knockout mice has provided additional tools to investigate cognition and psychosis in behavioral assays and to determine the receptor subtypes associated with parasympathomimetic physiology. Biochemical studies indicate that the M1 receptor plays a significant role in regulating G alpha q-mediated signal transduction in the hippocampus and cortex. Behavioral studies suggest that the M4 receptor is involved in movement regulation and prepulse inhibition of the startle reflex, a measure of attention. These findings support a role for the development of M1 and M4 receptor agonists for diseases in which symptoms include cognitive impairment and psychotic behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Felder</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Neuroscience Division, Eli Lilly Research Laboratories, Indianapolis, IN 46285, USA. felder@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Skillman</LastName><ForeName>T L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>F P</ForeName><Initials>FP</Initials></Author><Author ValidYN="Y"><LastName>Nathanson</LastName><ForeName>N M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Gomeza</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wess</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McKinzie</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Life Sci</MedlineTA><NlmUniqueID>0375521</NlmUniqueID><ISSNLinking>0024-3205</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>37589-80-3</RegistryNumber><NameOfSubstance UI="D016244">Guanosine 5'-O-(3-Thiotriphosphate)</NameOfSubstance></Chemical><Chemical><RegistryNumber>5RY0UWH1JL</RegistryNumber><NameOfSubstance UI="D010095">Oxotremorine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.1</RegistryNumber><NameOfSubstance UI="D043802">GTP-Binding Protein alpha Subunits, Gq-G11</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.1</RegistryNumber><NameOfSubstance UI="D020962">Heterotrimeric GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J1DOI7UV76</RegistryNumber><NameOfSubstance UI="D010622">Phencyclidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043802" MajorTopicYN="N">GTP-Binding Protein alpha Subunits, Gq-G11</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016244" MajorTopicYN="N">Guanosine 5'-O-(3-Thiotriphosphate)</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020962" MajorTopicYN="N">Heterotrimeric GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010095" MajorTopicYN="N">Oxotremorine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010622" MajorTopicYN="N">Phencyclidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11392633</ArticleId><ArticleId IdType="doi">10.1016/s0024-3205(01)01059-1</ArticleId><ArticleId IdType="pii">S0024-3205(01)01059-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">11389805</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8480</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current treatment options in neurology</Title><ISOAbbreviation>Curr Treat Options Neurol</ISOAbbreviation></Journal><ArticleTitle>Psychosis Due to Neurologic Conditions.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>366</EndPage><MedlinePgn>347-366</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis arises with considerable frequency in a number of neurologic conditions. The treatment of such patients is often challenging, as many of the treatments for psychosis pose some risk of worsening the underlying neurologic condition. Although psychosis may emerge in the context of any neurologic condition that sufficiently disrupts the functioning of or connections between limbic, paralimbic, frontal, subcortical areas mediating complex sensory perception, interpretation, and thought or language organization, secondary psychoses are most often encountered in patients with Alzheimer's disease (Parkinson's disease receives dopaminomimetic therapies) and epilepsy. Psychosis, and particularly delusions and visual hallucinations, may arise in Alzheimer's disease. Based on the available literature, the first-line therapy for this problem is risperidone 0.5 to 3 mg per day. If this treatment proves unsuccessful, low-dose haloperidol or olanzapine should be considered next. If these treatments prove unsuccessful, quetiapine should then be considered. Finally, clozapine may be useful for treatment-refractory psychosis due to Alzheimer's disease, but due caution is warranted given its considerable anticholinergic properties and potential for worsening cognition in these patients. Although disease-emergent psychosis (paranoid delusions and visual hallucinations) may develop in patients with Parkinson's disease, psychosis due to dopaminomimetic therapy is much more common. When such symptoms develop, the accepted first step is to taper anti-parkinsonian medications were possible. Anticholinergic medications, amantadine, selegiline, and dopamine receptor agonists should be reduced or discontinued, provided that the patient can tolerate changes in motor symptoms attendant to such reductions. When these reductions are not feasible or fail to improve treatment-emergent psychosis, low-dose quetiapine or clozapine may be useful. The greatest body of evidence supports the effectiveness of these treatments and their relative lack of adverse effects on motor function. When psychosis develops in the context of epilepsy, the generally accepted first step is to maximize anticonvulsant therapy in an effort to reduce the possible contribution of electrophysiologic disturbances in the described areas to psychotic symptoms. When interictal psychosis persists despite such adjustments, initiation with low-dose atypical antipsychotics carries the least risk of lowering seizure threshold and should be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arciniegas</LastName><ForeName>David B.</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C268-68, Denver, CO 80262, USA. david.arciniegas@UCHSC.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topkoff</LastName><ForeName>Jeannie L.</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Kerri</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Neurol</MedlineTA><NlmUniqueID>9815940</NlmUniqueID><ISSNLinking>1092-8480</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11389805</ArticleId><ArticleId IdType="doi">10.1007/s11940-001-0039-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int Clin Psychopharmacol. 1998 Nov;13(6):273-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9861578</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Oct;57(10 ):968-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1992 Mar;31(3):342-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1386210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Summer;11(3):392-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10440017</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2000 Mar;15(2):117-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10759344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2000 May;15(3):579-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10830427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1982 Dec;45(12):1161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7161613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2000 Mar;15(2):301-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10752580</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Neurol Sci. 1988 Feb;15(1):32-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3345460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 1997 Jul;12(4):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">9251065</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1987 Feb;50(2):183-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3572433</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Sep 28;343 (13):973-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11012330</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 8:54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10335671</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 1999;40 Suppl 10:S2-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10609602</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1994;8 Suppl 3:122-37</Citation><ArticleIdList><ArticleId IdType="pubmed">7999339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1992 Oct;17(4):134-45</Citation><ArticleIdList><ArticleId IdType="pubmed">1450186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontology. 1999;45 Suppl 1:15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9876214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):774-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9810956</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1992 Sep 19;305(6855):673-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1356550</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1991 Jun;48(6):619-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1982 May;11(2):121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7102472</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1997 Feb;42(1):90-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9040932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 May;60(5):292-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10362435</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996;57 Suppl 14:37-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9024335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995 Dec;56(12):556-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8530331</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Nov;43(11):2227-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8232934</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 May;50(5):1222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9595967</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1998 Sep;10(3):229-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9785144</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Nov;155(11):1512-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Oct;47(4):1085-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8857751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1997 Fall;9(4):594-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9447503</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Nov 25;341(22):1670-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10572156</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1988 Jan;1(1):16-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3266997</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Jun 15;37(12):895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7548465</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Apr 1;33(7):536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8513039</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Mar 11;340(10):801-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10072418</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Mar;15(3):280-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10713588</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Dec;48(12):1113-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1845230</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1998 Sep-Oct;21(5):285-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9789708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):216-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9608412</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1995 Jul;45(7):1305-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7617188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1997 Apr;17(2):132-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10950486</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1999 Feb;19(1):101-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9934953</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1963 Jan;109:95-150</Citation><ArticleIdList><ArticleId IdType="pubmed">13989174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Apr;149(4):443-54</Citation><ArticleIdList><ArticleId IdType="pubmed">1372794</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1991 Jun;36(5):388-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1884344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2000 Mar;15(2):201-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10752567</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Nurs Res. 1995 Aug;8(3):118-22</Citation><ArticleIdList><ArticleId IdType="pubmed">7668853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Jun 12;353(9169):2041-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10376627</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999;52(7 Suppl 3):S10-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10227604</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1999 Jun;14 (6):459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10398356</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1992 May;55(5):377-82</Citation><ArticleIdList><ArticleId IdType="pubmed">1602311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):304-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7580188</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1990;358:92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1978500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9547467</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Mar 11;340(10 ):757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10072410</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Nov;47(5):1113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Neurol. 1993;60:703-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8420214</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 1998 Jun;32(3):454-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9672737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1995 Sep 9;346(8976):699</Citation><ArticleIdList><ArticleId IdType="pubmed">7544860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2000 Jan;20(1):23-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10641973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 1997 Jul;12(4):610-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9251085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Feb;20(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10653209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Sep;11(3):141-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10482124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Jul 15;17(14):5573-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9204938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 1999 Nov;14 (6):1014-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10584679</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 May;15(5):387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10822236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11352329</PMID><DateCompleted><Year>2001</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>128</EndPage><MedlinePgn>121-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the applicability of the Chinese version of the Neuropsychiatric Inventory Scale (NPI), and to explore the neuropsychiatric manifestations of Taiwanese patients with Alzheimer's disease (AD) and caregiver distress.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Mini-Mental State Examination (MMSE) was administered to 95 patients with AD, and their caregivers were interviewed with the NPI. To assess the test-retest reliability of the Chinese version of the NPI, 86 caregivers underwent a second NPI 3 weeks later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Cronbach's alpha coefficient of the Chinese version of the NPI was .76. The test-retest reliabilities of frequency, severity, and caregiver burden scores were significantly correlated; overall correlations were .85 for frequency (p &lt; .001), .82 for severity (p &lt; .001), and .79 (p &lt; .001) for distress. Factor analysis was carried out, and three groups, "mood and psychosis," "psychomotor regulation," and "social engagement," were found. Aberrant motor behavior was the most frequently recorded behavior; euphoria was the least. There was no significant correlation between the patient's MMSE and the caregiver distress score, except for aberrant motor activity (r = -.23, p = .03). The symptoms most frequently reported to be severely distressing to caregivers were aberrant motor activity, anxiety, agitation, and delusions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that the NPI is a reliable tool to assess behavioral disturbance and caregiver distress in Taiwanese AD patients. These findings also confirm the high prevalence of psychopathology among AD patients and the marked distress produced by many of these behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuh</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Neurological Institute, Veterans General Hospital-Taipei, National Yang-Ming University Schools of Medicine, Taiwan. jlfuh@vghtpe.gov.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>C K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Mega</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08AG100784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int Psychogeriatr. 2009 Dec;21(6):1031-6. doi: 10.1017/S1041610209990913</RefSource><PMID Version="1">19781110</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11352329</ArticleId><ArticleId IdType="doi">10.1017/s1041610201007517</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11352328</PMID><DateCompleted><Year>2001</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Use of psychotropics in Sydney nursing homes: associations with depression, psychosis, and behavioral disturbances.</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>120</EndPage><MedlinePgn>107-20</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this study was to determine the prevalence of psychotropic use in nursing home residents, the extent to which psychotropic dosage is consistent with published guidelines, and the relationships between psychotropic class and psychiatric and behavioral disturbances. Six hundred forty-seven subjects, mean age 82.3 years, residing in 11 nursing homes in the eastern suburbs of Sydney, Australia, were assessed using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), the Abbreviated Mental Test Scale, and the Even Briefer Assessment Scale for Depression (EBAS-DEP). Details of psychotropic prescription and diagnoses of depression, dementia, and psychosis were obtained from nursing home charts. Psychotropics were prescribed for 333 (51.5%) residents, 381 (58.9%) if "as required" (PRN) use is included. Prescription of multiple psychotropics was present in 148 (22.7%) residents. Antidepressants were prescribed for 19.8% of residents, with subtherapeutic doses less likely in residents on selective serotonin reuptake inhibitors. On logistic regression, the use of antidepressants was predicted by the affective disturbances subscale on the BEHAVE-AD. Only 30.4% of residents with significant depressive symptoms on the EBAS-DEP were prescribed antidepressants. Antipsychotics were prescribed for 21.3% residents at a mean dosage of 73 mg chlorpromazine equivalence. Residents on antipsychotics had significantly higher scores on the delusions, hallucinations, activity disturbance, and aggressiveness subscales of the BEHAVE-AD. On logistic regression, only the activity disturbance subscale and chart diagnoses of dementia and psychosis were significant predictors. Psychosis (58.8%) and behavioral disturbances (91.9%) were more prevalent in residents prescribed antipsychotics than in residents not prescribed antipsychotics (42.5% and 76.6%, respectively). High rates of behavioral and psychological symptoms of dementia remained in residents prescribed antipsychotics and high rates of depressive symptoms in residents prescribed antidepressants, suggesting a role for nonpharmacological strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Schools of Psychiatry and Community Medicine, University of New South Wales, Sydney, Australia. b.draper@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>L F</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Saab</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Paton</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009517" MajorTopicYN="N" Type="Geographic">New South Wales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11352328</ArticleId><ArticleId IdType="doi">10.1017/s1041610201007505</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11349485</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0025-7125</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>May</Month></PubDate></JournalIssue><Title>The Medical clinics of North America</Title><ISOAbbreviation>Med Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease and related disorders.</ArticleTitle><Pagination><StartPage>803</StartPage><EndPage>817</EndPage><MedlinePgn>803-17</MedlinePgn></Pagination><Abstract><AbstractText>The cholinesterase inhibitors provide the first clearly effective treatments for the cognitive deficits of AD and appear to have a beneficial effect on activities of daily living function and noncognitive behavior. There is increasing support for starting donepezil, rivastigmine, or galantamine early in the disease course and maintaining treatment at least during the early and middle stages of AD. Depressive signs and symptoms complicating AD are treated best with SSRIs. Placebo-controlled trials support the use of citalopram and sertraline in AD complicated by depression. The atypical antipsychotics are the first choice for managing psychosis and disruptive agitation in AD and particularly in the Lewy body variant of AD. Studies suggest that low-dose treatment with risperidone, 1 mg/d, or olanzapine, 5 mg/d, offers the optimal ratio of therapeutic to adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Northwest Network Veterans Affairs Mental Illness Research, Education and Clinical Center (MIRECC), Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Clin North Am</MedlineTA><NlmUniqueID>2985236R</NlmUniqueID><ISSNLinking>0025-7125</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="N">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11349485</ArticleId><ArticleId IdType="doi">10.1016/s0025-7125(05)70341-2</ArticleId><ArticleId IdType="pii">S0025-7125(05)70341-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11343862</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>1-2</Issue><PubDate><Year>2001</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>A review of MRI findings in schizophrenia.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>52</EndPage><MedlinePgn>1-52</MedlinePgn></Pagination><Abstract><AbstractText>After more than 100 years of research, the neuropathology of schizophrenia remains unknown and this is despite the fact that both Kraepelin (1919/1971: Kraepelin, E., 1919/1971. Dementia praecox. Churchill Livingston Inc., New York) and Bleuler (1911/1950: Bleuler, E., 1911/1950. Dementia praecox or the group of schizophrenias. International Universities Press, New York), who first described 'dementia praecox' and the 'schizophrenias', were convinced that schizophrenia would ultimately be linked to an organic brain disorder. Alzheimer (1897: Alzheimer, A., 1897. Beitrage zur pathologischen anatomie der hirnrinde und zur anatomischen grundlage einiger psychosen. Monatsschrift fur Psychiarie und Neurologie. 2, 82-120) was the first to investigate the neuropathology of schizophrenia, though he went on to study more tractable brain diseases. The results of subsequent neuropathological studies were disappointing because of conflicting findings. Research interest thus waned and did not flourish again until 1976, following the pivotal computer assisted tomography (CT) finding of lateral ventricular enlargement in schizophrenia by Johnstone and colleagues. Since that time significant progress has been made in brain imaging, particularly with the advent of magnetic resonance imaging (MRI), beginning with the first MRI study of schizophrenia by Smith and coworkers in 1984 (Smith, R.C., Calderon, M., Ravichandran, G.K., et al. (1984). Nuclear magnetic resonance in schizophrenia: A preliminary study. Psychiatry Res. 12, 137-147). MR in vivo imaging of the brain now confirms brain abnormalities in schizophrenia. The 193 peer reviewed MRI studies reported in the current review span the period from 1988 to August, 2000. This 12 year period has witnessed a burgeoning of MRI studies and has led to more definitive findings of brain abnormalities in schizophrenia than any other time period in the history of schizophrenia research. Such progress in defining the neuropathology of schizophrenia is largely due to advances in in vivo MRI techniques. These advances have now led to the identification of a number of brain abnormalities in schizophrenia. Some of these abnormalities confirm earlier post-mortem findings, and most are small and subtle, rather than large, thus necessitating more advanced and accurate measurement tools. These findings include ventricular enlargement (80% of studies reviewed) and third ventricle enlargement (73% of studies reviewed). There is also preferential involvement of medial temporal lobe structures (74% of studies reviewed), which include the amygdala, hippocampus, and parahippocampal gyrus, and neocortical temporal lobe regions (superior temporal gyrus) (100% of studies reviewed). When gray and white matter of superior temporal gyrus was combined, 67% of studies reported abnormalities. There was also moderate evidence for frontal lobe abnormalities (59% of studies reviewed), particularly prefrontal gray matter and orbitofrontal regions. Similarly, there was moderate evidence for parietal lobe abnormalities (60% of studies reviewed), particularly of the inferior parietal lobule which includes both supramarginal and angular gyri. Additionally, there was strong to moderate evidence for subcortical abnormalities (i.e. cavum septi pellucidi-92% of studies reviewed, basal ganglia-68% of studies reviewed, corpus callosum-63% of studies reviewed, and thalamus-42% of studies reviewed), but more equivocal evidence for cerebellar abnormalities (31% of studies reviewed). The timing of such abnormalities has not yet been determined, although many are evident when a patient first becomes symptomatic. There is, however, also evidence that a subset of brain abnormalities may change over the course of the illness. The most parsimonious explanation is that some brain abnormalities are neurodevelopmental in origin but unfold later in development, thus setting the stage for the development of the symptoms of schizophrenia. Or there may be additional factors, such as stress or neurotoxicity, that occur during adolescence or early adulthood and are necessary for the development of schizophrenia, and may be associated with neurodegenerative changes. Importantly, as several different brain regions are involved in the neuropathology of schizophrenia, new models need to be developed and tested that explain neural circuitry abnormalities effecting brain regions not necessarily structurally proximal to each other but nonetheless functionally interrelated. (ABSTRACT TRUNCATED)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shenton</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Clinical Neuroscience Division, Laboratory of Neuroscience, Department of Psychiatry, Harvard Medical School, Brockton, MA 02301, USA. martha_shenton@hms.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>C C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Frumin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McCarley</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH040799</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH050740</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 40799</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 50740</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH050740-06</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 01110</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 MH001110-06</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH040799-13</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11343862</ArticleId><ArticleId IdType="mid">NIHMS166514</ArticleId><ArticleId IdType="pmc">PMC2812015</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(01)00163-3</ArticleId><ArticleId IdType="pii">S0920-9964(01)00163-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 1998;24:189&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9613620</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S, Bunney WE, Jr, Potkin SG, et al. Altered distribution of nicotinamideadenine dinucleotide phosphatedia-phorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry. 1993a;50:169&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679891</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S, Vinuela A, Kim JJ, et al. Distorted distribution of nicotinamideadenine dinucleotide phosphatediaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch. Gen. Psychiatry. 1993b;50:178&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679892</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler LL, Bartzokis G, Grieder T, et al. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity [letter] Arch. Gen. Psychiatry. 1998;55:663&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">9672058</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. Beitrage zur pathologischen anatomie der hirnrinde und zur anatomischen grundlage einiger psychosen. Monatsschrift fur Psychiarie und Neurologie. 1897;2:82&#x2013;120.</Citation></Reference><Reference><Citation>Anderson J, Umans C, Halle M, et al.  Anatomy Browser: Java based interactive teaching tool for learning human neuro-anatomy. RSNA Electronic Journal. 1998;2:50&#x2013;97.  http://ej.rsna.org/ej2/0050-97.fin/index.html.</Citation></Reference><Reference><Citation>Andreasen N, Nasrallah HA, Dunn V, et al. Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch. Gen. Psychiatry. 1986;43:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">3947208</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Ehrhardt JC, Swayze VW, II, et al. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch. Gen. Psychiatry. 1990;47:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">2294854</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neurolepticnaive patients and in patients with chronic schizophrenia. Assessment with xenon 133 singlephoton emission computed tomography and the Tower of London. Arch. Gen. Psychiatry. 1992;49:943&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">1360199</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Flashman L, Flaum M, et al. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 1994a;272:1763&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pubmed">7966925</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Arndt S, Swayze VW, II, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging . Science. 1994b;266:294&#x2013;298. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">7939669</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science. 1997;275:1586&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054346</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, Nopoulos P, O&#x2019;Leary DS, et al. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol. Psychiatry. 1999;46:908&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">10509174</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC. Schizophrenia: the fundamental questions. Brain Res. Brain Res. Rev. 2000;31:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10719138</ArticleId></ArticleIdList></Reference><Reference><Citation>Arciniegas D, Rojas DC, Teale P, et al. The thalamus and the schizophrenia phenotype: failure to replicate reduced volume. Biol. Psychiatry. 1999;45:1329&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">10349040</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt S, Cohen G, Alliger RJ, et al. Problems with ratio and proportion measures of imaged cerebral structures. Psychiatry Res. 1991;40:79&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1946842</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt S, Rajarethinam R, Cizadlo T, et al. Landmark-based MR image registration and measurement: a reliability and validation study. J. Psychiatr. Res. Neuroimaging. 1996;67:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8876014</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward EH, Reiss AL, Barta PE, et al. Magnetic resonance imaging measurement of posterior fossa structures in schizophrenia. Am. J. Psychiatry. 1994;151:1448&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">8092338</ArticleId></ArticleIdList></Reference><Reference><Citation>Baar&#xe9; WF, Hulshoff Pol HE, Hijman R, et al. Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol. Psychiatry. 1999;45:1597&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">10376121</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr WB, Ashtari M, Bilder RM, et al. Brain morphometric comparison of firstepisode schizophrenia and temporal lobe epilepsy. Br. J. Psychiatry. 1997;170:515&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330016</ArticleId></ArticleIdList></Reference><Reference><Citation>Barta PE, Pearlson GD, Powers RE, et al. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am. J. Psychiatry. 1990;147:1457&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">2221156</ArticleId></ArticleIdList></Reference><Reference><Citation>Barta PE, Pearlson GD, Brill LB, II, et al. Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Am. J. Psychiatry. 1997a;154:661&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">9137122</ArticleId></ArticleIdList></Reference><Reference><Citation>Barta PE, Powers RE, Aylward EH, et al. Quantitative MRI volume changes in late onset schizophrenia and Alzheimer&#x2019;s disease compared to normal controls. Psychiatry Res. 1997b;68:65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9104754</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley AJ, Jones DW, Torrey EF, et al. Sylvian fissure asymmetries in monozygotic twins: a test of laterality in schizophrenia. Biol. Psychiatry. 1993;34:853&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">8110912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Nuechterlein KH, Marder SR, et al. Age at illness onset and left temporal lobe length in males with schizophrenia. Psychiatry Research: Neuroimaging. 1996;67:189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8912958</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker T, Elmer K, Mechela B, et al. MRI findings in medial temporal lobe structures in schizophrenia. Eur. Neuropsychopharmacol. 1990;1:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2136220</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker T, Elmer K, Schneider F, et al. Confirmation of reduced temporal limbic structure volume on magnetic resonance imaging in male patients with schizophrenia. Psychiatry Res. 1996;67:135&#x2013;143. [published erratum appears in Psychiatry Res 1997 May 16;74(2):1278]</Citation><ArticleIdList><ArticleId IdType="pubmed">8876013</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch. Gen. Psychiatry. 1987;44:608&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">3606326</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Paskevich PA, Domesick VB. Haloperiodol-induced plasticity of axon terminals in rat substantia nigra. Science. 1983;221:969&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">6879197</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM. Myelination of corticalhippocampal relays during late adolescence. Schizophr. Bull. 1989;15:585&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">2623440</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Sorensen I, Bird ED. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr. Bull. 1991;17:597&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">1805353</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes FM, Vincent SL, Alsterberg G, et al. Increased GABAa receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 1992;12:924&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576044</ArticleId><ArticleId IdType="pubmed">1372045</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes F. Is there a neuroanatomic basis for schizophrenia? An old question revisited. Neuroscientist. 1995;1:104&#x2013;115.</Citation></Reference><Reference><Citation>Bilder RM, Wu H, Bogerts B, et al. Absence of regional hemispheric volume asymmetries in firstepisode schizophrenia. Am. J. Psychiatry. 1994;151:1437&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8092337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilder RM, Bogerts B, Ashtari M, et al. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr. Res. 1995;17:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">8541249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilder RM, Wu H, Bogerts B, et al. Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. Int. J. Psychophysiol. 1999;34:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">10610044</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder J. Functional magnetic resonance imaging. Language mapping. Neurosurg. Clin. N. Am. 1997;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">9188545</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwood DH, Young AH, McQueen JK, et al. Magnetic resonance imaging in schizophrenia: altered brain morphology associated with P300 abnormalities and eye tracking dysfunction. Biol. Psychiatry. 1991;30:753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleuler E. Dementia praecox or the group of schizophrenias. New York: International Universities Press; 1911&#x2013;1950.</Citation></Reference><Reference><Citation>Bogerts B. Neuropathology of schizophrenias. Fortschr. Neural. Psychiatr. 1984;52:428&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">6519627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerts B, Meertz E, SchonfeldtBausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch. Gen. Psychiatry. 1985;42:784&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">4015323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerts B, Ashtari M, Degreef G, et al. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 1990;35:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">2367608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerts B, Falkai P, Greve B, et al. The neuropathology of schizophrenia: past and present. J. Hirnforsch. 1993a;34:193&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8228181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerts B, Lieberman JA, Ashtari M, et al. Hippocampusamygdala volumes and psychopathology in chronic schizophrenia. Biol. Psychiatry. 1993b;33:236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">8471676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogerts B. The neuropathology of schizophrenic diseases: historical aspects and present knowledge. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249:2&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookstein F. Morphometric tools for landmark data: geometry and biology. Cambridge University Press: Cambridge; 1991.</Citation></Reference><Reference><Citation>Bookstein FL. Shape and information in medical images: A decade of the morphometric synthesis. Computer Vision and Image Understanding. 1997a;66:97&#x2013;118.</Citation></Reference><Reference><Citation>Bookstein FL. Landmark methods for forms without landmarks: Morphometrics of group differences in outline shape. Medical Image Analysis. 1997b;1:225&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein RA, Schwarzkopf SB, Olson SC, et al. Third-ventricle enlargement and neuropsychological deficit in schizophrenia. Biol. Psychiatry. 1992;31:954&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637933</ArticleId></ArticleIdList></Reference><Reference><Citation>Brechb&#xfc;hler C, Gerig G, K&#xfc;bler O. Parametrization of closed surfaces for 3-D shape description. CVGIP: Image Understanding. 1995;61:154&#x2013;170.</Citation></Reference><Reference><Citation>Breier A, Buchanan RW, Elkashef A, et al. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry. 1992;49:921&#x2013;926. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">1449382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am. J. Psychiatry. 1995;152:973&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233767</ArticleId><ArticleId IdType="pubmed">7793467</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R, Colter N, Corsellis JA, et al. Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch. Gen. Psychiatry. 1986;43:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2935114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant NL, Buchanan RW, Vladar K, et al. Gender differences in temporal lobe structures of patients with schizophrenia: a volumetric MRI study. Am. J. Psychiatry. 1999;156:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200741</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan RW, Breier A, Kirkpatrick B, et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am. J. Psychiatry. 1993;150:59&#x2013;65. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">8417581</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan RW, Vladar K, Barta PE, et al. Structural evaluation of the prefrontal cortex in schizophrenia. Am. J. Psychiatry. 1998;155:1049&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">9699693</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchsbaum MS. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr. Bull. 1990;16:379&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">2287929</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchsbaum MS, Someya T, Teng CY, et al. PET and MRI of the thalamus in nevermedicated patients with schizophrenia. Am. J. Psychiatry. 1996;153:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8561198</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchsbaum MS, Yang S, Hazlett E, et al. Ventricular volume and asymmetry in schizotypal personality disorder and schizophrenia assessed with magnetic resonance imaging. Schizophr. Res. 1997;27:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9373894</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchsbaum MS, Tang CY, Peled S, et al. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport. 1998;9:425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512384</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley PF. Structural brain imaging in schizophrenia. Psychiatr. Clin. North Am. 1998;21:77&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9551492</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley PF, Dean D, Bookstein FL, et al. Threedimensional magnetic resonancebased morphometrics and ventricular dysmorphology in schizophrenia. Biol. Psychiatry. 1999;45:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894576</ArticleId></ArticleIdList></Reference><Reference><Citation>Callicott JH, Egan MF, Bertolino A, et al. Hippocampal nacetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol. Psychiatry. 1998;44:941&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">9821558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon TD, van Erp TG, Huttunen M, et al. Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch. Gen. Psychiatry. 1998;55:1084&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862551</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter M. Core Text of Neuroanatomy. Human Neuroanatomy. Baltimore, MD: Williams and Wilkins; 1983.</Citation></Reference><Reference><Citation>Casanova MF, Zito M, Goldberg T, et al. Shape distortion of the corpus callosum of monozygotic twins discordant for schizophrenia [letter] Schizophr. Res. 1990;3:155&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">2278979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavada C, Goldman-Rakic PS. Posterior parietal cortex in rhesus monkeys, I: Parcellation of areas based on distinctive limbic and sensory corticocortical connections. J. Comp. Neurol. 1989;287:393&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">2477405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 1994;151:1430&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakos MH, Lieberman JA, Alvir J, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine [letter] Lancet. 1995;345:456&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">7853978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi JG, Dooling EC, Gilles FH. Gyral development of the human brain. Ann. Neurol. 1977;1:86&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">560818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien D, Buxton RB, Kwong KK, et al. MR diffusion imaging of the human brain. J. Comput. Assist. Tomogr. 1990;14:514&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">2370348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua SE, McKenna PJ. Schizophrenia brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br. J. Psychiatry. 1995;166:563&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua SE, Sharma T, Takei N, et al. A magnetic resonance imaging study of corpus callosum size in familial schizophrenic subjects, their relatives, and normal controls. Schizophr. Res. 2000;41:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728717</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffman JA, Schwarzkopf SB, Olson SC, et al. Midsagittal cerebral anatomy by magnetic resonance imaging. The importance of slice position and thickness. Schizophr. Res. 1989;2:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2487168</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Dai W, Peters TM, Evans AC. Model based segmentation of individual brain structures from MRI data. In: Robb RA, editor. Proc. SPIE 1808. Chapel Hill, NC: Visualization in Biomedical Computing II; 1992. pp. 10&#x2013;23.</Citation></Reference><Reference><Citation>Colombo C, Abbruzzese M, Livian S, et al. Memory functions and temporallimbic morphology in schizophrenia. Psychiatry Res. 1993;50:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8511223</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo C, Bonfanti A, Scarone S. Anatomical characteristics of the corpus callosum and clinical correlates in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1994;243:244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">8172939</ArticleId></ArticleIdList></Reference><Reference><Citation>Colter N, Battal S, Crow TJ, et al. White matter reduction in the parahippocampal gyrus of patients with schizophrenia [letter] Arch. Gen. Psychiatry. 1987;44:1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">3675129</ArticleId></ArticleIdList></Reference><Reference><Citation>Copolov D, Velakoulis D, McGorry P, et al. Neurobiological findings in early phase schizophrenia. Brain Res. Brain Res. Rev. 2000;31:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">10719144</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J, Jernigan T, Archibald S, et al. Quantitative magnetic resonance imaging of the brain in latelife schizophrenia. Am. J. Psychiatry. 1995;152:447&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">7864275</ArticleId></ArticleIdList></Reference><Reference><Citation>Corson PW, Nopoulos P, Andreasen NC, et al. Caudate size in first episode neurolepticnaive schizophrenic patients measured using an artificial neural network. Biol. Psychiatry. 1999a;46:712&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">10472424</ArticleId></ArticleIdList></Reference><Reference><Citation>Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am. J. Psychiatry. 1999b;156:1200&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10450260</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">7901908</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatr. 1996;3:241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384954</ArticleId></ArticleIdList></Reference><Reference><Citation>Crichton-Browne J. On the weight of the brain and its components parts in the insane. Brain. 1879;2:42&#x2013;67.</Citation></Reference><Reference><Citation>Crow TJ, Ball J, Bloom SR, et al. Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. Arch. Gen. Psychiatry. 1989;46:1145&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">2589928</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow TJ. The continuum of psychosis and its genetic origins. The sixty-fifth Maudsley lecture. Br. J. Psychiatry. 1990a;156:788&#x2013;797. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">2207509</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow TJ. Temporal lobe asymmetries as the key to the etiology of schizophrenia. Schizophr. Bull. 1990b;16:433&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">2287933</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow TJ. Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature? Schizophr. Bull. 1997;23:521&#x2013;523. [comment]</Citation><ArticleIdList><ArticleId IdType="pubmed">9327516</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow TJ. Schizophrenia as a transcallosal misconnection syndrome. Schizophr. Res. 1998;30:111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9549773</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Joshi S, Wang L, et al. Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc. Natl. Acad. Sci. USA. 1998;95:11406&#x2013;11411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21655</ArticleId><ArticleId IdType="pubmed">9736749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari M, Friedman L, Jesberger J, et al. A magnetic resonance imaging study of thalamic area in adolescent patients with either schizophrenia or bipolar disorder as compared to healthy controls. Psychiatry Res. 1999;91:155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">10641579</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauphinais ID, DeLisi LE, Crow TJ, et al. Reduction in temporal lobe size in siblings with schizophrenia: a magnetic resonance imaging study. Psychiatry Res. 1990;35:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">2100805</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Dauphinais ID, Gershon ES. Perinatal complications and reduced size of brain limbic structures in familial schizophrenia. Schizophr. Bull. 1988;14:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">3201176</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Hoff AL, Schwartz JE. Brain morphology in firstepisode schizophreniclike psychotic patients: a quantitative magnetic resonance imaging study. Biol. Psychiatry. 1991;29:159&#x2013;175. [published erratum appears in Biol. Psychiatry 1991 Mar 1;29(5):519]</Citation><ArticleIdList><ArticleId IdType="pubmed">1995085</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Stritzke P, Riordan H, et al. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. Biol. Psychiatry. 1992;31:241&#x2013;254. [published erratum appears in Biol. Psychiatry 1992 jun 1;31(11):1172]</Citation><ArticleIdList><ArticleId IdType="pubmed">1547298</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Hoff AL, Kushner M, et al. Increased prevalence of cavum septum pellucidum in schizophrenia. Psychiatry Res. 1993;50:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8272454</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Hoff AL, Neale C, et al. Asymmetries in the superior temporal lobe in male and female first-episode schizophrenic patients: measures of the planum temporale and superior temporal gyrus by MRI. Schizophr. Res. 1994;12:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018582</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Tew W, Xie S, et al. A prospective followup study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol. Psychiatry. 1995;38:349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">8547454</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Sakuma M, Tew W. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997;74:129&#x2013;140. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9255858</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Sakuma M, Ge S, et al. Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization. Psychiatry Res. 1998;84:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10710165</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMyer MK, Gilmor RL, Hendrie HC, et al. Magnetic resonance brain images in schizophrenic and normal subjects: influence of diagnosis and education. Schizophr. Bull. 1988;14:21&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">3387916</ArticleId></ArticleIdList></Reference><Reference><Citation>DeQuardo JR, Bookstein FL, Green WD, et al. Spatial relationships of neuroanatomic landmarks in schizophrenia. Psychiatry Res. 1996;67:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797245</ArticleId></ArticleIdList></Reference><Reference><Citation>DeQuardo JR, Keshavan MS, Bookstein FL, et al. Landmark based morphometric analysis of firstepisode schizophrenia. Biol. Psychiatry. 1999;45:1321&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10349039</ArticleId></ArticleIdList></Reference><Reference><Citation>Degreef G, Bogerts B, Ashtari M, et al. Ventricular system morphology in first episode schizophrenia: a volumetic study of ventricular subdivisions on MRI. Schizophr. Res. 1990;3:18.</Citation></Reference><Reference><Citation>Degreef G, Ashtari M, Wu HW, et al. Follow up MRI study in first episode schizophrenia. Schizophr. Res. 1991;5:204&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">1760397</ArticleId></ArticleIdList></Reference><Reference><Citation>Degreef G, Ashtari M, Bogerts B, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in firstepisode schizophrenic patients. Arch. Gen. Psychiatry. 1992a;49:531&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">1627044</ArticleId></ArticleIdList></Reference><Reference><Citation>Degreef G, Lantos G, Bogerts B, et al. Abnormalities of the septum pellucidum on MR scans in firstepisode schizophrenic patients. Am. J. Neuroradiol. 1992b;13:835&#x2013;840. [see comments]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8331710</ArticleId><ArticleId IdType="pubmed">1590179</ArticleId></ArticleIdList></Reference><Reference><Citation>Degreef G, Bogerts B, Falkai P, et al. Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and postmortem brains of schizophrenic patients. Psychiatry Res. 1992c;45:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1410074</ArticleId></ArticleIdList></Reference><Reference><Citation>Deicken RF, Pegues M, Amend D. Reduced hippocampal nacetylaspartate without volume loss in schizophrenia. Schizophr. Res. 1999;37:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">10403193</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Michele V, Rossi A, Stratta P, et al. Neuropsychological and clinical correlates of temporal lobe anatomy in schizophrenia. Acta Psychiatr. Scand. 1992;85:484&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">1642134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CC, McCarley RW, Voglmaier MM, et al. Schizotypal personality disorder and MRI abnormalities of temporal lobe gray matter. Biol. Psychiatry. 1999;45:1393&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832794</ArticleId><ArticleId IdType="pubmed">10356620</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran M, Hajnal JV, Van Bruggen N, et al. Normal and abnormal white matter tracts shown by MR imaging using directional diffusion weighted sequences. J. Comput. Assist. Tomogr. 1990;14:865&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">2229559</ArticleId></ArticleIdList></Reference><Reference><Citation>Douek P, Turner R, Pekar J, et al. MR color mapping of myelin fiber orientation. J. Comput. Assist. Tomogr. 1991;15:923&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">1939769</ArticleId></ArticleIdList></Reference><Reference><Citation>Downhill JE, Jr, Buchsbaum MS, Wei T, et al. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr. Res. 2000;42:193&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785578</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Videen T, Price JL, et al. A functional anatomical study of unipolar depression. J. Neurosci. 1992;12:3628&#x2013;3641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575746</ArticleId><ArticleId IdType="pubmed">1527602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlap C. Dementia praecox: Some preliminary observations on brains from carefully selected cases, and a consideration of certain sources of error. Am. J. Psychiatry. 1924;80:403&#x2013;421.</Citation></Reference><Reference><Citation>Egan MF, Duncan CC, Suddath RL, et al. Eventrelated potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr. Res. 1994;11:259&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910755</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidelberg D, Galaburda AM. Inferior parietal lobule: divergent architectonic asymmetries in the human brain. Arch. Neurol. 1984;41:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">6466160</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkashef AM, Buchanan RW, Gellad F, et al. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am. J. Psychiatry. 1994;151:752&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909412</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat. Med. 1998;11:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans A, Marret S, Torrescorzo J, et al. MRI-PET correlation in three dimensions using a volume-of-interest (VOI) atlas. J. Cerebral Blood Flow Metab. 1991;11:A69&#x2013;A78.</Citation><ArticleIdList><ArticleId IdType="pubmed">1997491</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatry Neurol. Sci. 1986;236:154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">3803399</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: The entorhinal regiona morphometric study. Biol. Psychiatry. 1988;24:515&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">3167140</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatr. Res. 1982;17:319&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">7187776</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaum M, Andreasen NC, Swayze VW, et al. I.Q. and brain size in schizophrenia. Psychiatr. Res. 1994;53:243&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870846</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaum M, Swayze VW, II, O&#x2019;Leary DS, et al. Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. Am. J. Psychiatry. 1995;152:704&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">7726310</ArticleId></ArticleIdList></Reference><Reference><Citation>Foong J, Maier M, Barker GJ, et al. In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J. Neurol. Neurosurg. Psychiatry. 2000a;68:70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1760631</ArticleId><ArticleId IdType="pubmed">10601405</ArticleId></ArticleIdList></Reference><Reference><Citation>Foong J, Maier M, Clark CA, et al. Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J. Neurol. Neurosurg. Psychiatry. 2000b;68:242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736778</ArticleId><ArticleId IdType="pubmed">10644799</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak RS. Functional mapping of verbal memory and language. Trends Neurosci. 1994;17:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515526</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou S, Sharma T, Sigmudsson T, et al. The Maudsley Family Study. 4. Normal planum temporale asymmetry in familial schizophrenia. A volumetric MRI study. Br. J. Psychiatry. 1997;170:328&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9246250</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier JA, Giedd JN, Hamburger SD, et al. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Arch. Gen. Psychiatry. 1996;53:617&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660128</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier JA, Alaghband-Rad J, Jacobsen L, et al. Pubertal development and onset of psychosis in childhood onset of schizophrenia. Psychiatr. Res. 1997;70:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9172272</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederikse M, Lu A, Aylward E, et al. Sex differences in inferior parietal lobule volume in schizophrenia. Am. J. Psychiatry. 2000;157:422&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10698819</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman L, Findling RL, Kenny JT, et al. An MRI study of adolescent patients with either schizophrenia or bipolar disorder as compared to healthy control subjects. Biol. Psychiatry. 1999;46:78&#x2013;88. [published erratum appears in Biol. Psychiatry 1999 Aug 15;46(4):Follow-ing 584]</Citation><ArticleIdList><ArticleId IdType="pubmed">10394476</ArticleId></ArticleIdList></Reference><Reference><Citation>Frumin M, Golland P, McCarley RW, et al. Shape differences in the corpus callosum in first episode schizophrenia and affective disorder. 37th Annual Meeting of the American College of Neuropsychopharmacology; Puerto Rico. 1998. Dec,</Citation></Reference><Reference><Citation>Fukuzako H, Fukazako T, Hashiguchi T, et al. Reduction in hippocampal formation volume is caused mainly by its shortening in chronic schizophrenia: assessment by MRI. Biol. Psychiatry. 1996a;39:938&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9162205</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuzako T, Fukuzako H, Kodama S, et al. Cavum septum pellucidum in schizophrenia: a magnetic resonance imaging study. Psychiatry Clin. Neurosci. 1996b;50:125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201757</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuzako H, Yamada K, Kodama S, et al. Hippocampal volume asymmetry and age at illness onset in males with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1997;247:248&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">9444493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JM. The Prefrontal Cortex. New York: Raven Press; 1989.</Citation></Reference><Reference><Citation>Galaburda A, Geschwind N. The human language areas and cerebral asymmetries. Rev. Med. Suisse Romande. 1980;100:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">6990448</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaburda AM, Sanides F. Cytoarchitectonic organization of the human auditory cortex. J. Comp. Neurol. 1980;190:597&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">6771305</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaburda AM, Sanides F, Geschwind N. Human brain: cytoarchitectonic left-right asymmetries in the temporal speech region. Arch. Neurol. 1978;35:812&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">718483</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaburda AM, Corsiglia J, Rosen GD, et al. Planum temporale asymmetry, reappraisal since Geschwind and Levitsky. Neuropsychologia. 1987;25:853.</Citation></Reference><Reference><Citation>Galderisi S, Mucci A, Mignone ML, et al. Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. Int. J. Psychophysiol. 1999;34:293&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">10610053</ArticleId></ArticleIdList></Reference><Reference><Citation>Galderisi S, Vita A, Rossi A, et al. Qualitative MRI findings in patients with schizophrenia: a controlled study. Psychiatry Res. 2000;98:117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaser C, Volz HP, Kiebel S, et al. Detecting structural changes in whole brain based on nonlinear deformations-application to schizophrenia research. Neuroimage. 1999;10:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee JC, Reivich M, Bajcsy R. Elastically deforming 3D atlas to match anatomical brain images. J. Computer-Assisted Tomog. 1993;17:225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">8454749</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind N, Galaburda AM. Cerebral lateralization: Biological mechanisms, associations and pathology: I. A hypothesis and program for research. Arch. Neurol. 1985;42:428&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">3994562</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind N, Levitsky W. Human brain: left-right asymmetries in temporal speech region. Science. 1968;161:186&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">5657070</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass G, McGraw B, Smith M. Metaanalysis in Social Research. Newbury Park, CA: Sage Publications; 1981.</Citation></Reference><Reference><Citation>Gloor P. The role of the limbic system in perception, memory, and affect. In: Livingston BDK, editor. The Limbic System. New York: Raven Press; 1986.</Citation></Reference><Reference><Citation>Goldberg TE, Weinberger DR, Berman KF, et al. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch. Gen. Psychiatry. 1987;44:1008&#x2013;1014. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">3675128</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, Torrey EF, Berman KF, et al. Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia. Psychiatry Res. 1994;55:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8047629</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997;23:437&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">9327508</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic PS, Selemon LD, Schwartz ML. Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey. Neuroscience. 1984;12:719&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">6472617</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JM, Goodman JM, Seidman LJ, et al. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch. Gen. Psychiatry. 1999;56:537&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10359468</ArticleId></ArticleIdList></Reference><Reference><Citation>Golland P, Grimson WE. Fixed topology skeletons. Computer Vision and Pattern Recognition: IEEE Computer Society. 2000:10&#x2013;17.</Citation></Reference><Reference><Citation>Golland P, Grimson WE, Kikinis R. Statistical shape analyses using fixed topology skeletons: corpus callosum study. In: Kuba A, Smal M, Todd-Polropek A, editors. Sixteenth International Conference on Information Processing and Medical Imaging. Springer-Verlag: Visegrad, Hungary; 1999. pp. 382&#x2013;387.</Citation></Reference><Reference><Citation>Golomb J, de Leon MJ, Kluger A, et al. Hippocampal atrophy in normal aging: an association with recent memory impairment. Arch. Neurol. 1993;50:967&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363451</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunze HC, Rainnie DG, Hasselmo ME, et al. NMDA-dependent modulation of cal local circuit inhibition. J. Neurosci. 1996;16:2034&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578507</ArticleId><ArticleId IdType="pubmed">8604048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruzelier JH. Hemispheric imbalance: syndromes of schizophrenia, premorbid personality, and neurodevelopmental influences. In: Steinhauer SR, Gruzelier JH, Zubin J, editors. Handbook of Schizophrenia: Neuropsychology, Psychophysiology and Information Processing. vol. 5. New York, NY: Elsevier; 1991. pp. 599&#x2013;650.</Citation></Reference><Reference><Citation>Guenther W, Moser E, Petsch R, et al. Pathological cerebral blood blow and corpus callosum abnormalities in schizophrenia: Relations to EEG mapping and PET data. Psychiatry Res. 1989;29:453&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">2608818</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerguerian R, Lewine RR. Brain torque and sex differences in schizophrenia. Schizophr. Res. 1998;30:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">9549782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther W, Petsch R, Steinberg R, et al. Brain dysfunction during motor activation and corpus callosum alterations in schizophrenia measured by cerebral blood flow and magnetic resonance imaging. Biol. Psychiatry. 1991;29:535&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">1905162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Pearlson GD. Neuroimaging in schizophrenia research. Schizophr. Bull. 1993;19:337&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">8322037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Mozley PD, Shtasel DL, et al. Clinical subtypes of schizophrenia: Differences in brain and CSF volume. Am. J. Psychiatry. 1994;151:343&#x2013;350. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">8109642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Maany V, Mozley PD, et al. Subcortical MRI volumes in neurolepticnaive and treated patients with schizophrenia. Am. J. Psychiatry. 1998a;155:1711&#x2013;1717. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9842780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Cowell P, Turetsky BI, et al. A followup magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch. Gen. Psychiatry. 1998b;55:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9477928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Turetsky BI, Bilker WB, et al. Reduced gray matter volume in schizophrenia. Arch. Gen. Psychiatry. 1999;56:905&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">10530632</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Turetsky BI, Cowell PE, et al. Temporolimbic volume reductions in schizophrenia. Arch. Gen. Psychiatry. 2000a;57:769&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pubmed">10920465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur RE, Cowell PE, Latshaw A, et al. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch. Gen. Psychiatry. 2000b;57:761&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">10920464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurvits TV, Shenton ME, Hokama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related post-traumatic stress disorder. Biol. Psychiatry. 1996;40:1091&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910907</ArticleId><ArticleId IdType="pubmed">8931911</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf8;tzsche PC. Why we need a broad perspective on meta-analysis: it may be crucially important for patients. [Letter] BMJ. 2000;321:585&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1118486</ArticleId><ArticleId IdType="pubmed">10977820</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund MM, Ojemann GA, Hochman DW. Optical imaging of epileptiform and functional activity in human cerebral cortex. Nature. 1992;358:668&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">1495561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajek M, Huonker R, Boehle C, et al. Abnormalities of auditory evoked magnetic fields and structural changes in the left hemisphere of male schizophrenicsa magnetoencephalographicmagnetic resonance imaging study. Biol. Psychiatry. 1997;42:609&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">9376457</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajnal JV, Doran M, Hall AS, et al. MR imaging of anisotropically restricted diffusion of water in the nervous system: Technical, anatomic, and pathologic considerations. J. Comput. Assist. Tomogr. 1991;15:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">1987175</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller JW, Banerjee A, Christensen GE, et al. Threedimensional hippocampal MR morphometry with highdimensional transformation of a neuroanatomic atlas. Radiology. 1997;202:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">9015081</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PJ. The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain. 1999;122:593&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219775</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey I, Ron MA, Du Boulay G, et al. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. Psychol. Med. 1993;23:591&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">8234567</ArticleId></ArticleIdList></Reference><Reference><Citation>Haug J. Pneumoencephalographic studies in mental disease. Acta Psychiatr. Neurol. 1962;165:11&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">13960992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser P, Dauphinais ID, Berrettini W, et al. Corpus callosum dimensions measured by magnetic resonance imaging in bipolar affective disorder and schizophrenia. Biol. Psychiatry. 1989;26:659&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">2804188</ArticleId></ArticleIdList></Reference><Reference><Citation>Havermans R, Honig A, Vuurman EF, et al. A controlled study of temporal lobe structure volumes and P300 responses in schizophrenic patients with persistent auditory hallucinations. Schizophr. Res. 1999;38:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">10463460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazlett EA, Buchsbaum MS, Byne W, et al. Threedimensional analysis with MRI and pet of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry. 1999;156:1190&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">10450259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecker E. Die hebephrenic. Arch. Patholiche Anat. und fur Physiol. Klinische Medicin. 1871;52:394&#x2013;429.</Citation></Reference><Reference><Citation>Heckers S, Heinsen H, Heinsen Y, et al. Cortex, white matter, and basal ganglia in schizophrenia: a volumetric postmortem study. Biol. Psychiatry. 1991;29:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">2054430</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr. Bull. 1997;23(3):403&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9327506</ArticleId></ArticleIdList></Reference><Reference><Citation>Henn FA, Braus DF. Structural neuroimaging in schizophrenia. An integrative view of neuromorphology. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249:48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654109</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman I, Murray RM. Schizophrenia and neurodevelopment. J. R. Coll. Physicians Lond. 1992;26:143&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5375501</ArticleId><ArticleId IdType="pubmed">1588520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hier D, LeMay M, Rosenberger P. Autism-association with reversed cerebral asymmetry. Neurology. 1978;28:348&#x2013;349.</Citation></Reference><Reference><Citation>Hier D, LeMay M, Rosenberger PB. Autism and unfavorable left-right asymmetries of the brain. J. Autism Dev. Disord. 1979;9:153&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">479099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayasu Y, Shenton ME, Salisbury DF, et al. Lower left temporal lobe MRI volumes in patients with firstepisode schizophrenia compared with psychotic patients with firstepisode affective disorder and normal subjects. Am. J. Psychiatry. 1998;155:1384&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">9766770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayasu Y, Shenton ME, Salisbury DF, et al. Subgenual cingulate cortex volume in first-episode psychosis. Am. J. Psychiatry. 1999;156:1091&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845843</ArticleId><ArticleId IdType="pubmed">10401458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayasu Y, McCarley RW, Salisbury DF, et al. Planum temporale and Hesch gyrus volume reduction in schizophrenia: A magnetic resonance imaging study of first-episode patients. Arch. Gen. Psychiatry. 2000;57:692&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850271</ArticleId><ArticleId IdType="pubmed">10891040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoff AL, Riordan H, O&#x2019;Donnell D, et al. Anomalous lateral sulcus asymmetry and cognitive function in first-episode schizophrenia. Schizophr. Bull. 1992;18:257&#x2013;272. [published erratum appears in Schizophr. Bull. 1994;20(2):248]</Citation><ArticleIdList><ArticleId IdType="pubmed">1621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoff AL, Neal C, Kushner M, et al. Gender differences in corpus callosum size in first-episode schizophrenics. Biol. Psychiatry. 1994;35:913&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokama H, Shenton ME, Nestor PG, et al. Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Res. 1995;61:209&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748466</ArticleId></ArticleIdList></Reference><Reference><Citation>Holinger DP, Shenton ME, Wible CG, et al. Superior temporal gyrus volume abnormalities and thought disorder in left-handed schizophrenic men. Am. J. Psychiatry. 1999;156:1730&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845841</ArticleId><ArticleId IdType="pubmed">10553736</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer WG, Bassett AS, Smith GN, et al. Temporal lobe abnormalities in multigenerational families with schizophrenia. Biol. Psychiatry. 1994;36:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160970</ArticleId><ArticleId IdType="pubmed">7858069</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard D, Patterson K, Wise R, et al. The cortical localization of the lexicons: positron emission tomography evidence. Brain. 1992;115:1769&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">1486460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter J, Schmidt F. Methods of Metaanalysis. Newbury Park, CA: Sage Publications; 1990.</Citation></Reference><Reference><Citation>Iosifescu DV, Shenton ME, Warfield SK, et al. An automated registration algorithm for measuring MRI subcortical brain structures. Neuroimage. 1997;6:13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245652</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi W, Winkler H. Encephalographische studien an schizophrenen. Arch. Psychiatrie. 1928;84:208&#x2013;226.</Citation></Reference><Reference><Citation>Jacobsen LK, Giedd JN, Vaituzis AC. Temporal lobe morphology in childhoodonset schizophrenia. Am. J. Psychiatry. 1996;153:355&#x2013;361. [published erratum appears in Am. J. Psychiatry 1996 jun;153(6):851]</Citation><ArticleIdList><ArticleId IdType="pubmed">8610822</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen LK, Giedd JN, Rajapakse JC, et al. Quantitative magnetic resonance imaging of the corpus callosum in childhood onset schizophrenia. Psychiatry Res. 1997;68:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9104755</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen LK, Giedd JN, Castellanos FX, et al. Progressive reduction of temporal lobe structures in childhood-onset schizophrenia. Am. J. Psychiatry. 1998;155:678&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">9585721</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J. Neural. Transm. 1986;65:303&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">3711886</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob H, Beckmann H. Gross and histological criteria for developmental disorders in brains of schizophrenics. J. R. Soc. Med. 1989;82:466&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1292251</ArticleId><ArticleId IdType="pubmed">2674429</ArticleId></ArticleIdList></Reference><Reference><Citation>James AC, Crow TJ, Renowden S, et al. Is the course of brain development in schizophrenia delayed? Evidence from onsets in adolescence. Schizophr. Res. 1999;40:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10541001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernigan TL, Zisook S, Heaton RK, et al. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch. Gen. Psychiatry. 1991;48:881&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">1929757</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Lohr JB. Hippocampal pathologic findings in schizophrenia. A morphometric study. Arch. Gen. Psychiatry. 1989;46:1019&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">2818139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, McAdams LA, Palmer BW, et al. Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. Acta Psychiatr. Scand. 1998;98:156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">9718243</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone EC, Crow TJ, Frith CD, et al. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">62160</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone EC, Owens DG, Crow TJ, et al. Temporal lobe structure as determined by nuclear magnetic resonance in schizophrenia and bipolar affective disorder. J. Neurol. Neurosurg. Psychiatry. 1989;52:736&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032025</ArticleId><ArticleId IdType="pubmed">2746266</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EG. The Thalamus. New York, NY: Plenum Press; 1985.</Citation></Reference><Reference><Citation>Jurjus GJ, Nasrallah HA, Olson SC, et al. Cavum septum pellucidum in schizophrenia, affective disorder and healthy controls: A magnetic resonance imaging study. Psychol. Med. 1993;23:319&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlbaum K. Die Katatonie oder der Spannungsirresein. Berlin: Hirshwald; 1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">23170304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki Y, Maeda Y, Urata K, et al. A quantitative magnetic resonance imaging study of patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1993;242:268&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8499495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki Y, Maeda Y, Higashima M, et al. Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia. Schizophr. Res. 1997;26:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay SR, Opler LA, Fizbein A. Positive and Negative Syndrome Scale. North Tonawanda, New York: Multi-Health Systems Inc; 1986.</Citation></Reference><Reference><Citation>Kegeles LS, Shungu DC, Anjilvel S, et al. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 2000;98:163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsoe JR, Jr, Cadet JL, Pickar D, et al. Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. Arch. Gen. Psychiatry. 1988;45:533&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">3377640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler KS, McGuire M, Gruenberg AM, et al. The Roscommon family study, I: methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch. Gen. Psychiatry. 1993;50:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">8317947</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan MS, Bagwell WW, Haas GL, et al. Changes in caudate volume with neuroleptic treatment [letter] Lancet. 1994;344:1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7968091</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan MS, Bagwell WW, Haas GL, et al. Does caudate volume increase during follow up in first-episode psychosis? Schizophr. Res. 1995;15:87.</Citation></Reference><Reference><Citation>Keshavan MS, Rosenberg D, Sweeney JA, et al. Decreased caudate volume in neurolepticnaive psychotic patients. Am. J. Psychiatry. 1998a;155:774&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">9619149</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan MS, Haas GL, Kahn CE, et al. Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? J. Psychiatr. Res. 1998b;32:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">9793869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kety SS. Biochemical theories of schizophrenia. Science. 1959;129:1528&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pubmed">13658985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikinis R, Shenton ME, Gerig G, et al. Temporal lobe sulcogyral pattern anomalies in schizophrenia: an in vivo MR three-dimensional surface rendering study. Neurosci. Lett. 1994;182:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikinis R, Shenton ME, Iosifescu DV, et al. A digital brain atlas for surgical planning, model driven segmentation, and teaching. IEEE Transactions on Visualization and Computer Graphics. 1996;2:232&#x2013;241.</Citation></Reference><Reference><Citation>Kleinschmidt A, Falkai P, Huang Y, et al. In vivo morphometry of planum temporale asymmetry in first-episode schizophrenia. Schizophr. Res. 1994;12:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018589</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science. 1993;260:95&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">8096653</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuro H, Rakic P. Orchestration of neural migration by activity of ion channels, neurotransmitter receptors, and intra-cellular Ca2 + fluctuations. J. Neurobiol. 1998;37:110&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol. Psychiatry. 1984;19:1601&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">6518211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraepelin E. Dementia Praecox. New York: Churchill Livingston Inc; 1919&#x2013;1971.</Citation></Reference><Reference><Citation>Kretschmer E. Physique and Character. New York: Harcourt Brace Jovanovich Publishers; 1925.</Citation></Reference><Reference><Citation>Krishnan K, McDonald WM, Escalona PR, et al. Magnetic resonance imaging of the caudate nuclei in depression: preliminary observations. Arch. Gen. Psychiatry. 1992;49:553&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">1627046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulynych JJ, Vladar K, Fantie BD, et al. Normal asymmetry of the planum temporale in patients with schizophrenia. Three-dimensional cortical morphometry with MRI. Br. J. Psychiatry. 1995;166:742&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">7663822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulynych JJ, Vladar K, Jones DW, et al. Superior temporal gyrus volume in schizophrenia: a study using MRI morphometry assisted by surface rendering. Am. J. Psychiatry. 1996;153:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8540591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulynych JJ, Luevano LF, Jones DW, et al. Cortical abnormality in schizophrenia: an in vivo application of the gyrification index. Biol. Psychiatry. 1997;41:995&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">9129779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JS, Shenton ME, Hirayasu Y, et al. MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. Am. J. Psychiatry. 1998;155:509&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826366</ArticleId><ArticleId IdType="pubmed">9545997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JS, McCarley RW, Hirayasu Y, et al. Left planum temporale volume reduction in schizophrenia. Arch. Gen. Psychiatry. 1999;56:142&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauriello J, Hoff A, Wieneke MH, et al. Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Am. J. Psychiatry. 1997;154:819&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9167510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry. 1998;172:110&#x2013;120. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9519062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrie SM, Whalley H, Kestelman JN, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet. 1999;353:30&#x2013;33. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">10023948</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bihan D, Breton E, Lallemand D. MR imaging of intravoxel incoherent motions: Application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">3763909</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bihan D. Diffusion and Perfusion Magnetic Resonance Imaging. New York: Raven Press; 1995.</Citation></Reference><Reference><Citation>LeMay M, Kidd DK. Asymmetry of cerebral hemispheres on computed tomograms. J. Comput. Assist. Tomogr. 1978;2:471&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">708500</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMay M. Leftright temporal region asymmetry in infants and children [letter] AJNR Am. J. Neuroradiol. 1986;7:974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8331979</ArticleId><ArticleId IdType="pubmed">3096123</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard CM, Kuldau JM, Breier JI, et al. Cumulative effect of anatomical risk factors for schizophrenia: an MRI study. Biol. Psychiatry. 1999;46:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10435203</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan C, Ward PB, Catts SV. Superior temporal gyral volumes and laterality correlates of auditory hallucinations in schizophrenia. Biol. Psychiatry. 1999;46:955&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">10509178</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitt JJ, Shenton ME, McCarley RW, et al. Premorbid adjustment in schizophrenia: Implications for psychosocial and ventricular pathology. Schizophr. Res. 1994;12:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043526</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitt JJ, McCarley RW, Nestor PG, et al. Quantitative volumetric MRI study of the cerebellum and vermis in schizophrenia: clinical and cognitive correlates. Am. J. Psychiatry. 1999;156:1105&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845842</ArticleId><ArticleId IdType="pubmed">10401463</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitt JJ, McCarley RW, Ciszewski AA, et al. Caudate and ventricular volume in neuroleptic-naive schizotypal personality disorder. [Abstract] American Psychiatric Association New Research Abstracts. 2000;140</Citation></Reference><Reference><Citation>Lewine RR, Gulley LR, Risch SC, et al. Sexual dimorphism, brain morphology, and schizophrenia. Schizophr. Bull. 1990;16:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">2374880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewine RR, Hudgins P, Brown F, et al. Differences in qualitative brain morphology findings in schizophrenia, major depression, bipolar disorder, and normal volunteers. Schizophr. Res. 1995;15:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">7632622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SW, Mezey GC. Clinical correlates of septum pellucidum cavities: an unusual association with psychosis. Psychol. Med. 1985;15:43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2581281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman J, Bogerts B, Degreef G, et al. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am. J. Psychiatry. 1992;149:784&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA, Jody D, Alvir JM, et al. Brain morphology, dopamine, and eyetracking abnormalities in first episode schizophrenia. Prevalence and clinical correlates. Arch. Gen. Psychiatry. 1993;50:357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14:135&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KO, Tew W, Kushner M, et al. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am. J. Psychiatry. 1996;153:1548&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8942450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KO, Hedehus M, Moseley M, et al. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch. Gen. Psychiatry. 1999;56:367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipska B, Jaskiw G, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology. 1993;9:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipska B, Swerdlow N, Geyer M, et al. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology. 1995;122:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">8711062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipska B, Al-Amin HA, Weinberger DR. Excitotoxic lesions of the rat medial prefrontal cortex: effects on abnormal behaviors associated with neonatal hippocampal damage. Neuropsychopharmacology. 1998;19:451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">9803421</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean PD. Some psychiatric implications of physiological studies on frontotemporal portion of limbic system (visceral brain) Electroencephalogr. Clin. Neurophysiol. 1952;4:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">12998590</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnotta VA, Heckel D, Andreasen NC, et al. Measurement of brain structures with artificial neural networks: two and three-dimensional applications. Radiology. 1999;211:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">10352607</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnotta VA, Gold S, Andreasen NC, et al. Visualization of subthalamic nuclei with cortex attenuated inversion recovery MR imaging. Neuroimage. 2000;11:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">10725190</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher BA, Manschreck TC, Woods BT, et al. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol. Psychiatry. 1995;37:144&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">7727622</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher BA, Manschreck TC, Yurgelun-Todd DA, et al. Hemispheric asymmetry of frontal and temporal gray matter and age of onset in schizophrenia. Biol. Psychiatry. 1998;44:413&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777170</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier SE, Gudbjartsson H, Patz S, et al. Line scan diffusion imaging: characterization in healthy subjects and stroke patients. Am. J. Roentgenol. 1998;171:85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648769</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh L, Suddath RL, Higgins N, et al. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr. Res. 1994;11:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">8193061</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh L, Harris D, Lim KO, et al. Structural magnetic resonance imaging abnormalities in men with severe chronic schizophrenia and an early age at clinical onset. Arch. Gen. Psychiatry. 1997;54:1104&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">9400346</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh L, Lim KO, Hoff AL, et al. Severity of schizophrenia and magnetic resonance imaging abnormalities: a comparison of State and Veterans hospital patients. Biol. Psychiatry. 1999;45:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathalon DH, Sullivan EV, Rawles JM, et al. Correction for head size in brainimaging measurements. Psychiatry Res. 1993;50:121&#x2013;139. [see comments] [published erratum appears in Psychiatry Res, 1994 sep;55(3):179]</Citation><ArticleIdList><ArticleId IdType="pubmed">8378488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew RJ, Partain CL. Midsagittal sections of the cerebellar vermis and fourth ventricle obtained with magnetic resonance imaging of schizophrenic patients. Am. J. Psychiatry. 1985a;142:970&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">4025598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew RJ, Partain CL, Prakash R, et al. A study of the septum pellucidum and corpus callosum in schizophrenia with MR imaging. Acta Psychiatr. Scand. 1985b;72:414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">4091025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg HS. Neuroimaging studies of depression in neurologic disease. In: Starkstein SE, Robinson RG, editors. Depression in Neurological Disease. Johns Hopkins University Press; 1993. pp. 186&#x2013;216.</Citation></Reference><Reference><Citation>McCarley RW, Faux SF, Shenton ME, et al. Event-related potentials in schizophrenia: their biological and clinical correlates and a new model of schizophrenic pathophysiology. Schizophr. Res. 1991;4:209&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">2039762</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarley RW, Shenton ME, O&#x2019;Donnell BF, et al. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Arch. Gen. Psychiatry. 1993;50:190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">8439239</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarley RW, Hsiao JK, Freedman R, et al. Neuroimaging and the cognitive neuroscience of schizophrenia. Schizophr. Bull. 1996;22:703&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938923</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarley RW, Niznikiewicz MA, Salisbury DF, et al. Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects. Eur. Arch. Psychiatry Clin. Neurosci. 1999a;249:69&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855690</ArticleId><ArticleId IdType="pubmed">10654112</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol. Psychiatry. 1999b;45:1099&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846838</ArticleId><ArticleId IdType="pubmed">10331102</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann. N.Y. Acad. Sci. 1997;821:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9238211</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil TF, CantorGraae E, Weinberger DR. Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia. Am. J. Psychiatry. 2000;157:203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671388</ArticleId></ArticleIdList></Reference><Reference><Citation>Mednick SA, McNeil TF. Current methodology in research on the etiology of schizophrenia: Serious difficulties which suggest the use of the high-risk-group method. Psychol. Bull. 1968;70:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">4889572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am. Psychologist. 1962;17:827&#x2013;838.</Citation></Reference><Reference><Citation>Meisenzahl EM, Frodl T, Greiner J, et al. Corpus callosum size in schizophrenia&#x2014;a magnetic resonance imaging analysis. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653287</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisenzahl EM, Frodl T, Zetzsche T, et al. Adhesio interthalamica in male patients with schizophrenia. Am. J. Psychiatry. 2000;157:823&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784480</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon RR, Barta PE, Aylward EH, et al. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr. Res. 1995;16:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">7577766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M-M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann. Neural. 1990;28:597&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">2260847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M-M. From sensation to cognition. Brain. 1998;121:1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Research Reviews. 2000;31:236&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">10719151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mion CC, Andreasen NC, Arndt S, et al. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 1991;40:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">1685788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizoguchi K, Kunishita T, Chui DH, et al. Stress induces neuronal death in the hippocampus of castrated rats. Neurosci. Lett. 1992;138:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407656</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseley ME, Kucharczyk J, Mintorovitch J. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR. 1990;11:423&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367476</ArticleId><ArticleId IdType="pubmed">2161612</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? [editorial] Br. Med. J. (Clin. Res. Ed.) 1987;295:681&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1247717</ArticleId><ArticleId IdType="pubmed">3117295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair TR, Christensen JD, Kingsbury SJ, et al. Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res. 1997;74:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">9255859</ArticleId></ArticleIdList></Reference><Reference><Citation>Narr KL, Thompson PM, Sharma T, et al. Mapping morphology of the corpus callosum in schizophrenia. Cereb. Cortex. 2000;10:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10639394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah HA, Andreasen NC, Coffman JA, et al. A controlled magnetic resonance imaging study of corpus callosum thickness in schizophrenia. Biol. Psychiatry. 1986;21:274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">3947709</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah HA, Schwarzkopf SB, Olson SC, et al. Gender differences in schizophrenia on MRI brain scans. Schizophr. Bull. 1990;16:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">2374881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah HA, Sharma S, Olson SC. The volume of the entorhinal cortex in schizophrenia: a controlled MRI study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1997;21:1317&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460094</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MD, Saykin AJ, Flashman LA, et al. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch. Gen. Psychiatry. 1998;55:433&#x2013;440. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9596046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PG, Shenton ME, McCarley RW, et al. Neuropsychological correlates of MRI temporal lobe abnormalities in schizophrenia. Am. J. Psychiatry. 1993;150:1849&#x2013;1855. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">8238641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PG, Kimble MO, O&#x2019;Donnell BF, et al. Aberrant semantic activation in schizophrenia: a neurophysiological study. Am. J. Psychiatry. 1997;154:640&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9137119</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol. Psychiatry. 1999;46:1418&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pubmed">10578456</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemann K, Hammers A, Coenen VA, et al. Evidence of a smaller left hippocampus and left temporal horn in both patients with first episode schizophrenia and normal control subjects [in process citation] Psychiatry Res. 2000;99:93&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963985</ArticleId></ArticleIdList></Reference><Reference><Citation>Niznikiewicz M, Donnino R, McCarley RW, et al. Abnormal angular gyrus asymmetry in schizophrenia. Am. J. Psychiatry. 2000;157:428&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846293</ArticleId><ArticleId IdType="pubmed">10698820</ArticleId></ArticleIdList></Reference><Reference><Citation>Noga JT, Aylward E, Barta PE, et al. Cingulate gyrus in schizophrenic patients and normal volunteers. Psychiatry Res. 1995;61:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos P, Torres I, Flaum M, et al. Brain morphology in first-episode schizophrenia. Am. J. Psychiatry. 1995;152:1721&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">8526236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos P, Swayze V, Andreasen NC. Pattern of brain morphology in patients with schizophrenia and large cavum septi pellucidi. J. Neuropsychiatry Clin. Neurosci. 1996;8:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9081549</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos P, Swayze V, Flaum M, et al. Cavum septi pellucidi in normals and patients with schizophrenia as detected by magnetic resonance imaging. Biol. Psychiatry. 1997;41:1102&#x2013;1108. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9146821</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos PC, Giedd JN, Andreasen NC, et al. Frequency and severity of enlarged cavum septi pellucidi in childhood-onset schizophrenia. Am. J. Psychiatry. 1998a;155:1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">9699696</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos P, Swayze V, Flaum M, et al. Incidence of ectopic gray matter in patients with schizophrenia and healthy control subjects studied with MRI. J. Neuropsychiatry Clin. Neurosci. 1998b;10:351&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">9706544</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopoulos PC, Ceilley JW, Gailis EA, et al. An MRI study of cerebellar vermis morphology in patients with schizophrenia: Evidence in support of the cognitive dysmetria concept. Biol. Psychiatry. 1999;46:703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">10472423</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris SD, Krishnan KR, Ahearn E. Structural changes in the brain of patients with bipolar affective disorder by MRI: a review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1997;21:1323&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuechterlein KR, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984;10:160&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">6729409</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;f M, K&#xfc;bler O, Kikinis R, Shenton ME, et al. Characterization and recognition of 3D organ shapes in medical image analysis using skeletonization. IEEE Mathematical Methods in Biomedical Image Analysis. 1996:139&#x2013;150.</Citation></Reference><Reference><Citation>O&#x2019;Donnell BF, Shenton ME, McCarley RW, et al. The auditory N2 component in schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biol. Psychiatry. 1993;34:26&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8373937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnuma T, Kimura M, Takahashi T, et al. A magnetic resonance imaging study in first-episode disorganized-type patients with schizophrenia. Psychiatry Clin. Neurosci. 1997;51:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9076854</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol. Psychiatry. 1989;26:505&#x2013;525. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">2571362</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW. Excitotoxic amino acids and neuropsychiatric disorders. Ann. Rev. Pharmacol. Toxicology. 1990;30:47&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">2188577</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;52:998&#x2013;1007. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">7492260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakkenberg B. Postmortem study of chronic schizophrenic brains. Br. J. Psychiatry. 1987;151:744&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">3502800</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya DN, Seltzer B. Association areas of the cerebral cortex. Trends in Neuroscience. 1982;5:386&#x2013;394.</Citation></Reference><Reference><Citation>Pandya DN, Van Hoesen GW, Mesulam MM. Efferent connections of the cingulate gyrus in the rhesus monkey. Exp. Brain Res. 1981;42:319&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">6165607</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch. Gen. Psychiatry. 1992;49:975&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">1449384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson GD, Marsh L. MRI in psychiatry. In: Oldham J, B R, A T, editors. American Psychiatric Association Press Review of Psychiatry. Washington DC: American Psychiatric Association; 1993. pp. 347&#x2013;381.</Citation></Reference><Reference><Citation>Pearlson GD, Barta PA, Schrami FV, et al. Brain size in schizophrenia [Letter] Arch. Gen. Psychiatry. 1991;48:181&#x2013;182.</Citation></Reference><Reference><Citation>Pearlson GD, Petty RG, Ross CA, et al. Schizophrenia: a disease of heteromodal association cortex? Neuropsychopharmacology. 1996;14:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8719025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson GD. Superior temporal gyrus and planum temporale in schizophrenia: a selective review. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1997a;21:1203&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460087</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson GD, Marsh L. Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry. 1999;46:627&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">10472416</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson GD, Barta PE, Powers RE, et al. Ziskind-Somerfeld research award 1996. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biol. Psychiatry. 1997b;41:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8988790</ArticleId></ArticleIdList></Reference><Reference><Citation>Peled S, Gudbjartsson H, Westin CF, et al. Magnetic resonance imaging shows orientation and asymmetry of white matter fiber tracts. Brain Res. 1998;780:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9473573</ArticleId></ArticleIdList></Reference><Reference><Citation>Penfield W, Perot P. The brain&#x2019;s record of auditory and visual experience: a final summary and discussion. Brain. 1963;86:595&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">14090522</ArticleId></ArticleIdList></Reference><Reference><Citation>Penfield W, Roberts L. Speech and Brain Mechanisms. Princeton, NJ: Princeton University Press; 1959.</Citation></Reference><Reference><Citation>Petitti D. Metaanalysis, Decision Analysis, and Cost Effectiveness Analysis. New York: Oxford University Press; 1994.</Citation></Reference><Reference><Citation>Petty RG, Barta PE, Pearlson GD, et al. Reversal of asymmetry of the planum temporale in schizophrenia. Am. J. Psychiatry. 1995;152:715&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">7726311</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum A, Zipursky RB. Neuroimaging studies of schizophrenia. Schizophr. Res. 1991;4:193&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">2039761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum A, Lim KO, Rosenbloom M, et al. Brain magnetic resonance imaging: approaches for investigating schizophrenia. Schizophr. Bull. 1990;16:453&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">2287935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum A, Sullivan EV, Hedehus M, et al. Brain gray and white matter transverse relaxation time in schizophrenia. Psychiatry Res. 1999;91:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515464</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinel P. Traite medico philosophique sur l&#x2019;alienation mentale boulamania. Paris: Richard Caille et Ravier; 1801.</Citation></Reference><Reference><Citation>Pizer SM, Eberly D, Fritsch DS, et al. Zoom-invariant vision of figural shape: the mathematics of cores. Computer Vision and Image Understanding. 1998;69:55&#x2013;71.</Citation></Reference><Reference><Citation>Plum F. Prospects for research on schizophrenia. 3. Neurophysiology. Neuropathological findings. Neurosci. Res Program Bull. 1972;10:384&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">4663816</ArticleId></ArticleIdList></Reference><Reference><Citation>Portas CM, Goldstein JM, Shenton ME, et al. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging. Biol. Psychiatry. 1998;43:649&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9582998</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner MI, Early TS, Reiman E, et al. Asymmetries in hemispheric control of attention in schizophrenia. Arch. Gen. Psychiatry. 1988;45:814&#x2013;821. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">3415424</ArticleId></ArticleIdList></Reference><Reference><Citation>Raine A, Harrison GN, Reynolds GP, et al. Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls, and normal controls. A magnetic resonance imaging and neuropsychological evaluation. Arch. Gen. Psychiatry. 1990;47:1060&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">2241507</ArticleId></ArticleIdList></Reference><Reference><Citation>Raine A, Lencz T, Reynolds GP, et al. An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res. 1992;45:123&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">1362615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajarethinam RP, DeQuardo JR, Nalepa R, et al. Superior temporal gyrus in schizophrenia: a volumetric magnetic resonance imaging study. Schizophr. Res. 2000;41:303&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10708339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P, Yakovlev PI. Development of the corpus callosum and cavum septi in man. J. Comp. Neurol. 1968;132:45&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">5293999</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport JL, Giedd J, Kumra S, et al. Childhoodonset schizophrenia. Progressive ventricular change during adolescence. Arch. Gen. Psychiatry. 1997;54:897&#x2013;903. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9337768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport JL, Giedd JN, Blumenthal J, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry. 1999;56:649&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch SL, Renshaw PF. Clinical neuroimaging in psychiatry. Harv. Rev. Psychiatry. 1995;2:297&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384916</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz S, Raz N. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. Psychological Bulletin. 1990;108:93&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">2143298</ArticleId></ArticleIdList></Reference><Reference><Citation>Razi K, Greene KP, Sakuma M, et al. Reduction of the parahippocampal gyrus and the hippocampus in patients with chronic schizophrenia. Br. J. Psychiatry. 1999;174:512&#x2013;519. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">10616629</ArticleId></ArticleIdList></Reference><Reference><Citation>Reite M, Sheeder J, Teale P, et al. Magnetic source imaging evidence of sex differences in cerebral lateralization in schizophrenia. Arch. Gen. Psychiatry. 1997;54:433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152097</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MB, Coyle JT. Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB Journal. 1987;1:446&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">2890549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger PB, Hier DB. Cerebral asymmetry and verbal intellectual deficits. Ann. Neurol. 1980;8:300&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">7436373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal R, Bigelow LB. Quantitative brain measurements in chronic schizophrenia. Br. J. Psychiatry. 1972;121:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">5073779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal R. Design, Analysis, and Meta-analysis. Cambridge, MA: Cambridge University Press; 1987. Judgement Studies.</Citation></Reference><Reference><Citation>Rosenthal R, Rubin DB. Comparing significance levels of independent studies. Psychol. Bull. 1979;56:1163&#x2013;1168.</Citation></Reference><Reference><Citation>Rosenthal R, Rubin DB. Comparing effect sizes of independent studies. Psychol. Bull. 1982;92:500&#x2013;504.</Citation></Reference><Reference><Citation>Rosenthal R, Rubin DB. Meta-analysis procedures for combining studies with multiple effect sizes. Psychol. Bull. 1986;99:400&#x2013;406.</Citation></Reference><Reference><Citation>Rossi A, Stratta P, Gallucci M, et al. Standardized magnetic resonance image intensity study in schizophrenia. Psychiatry Res. 1988;25:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">3174904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, D&#x2019;Albenzio L, et al. Reduced temporal lobe area in schizophrenia by magnetic resonance imaging: preliminary evidence. Psychiatry Res. 1989a;29:261&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">2608770</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, Gallucci M, et al. Quantification of corpus callosum and ventricles in schizophrenia with nuclear magnetic resonance imaging: a pilot study. Am. J. Psychiatry. 1989b;146:99&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, D&#x2019;Albenzio L, et al. Reduced temporal lobe areas in schizophrenia: preliminary evidences from a controlled multiplanar magnetic resonance imaging study. Biol. Psychiatry. 1990;27:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">2297553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, et al. Di Michele, V. Temporal lobe structure by magnetic resonance in bipolar affective disorders and schizophrenia. J. Affect. Disord. 1991;21:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1827473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, Mattei P, et al. Planum temporale in schizophrenia: a magnetic resonance study. Schizophr. Res. 1992;7:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1591193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, Mancini F, et al. Cerebellar vermal size in schizophrenia: a male effect. Biol. Psychiatry. 1993;33:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8471693</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Stratta P, Mancini F, et al. Magnetic resonance imaging findings of amygdala-anterior hippocampus shrinkage in male patients with schizophrenia. Psychiatry Res. 1994a;52:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8047621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Serio A, Stratta P, et al. Planum temporale asymmetry and thought disorder in schizophrenia. Schizophr. Res. 1994b;12:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L, Mettler F. Cell concentration and laminar thickness of frontal cortex of psychotic patients. J. Comp. Neurol. 1949;90:225.</Citation><ArticleIdList><ArticleId IdType="pubmed">18136716</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy PD, Zipursky RB, SaintCyr JA, et al. Temporal horn enlargement is present in schizophrenia and bipolar disorder. Biol. Psychiatry. 1998;44:418&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdev PS, Brodaty H. Midsagittal anatomy in late onset schizophrenia. Psychol. Med. 1999;29:963&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">10473323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilipo M, Lafargue T, Arena L, et al. Fine volumetric analysis of the cerebral ventricular system in schizophrenia: further evidence for multifocal mild to moderate enlargement. Schizophr. Bull. 2000a;26:201&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilipo M, Lafargue T, Rusinek H, et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch. Gen. Psychiatry. 2000b;57:471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807487</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders RC, Kolachana BS, Bachevalier J, et al. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature. 1998;393:169&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603519</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel AB, Kovelman JA. Dendritic disarray in the hippocampus of paranoid schizophrenia. Annual Meeting of the Society of Biological Psychiatry. 1979</Citation></Reference><Reference><Citation>Scheibel AB, Kovelman JA. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient. Biol. Psychiatry. 1981;16:101&#x2013;102.</Citation></Reference><Reference><Citation>SchellerGilkey G, Lewine RR. Age at onset and sex differences in corpus callosum area in schizophrenia. Schizophr. Res. 1999;40:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10638861</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlaepfer TE, Harris GJ, Tien AY, et al. Decreased regional cortical gray matter volume in schizophrenia. Am. J. Psychiatry. 1994;151:842&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">8184992</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmahmann JD. From movement to thought: Anatomic substrates of the cerebellar contribution to cognitive processing. Human Brain Mapping. 1996;4:174&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">20408197</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JM, Aylward E, Barta PE, et al. Sylvian fissure size in schizophrenia measured with the magnetic resonance imaging rating protocol of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am. J. Psychiatry. 1992;149:1195&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1503132</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzkopf SB, Olson SC, Coffman JA, et al. Third and lateral ventricular volumes in schizophrenia: support for progressive enlargement of both structures. Psychopharmacol. Bull. 1990;26:385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">2274640</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott TF, Price TR, George MS, et al. Midline cerebral malformations and schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1993;5:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8369638</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman LJ. Schizophrenia and brain dysfunction: An integration of recent neurodiagnostic findings. Psychol. Bull. 1983;94:195&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">6356196</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman LJ, Yurgelun-Todd D, Kremen WS, et al. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol. Psychiatry. 1994;35:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">8186328</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman LJ, Faraone SV, Goldstein JM, et al. Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients. Am. J. Med. Genetics (Neuropsychiatric Genetics) 1997;74:507&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">9342202</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman LJ, Faraone SV, Goldstein JM, et al. Thalamic and amygdalahippocampal volume reductions in firstdegree relatives of patients with schizophrenia: an MRIbased morphometric analysis. Biol. Psychiatry. 1999;46:941&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">10509177</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman LJ, Goldstein JM, Makris NN, et al. Subcortical brain abnormalities in patients with schizophrenia: an MRI morphometric study. Biol. Psychiatry. 2000;47(8s):24s. [Abstract]</Citation></Reference><Reference><Citation>Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 1995;52:805&#x2013;818. discussion 819&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">7575100</ArticleId></ArticleIdList></Reference><Reference><Citation>Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 1998;392:402&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">9511926</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltzer B, Pandya DN. Further observations on parietotemporal connections in the rhesus monkey. Exp. Brain Res. 1984;55:301&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">6745368</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapleske J, Rossell SL, Woodruff PW, et al. The planum temporale: a systematic, quantitative review of its structural, functional and clinical significance. Brain Res. Brain Res. Rev. 1999;29:26&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">9974150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma T, DuBoulay G, Lewis S, et al. The Maudsley Family Study I: structural brain changes on magnetic resonance imaging in familial schizophrenia. Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiatry. 1997;21:1297&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw CM, Alvord EC., Jr Cava septi pellucidi et vergae: Their normal and pathological states. Brain. 1969;92:213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">5774029</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton RC, Weinberger DR. X-ray computerized tomography studies in schizophrenia: a review and synthesis. In: Nasrallah HA, Weinberger DR, editors. Handbook of Schizophrenia: The Neuropathology of Schizophrenia. vol. I. New York: Elsevier Science Publishers; 1986. pp. 207&#x2013;225.</Citation></Reference><Reference><Citation>Shenton ME, Kikinis R, McCarley RW, et al. Application of automated MRI volumetric measurement techniques to the ventricular system in schizophrenics and normal controls. Schizophr. Res. 1991;5:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">1931803</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenton ME, Kikinis R, Jolesz FA, et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N. Engl. J. Med. 1992;327:604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">1640954</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenton ME, Kikinis R, McCarley RW, et al. Harvard brain atlas: a teaching and visualization tool. IEEE Biomedical Visualization. 1995:10&#x2013;17.</Citation></Reference><Reference><Citation>Shenton ME. Temporal lobe structural abnormalities in schizophrenia: a selective review and presentation of new MR findings. In: Matthysse DLS, Kagan J, Benes FM, editors. Psychopathology: The Evolving Science of Mental Disorders. New York: Cambridge University Press; 1996. pp. 51&#x2013;99.</Citation></Reference><Reference><Citation>Shenton ME, Wible CG, McCarley RW. A review of magnetic resonance imaging studies of brain abnormalities in schizophrenia. In: Krishnan K, Doraiswamy P, editors. Brain Imaging in Clinical Psychiatry. New York: Marcel Dekker, Inc; 1997. pp. 297&#x2013;380.</Citation></Reference><Reference><Citation>Shenton M, Frumin M, McCarley R, et al. Morphometric MRI studies: Findings in schizophrenia. In: Dougherty D, Rauch S, Rosen J, et al., editors. Psychiatric Neuroimaging Strategies: Research and Clinical Applications. Washington, DC: American Psychiatric Association; 2001. (in press)</Citation></Reference><Reference><Citation>Shihabuddin L, Buchsbaum MS, Hazlett EA, et al. Dorsal striatal size, shape, and metabolic rate in nevermedicated and previously medicated schizophrenics performing a verbal learning task. Arch. Gen. Psychiatry. 1998;55:235&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">9510217</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioiri T, Oshitani Y, Kato T, et al. Prevalence of cavum septum pellucidum detected by MRI in patients with bipolar disorder, major depression and schizophrenia. Psychol. Med. 1996;26:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">8685300</ArticleId></ArticleIdList></Reference><Reference><Citation>Siever LJ. Biological factors in schizotypal personality disorders. Acta Psychiatr. Scand. 1994;90 Suppl. 384:45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7879643</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RC, Calderon M, Ravichandran GK, et al. Nuclear magnetic resonance in schizophrenia: a preliminary study. Psychiatry Res. 1984;12:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">6591219</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Bogerts B, Wu H, et al. Absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: an MRI and postmortem histologic study. J. Neuroimaging. 1998;8:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9664852</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares JC, Mann JJ. The anatomy of mood disordersreview of structural neuroimaging studies. Biol. Psychiatry. 1997;41:86&#x2013;106. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">8988799</ArticleId></ArticleIdList></Reference><Reference><Citation>Southard EE. A study of the dementia praecox group in the light of certain cases showing anomalies or scleroses in particular brain regions. Am. J. Insanity. 1910;67:119&#x2013;176.</Citation></Reference><Reference><Citation>Southard EE. On the topographic distribution of cortex lesions and anomalies in dementia praecox with some account of their functional significance. Am. J. Insanity. 1915;71:603&#x2013;671.</Citation></Reference><Reference><Citation>Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 1992;99:195&#x2013;231. [published erratum appears in Psychol. Rev. 1992 jul;99(3):582]</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Staal WG, Pulshoff Pol HE, Schnack H, et al. Partial volume decrease of the thalamus in relatives of patients with schizophrenia. Am. J. Psychiatry. 1998;155:1784&#x2013;1786. et al.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842796</ArticleId></ArticleIdList></Reference><Reference><Citation>Staal WG, Pulshoff Pol HE, Schnack H, et al. Structural brain abnormalities in patients with schizophrenia and their healthy siblings. Am. J. Psychiatry. 2000;157:416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">10698818</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkman MN, Gebarski SS, Berent S, et al. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing&#x2019;s syndrome. Biol. Psychiatry. 1992;32:756&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">1450290</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis N, Frangou S, Yakeley J, et al. Hippocampal volume reduction in schizophrenia: effects of genetic risk and pregnancy and birth complications. Biol. Psychiatry. 1999;46:697&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">10472422</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Krishnan KR. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol. Psychiatry. 1998;43:705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">9606523</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JR. An anatomy of schizophrenia? Arch. Gen. Psychiatry. 1973;29:177&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">4147475</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratta P, Rossi A, Gallucci M, et al. Hemispheric asymmetries and schizophrenia: a preliminary magnetic resonance imaging study. Biol. Psychiatry. 1989;25:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">2914152</ArticleId></ArticleIdList></Reference><Reference><Citation>Suddath RL, Casanova MF, Goldberg TE, et al. Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am. J. Psychiatry. 1989;146:464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">2929746</ArticleId></ArticleIdList></Reference><Reference><Citation>Suddath RL, Christison GW, Torrey EF, et al. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N. Engl. J. Med. 1990;322:789&#x2013;794. [published erratum appears in N.Engl. J. Med. 1990 may 31;322(22):1616] [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">2308615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan EV, Mathalon DH, Lim KO, et al. Patterns of regional cortical dysmorphology distinguishing schizophrenia and chronic alcoholism. Biol. Psychiatry. 1998;43:118&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9474444</ArticleId></ArticleIdList></Reference><Reference><Citation>Swayze VW, Andreasen NC, Alliger RJ, et al. Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry. 1992;31:221&#x2013;240. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">1547297</ArticleId></ArticleIdList></Reference><Reference><Citation>Symonds LL, Archibald SL, Grant I, et al. Does an increase in sulcal or ventricular fluid predict where brain tissue is lost? J. Neuroimaging. 1999;9:201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540599</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeszko PR, Bilder RM, Lencz T, et al. Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Res. 1999;90:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibbo P, Nopoulos P, Arndt S, et al. Corpus callosum shape and size in male patients with schizophrenia. Biol. Psychiatry. 1998;44:405&#x2013;412. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9777169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiede U, Bomans M, Hohne KH, et al. A computerized three-dimensional atlas of the human skull and brain. Am. J. Neuroradiology. 1993;14:551&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8333371</ArticleId><ArticleId IdType="pubmed">8517340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiihonen J, Katila H, Pekkonen E, et al. Reversal of cerebral asymmetry in schizophrenia measured with magnetoencephalography. Schizophr. Res. 1998;30:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">9589515</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres IJ, Flashman LA, O&#x2019;Leary DS, et al. Lack of an association between delayed memory and hippocampal and temporal lobe size in patients with schizophrenia and healthy controls. Biol. Psychiatry. 1997;42:1087&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">9426878</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrey EF, Peterson MR. Schizophrenia and the limbic system. Lancet. 1974;2:942&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">4138925</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai G, Coyle JT. Nacetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 1995;46:531&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tune L, Barta P, Wong D, et al. Striatal dopamine D2 receptor quantification and superior temporal gyrus: Volume determination in 14 chronic schizophrenic subjects. Psychiatry Res. 1996;67:155&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">8876015</ArticleId></ArticleIdList></Reference><Reference><Citation>Turetsky BI, Cowell PE, Gur RC, et al. Frontal and temporal lobe brain volumes in schizophrenia. Arch. Gen. Psychiatry. 1995;52:1061&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492258</ArticleId></ArticleIdList></Reference><Reference><Citation>Turetsky BI, Moberg PJ, Yousem DM, et al. Reduced olfactory bulb volume in patients with schizophrenia. Am. J. Psychiatry. 2000;157:828&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784482</ArticleId></ArticleIdList></Reference><Reference><Citation>Uematsu M, Kaiya H. The morphology of the corpus callosum in schizophrenia. An MRI study. Schizophr. Res. 1988;1:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">3154526</ArticleId></ArticleIdList></Reference><Reference><Citation>Uematsu M, Kaiya H. Midsagittal cortical pathomorphology of schizophrenia: A magnetic resonance imaging study. Psychiatry Res. 1989;30:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">2574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno H, Tarara R, Else J, Suleman M, et al. Hippocampal damage associated with prolonged and fatal stress in primates. J. Neurosci. 1989;9:1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569823</ArticleId><ArticleId IdType="pubmed">2723746</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DCA. tension-based theory of morphogenesis and compact wiring in the central nervous system. Nature. 1997;385:313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">9002514</ArticleId></ArticleIdList></Reference><Reference><Citation>Velakoulis D, Pantelis C, McGorry PD, et al. Hippocampal volume in firstepisode psychoses and chronic schizophrenia: a high resolution magnetic resonance imaging study. Arch. Gen. Psychiatry. 1999;56:133&#x2013;141. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">10025437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita A, Dieci M, Giobbio GM, et al. Language and thought disorder in schizophrenia: Brain morphological correlates. Schizophr. Res. 1995;15:243&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">7632621</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Pandya DN. Cingulate cortex of the rhesus monkey: II. Cortical afferents. J. Comp. Neurol. 1987;262:271&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">3624555</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Pandya DN, Rosene DL. Cingulate cortex of the rhesus monkey: I. Cytoarchitecture and thalamic afferents. J. Comp. Neurol. 1987;262:256&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">3624554</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldo MC, Cawthra E, Adler LE, et al. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr. Res. 1994;12:93&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043530</ArticleId></ArticleIdList></Reference><Reference><Citation>Warach S, Chien D, Li W, et al. Fast magnetic resonance diffusionweighted imaging of acute human stroke. Neurology. 1992;42:1717&#x2013;1723. [published erratum appears in Neurology 1992 Nov;42(11):2192]</Citation><ArticleIdList><ArticleId IdType="pubmed">1513459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward KE, Friedman L, Wise A, Schulz SC. Meta-analysis of brain and cranial size in schizophrenia. Schizophr. Res. 1996;22:197&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassink TH, Andreasen NC, Nopoulos P, et al. Cerebellar morphology as a predictor of symptom and psychosocial outcome in schizophrenia. Biol. Psychiatry. 1999;45:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894574</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y, Gould E, McEwen BS. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992;588:341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">1393587</ArticleId></ArticleIdList></Reference><Reference><Citation>Weight DG, Bigler ED. Neuroimaging in psychiatry. Psychiatr. Clin. North Am. 1998;21:725&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">9890119</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR. The pathogenesis: a neurodevelopmental theory. In: Nasrallah HA, Weinberger DR, editors. Handbook of Schizophrenia: The Neuropathology of Schizophrenia. vol. I. New York: Elsevier Science Publishers; 1986. pp. 397&#x2013;406.</Citation></Reference><Reference><Citation>Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 1987;44:660&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">3606332</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR, Berman KF, Suddath R, et al. Evidence of dysfunction of a prefrontallimbic network in schizophrenia: A magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry. 1992;149:890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">1609867</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR. From neuropathology to neurodevelopment. Lancet. 1995;346:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544856</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR. On the plausibility of &#x201c;The Neurodevelopmental Hypothesis&#x201d; of schizophrenia. Neuropsychopharmacology. 1996;14:1S&#x2013;11S.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866738</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR, Mattay V, Callicott J, et al. fMRI applications in schizophrenia research. Neuroimage. 1996;4:S118&#x2013;S126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345536</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DR. Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiatry. 1999;45:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernicke C. De aphasische symptomenkomplex. Breslau: Cohen and Weigart; 1874.</Citation></Reference><Reference><Citation>Whitworth AB, Honeder M, Kremser C, et al. Hippocampal volume reduction in male schizophrenic patients. Schizophr. Res. 1998;31:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9689711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wible CG, Shenton ME, Hokama H, et al. Prefrontal cortex and schizophrenia. A quantitative magnetic resonance imaging study. Arch. Gen. Psychiatry. 1995;52:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">7702444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wible CG, Shenton ME, Fischer LA, et al. Parcellation of the human prefrontal cortex using MRI. Psychiatry Res. 1997;76:29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498307</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson P, Pelz D, Merskey H, et al. Correlation of negative symptoms in schizophrenia with frontal lobe parameters on magnetic resonance imaging. Br. J. Psychiatry. 1991;159:130&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">1888960</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson P, Pelz D, Merskey H, et al. Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am. J. Psychiatry. 1992;149:549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">1554045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolkin A, Rusinek H, Vaid G, et al. Structural magnetic resonance image averaging in schizophrenia. Am. J. Psychiatry. 1998;155:1064&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">9699695</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff PW, Pearlson GD, Geer MJ, et al. A computerized magnetic resonance imaging study of corpus callosum morphology in schizophrenia. Psychol. Med. 1993;23:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8475214</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff PW, Phillips ML, Rushe T, et al. Corpus callosum size and interhemispheric function in schizophrenia. Schizophr. Res. 1997a;23:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075296</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff PW, Wright IC, Shuriquie N, et al. Structural brain abnormalities in male schizophrenics reflect frontotemporal dissociation. Psychol. Med. 1997b;27:1257&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403897</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods BT, Yurgelun-Todd D, Goldstein JM, et al. MRI brain abnormalities in chronic schizophrenia: One process or more? Biol. Psychiatry. 1996;40:585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">8886291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright IC, RabeHesketh S, Woodruff PW, et al. Metaanalysis of regional brain volumes in schizophrenia. Am. J. Psychiatry. 2000;157:16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10618008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo RA, Hodde-Vargas J, Hendren RL, et al. Brain abnormalities in schizophrenia-spectrum children: implications for a neurodevelopmental perspective. Psychiatry Res. 1997;76:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498305</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AH, Blackwood DH, Roxborough H, et al. A magnetic resonance imaging study of schizophrenia: Brain structure and clinical symptoms. Br. J. Psychiatry. 1991;158:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">2012905</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurgelun-Todd DA, Renshaw PF. Applications of functional MR imaging to research in psychiatry. Neuroimaging Clin. N. Am. 1999;9:295&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10318716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakzanis KK, Heinrichs RW. Schizophrenia and the frontal brain: A quantitative review. J. Int. Neuropsychol. Soc. 1999;5:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">10561937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky RB, Lim KO, Pfefferbaum A. Brain size in schizophrenia. Arch. Gen. Psychiatry. 1991;48:179&#x2013;180.</Citation></Reference><Reference><Citation>Zipursky RB, Lim KO, Sullivan EV, et al. Widespread cerebral gray matter volume deficits in schizophrenia. Arch. Gen. Psychiatry. 1992;49:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">1567274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky RB, Marsh L, Lim KO, et al. Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biol. Psychiatry. 1994;35:501&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky RB, Seeman MV, Bury A, et al. Deficits in gray matter volume are present in schizophrenia but not bipolar disorder. Schizophr. Res. 1997;26:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky RB, Lambe EK, Kapur S, et al. Cerebral gray matter volume deficits in first episode psychosis. Arch. Gen. Psychiatry. 1998a;55:540&#x2013;546. [see comments]</Citation><ArticleIdList><ArticleId IdType="pubmed">9633673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipursky RB, ZhangWong J, Lambe EK, et al. MRI correlates of treatment response in first episode psychosis. Schizophr. Res. 1998b;30:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9542791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11336615</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-6566</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Use of olanzapine in non-psychotic psychiatric disorders.</ArticleTitle><Pagination><StartPage>667</StartPage><EndPage>680</EndPage><MedlinePgn>667-80</MedlinePgn></Pagination><Abstract><AbstractText>The history of antipsychotic medications begins in the 1950s with chlorpromazine, developed originally as an antihistamine but found to be an aid in the reduction of symptoms of delusions and hallucinations. This phenothiazine derivative was followed by numerous others in the same class (e.g., thioridazine) and then by antipsychotics in other classes (e.g., the popular haloperidol of the butyrophenone class). This group of medications is associated with a number of unpleasant side effects and complications. These included extrapyramidal symptoms (EPS), orthostatic hypotension, hyperprolactinemia and last, but certainly not least, tardive dyskinesia (TD). As a consequence, other alternative antipsychotics were developed in which D(2) blockade effect generally associated with EPS and TD was offset by 5-HT(2) antagonism. The first of this class was clozapine; however, it is associated with agranulocytopenia of sudden onset as well as seizure induction. However, olanzapine, a close structural relative, was soon synthesised for treatment of psychosis and particularly schizophrenia (Zyprexatrade mark, Eli Lilly). It was released in the US in November 1996 with FDA approval for that indication. However, antipsychotics have always been used for other psychiatric disorders, aside from schizophrenia. This includes, in particular, mania, where chlorpromazine use predated lithium as an effective treatment. Other uses for antipsychotics have included other mood disorders, dementia, childhood disorders and personality problems. Here, information on the application of olanzapine to non-schizophrenic disorders is reviewed. Despite the fact that the research post-dates FDA approval in 1996, there was already sufficient evidence for olanzapine's effectiveness in acute mania to obtain approval from the US FDA in March 2000. Other research supports its use as adjunctive therapy in depressive disorders. Phase IV studies and case reports have found limited support for olanzapine's use in a variety of other psychiatric disorders, behavioural disorders of dementia (including Alzheimer's disease), pervasive developmental disorder of childhood, obsessive-compulsive disorder and borderline personality disorder. In each of these latter diagnoses, double-blind studies are either underway or are planned to establish efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodnick</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of Miami School of Medicine, D79, 1400 NW 10 Avenue, Miami, Florida 33136, USA. pgoodnick@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrios</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11336615</ArticleId><ArticleId IdType="doi">10.1517/14656566.2.4.667</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11336605</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-6566</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective.</ArticleTitle><Pagination><StartPage>543</StartPage><EndPage>548</EndPage><MedlinePgn>543-8</MedlinePgn></Pagination><Abstract><AbstractText>The past decade has seen the introduction of several new antipsychotics for the treatment of schizophrenia. These drugs demonstrate substantially lower levels of extrapyramidal side effects (EPS) than the classical antipsychotics, as well as having (often poorly supported) claims of increased efficacy at ameliorating certain schizophrenic syndromes. Increasingly, these 'atypical' drugs are being used in the treatment of psychotic or related behavioural disturbances in patients with neurodegenerative disease. Thus, some newer antipsychotics are particularly valuable in ameliorating the L-dopa-induced psychosis in Parkinson's disease, while behavioural problems in dementing disorders, such as those occurring in Alzheimer's disease, are also frequently treated by antipsychotic drugs. The relationship between drug pharmacology and neurotransmitter pathology is essential to understanding the relative efficacy of individual antipsychotic drugs in treating the psychotic and behavioural disturbances of neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>G P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, The University of Sheffield, Sheffield, S10 2TN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11336605</ArticleId><ArticleId IdType="doi">10.1517/14656566.2.4.543</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11288166</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dementia with Lewy bodies in Down's syndrome.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>320</EndPage><MedlinePgn>311-20</MedlinePgn></Pagination><Abstract><AbstractText>The association between Down's syndrome (DS) and Alzheimer's disease is well established. This paper presents a review of the literature, suggesting a possible association between DS and the more recently recognised dementia with Lewy bodies (DLB). Patients with DLB frequently present with changes in affect and behaviour, and in particular with psychotic symptoms. The literature suggests a possible role for atypical neuroleptics in the management of psychosis in DLB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Psychologie, Universit&#xe9; de Moncton, Moncton, Nouveau-Brunswick, Canada. simardm@umoncton.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Reekum</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>67</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>4</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11288166</ArticleId><ArticleId IdType="doi">10.1002/gps.342</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11283463</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Noncognitive symptoms in Alzheimer's disease. A study of 150 community-dwelling patients using a questionnaire completed by the caregiver].</ArticleTitle><Pagination><StartPage>162</StartPage><EndPage>177</EndPage><MedlinePgn>162-77</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">We studied the noncognitive symptoms in 150 community-dwelling Alzheimer's patients using a questionnaire completed by the caregiver, the Echelle Psychopathologique de la D&#xe9;mence de Type Alzheimer, EPDTA (Psychopathologic Scale of Dementia of Alzheimer Type). EPDTA is a 44-item questionnaire derived from the BEHAVE-AD and the Depressive Mood Scale, covering many aspects of the behavior, affective and psychiatric disturbances. Each item is rated from 0 (never observed) to 6 (most of the time). Frequency (percentage of symptom present) and severity (mean score when the symptom was present) were assessed for each item. The cognitive status and severity of the disease were assessed by the MMSE and two scales completed by the caregiver assessing the Activities of Daily Living scale (ADL) and the Cognitive Difficulties Scale (CDS). Noncognitive symptoms were present in all patients but remained moderate in severity. A principal component analysis of the 33 items exploring the affective disturbances showed seven clinically relevant factors: apathy, anxiety, anosognosia-irritability, euphoria, dysphoria, emotional incontinence and agitation. The most frequent noncognitive symptoms were the affective disturbances, especially apathy, and the sexual behavioural disturbances. No correlation were found between the overall severity of behavioural disturbances and cognitive status, duration of the disease nor demographic variables. However, a slight negative correlation was found between scores on apathy and on the MMSE. A second evaluation was performed in 59 patients after a mean follow-up of 18,2 months. The patients showed a progression of the disease evidenced by the scores on the MMSE, ADL and CDS scales. However, the frequency and severity of the noncognitive symptoms remained identical except for eating disorders, psychotic symptoms and agitation which were more frequent at the second examination and negatively correlated with the MMSE score. Most patients showed affective disturbances and scored high for apathy and anxiety-emotional incontinence dimensions. Like in a previous study, we found a double dissociation between these two dimensions in some patients, suggesting that they depend from different mechanisms. Agressivity, mostly verbal, was found in three quarters of the patients and was correlated to apathy, anosognosia and psychotic symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The relationship between noncognitive manifestations and cognitive deficits in AD is not clear, suggesting that they depend from different biological and psychological mechanisms. Various dimensions may be described in the behavioural disturbances but their relationship with hypothetical biological mechanisms remains difficult. Our study stresses the importance of apathy, which was corelated with various noncognitive psychobehavioral manifestations in AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Derouesn&#xe9;</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Neurologie, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris. chderou@cybercable.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piquard</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thibault</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Baudouin-Madec</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Les manifestations non cognitives de la maladie d'Alzheimer. Etude de 150 cas &#xe0; l'aide d'un questionnaire rempli par le conjoint.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="Y">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010297" MajorTopicYN="N" Type="Geographic">Paris</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11283463</ArticleId><ArticleId IdType="pii">MDOI-RN-02-2001-157-2-0035-3787-101019-ART3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11281318</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Unrecognized dementia in elderly patients admitted to hospital with psychiatric symptoms.</ArticleTitle><Pagination><StartPage>7</StartPage><EndPage>10</EndPage><MedlinePgn>7-10</MedlinePgn></Pagination><Abstract><AbstractText>In this study, we hypothesized that elderly patients with first admission to a psychiatric hospital commonly suffer from dementia but did not have such a diagnosis on admission. Over a period of 5 years, we surveyed all medical journals from patients treated for the first time at the Department of Psychogeriatrics. By selecting all inpatients treated at the only regional psychiatric hospital within a defined geographic area, the selected patients became representative of this geographic area. After a diagnostic work-up at the hospital, 72 of 239 patients satisfied clinical criteria of dementia. Of these patients, 7 had Alzheimer's disease and 7 had evidence of vascular dementia. We identified 51 of 72 patients (71%) with an endpoint diagnosis of dementia made at the hospital without any clinical information suggesting dementia at the time of hospitalization. Nonspecific psychosis (35%), depression (15%), and behavioral disturbances (8%) represented the most common diagnoses proposed by the referring doctor. In conclusion, dementia may be a difficult diagnosis in elderly patients with psychiatric symptoms. This study reminds clinicians that dementia should be considered in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bekkelund</LastName><ForeName>S I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kujala</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rosenvinge</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="Y">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>13</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11281318</ArticleId><ArticleId IdType="doi">10.1177/089198870101400103</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11273170</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-5772</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of the Association of Physicians of India</Title><ISOAbbreviation>J Assoc Physicians India</ISOAbbreviation></Journal><ArticleTitle>Behavioural disturbances in dementia.</ArticleTitle><Pagination><StartPage>386</StartPage><EndPage>389</EndPage><MedlinePgn>386-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTS" NlmCategory="OBJECTIVE">To assess the frequency of behavioural disturbances in patients suffering from dementia and their relation to dementia severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study evaluated 75 patients referred to the Memory Clinic at our hospital. Patients meeting DSM-IV criteria for dementia were included in the study. Activities of daily living (ADL) and cognitive functioning were also assessed. Patients were then rated for dementia severity using the Clinical Dementia Rating scale. Clinical data regarding behavioural disturbances was obtained from the patient (where possible) and an informant (usually the primary caregiver) who had contact with the patient at least thrice a week.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results showed that behavioural disturbances were present in more than 60% of the sample. Psychotic and activity associated disturbances were most common, and that these were seen more frequently in Alzheimer's disease than any other type of dementia. Further, these disturbances occurred most frequently in dementias of moderate severity but reduced as the dementia progressed further.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that behavioural disturbances are a prominent part of dementia and that judicious use of psychiatric medication should form an important aspect of management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Holy Family Hospital, Bandra (W), Mumbai-400 050.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panikker</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Vas</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Assoc Physicians India</MedlineTA><NlmUniqueID>7505585</NlmUniqueID><ISSNLinking>0004-5772</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11273170</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11263720</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features.</ArticleTitle><Pagination><StartPage>547</StartPage><EndPage>558</EndPage><MedlinePgn>547-58</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms in Alzheimer's disease (AD) have been associated with increased rates of cognitive impairment and functional decline. Prior studies have been conflicting with regard to whether AD patients with psychosis (AD+P) have evidence of more severe neuropathologic findings at postmortem exam. We examined the severity of neuritic plaques and neurofibrillary tangles in six brain regions--middle frontal cortex, hippocampus, inferior parietal cortex, superior temporal cortex, occipital cortex, and transentorhinal cortex-in 24 AD+P subjects and 25 matched AD subjects without psychosis (AD-P). All analyses controlled for the presence of cortical Lewy bodies, and corrected for multiple comparisons. We found no significant associations between neuritic plaque and neurofibrillary tangle severity and AD+P, and no significant associations with any individual psychotic symptom. The association of AD+P with a more rapidly progressive course of AD appears to be mediated by a neuropathologic process other than increased severity of plaque and tangle formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, USA. Sweetra@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01153</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11263720</ArticleId><ArticleId IdType="doi">10.1017/s1041610200006657</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11255451</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.</ArticleTitle><Pagination><StartPage>466</StartPage><EndPage>472</EndPage><MedlinePgn>466-72</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lewy bodies (LB) are present in at least 20% to 30% of persons with Alzheimer disease (AD) and contribute to the risk of psychosis and to excess cognitive burden.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether altered striatal dopamine receptor binding is associated with LB and psychosis in AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Postmortem case control.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Alzheimer's Disease Research Center at the University of Pittsburgh (Pa).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Consecutive cases from the Alzheimer's Disease Research Center brain bank, neuroleptic free for at least 1 month prior to death, with neuropathologic diagnoses of AD with LB (AD + LB, n = 14), AD without LB (AD, n = 13), or normal brains (n = 8).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Dopamine D1, D2, and D3 receptor densities, and affinities as determined by selective saturation binding studies in striatal tissue.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with AD + LB, compared with those with AD, demonstrated increased D1 receptor density and decreased D2 and D3 receptor density. D3 receptor density was selectively increased, however, in AD subjects with a history of psychosis, independent of the presence or absence of LB. The effect of neuroleptic treatment on D3 binding was further examined in an additional group of subjects who had received neuroleptics near the time of death. Neuroleptic treatment reduced D3 affinity with no effect on D3 density.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Alzheimer disease with LB is associated with selective alterations in dopamine receptor density, which may contribute to the distinct clinical profile of this group. The D3 receptor may be an important target of neuroleptic treatment of psychosis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, Division of Geriatrics and Neuropsychiatry, Western Psychiatric Institute and Clinic, 3811 O'Hara St., Pittsburgh, PA 15213, USA. Sweetra@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Henteleff</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>B G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG15133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01153</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493593">DRD3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>RR7D75YDF4</RegistryNumber><NameOfSubstance UI="C031349">7-hydroxy-2-N,N-dipropylaminotetralin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11255451</ArticleId><ArticleId IdType="doi">10.1001/archneur.58.3.466</ArticleId><ArticleId IdType="pii">noc00096</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11249704</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1472-4472</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current opinion in investigational drugs (London, England : 2000)</Title><ISOAbbreviation>Curr Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>Dexanabinol Pharmos.</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>503</EndPage><MedlinePgn>494-503</MedlinePgn></Pagination><Abstract><AbstractText>Dexanabinol is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS) [311522]; it is in phase III trials for traumatic brain injury (TBI) [388709]. Dexanabinol was licensed to Pharmos for development from its originator, the Hebrew University of Jerusalem [180441]. Pharmos is seeking to enter into a strategic agreement with another company to develop and commercialize dexanabinol [317369]. Unlike its enantiomer, HU-210 (Yissum Research Development Co), dexanabinol does not interact with cannabinoid receptors [223330]. It has also exhibited more effective antioxidant and anti-inflammatory properties than MK-801 (dizocilpine; Merck &amp; Co Inc) [167980], [168212]. In addition, dexanabinol is generally well tolerated and appears toxicologically safe [170116]. Pharmos has been awarded a Small Business Innovation Research grant from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke, Division of Stroke and Trauma. The grant covers the development of new prodrugs and novel formulations of dexanabinol and will support additional study of dexanabinol compounds for various indications. The prodrugs being studied are part of the group of compounds that include dexanabinol [247958]. A Notice of Allowance was received in March 1999 on a patent covering the use of the drug in the treatment of MS [324163]. The use of dexanabinol and its derivatives to treat MS is described in US-05932610 [358503]. An oral formulation of dexanabinol is claimed in US-05891468. Dexanabinol analogs with special utility in acute and chronic pain are claimed in US-04876276, while dexanabinol analogs for neuroprotection are claimed in US-06096740. Pharmos estimates that the worldwide market for dexanabinol in the treatment of severe head trauma may reach $1 billion per year [319244].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pop</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alchem Laboratories Corporation, Alachua, FL 32615, USA. emilpop@aol.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Investig Drugs</MedlineTA><NlmUniqueID>100965718</NlmUniqueID><ISSNLinking>1472-4472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015306">Biogenic Monoamines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015306" MajorTopicYN="N">Biogenic Monoamines</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>103</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11249704</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11249516</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-6566</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Review of quetiapine and its clinical applications in schizophrenia.</ArticleTitle><Pagination><StartPage>783</StartPage><EndPage>801</EndPage><MedlinePgn>783-801</MedlinePgn></Pagination><Abstract><AbstractText>Preclinical studies have shown that quetiapine (Seroquel, AstraZeneca) is an atypical antipsychotic with many similarities to clozapine. Both placebo-controlled and comparative studies in patients with schizophrenia have demonstrated that quetiapine has long-term efficacy in both positive and negative domains, as well as beneficial effects on affective and cognitive symptoms. Comparative clinical studies confirm that quetiapine is at least as effective as the standard antipsychotics, chlorpromazine and haloperidol and response rates with quetiapine are similar to those reported with other atypical antipychotics. Quetiapine has also demonstrated superior efficacy to haloperidol in partially responsive patients, who can be particularly difficult to treat. Quetiapine has a wide clinical dosing range (150-750 mg/day), although doses of 400 mg or above should be used in patients who do not fully respond to lower doses of the drug. Quetiapine is generally well tolerated with no requirement for routine ECG or blood monitoring and it has minimal effects on weight. Uniquely among other first-line atypical antipsychotics, quetiapine is associated with a placebo-level incidence of EPS and an indistinguishable effect from placebo on plasma prolactin at all doses. Thus, clinicians can confidently increase the dose of quetiapine, without increasing the risk of EPS or hyperprolactinaemia. A number of studies have also shown that quetiapine is well-tolerated and effective in patients who are particularly susceptible to EPS, including elderly and adolescent patients and those with pre-existing dopaminergic pathology, such as Alzheimer's disease and Parkinson's disease. The consistent efficacy in treating all schizophrenic domains and good tolerability, particularly placebo-level EPS, make quetiapine acceptable to patients, as demonstrated in a survey of patient satisfaction. Thus quetiapine is a suitable first-line therapy for the treatment of schizophrenia and psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Psychiatry, University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller-Spahn</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>87</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11249516</ArticleId><ArticleId IdType="doi">10.1517/14656566.1.4.783</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11244213</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study.</ArticleTitle><Pagination><StartPage>198</StartPage><EndPage>205</EndPage><MedlinePgn>198-205</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare medial and lateral temporal lobe atrophy on magnetic resonance imaging (MRI) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), and to examine the relationship between volumetric indices and cognitive and non-cognitive symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">T(1)-weighted 1.0-tesla MRI scans were acquired in elderly subjects with DLB (n = 26; mean age = 75.8 years) and AD (n = 22; 77.3 years) and normal controls (n = 26; 76.2 years). MRI-based volume measurements of the hippocampus, parahippocampus, fusiform gyrus, combined inferior and middle temporal gyri, and superior temporal gyrus were acquired.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Hippocampal and parahippocampal volumes were significantly larger in subjects with DLB compared to AD. Differences in hippocampal volumes between DLB and AD were observed across the entire length, and in all subjects with dementia there was a loss of hippocampal asymmetry compared to normal controls. Atrophy of temporal lobe structures correlated with memory impairment in both groups, and with age in DLB. There was no association between atrophy and psychotic symptoms in either group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subjects with DLB and AD have a different pattern of temporal lobe atrophy with the most striking differences relating to medial rather than lateral temporal lobe structures. These structural differences could explain the relative preservation of memory function in DLB compared to AD.</AbstractText><CopyrightInformation>Copyright 2001 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK. Robert.Barber@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gholkar</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>29</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>13</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11244213</ArticleId><ArticleId IdType="doi">10.1159/000051258</ArticleId><ArticleId IdType="pii">51258</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11241716</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Relationship of psychosis to aggression, apathy and function in dementia.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>130</EndPage><MedlinePgn>123-30</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosis has been associated with aggression in dementia, but the nature of this relationship has been unclear. There has been very little research into the relations between apathy and functional status to psychosis in dementia. The purpose of this study is to investigate the relationship between psychosis and aggression, apathy, and functional status in outpatients with dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The presence of psychosis was assessed by clinical interview and two scales: the Neuropsychiatric Inventory and the Columbia University Scale for Psychopathology in Alzheimer's Disease. The maximum likelihood estimation technique was used to determine the best estimate of the presence of psychosis. Aggression, apathy, and functional status (activities of daily living: ADLs) were measured using structured instruments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-one subjects were included. The CUSPAD and NPI provided low false positive and negative rates. ANCOVA analyses showed that psychosis was significantly associated with aggression, even when controlling for apathy, depression, and ADLs. Psychosis was related to apathy only when depression was controlled for. Hallucinations were related to impaired basic ADLs, even when depression and apathy were controlled for.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Relationships were found between psychotic symptoms in dementia and aggression as well as apathy and impaired functional status. These relationships suggest pathophysiologic mechanisms and have possible treatment implications.</AbstractText><CopyrightInformation>Copyright 2001 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, North York, Toronto, Ontario, Canada M4N 3MS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Reekum</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Streiner</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Conn</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="Y">Affective Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="Y">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11241716</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200102)16:2&lt;123::aid-gps260&gt;3.0.co;2-1</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200102)16:2&lt;123::AID-GPS260&gt;3.0.CO;2-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11235928</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up.</ArticleTitle><Pagination><StartPage>46</StartPage><EndPage>49</EndPage><MedlinePgn>46-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few data are available regarding the natural course of psychiatric symptoms in dementia with Lewy bodies and Alzheimer's disease. To acquire this information is essential to inform differential diagnosis and treatment decisions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The current study provides prospective data regarding a representative case-register cohort of patients with operationalized clinical diagnoses of dementia with Lewy bodies (N = 82) or Alzheimer's disease (N = 132), with verified accuracy of clinical diagnosis against postmortem examination. Psychosis (Columbia University Scale for Psychopathology in Alzheimer's Disease) and depression (Cornell Scale for Depression in Dementia) were assessed at baseline and annual follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Visual hallucinations were significantly more likely to be persistent in patients suffering from dementia with Lewy bodies (chi2 = 19.1, df = 1, p &lt; .0001). Although a number of other psychiatric symptoms were also more frequent at baseline in dementia with Lewy body patients, they were not significantly more likely to persist. Delusions and auditory hallucinations did, however, persist in more than 40% of patients across both diagnostic groups. Patients suffering from dementia with Lewy bodies were significantly more likely to develop new auditory hallucinations over the year of follow-up (chi2 = 14.4, df= 1, p &lt; .0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results confirm that, although a number of psychiatric symptoms are common in dementia with Lewy bodies, it is only visual hallucinations that are significantly more persistent, with important treatment implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Medical Research Council, Neurochemical Pathology Unit, Newcastle Upon Tyne, England. c.g.ballard@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Neill</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="N">Auditory Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11235928</ArticleId><ArticleId IdType="doi">10.4088/jcp.v62n0110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11235926</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>34</StartPage><EndPage>40</EndPage><MedlinePgn>34-40</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elderly patients with Alzheimer's disease (AD) commonly exhibit psychotic symptoms, prompting clinicians to administer antipsychotics. This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A multicenter, double-blind, placebo-controlled study was conducted in nursing home patients with AD according to DSM-IV criteria and symptoms of agitation/aggression and/or psychosis. Patients (N = 206) were randomly assigned to receive either placebo or fixed-dose olanzapine (5, 10, or 15 mg/day) for up to 6 weeks. This article analyzes data from a subgroup of patients (N = 165) with no or minimal delusions and/or hallucinations at baseline as measured by the Neuropsychiatric Inventory-Nursing Home Version (NPI/NH). Three subsets of patients were identified on the basis of their symptoms at baseline: those with no clinically significant hallucinations, those with no clinically significant delusions, and those with no clinically significant delusions or hallucinations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the patients without hallucinations or delusions at baseline (N = 75), the placebo-treated patients showed significantly greater development of these symptoms compared with olanzapine-treated patients overall (NPI/NH hallucinations + delusions mean change score, +2.73 vs. +0.27, p = .006). Similarly, of the patients without baseline hallucinations (N = 153), the placebo-treated patients showed greater hallucinations score increases than did olanzapine-treated patients overall (+1.25 vs. +0.33, p = .026), whereas patients without baseline delusions (N = 87) showed no significant treatment effects. Olanzapine had a favorable safety profile in each patient subset.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest that, overall, olanzapine effectively attenuated emergence of psychosis in a short-term trial of patients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>W S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Indianapolis, Ind 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Street</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11235926</ArticleId><ArticleId IdType="doi">10.4088/jcp.v62n0108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11226550</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0163-8343</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>General hospital psychiatry</Title><ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Changes in psychiatric diagnoses from admission to discharge: review of the charts of 159 patients consecutively admitted to a geriatric psychiatry inpatient unit.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>7</EndPage><MedlinePgn>3-7</MedlinePgn></Pagination><Abstract><AbstractText>The diagnosis of psychopathology among geriatric acute inpatients requires comprehensive evaluation. To our knowledge, no recently published papers in the geriatric psychiatry literature have systematically examined diagnostic changes during single admissions. We reviewed the charts of 159 patients consecutively admitted to an acute geriatric psychiatry unit over 18 months. We recorded admission diagnoses from initial treatment plans, and discharge diagnoses from discharge summaries. Mean patient age was 80 years and average length of stay was 17 days. The most common primary diagnoses were psychotic and depressive disorders. The most common secondary diagnoses were dementias and depressive disorders. Primary diagnoses changed from admission to discharge in 31 patients (20%), and secondary diagnoses changed in 76 patients (48%). There was a significant change involving the diagnosis of dementia, but not that of depressive or psychotic disorders. A large proportion of inpatients had their diagnoses altered, especially those involving dementias, during hospitalization. Inpatient admission may be valuable for clarifying the diagnoses of elderly psychiatric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashley</LastName><ForeName>R V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California-San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladsjo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Judd</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Sewell</LastName><ForeName>D D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Rockwell</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH19934</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43695</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH49671</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gen Hosp Psychiatry</MedlineTA><NlmUniqueID>7905527</NlmUniqueID><ISSNLinking>0163-8343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="Y">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="Y">Patient Discharge</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11226550</ArticleId><ArticleId IdType="doi">10.1016/s0163-8343(00)00118-3</ArticleId><ArticleId IdType="pii">S0163834300001183</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11225688</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Fluvoxamine for psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>129</EndPage><MedlinePgn>126-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levkovitz</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shalvata Mental Health Center, Israel, Department of Psychiatry, Sackler School of Medicine, Tel Aviv University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Diskin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Abramovitchi</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>FTA7XXY4EZ</RegistryNumber><NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11225688</ArticleId><ArticleId IdType="doi">10.1097/00005053-200102000-00011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11209286</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">8750-9652</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Contemporary longterm care</Title><ISOAbbreviation>Contemp Longterm Care</ISOAbbreviation></Journal><ArticleTitle>New Rx for psychoses in Alzheimer's, Parkinson's.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>40</EndPage><MedlinePgn>39-40</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Targum</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Contemp Longterm Care</MedlineTA><NlmUniqueID>8508328</NlmUniqueID><ISSNLinking>1934-4589</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11209286</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11207329</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The psychotic phenomenon in probable Alzheimer's disease: a positron emission tomography study.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>55</EndPage><MedlinePgn>50-5</MedlinePgn></Pagination><Abstract><AbstractText>Positron emission tomography was used to examine the mechanisms of the psychotic phenomenon in Alzheimer's disease (AD). Data from 2 patients with delusions and 2 with hallucinations were compared with those of 5 AD patients without psychosis. The patients with paranoid delusions had diminished relative regional cerebral blood flow (rel-CBF) in the left dorsolateral prefrontal and left medial temporal cortices. The patients with visual hallucinations showed diminished rel-CBF in the right parietal, left medial temporal, and left dorsolateral prefrontal cortices. These findings support the hypothesis that a frontal-temporal abnormality is associated with paranoid delusions in AD. By contrast, visual hallucinations are associated with parietal as well as frontal and temporal lobe dysfunction. In these patients, a left prefrontal-temporal cortex dysfunction appears to be a common denominator for the development of the psychotic phenomenon in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH57078</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>29</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11207329</ArticleId><ArticleId IdType="doi">10.1176/jnp.13.1.50</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11176958</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>213</EndPage><MedlinePgn>209-13</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Visual hallucinations in Parkinson disease (PD) occur in approximately one third of patients treated long-term with dopaminergic medications. In Alzheimer disease, hallucinations and psychosis have been linked to increased representations of B2/B2 homozyogotes for the dopamine receptor gene DRD1 and 1/1 or 2/2 homozygotes for DRD3. In addition, a previous study of PD patients with and without hallucinations did not show differences in D2 and D3 polymorphisms, although careful case-control matching was not performed. Another study linked the apolipoprotein E4 (APOE4) allele to hallucinations in PD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether the frequency of dopamine receptor genetic variants and APOE alleles in patients with PD with and without chronic visual hallucinations resembles the pattern previously documented in patients with Alzheimer disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a case-control study of 44 patients with PD and chronic hallucinations and 44 patients with PD who had never hallucinated. Cases and controls were matched for current age and medications. DNA was isolated from blood samples and assayed for DRD1, DRD2, DRD3, DRD4, and APOE polymorphisms. Receptor polymorphisms were genotyped by polymerase chain reaction. Genotypes in hallucinators and nonhallucinators were compared using Mantel-Haenszel tests stratified by pair, and allele frequencies were compared using Wilcoxon signed rank tests within pairs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neither D1 receptor genotypes (P =.37) nor allele frequencies (P =.38) differed, and there was no predominance of B2/B2 homozygotes in the hallucinators. For D3, there was a higher frequency of allele 2 (P =.047), but there was no significant difference between frequencies of homozygotes vs heterozygotes (P =.39) as reported in Alzheimer disease. D4 receptor distribution of long and short alleles did not differ between the 2 patient groups, and there were too few C alleles (3 of 86) to compare D2 allele genotypes or frequencies. For APOE, 12 cases and 12 controls carried E4 alleles (P&gt;.99).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With careful case-control matching, visual hallucinations in PD are not associated with the pattern seen for patients with Alzheimer disease and visual hallucinations. Furthermore, there was no association between hallucinations and APOE. Similar methods using larger sample sizes might be adapted to test whether specific dopaminergic receptor genetic variants are associated with visual hallucinations in PD. Based on our data, the DRD3 allele 2 may merit further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University/Rush-Presbyterian-St Luke's Medical Center, 1725 W Harrison St, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>P F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Berry-Kravis</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Blasucci</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11176958</ArticleId><ArticleId IdType="doi">10.1001/archneur.58.2.209</ArticleId><ArticleId IdType="pii">noc00228</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11173880</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1420-8008</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Regional cerebral blood flow and prognostic evaluation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>97</EndPage><MedlinePgn>89-97</MedlinePgn></Pagination><Abstract><AbstractText>The present investigation reports the application of regional cerebral blood flow (rCBF; (133)Xe method) to prognostic purposes in a consecutive series of 76 patients (mean age 68.4 +/- 8.7 years) with probable Alzheimer's disease (AD; NINCDS-ADRDA criteria). The likelihood that rCBF from a posterior temporal-inferior parietal area in each hemisphere at the first visit may predict timing of achievement of three endpoints (i.e. loss of activity of daily living, ADL, incontinence and death due to end-stage AD) was tested by the 'lifereg' procedure of the Statistical Analysis System package. With respect to baseline evaluation, 32 patients lost ADL 20.6 +/- 17.4 months later, 31 developed incontinence 27.1 +/- 19.0 months later, and 16 patients died after 40.9 +/- 23.8 months of follow-up. Baseline rCBF significantly predicted all end-points: the loss of ADL (left hemisphere: p = 0.04; right hemisphere: p = 0.02), incontinence (p = 0.02 in both hemispheres) and death (p = 0.01 in both hemispheres). Statistical significance was maintained for the loss of ADL and incontinence both in a subgroup of mildly demented patients, in whom death was not considered due to the low number of patients who died, and in a multivariate analysis including patient age, age at onset, sex, duration of illness, Mini-Mental State Examination score and presence of extrapyramidal signs and psychotic symptoms at the first visit. This study shows that rCBF measurement in a posterior temporal-inferior parietal area may give prognostic information on timing of evolution of AD, whenever performed during the course of the disease, and may be utilized both in clinical practice and for social planning.</AbstractText><CopyrightInformation>Copyright 2001 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Neurophysiology Service, Department of Internal Medicine, University of Genoa, Genoa, Italy. flavionobili@smartino.ge.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Copello</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Buffoni</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vitali</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Girtler</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bordoni</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Safaie-Semnani</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>13</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11173880</ArticleId><ArticleId IdType="doi">10.1159/000051241</ArticleId><ArticleId IdType="pii">51241</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11154017</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61 Suppl 14</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antipsychotic treatment of psychosis and agitation in the elderly.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>52</EndPage><MedlinePgn>49-52</MedlinePgn></Pagination><Abstract><AbstractText>Agitated, aggressive behavior and psychosis are common manifestations of Alzheimer's disease that frequently lead to institutionalization. The usefulness of conventional neuroleptic treatment in this population is limited by narrow therapeutic windows because of limited efficacy and high sensitivity to side effects. More recently, investigational clinical trials have suggested potential utility for atypical antipsychotics such as risperidone, olanzapine, and quetiapine in treatment of behaviorally disturbed individuals and for the psychotic manifestations of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11154017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11124429</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis.</ArticleTitle><Pagination><StartPage>845</StartPage><EndPage>861</EndPage><MedlinePgn>845-61</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is manifested by core features of progressive memory impairment, visuospatial decline, aphasia, and loss of executive function. In addition, patients may evidence a variety of other cognitive and behavioral features. The neurobiological basis for this clinical heterogeneity is uncertain but corresponding abnormalities on functional imaging suggest that variations in the distribution of the pathogenic changes in AD account for some of the observed clinical differences. Behavioral as well as cognitive variability has been correlated with disturbances on positron emission tomography and single photon emission computerized tomography. Functional imaging can reveal characteristic brain activity changes in AD, distinguish AD from other dementia syndromes, assess the integrity of transmitter systems in AD, determine the effect of cognitive enhancing and psychotropic drugs on metabolism and transmitter system function in AD, and possibly predict treatment responsiveness. Animal models of AD may improve our understanding of clinical variations in human AD. Thus far, development of cognitive tests for transgenic mice with AD pathology has been limited. Evaluations paralleling human neuropsychological tests are needed. In addition, technologies facilitating behavioral observations relevant to psychosis, depression, apathy, and agitation in AD have not been developed for transgenic models. Application of experiments inducing animal equivalents of depression and psychosis to determine the vulnerability of animal models of AD to these conditions may provide additional insights into human neuropsychiatric symptoms in AD. The efficacy of psychotropic drugs can be assessed in animal models of AD subjected to the provocative stimuli used in experimental models of psychopathology. There are a plethora of opportunities for basic scientists to offer insights, develop strategies, and provide techniques and technologies relevant to understanding the clinical manifestations of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles CA 90095-1769, USA. cummings@ucla.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2000 Nov-Dec;21(6):863-4; discussion 875-7. doi: 10.1016/s0197-4580(00)00184-6</RefSource><PMID Version="1">11124430</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2000 Nov-Dec;21(6):865; discussion 875-7. doi: 10.1016/s0197-4580(00)00186-x</RefSource><PMID Version="1">11124431</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2000 Nov-Dec;21(6):867-9; discussion 875-7. doi: 10.1016/s0197-4580(00)00187-1</RefSource><PMID Version="1">11124432</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2000 Nov-Dec;21(6):871-2; discussion 875-7. doi: 10.1016/s0197-4580(00)00185-8</RefSource><PMID Version="1">11124433</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurobiol Aging. 2000 Nov-Dec;21(6):873; discussion 875-7. doi: 10.1016/s0197-4580(00)00188-3</RefSource><PMID Version="1">11124434</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>176</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>22</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>22</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11124429</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(00)00183-4</ArticleId><ArticleId IdType="pii">S0197458000001834</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11122998</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents.</ArticleTitle><Pagination><StartPage>473</StartPage><EndPage>478</EndPage><MedlinePgn>473-8</MedlinePgn></Pagination><Abstract><AbstractText>Acetylcholinesterase inhibitors (ChEIs) enhance neuronal transmission by increasing the availability of acetylcholine in muscarinic and nicotinic receptors. This effect is believed to be responsible for the beneficial and protective effects of ChEIs on cognition in patients with Alzheimer's disease (AD). Effects of ChEIs on mood and behavior have also been reported. Earlier observations were limited by the exclusive availability of intravenous forms of administration, the short half-life of the formulations, and the high frequency of peripheral side effects. The introduction, in recent years, of better tolerated and less invasive compounds has rekindled the interest in cholinergic central nervous system mechanisms and has given rise to studies in areas other than cognition. The ChEI donepezil has been involved in the largest number of studies and positive reports. Preliminary observations suggest the possible value of ChEIs in the management of behavioral dysregulation, apathy, irritability, psychosis, depression, mania, tics, and delirium and in the diagnosis of depression, panic, and personality disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burt</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical Director, Depression/Anxiety Worldwide Team, Pfizer Inc. 235 East 42nd Street, 235/10/29, New York, NY 10023, USA. tal.burt@pfizer.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11122998</ArticleId><ArticleId IdType="doi">10.1007/s11920-000-0005-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9539412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Mar 27;353(9158):1064-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10199357</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jun 27;54(12):2269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Apr 15;45(8):959-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10386177</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Mar 6;318(7184):633-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 May;139(5):571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7072840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1950 Feb;13(1):47-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15405311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm. 1987;70(3-4):295-312</Citation><ArticleIdList><ArticleId IdType="pubmed">3316493</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1997 Oct;17(4):264-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9326751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1973 Feb 24;1(7800):427-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4119737</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Dec 13;89(1):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10643873</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull Johns Hopkins Hosp. 1947 Oct;81(4):257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">20267050</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1999 Aug;19(4):381-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10440471</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 1;42(9):827-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9347132</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1964 Apr;138:383-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14141895</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1978 Feb;13(1):23-49</Citation><ArticleIdList><ArticleId IdType="pubmed">146524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Jun;20(3):350-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10831023</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 May;50(5):1222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9595967</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Jul;156(7):1117-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10401470</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Feb;57(2):157-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10665618</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1994 Dec 15;54(4):335-44</Citation><ArticleIdList><ArticleId IdType="pubmed">7726206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1972 Jun 3;1(7762):1236-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4113219</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1971;3(4):347-55</Citation><ArticleIdList><ArticleId IdType="pubmed">4950489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 May;60(5):318-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 Feb;170:159-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9093506</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1986;89(2):150-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3088629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1998 Fall;11(3):159-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9894735</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Spring;8(2):134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10804074</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1987;23(1):162-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3496624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1998;9 Suppl 2:8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9718229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Jul;61(7):487-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10937606</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Ther. 1997 Jul;23(7):492-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9262925</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2000 Apr;15(4):338-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10767734</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1997 Jul;54(7):836-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9236571</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatry Neuropsychol Behav Neurol. 2000 Oct;13(4):246-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11186160</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1999 Nov;56(11):1388-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10555660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1972 Sep 23;2(7778):632-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4116781</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jun 27;54(12):2261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10881250</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2000 Spring;12 (2):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">11001599</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Apr 12;52(6):1146-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10214735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11122908</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.</ArticleTitle><Pagination><StartPage>78</StartPage><EndPage>84</EndPage><MedlinePgn>78-84</MedlinePgn></Pagination><Abstract><AbstractText>Acetylcholine is a modulatory central nervous system (CNS) neurotransmitter involved in diverse brain processes. Historically, drugs that increase CNS cholinergic transmission have been investigated primarily for relieving cognitive symptoms in Alzheimer"s disease (AD). Emerging from these efforts are recent findings that several cholinesterase-inhibitor agents also have a beneficial effect on selected noncognitive symptoms in AD, such as apathy, psychosis, and purposeless motor behaviors. The broad psychotropic effects of cholinergic agents observed in AD and other degenerative conditions highlight potential symptom-based therapeutic indications for these drugs across a variety of neurologic disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>D I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Dementia Treatment Program, and University of Pittsburgh Alzheimer"s Disease Research Center, 4W ADRC, UPMC Montefiore, 200 Lothrop Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11122908</ArticleId><ArticleId IdType="doi">10.1007/s11920-999-0013-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer Dis Assoc Disord. 1994;8 Suppl 3:54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7999346</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Spring;11(2):268-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10333999</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1997 Sep;11(3):206-28</Citation><ArticleIdList><ArticleId IdType="pubmed">9303280</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1998 Sep;10(3):229-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9785144</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1997 Feb;23(1-2):28-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9063585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47</Citation><ArticleIdList><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):324-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8795611</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Apr 1;33(7):536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8513039</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S23-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9339269</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Mar 10;52(4):691-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10078712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Gen Sect. 1993;91(2-3):135-59</Citation><ArticleIdList><ArticleId IdType="pubmed">8099796</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 1998 May;23(5):787-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9566619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Oct;47(4):876-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8857712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1998;9 Suppl 2:8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9718229</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Apr 21;281(15):1401-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10217056</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Nov;51(5):1512</Citation><ArticleIdList><ArticleId IdType="pubmed">9818904</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9547467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Nov;47(5):1113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1998 Feb;46(2):210-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1999 Jun;22(6):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10354606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1988 Apr;84(2-3):125-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2898011</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1997 Jul;54(7):836-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9236571</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Jul;51(1 Suppl 1):S18-29; discussion S65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9674759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1996 Jan;9(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8679057</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2 Suppl 1):S64-78</Citation><ArticleIdList><ArticleId IdType="pubmed">9581223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11122905</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric aspects of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>60</EndPage><MedlinePgn>49-60</MedlinePgn></Pagination><Abstract><AbstractText>The increase in research studies focusing on neuropsychiatric symptoms over the last decade has greatly increased our knowledge base, particularly with regard to the frequency of these symptoms and their impact on both patients and carers. We still have a poor understanding of the natural course of these symptoms and their biologic correlates, however, and more specific treatment studies are needed to inform clinical management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Neurochemical Pathology Unit, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>142</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11122905</ArticleId><ArticleId IdType="doi">10.1007/s11920-999-0010-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 1978 Jun;35(6):773-82</Citation><ArticleIdList><ArticleId IdType="pubmed">655775</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1988 Apr-Jun;1(2):71-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3266998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1997 Sep;45(9):1074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 1993 Jul;88(1):5-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8372630</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Apr;147(4):452-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2316731</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1995 May;25(3):505-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7480431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1998 Jun;38(3):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9640855</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jan;89(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8140901</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1989 Jan;37(1):29-34</Citation><ArticleIdList><ArticleId IdType="pubmed">2642498</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Sep 15;34(6):386-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8218606</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Neurol Neurochir. 1973 Nov-Dec;76(6):411-20</Citation><ArticleIdList><ArticleId IdType="pubmed">4592700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Mar;146(3):350-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2919692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1996 Sep;44(9):1078-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8790235</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1988 Nov;45(11):1182-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3190497</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1994 Jul;51(7):676-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8018040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1988 Aug;24(2):233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3178178</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Jan;46(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1985 Feb;146:184-97</Citation><ArticleIdList><ArticleId IdType="pubmed">3156653</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Oct;152(10 ):1470-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7573586</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1996 Sep;169(3):293-307</Citation><ArticleIdList><ArticleId IdType="pubmed">8879715</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1983 Feb;140(2):233-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6849443</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Aug;147(8):1049-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1996 Winter;8(4):609-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9147174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Sep;148(9):1159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1882992</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Jul;165(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Oct;167(4):537-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8829726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1991 Jun;48(6):619-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1964 Jun;120:1190-2</Citation><ArticleIdList><ArticleId IdType="pubmed">14154755</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1993 Jun;87(6):395-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8356890</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 1996 Jan-Feb;22(1):49-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15374192</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1996 Mar;168(3):287-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8833681</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1998 Sep;27(5):631-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12675102</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1987 Apr;44(4):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3827694</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1982 May;11(2):121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7102472</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Nov;12(11):1074-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9427091</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1960 Dec 17;174:2036-42</Citation><ArticleIdList><ArticleId IdType="pubmed">13681165</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Jul;147(7):855-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2356870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1994 Nov;42(11):1160-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7963202</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1998 Aug;13(2):119-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9739501</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Mar;147(3):299-302</Citation><ArticleIdList><ArticleId IdType="pubmed">2309945</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1982 Mar;140:257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7093593</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 May;166(5):613-20</Citation><ArticleIdList><ArticleId IdType="pubmed">7620746</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1996 Feb;168(2):149-57</Citation><ArticleIdList><ArticleId IdType="pubmed">8837903</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1982 Jul 16;248(3):333-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol. 1986 Nov;41(6):778-84</Citation><ArticleIdList><ArticleId IdType="pubmed">3772056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 May;64(5):648-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1989 Sep;37(9):856-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2760379</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Nov;146(11):1472-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2817121</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Dec;150(12):1806-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8238634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1997 Jan;45(1):123-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8994506</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1993 Sep;163:364-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8401967</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1988 Jan;1(1):16-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3266997</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1997 Jan 25;314(7076):266-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9022490</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1991 May;21(2):363-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1876641</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1990 Spring;2(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">2101297</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 May;139(5):623-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7072849</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 Jul;171:47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9328494</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Feb;149(2):184-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 1992 Apr;70(2):515-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1598370</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatrics. 1962 Sep;17:596-601</Citation><ArticleIdList><ArticleId IdType="pubmed">13904111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1994 Feb;42(2):186-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8126334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1992 Sep;42(9):1689-96</Citation><ArticleIdList><ArticleId IdType="pubmed">1513455</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1997 Mar;20(1):91-110</Citation><ArticleIdList><ArticleId IdType="pubmed">9139298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):199-204</Citation><ArticleIdList><ArticleId IdType="pubmed">9608409</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1992 Apr;49(4):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1558517</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 May;48 Suppl:9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1982 Feb;32(2):164-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7198741</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1988 Feb 1;23(3):271-84</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Psychiatr Nurs. 1994 Jun;8(3):150-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8080303</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Nov;143(11):1446-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3777239</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1991 Fall;3(4):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1997 Dec;9(4):423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9549591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1998 Jul;55(7):969-78</Citation><ArticleIdList><ArticleId IdType="pubmed">9678315</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1997 Winter;5(1):60-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9169246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Aug;40(8):768-73</Citation><ArticleIdList><ArticleId IdType="pubmed">1634719</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Jul;157:72-6, 92-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2397365</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 May;38(5):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Dec;157:894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">1705151</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1998 Jan;46(1):27-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9434662</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1989 Jan;25(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1997 Mar;9(1):57-64</Citation><ArticleIdList><ArticleId IdType="pubmed">9195279</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1991 Fall;3(4):364-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1821254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1962 Feb;10:140-7</Citation><ArticleIdList><ArticleId IdType="pubmed">13904112</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 Sep;139(9):1170-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7114310</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9526179</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Aging. 1991 Jun;6(2):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1863397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1982 Apr;2(2):122-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7042770</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Nov;47(5):1113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 Aug;38(8):867-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2201714</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1976 Mar;24(3):105-7</Citation><ArticleIdList><ArticleId IdType="pubmed">765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1999 Jun;22(6):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10354606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Park Dis Dement Sect. 1993;6(3):167-77</Citation><ArticleIdList><ArticleId IdType="pubmed">8123190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol B Psychol Sci Soc Sci. 1997 Jul;52(4):P159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">9224439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol. 1993 Nov;48(6):M255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8227995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1995 Aug;59(2):185-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7629537</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1997 Jul;54(7):836-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9236571</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1994 Spring;2(2):157-164</Citation><ArticleIdList><ArticleId IdType="pubmed">28530995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1993 Mar;26(2):37-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8378411</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1995 Mar-Apr;2(6):327-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9384918</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Jan;146(1):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2643356</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Feb;85(2):131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1543038</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Jan 22;36(3-4):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8821316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 1995 Nov;70(11):1108-15</Citation><ArticleIdList><ArticleId IdType="pubmed">7475342</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 Aug;145(8):955-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3394879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 13:23-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9771827</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Dec;47(6):1403-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8960718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1990 Jan-Mar;3(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">2346584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Jun;41(6):906-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2046938</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 Nov;22(4):877-84</Citation><ArticleIdList><ArticleId IdType="pubmed">1488485</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 Feb;22(1):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1574559</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1995 Summer;3(3):198-205</Citation><ArticleIdList><ArticleId IdType="pubmed">28531041</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11117543</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>868</StartPage><EndPage>876</EndPage><MedlinePgn>868-76</MedlinePgn></Pagination><Abstract><AbstractText>The relation between disturbances of cholinergic neurotransmission and delusions (DELs) has not been investigated in degenerative dementias such as dementia with Lewy bodies (DLB). A cohort of dementia patients were assessed with standardized clinical evaluations (including the Columbia University Scale for Psychopathology in Alzheimer's Disease), which were repeated annually until death. DLB was confirmed neuropathologically in 21 patients. Neurochemical evaluation included M1 receptor autoradiography (pirenzepine binding), biochemical measurement of choline acetyltransferase (ChAT), and acetylcholinesterase (AChE) histochemistry in brain regions hypothesized to be involved in the genesis of psychosis. Compared with 11 age-matched controls, CHAT and pirenzepine levels were most extensively reduced in the temporal and parietal neocortex of DLB patients. In Brodmann area 36, DELs were significantly associated with elevated pirenzepine binding (131.0 vs 93.5, t = 2.7), whereas visual hallucinations were associated with significant reductions in ChAT (1.7 vs 2.5, t = 2.5). There were no significant associations with other areas or with cholinesterase. Although DELs and visual hallucinations were both linked with disturbances in cholinergic neurotransmission, the nature of the associations was different. Upregulation of the postsynaptic muscarinic receptor may be central in the genesis of DELs, with important treatment implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piggott</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jaros</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11117543</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11115331</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>12</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis.</ArticleTitle><Pagination><StartPage>1165</StartPage><EndPage>1173</EndPage><MedlinePgn>1165-73</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosis is common in patients with Alzheimer disease. While the relationship between psychosis and clinical variables has been examined frequently, few studies have examined the relationship between psychosis and the 2 major neuropathological hallmarks of Alzheimer disease: neurofibrillary tangles and senile plaques. We characterized the occurrence of psychosis in relation to dementia severity and determined if subjects with Alzheimer disease and psychosis had a greater neurofibrillary tangle or senile plaque burden than subjects with Alzheimer disease and no psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred nine subjects with Alzheimer disease were followed longitudinally with semistructured assessments in order to assign a Clinical Dementia Rating and determine whether psychosis was present. After the subjects died, their brains were obtained for histological examination. Analysis of variance was used to compare the densities of neurofibrillary tangles, total senile plaques, and cored senile plaques in subjects with psychosis vs subjects without psychosis, in several neocortical regions, the hippocampus, and the entorhinal cortex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Psychosis occurred commonly in Alzheimer disease, affecting 63% of subjects. The frequency of psychosis increased with increasing dementia severity. More importantly, we found that subjects with psychosis had a 2.3-fold (95% confidence interval, 1.2-3.9) greater density of neocortical neurofibrillary tangles than did subjects without psychosis. The increase was independent of dementia severity. No similar relationship with psychosis was seen for total senile plaques or cored senile plaques.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The increase in psychosis frequency that occurs with the progression of dementia severity and the independent association between psychosis and neurofibrillary tangle density suggest the possibility that some common underlying process or processes specific to Alzheimer disease may regulate both phenomena. Arch Gen Psychiatry. 2000;57:1165-1173.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>N B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Washington University, Department of Psychiatry, Campus Box 8134, 660 S Euclid Ave, St Louis, MO 63110-1009, USA. farbern@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Newcomer</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Kinscherf</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Olney</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>McKeel</LastName><ForeName>D W</ForeName><Initials>DW</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>DA 00290</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA 05072</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 01510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.57.12.1165</ArticleId><ArticleId IdType="pii">yoa9465</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11105471</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1355-6177</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of the International Neuropsychological Society : JINS</Title><ISOAbbreviation>J Int Neuropsychol Soc</ISOAbbreviation></Journal><ArticleTitle>Neurobehaviors and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>815</StartPage><EndPage>820</EndPage><MedlinePgn>815-20</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms are common in Alzheimer's disease (AD) and clinicoanatomical and neuropsychological evidence indicate an association between these symptoms and frontal lobe dysfunction. Neuro-behaviors associated with frontal dysfunction were assessed in Alzheimer's disease (AD) patients with (n = 20) and without psychotic symptoms (n = 21) matched for mean age, education, gender, and dementia severity. The Frontal Lobe Personality Scale (FLOPs) was completed by patient caregivers to measure behaviors typically associated with frontal dysfunction. Findings indicated that AD patients with psychotic symptoms exhibited significantly greater neurobehavioral dysfunction (FLOPs M = 130.69, SD = 24.70) than AD patients without psychotic symptoms (FLOPs M = 111.10, SD = 25.83). Subscale analyses indicated that psychotic AD patients were more dis-inhibited (M = 28.28, SD = 7.54) than patients without psychotic symptoms (M = 20.92, SD = 4.9). Findings are consistent with and contribute to previous neuropsychological and clinicoanatomical research suggesting increased frontal dysfunction in AD with psychotic symptoms and lend additional empirical support to subtyping AD based on the presence of psychotic symptoms. Furthermore, findings provide preliminary evidence indicating which specific type of neurobehavioral abnormalities are related to the presence of distressing psychotic symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paulsen</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Iowa, Iowa City, USA. jane-paulsen@uiowa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ready</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Stout</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG-05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-05561</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-12963</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Neuropsychol Soc</MedlineTA><NlmUniqueID>9503760</NlmUniqueID><ISSNLinking>1355-6177</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11105471</ArticleId><ArticleId IdType="doi">10.1017/s1355617700677081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11094098</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Cholinergic deficits contribute to behavioral disturbance in patients with dementia.</ArticleTitle><Pagination><StartPage>1460</StartPage><EndPage>1467</EndPage><MedlinePgn>1460-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Noncognitive behavioral changes such as depression, aggressive behavior, psychosis, and overactivity occur frequently in patients with dementia, in addition to cognitive impairment, and often determine the need for institutionalization. The biochemical basis of such changes is poorly understood. Clinical trial data indicate that cholinomimetics improve noncognitive behaviors. This study investigated the relationship between markers of the cholinergic and dopaminergic neurotransmitter systems and noncognitive behavioral symptoms assessed during the course of dementing illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Brains from 46 patients with dementia (36 with AD and 10 with mixed or other dementias using Consortium to Establish a Registry for AD criteria) were examined together with 32 normal controls. The patients with dementia had been evaluated every 4 months, often over several years, for cognitive performance (Mini-Mental State Examination) and behavior (Present Behavioral Examination). Concentrations of dopamine (DA) and major metabolites, choline acetyltransferase activity (ChAT), and density (Bmax) of DA D1 receptors in frontal and temporal cortex were studied by radioligand binding protocols. None of the patients was receiving cholinomimetic drugs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ChAT activity, but no other neurochemical markers, was reduced in AD compared with controls. Loss of ChAT activity correlated with cognitive impairment. Lowered ChAT activity also correlated with increasing overactivity in patients with dementia in both frontal and temporal cortex whereas ChAT:DA and ChAT:D1 ratios in temporal cortex correlated negatively with aggressive behavior.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Disturbance of the cholinergic system may underlie both cognitive and some noncognitive behavioral changes in dementia, providing a basis for rational therapy.-1467</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minger</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Dementia Research Laboratory, Centre for Neuroscience Research, GKT School of Biomedical Sciences, King's College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esiri</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hope</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>P T</ForeName><Initials>PT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11094098</ArticleId><ArticleId IdType="doi">10.1212/wnl.55.10.1460</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11087905</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0047-6374</ISSN><JournalIssue CitedMedium="Print"><Volume>120</Volume><Issue>1-3</Issue><PubDate><Year>2000</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Mechanisms of ageing and development</Title><ISOAbbreviation>Mech Ageing Dev</ISOAbbreviation></Journal><ArticleTitle>Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>65</StartPage><EndPage>75</EndPage><MedlinePgn>65-75</MedlinePgn></Pagination><Abstract><AbstractText>Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD). The present study was designed to assay dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) in 20 patients with AD and in 25 healthy controls by radioligand binding assay techniques with [3H][R]-(+)-(-)chloro-2,3,4,5 tetrahydro-5-phenyl-1H-3-benzazepin-al-hemimaleate (SCH 23390) and [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetraline (7OH-DPAT) as radioligands. The density of dopamine D1-like receptors and the affinity of [3H]SCH 23390 and [3H]7OH-DPAT binding to PBL were similar in both groups investigated. AD patients revealed a lower density of dopamine D2-like receptors on PBL than controls (P=0. 0016). The pharmacological profile of [3H]SCH 23390 and [3H]7OH-DPAT binding to PBL was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. The reduced density of dopamine D2-like receptors on PBL is consistent with the observation of changes in the expression of D2-like receptors in dopaminergic brain areas in AD. Our findings support the hypothesis of an involvement of dopamine in AD, even in those patients with no evidence of Parkinsonism, behavioral abnormalities or psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbanti</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Neurologiche, Universit&#xe0; La Sapienza 00161, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrini</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cerbo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bronzetti</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Amenta</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Luigi Lenzi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Mech Ageing Dev</MedlineTA><NlmUniqueID>0347227</NlmUniqueID><ISSNLinking>0047-6374</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>RR7D75YDF4</RegistryNumber><NameOfSubstance UI="C031349">7-hydroxy-2-N,N-dipropylaminotetralin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11087905</ArticleId><ArticleId IdType="doi">10.1016/s0047-6374(00)00183-4</ArticleId><ArticleId IdType="pii">S0047-6374(00)00183-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11083160</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>A review of the cognitive and behavioral symptoms in dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>425</StartPage><EndPage>450</EndPage><MedlinePgn>425-50</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies is a relatively common cause of dementia. Much has been learned about this disorder, yet much remains to be elucidated, especially in regard to early clinical diagnosis. To clarify the future research agenda in this area, the authors critically appraise the literature on cognitive and behavioral changes in DLB and provide a brief overview of the history of DLB, the main pathological changes, and the findings related to extrapyramidal symptoms and treatment issues. Twenty-one studies on cognition and 47 on behavioral changes in DLB are reviewed. Impairments of working memory and visuospatial functions, visual hallucinations, and depression (or symptoms of depression such as apathy and anxiety) have been identified as early indicators of DLB. However, longitudinal and cross-sectional data are lacking, particularly for different aspects of working memory, visual perception, and non-psychotic behavioral symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Reekum</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>168</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11083160</ArticleId><ArticleId IdType="doi">10.1176/jnp.12.4.425</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11072482</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-5283</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Medical journal of Malaysia</Title><ISOAbbreviation>Med J Malaysia</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of Alzheimer's disease--an update.</ArticleTitle><Pagination><StartPage>541</StartPage><EndPage>550</EndPage><MedlinePgn>541-9; quiz 550</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) has become recognised as a major cause of morbidity and mortality in the ageing population worldwide. Over 20 million people worldwide are affected by AD, which ensures that the disease imposes a major economic burden. Alzheimer's disease is a progressive neurodegenerative disorder with characteristic clinical and neuropathological features. Neurofibrillary tangles, neuritic plaques and amyloid angiopathy occur in varying severity in brains of patient's with Alzheimer's disease. Biological markers of AD allowing an early definitive premorbid diagnoses are currently not available. Memory loss for recent events is invariable and often the earliest prominent symptom. Language disorders, difficulties with complex tasks, depression, psychotic symptoms and behavioral changes are other common manifestations of AD. Diagnosis involves the early detection of cognitive decline and ruling out other causes of dementia like vascular dementia, Lewy body dementia, fronto-temporal degeneration or reversible causes like hypothyroidism. Acetylcholinesterase inhibitors have shown to be effective in mild to moderate AD in improving the cognitive function of patients in clinical trials. Caregiver intervention programs have considerable potential to improve both the caregiver and patient quality of life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Srinivas</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Malaya, Kuala Lumpur.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Malaysia</Country><MedlineTA>Med J Malaysia</MedlineTA><NlmUniqueID>0361547</NlmUniqueID><ISSNLinking>0300-5283</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11072482</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11072263</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0733-8619</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurologic clinics</Title><ISOAbbreviation>Neurol Clin</ISOAbbreviation></Journal><ArticleTitle>Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.</ArticleTitle><Pagination><StartPage>829</StartPage><EndPage>846</EndPage><MedlinePgn>829-46</MedlinePgn></Pagination><Abstract><AbstractText>Neuropsychiatric symptoms are common in Alzheimer's disease. Personality changes, mood disturbance, and psychosis are frequently seen and may coexist in the same patient. Neuropsychiatric symptoms may signal the onset of disease and often fluctuate and recur. These symptoms are associated with a more rapid cognitive and functional decline that can lead to institutionalization. Cholinergic therapy, disease-modifying therapy, and psychotropic medications can improve these symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Los Angeles, Los Angeles, California 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Clin</MedlineTA><NlmUniqueID>8219232</NlmUniqueID><ISSNLinking>0733-8619</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>92</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11072263</ArticleId><ArticleId IdType="doi">10.1016/s0733-8619(05)70228-0</ArticleId><ArticleId IdType="pii">S0733-8619(05)70228-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11052455</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-9684</ISSN><JournalIssue CitedMedium="Print"><Volume>92</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the National Medical Association</Title><ISOAbbreviation>J Natl Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics of community-dwelling black Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>424</StartPage><EndPage>429</EndPage><MedlinePgn>424-9</MedlinePgn></Pagination><Abstract><AbstractText>There is a relative dearth of studies examining the cognitive and neuropsychiatric features of black Alzheimer's disease (AD) patients in the United States. Therefore, this cross-sectional investigation reported on the prevalence and clinical correlates of depression and psychosis in a community-dwelling black AD sample. The study participants comprised 55 English-speaking black patients evaluated consecutively at a university-affiliated memory disorders clinic. All patients were evaluated utilizing standardized procedures and diagnosed with possible or probable AD according to the criteria established by the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association. The presence of neuropsychiatric symptoms, including major depression and psychosis (delusions or hallucinations) was established via a semistructured psychiatric interview with the patient and primary care giver. The level of global cognitive impairment was rated with the Mini-Mental State Examination. The results showed that major depression and psychosis were observed in 20% and 58% of the sample, respectively. Mood disturbance was linked with low education, whereas psychosis was associated with greater cognitive dysfunction. This study provides important insight into the clinical characteristics of community-dwelling black AD patients. It is clear that continued research in the area of ethnicity and dementia is warranted to better understand the clinical needs of blacks and other minority populations in the United States that are afflicted with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>W W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Natl Med Assoc</MedlineTA><NlmUniqueID>7503090</NlmUniqueID><ISSNLinking>0027-9684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="Y">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005431" MajorTopicYN="N" Type="Geographic">Florida</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11052455</ArticleId><ArticleId IdType="pmc">PMC2608526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Jun;40(6):549-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1587970</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Sep;148(9):1159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1882992</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1991 May;21(2):363-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1876641</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Aging. 1991 Jun;6(2):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1863397</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1991 Jun;48(6):619-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1991 Feb 1;29(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2015329</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Aug;147(8):1049-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 May;38(5):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1989 Dec;37(12):1117-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2592718</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 May;146(5):577-87</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1989 Jan;25(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1988 May-Jun;29(3):285-97</Citation><ArticleIdList><ArticleId IdType="pubmed">3378415</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1987 Oct;37(10):1649-53</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1987 Jun;27(3):281-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3609795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1986 Dec;34(12):855-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3782698</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Sep;40(9):922-35</Citation><ArticleIdList><ArticleId IdType="pubmed">1512391</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1999 Jun;14(6):481-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10398359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1999 Apr;47(4):482-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10203126</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1999 Winter;7(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9919321</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1998 Dec;12(4):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9876963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1998 Jun;38(3):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9640855</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 May;50(5):1222-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9595967</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2):162-75</Citation><ArticleIdList><ArticleId IdType="pubmed">9581212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Med Assoc. 1998 Feb;90(2):78-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9510621</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1996;8 Suppl 3:483-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9154612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementia. 1996 Nov-Dec;7(6):293-303</Citation><ArticleIdList><ArticleId IdType="pubmed">8915035</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Jan;46(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Jul;165(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1994 Aug;84(8):1261-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8059882</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Apr 6;271(13):985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8139083</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Med Assoc. 1993 May;85(5):379-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8496991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11048905</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0149-2918</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Long-Term use of quetiapine in elderly patients with psychotic disorders.</ArticleTitle><Pagination><StartPage>1068</StartPage><EndPage>1084</EndPage><MedlinePgn>1068-84</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Quetiapine is an atypical antipsychotic agent that does not appear to increase patient risk for treatment-emergent extrapyramidal symptoms (EPS) or anticholinergic symptoms. Previous studies of quetiapine use in elderly patients with schizophrenia and other psychoses examined short-term administration (&lt; or = 12 weeks). Given the growing elderly population, the commensurate increase in elderly patients with psychoses, and the expected increase in disease treatment-years, the effect of long-term quetiapine administration in older patients is of considerable interest.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study assesses the long-term tolerability, safety, and clinical benefit of quetiapine in elderly patients with psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Elderly patients (&gt; or = 65 years of age) with psychotic disorders, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, participated in this 52-week, open-label, multicenter trial. Investigators increased (and later adjusted) daily doses of quetiapine on the basis of clinical response and tolerability, and assessed safety and efficacy. Efficacy assessments were made using the 18-item Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions (CGI), Simpson-Angus Scale, and the Abnormal Involuntary Movement Scale (AIMS). For patients who withdrew before week 52, analyses were performed using observed data and the last observation carried forward.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred eighty-four patients with psychotic disorders (98 women and 86 men) with a mean age of 76.1 years entered the trial. Seventy-two percent had psychotic disorders due to general medical conditions such as Alzheimer's disease, and 28% had other psychotic disorders, most commonly schizophrenia. Overall, 89 (48%) patients completed treatment through 52 weeks. Median total daily dose was 137.5 mg. Reasons, for withdrawal included lack of efficacy (19%), adverse events or intercurrent illness (15%), failure to return for follow-up (13%), protocol noncompliance (3%), and diminished need for treatment (2%). Somnolence (31%), dizziness (17%), and postural hypotension (15%) were common adverse events, but they rarely resulted in withdrawal from therapy. EPS-related adverse events occurred in 13% of patients. At end point (week 52), mean total score on the Simpson-Angus Scale had decreased from baseline by 1.8 points, whereas changes in AIMS scores were negligible. No clinically important effects were reported relative to mean changes in hematologic, thyroid function, or hepatic function variables. Quetiapine treatment appeared to have no associated cardiovascular adverse outcomes despite cardiovascular comorbidities and unrestricted use of concomitant cardiovascular medications. Significant decreases in BPRS total score (n = 170, P &lt; 0.001) and CGI Severity of Illness item score (n = 177, P &lt; 0.002) were seen at end point (observed data and last observation carried forward). Decreases of &gt; or = 20% in mean BPRS total score were observed in 83 (49%) patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results provide preliminary information to clinicians regarding tolerability, safety, and clinical improvement with quetiapine in elderly patients with psychotic symptoms, and support controlled studies of quetiapine in this patient population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>P N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salzman</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>P P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Pultz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rak</LastName><ForeName>I W</ForeName><Initials>IW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11048905</ArticleId><ArticleId IdType="doi">10.1016/s0149-2918(00)80085-5</ArticleId><ArticleId IdType="pii">S0149291800800855</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11021192</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1661-8157</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>35</Issue><PubDate><Year>2000</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Praxis</Title><ISOAbbreviation>Praxis (Bern 1994)</ISOAbbreviation></Journal><ArticleTitle>[Psychological disorders and behavioral symptoms in dementia and differential diagnostic significance].</ArticleTitle><Pagination><StartPage>1366</StartPage><EndPage>1370</EndPage><MedlinePgn>1366-70</MedlinePgn></Pagination><Abstract><AbstractText>Dementia is one of the most common diseases in the elderly. Rapid and comprehensive diagnosis and appropriate treatment are imperatives. Over the course of the disease, psychiatric disturbances and behavioral abnormalities will frequently occur with the most variable of manifestations and forms. The burden on caregivers is immense. Patients usually respond well to a combination of milieu therapy and pharmacological management. The nature and the manifestation of the disorder can provide important clues for differential diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uhde</LastName><ForeName>W H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Gerontopsychiatrisches Zentrum Hegibach, Psychiatrische Universit&#xe4;tsklinik Z&#xfc;rich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>U S</ForeName><Initials>US</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Psychische St&#xf6;rungen und Verhaltensauff&#xe4;lligkeiten bei Demenzerkrankungen und ihre differentialdiagnostische Bedeutung.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Praxis (Bern 1994)</MedlineTA><NlmUniqueID>101468093</NlmUniqueID><ISSNLinking>1661-8157</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11021192</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11021191</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1661-8157</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>35</Issue><PubDate><Year>2000</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Praxis</Title><ISOAbbreviation>Praxis (Bern 1994)</ISOAbbreviation></Journal><ArticleTitle>[Neuropathological principles of behavioral disorders in dementia].</ArticleTitle><Pagination><StartPage>1362</StartPage><EndPage>1365</EndPage><MedlinePgn>1362-5</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms, apathy, agitation and aggressiveness are behavioral disorders that occur frequently in patients with Alzheimer's dementia. They cause serious problems for patients, relatives and care-givers. These behavioral disorders are associated with neuropathologic changes and alterations of brain metabolism in specific brain areas. Disturbances in mesotemporal and frontal brain areas seem to be related to psychotic symptoms. Apathy is associated with dysfunction of frontal cortical areas. Agitation and impulsivity appear to result from a hypofunction of the serotonin system in association with a relative hyperfunction of dopaminergic and noradrenergic systems. These dysfunctions are the result of direct neuropathologic changes, but also due to cholinergic deficits that seem to both contribute synergistically to and independently cause behavioral disturbances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Umbricht</LastName><ForeName>D S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Psychiatrische Forschung, Psychiatrische Universit&#xe4;tsklinik Z&#xfc;rich.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Neuropathologische Grundlagen von Verhaltensst&#xf6;rungen bei Demenz.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Praxis (Bern 1994)</MedlineTA><NlmUniqueID>101468093</NlmUniqueID><ISSNLinking>1661-8157</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>10</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11021191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11015815</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.</ArticleTitle><Pagination><StartPage>968</StartPage><EndPage>976</EndPage><MedlinePgn>968-76</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P&lt;.001] and -6.1 vs -3. 7 [P =.006], respectively). Core Total improvement with olanzapine, 15 mg/d, was not significantly greater than placebo. The Occupational Disruptiveness score, reflecting the impact of patients' psychosis and behavioral disturbances on the caregiver, was significantly reduced in the 5-mg/d olanzapine group compared with placebo (-2.7 vs -1.5; P =.008). Somnolence was significantly more common among patients receiving olanzapine (25.0%-35.8%), and gait disturbance occurred in those receiving 5 or 15 mg/d (19.6% and 17.0%, respectively). No significant cognitive impairment, increase in extrapyramidal symptoms, or central anticholinergic effects were found at any olanzapine dose relative to placebo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Street</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>W S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Gannon</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>F P</ForeName><Initials>FP</Initials></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>R N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Mitan</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Kadam</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Sanger</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Tollefson</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>21</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.57.10.968</ArticleId><ArticleId IdType="pii">yoa20048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11001600</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Medication-induced dystonias in nine patients with dementia.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>225</EndPage><MedlinePgn>219-25</MedlinePgn></Pagination><Abstract><AbstractText>Evidence from previous studies of neuroleptic side effects suggests that acute dystonic reactions are rare in elderly patients. The authors report 9 cases of dystonic reactions in patients with dementia following the initiation of antipsychotic medication. The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magnuson</LastName><ForeName>T M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, University of Nebraska Medical Center, Omaha 68198-5580, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roccaforte</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Wengel</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11001600</ArticleId><ArticleId IdType="doi">10.1176/jnp.12.2.219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10984728</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses.</ArticleTitle><Pagination><StartPage>819</StartPage><EndPage>823</EndPage><MedlinePgn>819-23</MedlinePgn></Pagination><Abstract><AbstractText>Dementia with Lewy bodies (DLB) is believed to be the second most common form of dementia, after Alzheimer disease (AD). DLB has been reported to be associated with an increase in psychopathology; however, antemortem diagnosis of DLB cannot always be made with certainty. We searched the database of University of California, San Diego SOCARE (Seniors Only Care) outpatient program. There were 26 autopsy-confirmed cases of DLB. We matched them individually with 26 autopsy-confirmed cases of 'pure' AD on gender, ethnicity, and Mini-Mental State Examination score at the baseline evaluation. We compared the two groups on psychopathologic measures and possible risk factors for psychopathology based on the data obtained at the time of the initial diagnosis of dementia. Five psychiatric symptoms: hallucinations, delusions, anxiety, anhedonia, and loss of energy were significantly more common in DLB patients than in AD patients. DLB patients were younger at initial evaluation and death as compared to AD patients, but there was no difference in age of onset of dementia, level of education, or family or past history of any major neuropsychiatric disorder, prescription of psychotropic medications, or sensory impairment. Psychiatric symptoms were more common at time of initial diagnosis of dementia in DLB than in AD patients. This difference could not be attributed to any known risk factors for psychopathology examined. Psychopathology should be considered an integral part of DLB, and should be taken into account in the initial diagnosis of the type of dementia.</AbstractText><CopyrightInformation>Copyright 2000 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rockwell</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choure</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Olichney</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH43695-12</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH45131-10</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH49671-07</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>14</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>14</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10984728</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200009)15:9&lt;819::aid-gps206&gt;3.0.co;2-1</ArticleId><ArticleId IdType="pii">10.1002/1099-1166(200009)15:9&lt;819::AID-GPS206&gt;3.0.CO;2-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22034391</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1294-8322</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Dialogues in clinical neuroscience</Title><ISOAbbreviation>Dialogues Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>NMDA receptor function, memory, and brain aging.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>232</EndPage><MedlinePgn>219-32</MedlinePgn></Pagination><Abstract><AbstractText>An increasing level of N-methyl-D-aspartate (NMDA) receptor hypofunction within the brain is associated with memory and learning impairments, with psychosis, and ultimately with excitotoxic brain injury. As the brain ages, the NMDA receptor system becomes progressively hypofunctional, contributing to decreases in memory and learning performance. In those individuals destined to develop Alzheimer's disease, other abnormalities (eg, amyloidopathy and oxidative stress) interact to increase the NMDA receptor hypofunction (NRHypo) burden. In these vulnerable individuals, the brain then enters into a severe and persistent NRHypo state, which can lead to widespread neurodegeneration with accompanying mental symptoms and further cognitive deterioration. If the hypotheses described herein prove correct, treatment implications may be considerable. Pharmacological methods for preventing the overstimulation of vulnerable corticolimbic pyramidal neurons developed in an animal model may be applicable to the prevention and treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Newcomer</LastName><ForeName>J W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Departement of Psychiatry, Washington University School of Medicine, St Louis, Mo, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>N B</ForeName><Initials>NB</Initials></Author><Author ValidYN="Y"><LastName>Olney</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dialogues Clin Neurosci</MedlineTA><NlmUniqueID>101238198</NlmUniqueID><ISSNLinking>1294-8322</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La acentuaci&#xf3;n de la hipofunci&#xf3;n del receptor N-metil-D-aspartato (NMDA) en el cerebro se ha asociado con deterioro en la memoria y el aprendizaje, con psicosis y, &#xfa;ltimamente con da&#xf1;o exitot&#xf3;xico. As&#xed; como el cerebro envejece, el sistema de receptores NMDA progresivamente se torna hipofuncional, lo que contribuye a una disminuci&#xf3;n de los rendimientos de memoria y aprendizaje. En aquellos individuos vulnerables para desarrollar la enfermedad de Alzheimer hay otras anormalidades (como amiloidopat&#xed;as y el estr&#xe9;s oxidativo) que interact&#xfa;an para aumentar la carga de la hipofunci&#xf3;n del receptor NMDA. En estos individuos vulnerables, el cerebro entra en un severo y persistente estado de hipofunci&#xf3;n del receptor NMDA, el cual puede conducir a una neurodegenerac&#xed;on generalizada, con s&#xed;ntomas mentales asociados y a un posterior deterioro cognitivo. Si se demuestra que la hip&#xf3;tesis descrita previamente es correcta, las implicancias terap&#xe9;uticas de ella pueden ser considerables. Los m&#xe9;todos farmacol&#xf3;gicos para prevenir la sobreestimulaci&#xf3;n de neuronas piramidales c&#xf3;rtico-l&#xed;mbicas vulnerables desarrolladas en un modelo animal pueden ser aplicables a la prevenci&#xf3;n y al tratamiento de la enfermedad de Alzheimer.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="fre"><AbstractText>L'augmentation de l'hypofonctionnement des r&#xe9;cepteurs du N-m&#xe9;thyl-D-aspartate (NMDA) dans le cerveau est associ&#xe9;e &#xe0; des troubles de la m&#xe9;moire et de l'apprentissage, qui s'accompagnent de psychose et &#xe9;voluent vers des l&#xe9;sions c&#xe9;r&#xe9;brales excitotoxiques. Lors du vieillissement c&#xe9;r&#xe9;bral, le syst&#xe8;me des r&#xe9;cepteurs du NMDA devient progressivement hypofonctionnel, contribuant &#xe0; la diminution des performances mn&#xe9;siques et d'apprentissage. Chez les individus pr&#xe9;dispos&#xe9;s &#xe0; d&#xe9;velopper une maladie d'Alzheimer (MA), d'autres anomalies (telles que les amylo&#xef;dopathies et le stress oxydatif) interagissent pour augmenter le degr&#xe9; d'hypofonctionnement (NRHypo) des r&#xe9;cepteurs du NMDA. Chez ces individus fragiles, le cerveau s'installe alors dans un &#xe9;tat d'hypofonctionnement permanent et s&#xe9;v&#xe8;re qui peut conduire &#xe0; une neurod&#xe9;g&#xe9;n&#xe9;ration &#xe9;tendue associ&#xe9;e &#xe0; des sympt&#xf4;mes mentaux et d'autres d&#xe9;t&#xe9;riorations cognitives. Si les hypoth&#xe8;ses d&#xe9;crites ici s'av&#xe8;rent exactes, les implications th&#xe9;rapeutiques pourraient &#xea;tre consid&#xe9;rables. Les m&#xe9;thodes pharmacologiques de pr&#xe9;vention de l'hyperstimulation des neurones corticolimbiques vuln&#xe9;rables, d&#xe9;velopp&#xe9;es dans des mod&#xe8;les animaux, pourraient s'appliquer &#xe0; la pr&#xe9;vention et au traitement de la maladie d'Alzheimer.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">NMDA receptor</Keyword><Keyword MajorTopicYN="N">NMDA receptor hypofunction</Keyword><Keyword MajorTopicYN="N">brain aging</Keyword><Keyword MajorTopicYN="N">memory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22034391</ArticleId><ArticleId IdType="pmc">PMC3181613</ArticleId><ArticleId IdType="doi">10.31887/DCNS.2000.2.3/jnewcomer</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olney JW. Excitotoxic amino acids and neuropsychiatrie disorders. Annu Rev Pharmacol Toxicol. 1990;30:47&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">2188577</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD., Van Kammen M., LeveyAI, Martin LJ., Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotropic lateral sclerosis. Ann Neurol. 1995;38:73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomidou C., Qin YQ., Labruyere J., Olney JW. Motor neuron degeneration induced by excitotoxin agonists has features in common with that seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1996;55:211&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786380</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908446</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Newcomer JW., Wozniak DF., Olney JW. The glutamate synapse in neuropsychiatric disorders: focus on schizophrenia and Alzheimer's disease. In: Ottersen OP, Langmoen I, Gjerstad L, eds. Progress in Brain Research. New York, NY: Elsevier. 1998;116:421&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932393</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Wozniak DF., Price MT., et al. Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry. 1995;38:788&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">8750036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV., Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Collingridge GL., Bliss TVP. Memories of NMDA receptors and LTP. Trends Neurosci. 1995;18:54&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7537406</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CF., Sullivan J. Synaptic plasticity. Curr Biol. 1998;8:R151&#x2013;R153.</Citation><ArticleIdList><ArticleId IdType="pubmed">9501074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear MF., Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol. 1994;4:389&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">7919934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne HR., Nicoll R. Molecular machines integrate coincident synaptic signals. Cell. 1993;72(suppl):65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094038</ArticleId></ArticleIdList></Reference><Reference><Citation>Rison RA., Stanton PK. Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev. 1995;19:533&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">8684715</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC. Synaptic plasticity in the hippocampus: LTP and LTD. Cell. 1994;78:535&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069904</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM., Anderson E., Lynch GC., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319:774&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">2869411</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S., Butcher SP., Morris RGM. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci. 1992;12:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575679</ArticleId><ArticleId IdType="pubmed">1345945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 1992;258:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">1329206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 1994;17:31&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8210177</ArticleId></ArticleIdList></Reference><Reference><Citation>Monyer H., Sprengel R., Schoepfer R., et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 1992;256:1217&#x2013;1221 .</Citation><ArticleIdList><ArticleId IdType="pubmed">1350383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakimura K., Kutsuwada T., Ito I., et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature. 1995;373:151&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">7816096</ArticleId></ArticleIdList></Reference><Reference><Citation>Monyer H., Burnashev N., Laurie DJ., Sakmann B., Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">7512349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang TP., Shimizu E., Dube GR., et al. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Handelman GE., Contreras PC., O'Donohue TL. Selective memory impairment by phencyclidine in rats. Eur J Pharmacol. 1987;140:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3622624</ArticleId></ArticleIdList></Reference><Reference><Citation>Balster RL., Chait LD. The behavioral pharmacology of phencyclidine. Clin Toxicol. 1976;9:513&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">824088</ArticleId></ArticleIdList></Reference><Reference><Citation>McLamb RL., Williams LR., Nanary KP., Wilson WA., Tilson HA. MK-801 impedes the acquisition of a spatial memory in rats. Pharmacol Biochem Behav. 1990;37:41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">2148213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori C., Weiskrantz L., Buerki H., Petschke F., Fagg GE. NMDA receptor antagonists can enhance or impair learning performance in animals. Exp Brain Res. 1989;75:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">2545467</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM. Synaptic plasticity and learning: selective impairment of learning in rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. J Neurosci. 1989;9:3040&#x2013;3057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569656</ArticleId><ArticleId IdType="pubmed">2552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RGM., Davis S., Butcher SP. Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Phil Trans R Soc. 1990;329:187&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1978364</ArticleId></ArticleIdList></Reference><Reference><Citation>Puma C., Baudoin C., Bizot JC. Effects of intraseptal infusions of N-methyl-D-aspartate receptor ligands on memory in an object recognition task in rats. Neurosci Lett. 1998;244:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572594</ArticleId></ArticleIdList></Reference><Reference><Citation>Danysz W., Wroblewski JT., Costa E. Learning impairment in rats by N-methyl-D-asparate receptor antagonists. Neuropharmacol. 1988;27:653&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">2901678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward L., Mason SE., Abraham WC. Effects of the NMDA antagonists, CPP and MK-801 on the radial arm maze performance in rats. Pharmacol Biochem Behav. 1990;35:785&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">2189143</ArticleId></ArticleIdList></Reference><Reference><Citation>Butelman ER. A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task. Pharmacol Biochem Behav. 1989;34:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">2696982</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangler EL., Bresnahan EL., Garofalo P., Muth NJ., Heller B., Ingram DK. NMDA receptor channel antagonism by dizocilpine (MK-801) impairs performance of rats in aversively motivated complex maze tasks. Pharmacol Biochem Behav. 1991;40:949&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">1667826</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonkiss J., Morris RGM., Rawlins JNP. Intra-ventricular infusion of the NMDA antagonist AP5 impairs performance on a non-spatial operant DRL task in the rat. Exp Brain Res. 1988;73:181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">2905273</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooks EB., Robinson GS., Hatfield TJ., Graham PW., Gallagher M. Intraventricular administration of the NMDA antagonist APV disrupts learning of an odor aversion that is potentiated by taste. Soc Neurosc&#xed; Abstr. 1989;15:464.</Citation></Reference><Reference><Citation>Jones KW., Bauerle L., DeNoble V. Differential effects of sigma and phencyclidine receptor ligands on learning. Eur J Pharmacol. 1990;179:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2163853</ArticleId></ArticleIdList></Reference><Reference><Citation>Parada-Turska J., Turski WA. Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacol. 1990;29:1111&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">2149871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ., Clissold DB., White MF., Ferkany JW. N-Methyl-D-aspartate antagonists and working memory performance: comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine. Behav Neurosci. 1991;105:521&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">1657031</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DL., Gold PE. Effects of the novel NMDA antagonist, NPC 12626, on long-term potentiation, learning and memory. Brain Res. 1991;549:213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832074</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara RK., Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev. 1993;18:33&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8467349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Fanselow M., DeCola J., Landeira-Fernandez J. Selective impairment of long-term but not short-term conditional fear by the NMDA antagonist APV. Behav Neurosci. 1992;106:591&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">1354443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Rison R., Fanselow M. Effects of amygdala, hippocampus, and periaqueductal gray lesions on short- and long-term contextual fear. Behav Neurosci. 1993;107:1093&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">8136063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DM., Winsauer PJ., Mastropaolo J. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav. 1987;26:401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">2883665</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DM., Moerschbaecher JM. Phencyclidine in combination with d-amphetamine: differential effects on acquisition and performance of response chains in monkeys. Pharmacol Biochem Behav. 1984;20:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">6728878</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffalo EA., Gillam MP., Allen RR., Paule MG. Acute behavioral effects of MK-801 in rhesus monkeys: assessment using an operant test battery. Pharmacol Biochem Behav. 1994;48:935&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">7972299</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick DL., Gillam MP., Allen RR., Paule MG. Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Pharmacol Biochem Behav. 1995;52:789&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">8587921</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt DC., Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum G., Cohen BD., Luby ED., Gottlieb JS., Yelen D. Comparison of Sernyl with other drugs: simulation of schizophrenic performance with Sernyl, LSD-25, and amobarbital (Amytal). I. Attention, motor function and proprioception. Arch Gen Psychiatry. 1959;1:651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">14438905</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies BM., Beech HL. The effect of 1-arylcyclohexylamine (Sernyl) on 12 normal volunteers, J Ment Sci. 1960;106:912&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">13720081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker CB., Amini FB. Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry. 1961;2:269&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">13864199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen BD., Rosenbaum G., Luby ED., Gottlieb JS. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Arch Gen Psychiatry. 1962;6:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">13880223</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit SK., Dundee JW., Bovill JG. Clinical studies of induction agents XXXVII: amnesic action of ketamine. Br J Anaesth. 1971;43:362&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">5575186</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen KLR. Ketamine - can chronic use impair memory? Int J Addictions. 1990;25:133&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">2228329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev. 1995;20:250&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">7795658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton RY., Medzihradsky F., Woods JH., Dahlstrom PJ. Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sci. 1982;30:2147&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pubmed">7109842</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM., Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci. 1987;10:299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">7537407</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA., Biersner RJ., Edwards D., Bailey LW. Attention, learning and personality during ketamine emergence: a pilot study. Anesth Analg. 1975;54:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">1092205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoneim MM., Hinrichs JV., Mewaldt SP., Petersen RC. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol. 1985;5:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">3988972</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal JH., Karper LP., Seibyl JP., et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8122957</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra AK., Pinals DA., Weingartner H., et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703299</ArticleId></ArticleIdList></Reference><Reference><Citation>Harborne GC., Watson FL., Healy DT., Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol. 1996;10:134&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">22302890</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW., Farber NB., Jevtovic-Todorovic V., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in schizophrenia. Neuropsychopharmacology. 1999;20:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9885791</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CM., Goldberg TE., Malhotra AK., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry. 1998;43:811&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">9611670</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW., Selke G., Melson AK., et al. NMDA antagonist-induced decrease in working and declarative memory in healthy humans. Soc Neurosci Abstr. 1999;25:633.</Citation></Reference><Reference><Citation>Smith EE., Jonides J. Storage and executive processes in the frontal lobes. Science. 1999;283:1657&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA., Vogt LJ., Nimchinsky EA., Hof PR. Primate cingulate cortex chemoarchitecture and its disruption in Alzheimer's disease. In: Bloom FE, Bjorklund A, Hokfelt T, eds. Handbook of Chemical Neuroanatomy. Vol 13: The Primate Nervous System. Part I. New York, NY: Elsevier. 1997:455&#x2013;528.</Citation></Reference><Reference><Citation>Johnstone M., Evans V., Baigel S. Sernyl (CI-395) in clinical anaesthesia. Br J Anaesth. 1959;31:433&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">14407580</ArticleId></ArticleIdList></Reference><Reference><Citation>Luby ED., Cohen BD., Rosenbaum G., Gottlieb JS., Kelley R. Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry. 1959;81:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">13626287</ArticleId></ArticleIdList></Reference><Reference><Citation>Luby ED., Gottlieb JS., Cohen BD., Rosenbaum G., Domino EF. Model psychoses and schizophrenia. Am J Psychiatry. 1962;119:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">14467063</ArticleId></ArticleIdList></Reference><Reference><Citation>Corssen G., Domino EF. Dissociative anesthesia: further pharmacological studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg. 1966;45:29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">5325977</ArticleId></ArticleIdList></Reference><Reference><Citation>Domino EF., Luby ED. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino EF, &#xe9;d. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, Mich: NPP Books. 1981:401&#x2013;418.</Citation></Reference><Reference><Citation>Lodge D., Anis NA. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur J Pharmacol. 1982;77:203&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">7037432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodge D., Aram JA., Church J., et al. Excitatory amino acids and phencyclidine-like drugs. In: Hicks TP, Lodge D, McLennan H, eds. Excitatory Amino Acid Transmission. New York: Alan R Liss. 1987:83&#x2013;90.</Citation></Reference><Reference><Citation>Kristensen JD., Svensson B., Gordh T Jr. The NMDA receptor-antagonist CPP abolishes neurogenic &#x201c;wind-up pain&#x201d; after intrathecal administration in humans. Pain. 1992;51:249&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">1484720</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrling P. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans. Neuropsychopharmacology. 1994;10(3S/Part 1):591S.</Citation></Reference><Reference><Citation>Grotta J., Clark W., Coull B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 1995;26:602&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">7709405</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir KW., Grosset DG., Lees KR. Effects of prolonged infusion of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin Neuropharmacol. 1997;20:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">9260729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zukin RS., Zukin SR. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A. 1979;76:5372&#x2013;5376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413145</ArticleId><ArticleId IdType="pubmed">291953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JP., Kartalovski B., Geneste P., Kamenka JM., Lazdunski M. Interaction of phencyclidine (&#x201c;angel dust&#x201d;) with a specific receptor in rat brain membranes. Proc Natl Acad Sci U S A. 1979;76:4678&#x2013;4682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411644</ArticleId><ArticleId IdType="pubmed">41247</ArticleId></ArticleIdList></Reference><Reference><Citation>Angrist B., Gershon S. The phenomenology of experimentally induced amphetamine psychosis - preliminary observations. Biol Psychiatry. 1970;2:95&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">5459137</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DX. On the use and abuse of LSD. Arch Gen Psychiatry. 1968;18:330&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">4295595</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DX. LSD: the bridge from human to animal. In: Jacobs BL, ed. Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives. New York: Raven Press. 1984:203&#x2013;226.</Citation></Reference><Reference><Citation>Angrist B., Sathananthan G., Wilk S., Gershon S. Amphetamine psychosis: behavioral and Biochemical aspects. J Psychiatr Res. 1974;11:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">4461784</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowsky DS., Risch SC. Amphetamine psychosis and psychotic symptoms. Psychopharmacol (Berl). 1979;65:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">116294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA., Kane JM., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacol (Berl). 1987;91:415&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">2884687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers MB., Swigar ME., Jatlow PI., Hoffman F., Goicoechea N. Early neuroleptic response: clinical profiles and plasma catecholamine metabolites. J Clin Psychopharmacol. 1987;7:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2884237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillin JC., Kaplan J., Stillman R., Wyatt RJ. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am J Psychiatry. 1976;133:203&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">1062171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA., Freeman AM III. Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J Clin Psychiatry. 1978;44:664&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">681304</ArticleId></ArticleIdList></Reference><Reference><Citation>Erard R., Luisada PV., Peele R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs. 1980;12:235&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">7431420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban TA., Lohrena JJ., Lehmann HE. Observations on the action of Sernyl - a new psychotropic drug. Can Psychiatr Assoc J. 1961;6:150&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">13686510</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DL., Silvay G. Ketamine: an update on the first 25 years of clinical experience. Can J Anaesth. 1989;36:186&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">2650898</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BE., Longnecker DE. General anesthetics. In: Goodman LS, Gilman A, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon Press. 1990:285&#x2013;310.</Citation></Reference><Reference><Citation>Karp HN., Kaufman ND., Anand SK. Phencyclidine poisoning in young children. J Pediatr. 1980;97:1006&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">7441408</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch MJ., Correa GA. PCP intoxication in young children and infants. Clin Pediatr (Phila). 1980;19:510&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">7389238</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldridge EB., Bessen HA. Phencyclidine. Emerg Med Clin North Am. 1990;8:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">2201519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai G., Passani LA., Slusher BS., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52:829&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">7575102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulas J., Cotman CW. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience. 1997;79:973&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">9219960</ArticleId></ArticleIdList></Reference><Reference><Citation>D'souza DC., Charney DS., Krystal JH. Glycine site agonist of the NMDA receptor: a review. CNS Drug Rev. 1995;1:227&#x2013;260.</Citation></Reference><Reference><Citation>Olney JW. Endogenous excitotoxins and neuropathological disorders. In: Lodge D, ed. Excitatory Amino Acids in Health and Disease. Chichester, UK: John Wiley &amp; Sons Ltd. 1988:337&#x2013;351.</Citation></Reference><Reference><Citation>Olney JW., Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492260</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JY. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry. 1996;3:241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384954</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Newcomer JW., Olney JW. Glycine agonists: what can they teach us about schizophrenia? Arch Gen Psychiatry. 1999;56:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892251</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW., Farber NB., Selke G., Melson AK., Jevtovic-Todorovic V., Olney JW. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Soc Neurosci Abstr. 1998;24:525.</Citation></Reference><Reference><Citation>Anand A., Charney DS., Berman RM., Oren DA., Cappiello A., Krystal JH. Reduction in ketamine effects in humans by lamotrigine. Soc Neurosci Abstr. 1997;23:1755.</Citation></Reference><Reference><Citation>Goff DC., Tsai G., Levittt J., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892252</ArticleId></ArticleIdList></Reference><Reference><Citation>Heresco-Levy U., Javitt DC., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892253</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573099</ArticleId><ArticleId IdType="pubmed">9092613</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 1998;18:5545&#x2013;5554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793475</ArticleId><ArticleId IdType="pubmed">9651235</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannini MG., Mutolo D., Bianchi L., Michelassi A., Pepeu G. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J Neurosci. 1994;14:1358&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577531</ArticleId><ArticleId IdType="pubmed">8120631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Kinoshita H., Amano M., Hasegawa T., Kameyama T., Nabeshima T. MK 801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis. Neurosci Lett. 1993;150:53&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8469404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH., Price MT., Olney JW., Farber NB. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and &#x3b1;2-adrenergic agonists. Mol Psychiatry. 1999;4:344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10483051</ArticleId></ArticleIdList></Reference><Reference><Citation>Corso TD., Sesma MA., Tenkova Tl., et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 1997;752:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF., Dikranian K., Ishimaru M., et al. Disseminated corticolimbic neuronel degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol Dis. 1998;5:305&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">10069574</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW., Labruyere J., Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">2660263</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW., Labruyere J., Wang G., Wozniak DF., Price MT., Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">1835799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargreaves RJ., Rigby M., Smith D., Hill RG., Iversen LL. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res. 1993;18:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">7903796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp FR., Jasper P., Hall J., Noble L., Sagar SM. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol. 1991;30:801&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">1838680</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen HL., Iversen LL. Phencyclidine, dizocilpine, and cerebrocortical neurons. Science. 1990;247:221.</Citation><ArticleIdList><ArticleId IdType="pubmed">2403696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport. 1994;5:2688&#x2013;2692.</Citation><ArticleIdList><ArticleId IdType="pubmed">7696633</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath ZC., Czopf J., Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res. 1997;753:181&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125402</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Price MT., Labruyere J., et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry. 1993;34:119&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8373932</ArticleId></ArticleIdList></Reference><Reference><Citation>Price MT., Farber NB., Labruyere J., Foster J., Olney JW. Tracing the circuitry that mediates NMDA antagonist neurotoxicity. Soc Neurosci Abstr. 1994;20:1532.</Citation></Reference><Reference><Citation>Farber NB., Olney JW. &#x3b1;2-Adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 1995;12:347&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576011</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Kim SH., Dikranian K., et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp FR., Butman M., Koistinaho J., et al. Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage-gated calcium channels. Neuroscience. 1994;62:1079&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp FR., Butman M., Wang S., et al. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res. 1992;33:605&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">1484394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp JW., Petersen DL., Langford MT. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583295</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Kim SH., Olney JW. Costimulation of muscarinic and non-NMDA glutamate receptors reproduces NMDA antagonist neurotoxicity. Soc Neurosci Abstr. 1997;23:2308.</Citation></Reference><Reference><Citation>Kim SH., Farber NB., Price MT., Olney JW. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonist is reduced by GABAergic and &#x3b1;2-adrenergic agonists. Mol Psychiatry. 1999;4:344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10483051</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Hanslick J., Kirby C., McWilliams L., Olney JW. Serotonergic agents that activate 5-HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology. 1998;18:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jevtovic-Todorovic V., Olney JW., Farber NB. Lamotrigine prevents NMDA antagonist neurotoxicity. Soc Neurosci Abstr. 1998;24:745.</Citation></Reference><Reference><Citation>Farber NB., Foster J., Duhan NL., Olney JW. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res. 1996;21:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8998274</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra AK., Adler CM., Kennison SD., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42:664&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">9325559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzales RA., Brown LM., Jones TW., Trent RD., Westbrook SL., Leslie SW. N-methyl-D-aspartate-mediated responses decrease with age in Fischer 344 rat brain. Neurobiol Aging. 1991;12:219&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">1678878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk GL., Walker LC., Price DL., Cork LC. Loss of NMDA, but not GABA-A, binding in the brains of aged rats and monkeys. Neurobiol Aging. 1991;12:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646968</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson KR., Cotman CW. Age-related changes in excitatory amino acid receptors in two mouse strains. Neurobiol Aging. 1993;14:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">8391661</ArticleId></ArticleIdList></Reference><Reference><Citation>Saransaari P., Oja SS. Dizocilpine binding to cerebral cortical membranes from developing and ageing mice. Mech Ageing Develop. 1995;85:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786663</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson KR. The aging of the NMDA receptor complex. Front Biosci. 1998;3:e70&#x2013;e80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9576682</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggott MA., Perry EK., Perry RH., Court JA. [3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging. Brain Res. 1992;588:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">1393579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaley AH., Siegel SJ., Kordower JH., Mufson EJ., Morrison JH. Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Proc Natl Acad Sci USA. 1996;93:3121&#x2013;3125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39772</ArticleId><ArticleId IdType="pubmed">8610179</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson KR., Sammonds GE. Age-related changes in the expression of NMDA receptor subunits. FASEB J. 1998;12:4365.</Citation></Reference><Reference><Citation>Sheng M., Cummings J., Roldan LA., Yan YN., Yan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature. 1994;368:144&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139656</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe S., Collin C., Auerbach JM., et al. Hippocampal synaptic plasticity in mice overexpressing an embryonic subunit of the NMDA receptor. J Neurosci. 1998;18:4177&#x2013;4188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792823</ArticleId><ArticleId IdType="pubmed">9592097</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmignoto G., Vicini S. Activity-dependent decrease in NMDA receptor responses during development of the visual cortex. Science. 1992;258:1007&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">1279803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hestrin S. Activation and desensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex. Neuron. 1992;9:991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384578</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S., Giordani B., Berebt S., Frey KA., Foster NL., Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Bohl J. Retrosplenial region involvement in Alzheimer's disease. Neurodegeneration. 1992;1:53&#x2013;57.</Citation></Reference><Reference><Citation>Brun A., Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histological grading. Histopathology. 1981;5:549&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">7286917</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix AS., Wightman KA., O'Callaghan JP. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunohistochemistry. Neurotoxicology. 1995;16:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566683</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB., Rubin EH., Newcomer JW., et al. Increased neocortical neurofibrillary tangle density in Alzheimer's disease subjects with psychosis. Arch Gen Psychiatry. 2000. In press</Citation><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh JY., Yang LL., Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990;533:315&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">2289145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CW., Patel AJ. Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Brain Res. 1995;691:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">8590049</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AJ. Pretreatment with a sublethal concentration of &#x3b2;-amyloid25-35 potentiates neurodegeneration mediated by glutamate in cultured cortical neurons. Alzheimer's Res. 1995;1:41&#x2013;44.</Citation></Reference><Reference><Citation>Sano M., Ernesto C., Thomas RG., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study (see comments). N Engl J Med. 1997;336:1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10961431</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-6995</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Journal of neural transmission. Supplementum</Title><ISOAbbreviation>J Neural Transm Suppl</ISOAbbreviation></Journal><ArticleTitle>Morphological substrates of mental dysfunction in Lewy body disease: an update.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>212</EndPage><MedlinePgn>185-212</MedlinePgn></Pagination><Abstract><AbstractText>Mental dysfunction including cognitive, behavioural changes, mood disorders, and psychosis are increasingly recognized in patients with Parkinson's disease (PD) and related disorders. Their morphological correlates are complex due to multiple system degeneration. CNS changes contributing to cognitive changes in PD include 1. Dysfunction of subcorticocortical networks with neuron losses in a) the dopaminergic nigrostriatal loop, causing striato-(pre)frontal deafferentation and mesocortico-limbic system (medial substantia nigra, ventral tegmentum); b) noradrenergic (locus coeruleus), and serotonergic systems (dorsal raphe nuclei), c) cholinergic forebrain system (nucleus basalis of Meynert, etc), and d) specific nuclei of amygdala and limbic system (thalamic nuclei, hippocampus); 2. Limbic and/or cortical Lewy body and Alzheimer type pathologies with loss of neurons and synapses, 3. Combination of subcortical, cortical, and other pathologies. In general, degeneration of subcortical and striato-frontal networks causes cognitive, executive, behavioural, and mood disorders but less severe dementia than cortical changes which, when present in sufficient numbers, are important factors for overt dementia. In PD, cortical tau pathology with similar or differential patterns than in Alzheimer disease (AD) shows significant linear correlation with cognitive decline. In dementia with Lewy bodies (DLB), the second most frequent cause of dementia in the elderly, cortical Lewy bodies (LB) may or may not be associated with amyloid plaques and neuritic AD lesions. They predominantly affect the limbic system with less frequent isocortical Braak stages, whereas the cholinergic forebrain system is more severely affected than in AD. Both neuritic degeneration in limbic system in PD and DLB and the density of cortical synapse markers correlate with neuritic AD pathology and less with cortical LB counts. Apolipoprotein E epsilon4 allele frequency may represent a common genetic background for both AD and LB pathologies but there are different proportions of plaques between DLB (less Abeta1-40) and AD (more frequent Abeta1-40). Familial parkinsonism with dementia, linked to chromosome 17 (frontotemporal dementia with Parkinsonism (FTDP-17), and other tauopathies pathologically resembling PD plus AD, are often related to mutations of the tau gene, whereas familial PD with alpha-synuclein and Parkin mutations usually show no cognitive impairment. Mood disorders, in particular depression, and psychotic complications in both PD and DLB are related to complex involvement of noradrenergic and serotonergic systems, not confirmed in AD with depression, and both the prefrontal and limbic dopaminergic systems. The specific contributions of cortical and subcortical pathologies to mental dysfunction in PD and related disorders, their relationship to AD, and their genetic and aetiological backgrounds await further elucidation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jellinger</LastName><ForeName>K A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria. kurt.jellinger@univie.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm Suppl</MedlineTA><NlmUniqueID>0425126</NlmUniqueID><ISSNLinking>0303-6995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008967" MajorTopicYN="N">Molecular Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10961431</ArticleId><ArticleId IdType="doi">10.1007/978-3-7091-6781-6_21</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10951909</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Biological therapies of behavioral and psychological symptoms of dementia: update and prospects].</ArticleTitle><Pagination><StartPage>72</StartPage><EndPage>80</EndPage><MedlinePgn>72-80</MedlinePgn></Pagination><Abstract><AbstractText>In addition to cognitive deficits, dementia is characterized by noncognitive behavioral disorders that are highly prevalent as the disease progresses into its later stages. These "behavioral and psychological signs and symptoms of dementia" are probably more important on a day to day basis than the cognitive deficits: in some patients, they are not a source of major disability but rather just a nuisance and may not require active pharmacological treatment; in others, they can be source of substantial anxiety and distress. Among the many behavioral symptoms of dementia, the group of behaviors included under the label of depression, anxiety, agitation, aggressiveness or uncooperativeness are the most burdensome and frequently lead to the prescription of an antipsychotic drug. They often precipitate institutional placement. The rationale for the use of psychotropic drugs is partially based upon phenomenological similarities of some behaviors observed in elderly demented patients to signs and symptoms of psychiatric disorders such as depressive illnesses, anxiety or psychotic disorders in non-elderly patients. In fact, the "psychiatric symptoms" in Alzheimer's disease or other dementia are often qualitatively different from those that characterize depressive, anxious or psychotic disorders. Many monoaminergic acquired deficits in dementia may also explain why treatment outcome studies suggest that the psychotropic drugs are less effective in patients with Alzheimer's disease or frontal lobe dementia than in patients with psychiatric disorders. The role of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms in Alzheimer's disease may represent a novel and promising therapeutical approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallarda</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service Hospitalo-Universitaire de Sant&#xe9; Mentale et de Th&#xe9;rapeutique, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olie</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les th&#xe9;rapeutiques biologiques des signes et sympt&#xf4;mes comportementaux et psychologiques de la d&#xe9;mence: mise au point et perspectives.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>22</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>21</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>22</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10951909</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10939309</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-229X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs &amp; aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.</ArticleTitle><Pagination><StartPage>451</StartPage><EndPage>471</EndPage><MedlinePgn>451-71</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Risperidone is a benzisoxazole derivative which has proven efficacy against the positive and negative symptoms of schizophrenia. It has more recently been investigated and shown efficacy as a treatment for the behavioural and psychological symptoms associated with dementia in the elderly. Risperidone has pharmacological properties resembling those of the atypical antipsychotic clozapine and an improved tolerability profile compared with the conventional antipsychotic haloperidol. Risperidone has antagonistic activity primarily at serotonin 5-HT2A and dopamine D2 receptors. In the first 2 large, well controlled trials of an antipsychotic agent used in the treatment of elderly patients with Alzheimer's dementia, vascular dementia or mixed dementia, risperidone 1 mg/day was at least as effective as haloperidol and superior to placebo, as assessed by the rating scales for global behaviour, aggression and psychosis. In extension phases of the 2 trials, clinical benefits were maintained for treatment periods of up to 1 year, with an incidence rate of tardive dyskinesia (2.6%) one-tenth of that seen with conventional antipsychotics. Risperidone, administered at a low dosage of 1 mg/day was associated with fewer extrapyramidal symptoms compared with haloperidol in elderly patients. Risperidone was well tolerated with no clinically relevant abnormalities in laboratory tests, vital signs or electrocardiogram results.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly. Preliminary results from 1-year extension studies confirm the favourable efficacy and tolerability profile of risperidone 1 mg/day. Although head to head studies with other atypical antipsychotic agents are required and the long term use of the drug requires clarification, risperidone represents a generally well tolerated and effective treatment in the management of dementia-associated behavioural and psychological symptoms in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhana</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-62-4</RegistryNumber><NameOfSubstance UI="D011388">Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>74</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10939309</ArticleId><ArticleId IdType="doi">10.2165/00002512-200016060-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychopharmacology (Berl). 1993;110(3):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7530376</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jul;157(7):1150-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10873925</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8935801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1999 Summer;11(3):336-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10440009</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1997 Dec;9(4):431-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9549592</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S25-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9352343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Oct 29;344(8931):1228-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7523815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1999 Jan;33(1):73-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9972387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2):177-87</Citation><ArticleIdList><ArticleId IdType="pubmed">8690833</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Emerg Med. 1998 Sep;16(5):498-501</Citation><ArticleIdList><ArticleId IdType="pubmed">9725965</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1999 Feb;19(1):57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9934944</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1995 Dec;122(3):223-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8748391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):220-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9608413</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Fam Physician. 1998 Jan 1;57(1):107-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9447218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 8:54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10335671</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1999 Jan;14(1):41-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10069407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1998 Feb;32(2):267</Citation><ArticleIdList><ArticleId IdType="pubmed">9496415</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1992 Mar;41(3):494-508</Citation><ArticleIdList><ArticleId IdType="pubmed">1372084</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1997 Feb;10(2):95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">9061267</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1997 Mar;9(1):65-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9195280</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1997 Mar-Apr;8(2):73-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9065318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 May;60(5):315-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10362440</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 1998;8(3):151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9853689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 8:11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10335667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1995 Jun;29(6):610-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7545034</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1999 Mar;99(3):160-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10100910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1989 Dec;28(12):1431-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2482460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 1997 May-Jun;17(3):617-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9165568</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1996;8 Suppl 3:343-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9154586</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1994 Aug;48(2):253-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7527327</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1988 Nov;247(2):661-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2460616</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1997 Jan;12(1):73-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9050427</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1998 Oct;139(4):356-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9809856</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Oct;59(10):550-61; quiz 562-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9818639</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1993 Sep;38 Suppl 3:S80-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7504573</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1994 May;114(4):566-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7531854</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1994 Feb;114(1):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7531352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1999 Jun;47(6):716-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10366172</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1995 Apr 15;310(6985):970-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7728032</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1998 Nov;13(5):391-411</Citation><ArticleIdList><ArticleId IdType="pubmed">9829166</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1997 Dec;58(12):538-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9448657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Emerg Med. 1997 Nov;30(5):698-700</Citation><ArticleIdList><ArticleId IdType="pubmed">9360586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 May;48 Suppl:9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2000 Mar;16(3):199-226</Citation><ArticleIdList><ArticleId IdType="pubmed">10803860</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41</Citation><ArticleIdList><ArticleId IdType="pubmed">7507814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):19S-23S</Citation><ArticleIdList><ArticleId IdType="pubmed">7537284</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1995;388:24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">7604735</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1998 Mar;31(2):70-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9562212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1997 Jul;58(7):311-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9269252</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1995 Mar;10(1):19-30</Citation><ArticleIdList><ArticleId IdType="pubmed">7542676</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1993 Sep;54(3):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">7690693</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Sep 22;53(5):946-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2000 Jan;20(1):23-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10641973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1986 Oct;34(10):711-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1998 Feb;12 (2):115-27</Citation><ArticleIdList><ArticleId IdType="pubmed">9509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 1999 Nov;15(5):365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10600044</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 1998 Spring;6(2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9581208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996;57 Suppl 9:57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8823352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10910086</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0894-878X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neuropsychiatry, neuropsychology, and behavioral neurology</Title><ISOAbbreviation>Neuropsychiatry Neuropsychol Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Quantitative electroencephalographic correlates of psychosis in Alzheimer disease.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>170</EndPage><MedlinePgn>163-70</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We hypothesized that the distinctive neurobiology of Alzheimer disease (AD) with psychosis would be reflected in more severe abnormalities in frontal and temporal regions on quantitative electroencephalography (QEEG).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with AD and psychosis have more rapid cognitive decline and greater pathologic involvement of frontal and temporal cortex than AD patients without psychotic features.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We evaluated brain function using QEEG in a group of 44 patients who had a diagnosis of probable or possible AD. All patients were administered the Mini-Mental State Examination and the Neuropsychiatric Inventory to assess psychiatric symptoms, including the presence of hallucinations and delusions. Absolute and relative power in patients with and without psychosis were compared to determine if there were regional or global QEEG differences in these two groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with psychosis showed greater overall absolute and relative delta power but no regional predominance of slowing compared with those without psychosis. Those with psychosis had a concomitant decrease in relative alpha power. These differences remained after adjustment for different dementia severity in the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This finding suggests more severe brain dysfunction in patients with psychosis than in those with similar levels of cognitive impairment but without psychosis. The QEEG abnormalities were not regionally specific and involved all areas assessed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edwards-Lee</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California at Los Angeles School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fairbanks</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leuchter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG10072</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH40705</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychiatry Neuropsychol Behav Neurol</MedlineTA><NlmUniqueID>8811108</NlmUniqueID><ISSNLinking>0894-878X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10910086</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10896687</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebral correlates of psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>167</StartPage><EndPage>171</EndPage><MedlinePgn>167-71</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms are produced by distributed neuronal dysfunction. Abnormalities of reality testing and false inference implicate frontal lobe abnormalities.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify the functional imaging profile of patients with Alzheimer's disease manifesting psychotic symptoms as measured by single photon emission computed tomography (SPECT).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with Alzheimer's disease who had SPECT and clinical evaluations were divided into two equal groups with similar mini mental status examination (MMSE), age, sex, and the range of behaviours documented by the neuropsychiatric inventory (NPI), except delusions and hallucinations. SPECT studies, registered to a probabilistic anatomical atlas, were normalised across the combined group mean intensity level, and subjected to a voxel by voxel subtraction of the non-psychotic minus psychotic groups. Subvolume thresholding (SVT) corrected random lobar noise to produce a three dimensional functional significance map.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The significance map showed lower regional perfusion in the right and left dorsolateral frontal, left anterior cingulate, and left ventral striatal regions along with the left pulvinar and dorsolateral parietal cortex, in the psychotic versus non-psychotic group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with Alzheimer's disease who manifest psychosis may have disproportionate dysfunction of frontal lobes and related subcortical and parietal structures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mega</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology UCLA School of Medicine, UCLA School of Medicine, Los Angeles, California, USA. mega@loni.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dinov</LastName><ForeName>I D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Mishkin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08AG100784</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20MH/DA 52176</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3B744AG22N</RegistryNumber><NameOfSubstance UI="D019690">Technetium Tc 99m Exametazime</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):148-9. doi: 10.1136/jnnp.69.2.148</RefSource><PMID Version="1">10896684</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019690" MajorTopicYN="N">Technetium Tc 99m Exametazime</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10896687</ArticleId><ArticleId IdType="pmc">PMC1737034</ArticleId><ArticleId IdType="doi">10.1136/jnnp.69.2.167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 1972 Mar;120(556):321-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5040678</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1974;50(5):516-38</Citation><ArticleIdList><ArticleId IdType="pubmed">4618029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1980 Jun 20;243(23):2434-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6990044</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1984 Jun;144:662-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6743935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1985 Mar;5(3):776-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2983048</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1987 Apr;44(4):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3827694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1988 Jan;36(1):7-12</Citation><ArticleIdList><ArticleId IdType="pubmed">3335733</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1988;2(4):363-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3196470</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1989 Jan;25(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 May;146(5):577-87</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Lang. 1989 Nov;37(4):656-91</Citation><ArticleIdList><ArticleId IdType="pubmed">2479448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 Aug;38(8):867-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2201714</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1991 Jul-Aug;12(4):295-312</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;82(4):239-59</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1992 Jan;41(1):73-88</Citation><ArticleIdList><ArticleId IdType="pubmed">1561290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1991 Fall;3(4):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1990 Fall;2(4):373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">2136389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 1992 Nov-Dec;2(6):435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">1477524</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1993 Mar;50(3):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8442707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol. 1993 Nov;48(6):M255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8227995</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1994 Apr 14;368(6472):633-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8145849</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Nov;44(11):2055-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7969959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1994 Fall;6(4):358-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7841807</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1995 Apr;118 ( Pt 2):401-16</Citation><ArticleIdList><ArticleId IdType="pubmed">7735882</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Oct;152(10):1470-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7573586</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1995 May;25(3):505-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7480431</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Oct 1;38(7):438-49</Citation><ArticleIdList><ArticleId IdType="pubmed">8672604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1995 Fall;7(4):476-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8555751</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Jan;46(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Feb;153(2):243-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8561206</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1996 Aug;119 ( Pt 4):1365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8813298</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Nov;153(11):1438-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Nov;47(5):1113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1996 Oct;119 ( Pt 5):1627-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8931585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Assist Tomogr. 1998 Jan-Feb;22(1):153-65</Citation><ArticleIdList><ArticleId IdType="pubmed">9448780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1998 May;64(5):648-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 1998 Jun;13(6):410-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9658277</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10026387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10896684</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebral dysfunction and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>148</StartPage><EndPage>149</EndPage><MedlinePgn>148-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toone</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):167-71. doi: 10.1136/jnnp.69.2.167</RefSource><PMID Version="1">10896687</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10896684</ArticleId><ArticleId IdType="pmc">PMC1737072</ArticleId><ArticleId IdType="doi">10.1136/jnnp.69.2.148</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10837878</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Anxiety, depression and psychosis in vascular dementia: prevalence and associations.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>106</EndPage><MedlinePgn>97-106</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about psychiatric symptoms in Vascular dementia (VaD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">92 patients with VaD, and 92 patients with Alzheimer's disease (AD) are reported. The evaluation included standardised measures of mood and psychosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">72% of VaD patients and 38% of those with AD had two or more anxiety symptoms. VaD patients with severe dementia (94%) were the most likely to be anxious. Depression was also significantly more common in VaD patients (19% vs. 8%) whereas psychotic symptoms were prevalent in both dementias.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Psychiatric symptoms are common in VaD, especially in patients with moderate or severe dementia. Rigorous assessment of psychiatric symptoms in VaD should be part of good clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Neurochemical Pathology Unit, Newcastle General Hospital, Westgate Road, NE4 6BE, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neill</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Ince</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10837878</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(99)00057-9</ArticleId><ArticleId IdType="pii">S0165-0327(99)00057-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22034243</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1294-8322</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Dialogues in clinical neuroscience</Title><ISOAbbreviation>Dialogues Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>155</EndPage><MedlinePgn>139-55</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease typically presents with two often overlapping syndromes, one cognitive, the other behavioral. The behavioral syndrome is characterized by psychosis, aggression, depression, anxiety, agitation, and other common if less well-defined symptoms subsumed under the umbrella entity "behavioral and psychological symptoms of dementia" (BPSD), itself divided into a number of subsyndromes: psychosis, circadian rhythm (sleepwake) disturbance, depression, anxiety, and agitation, it is BPSD with its impact on care providers that ultimately precipitates the chain of events resulting in long-term institutional care. The treatment challenge involves eliminating unmet medical needs (undiagnosed hip fracture and asymptomatic urinary tract infection or pneumonia). Pharmacologic intervention relies on risperidone and, increasingly cholinesterase inhibitors for the control of psychosis (but with response rates of only 65% at tolerable doses), olanzapine and risperidone for anxiety, and carbamazepine and valproic acid for agitation. However, evidence increasingly favors nonpharmacologic interventions, to the extent that these should now be considered as the foundation of BPSD treatment. Problem behaviors are viewed as meaningful responses to unmet needs in the therapeutic milieu. Because the progression and impact of BPSD varies between patients, interventions must be explored, designed, implemented, and assessed on an individual basis. They include: family support and education, psychotherapy reality orientation, validation therapy, reminiscence and life review, behavioral interventions, therapeutic activities and creative arts therapies, environmental considerations (including restraint-free facilities), behavioral intensive care units, and workplace design and practices that aid the ongoing management of professional caregiver stress.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>E Mintzer</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F Mirski</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>S Hoernig</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dialogues Clin Neurosci</MedlineTA><NlmUniqueID>101238198</NlmUniqueID><ISSNLinking>1294-8322</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La Enfermedad de Alzheimer se presenta &#xfa;picamente como dos s&#xed;ndromes que se sobreponen, uno cognitivo y otro conductual. El s&#xed;ndrome conductual se caracteriza por psicosis, agresividad, depresi&#xf3;n, ansiedad, agitaci&#xf3;n y otros s&#xed;ntomas frecuentes, -pero no bien definidos- que se agrupan bajo la denominaci&#xf3;n gen&#xe9;rica de &#x201c;s&#xed;ntomas conductuales y psicol&#xf3;gicos de la demencia&#x201d; (SCPD). Este s&#xed;ndrome se divide a su vez en varios subs&#xed;ndromes: psicosis, trastornos del ritmo circadiano (sue&#xf1;o-vigilia), depresi&#xf3;n, ansiedad y agitaci&#xf3;n. Son los SCPD los que afectan a los cuidadores de estos pacientes y en definitiva los que precipitan la cadena de acontecimientos que llevan muchas veces a tener que hospitalizar al paciente en alguna instituci&#xf3;n por tiempo prolongado. El desaf&#xed;o terap&#xe9;utico consiste en eliminar las posibles causas m&#xe9;dicas ocultas (fractura de cadera no diagnosticada, infecci&#xf3;n urinaria asintom&#xe1;tica o una neumon&#xed;a). Las intervenciones farmacol&#xf3;gicas incluyen la risperidona y -cada vez con mayor frectuencia- los inhibidores de la colinesterasa para el control de la psicosis (aunque la frecuencia de respuesta favorable es de s&#xf3;lo un 65% con dosis tolerable); olanzapina, risperidona y citalopram para la ansiedad y, carbamazepina y &#xe1;cido valproico para la agitaci&#xf3;n. Sin embargo, existen evidencias crecientes a favor de intervenciones no farmacol&#xf3;gicas, las que podr&#xed;an llegar a ser cons&#xed;deradas como la base del tratamiento de los SCPD. Los trastornos de conducta pueden ser enfocados como respuestas significativas a necesidades insatisfechas en el medio terap&#xe9;utico. Ya que la progresi&#xf3;n e impacto de los SCPD var&#xed;an entre los paciantes, las intervenciones deben ser exploradas, dise&#xf1;adas, implementadas y evaluadas en forma individual. Estas intervenciones incluyen soporte y educaci&#xf3;n familiar, psicoterapia, orientaci&#xf3;n a la realidad, terapia de validaci&#xf3;n, recuerdos y revisi&#xf3;n de la vida, intervenciones conductuales, actividades terap&#xe9;uticas y terapias art&#xed;sticas creativas, consideraciones ambientales (incluyendo espacios de libre desplazamiento), unidades de cuidados intensivos conductuales y, dise&#xf1;o de lugares de trabajo y pr&#xe1;cticas que ayuden a los cuidadores profesionales al manejo continuo del estr&#xe9;s.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="fre"><AbstractText>La maladie d'Alzheimer se manifeste typiquement par deux syndromes fr&#xe9;quemment imbriqu&#xe9;s, l'un cognitif, l'autre comportemental. Le syndrome comportemental associe psychose, agressivit&#xe9;, d&#xe9;pression, anxi&#xe9;t&#xe9;, agitation ainsi que d'autres sympt&#xf4;mes fr&#xe9;quents quoique moins bien d&#xe9;finis. L'ensemble de ces manifestations est regroup&#xe9; sous l'entit&#xe9; g&#xe9;n&#xe9;rale &#xab;sympt&#xf4;mes comportementaux et psychologiques de d&#xe9;mence&#xbb; (SCPD), elle-m&#xea;me divis&#xe9;e en plusieurs sous-syndromes: psychose, troubles du rythme circadien (veille-sommeil), d&#xe9;pression, anxi&#xe9;t&#xe9; et agitation. C'est le SCPD, avec son retentissement sur les personnes prenant en charge ces patients, qui pr&#xe9;cipite la succession des &#xe9;v&#xe9;nements aboutissant &#xe0; l'hospitalisation en long s&#xe9;jour. Toute la difficult&#xe9; th&#xe9;rapeutique consiste &#xe0; traiter les situations rest&#xe9;es sans m&#xe9;dicalisation, telles une fracture de hanche non diagnostiqu&#xe9;e ou une infection urinaire ou une pneumonie asymptomatiques). Le traitement pharmacologique de la psychose repose sur la risp&#xe9;ridone et, de plus en plus, sur les inhibiteurs de la cholinest&#xe9;rase (mais avec un taux de r&#xe9;ponses de 65% seulement aux doses tol&#xe9;r&#xe9;es), tandis que l'anxi&#xe9;t&#xe9; est trait&#xe9;e par l'olanzapine, la risp&#xe9;ridone et le citalopram, et l'agitation par la carbamaz&#xe9;pine et l'acide valpro&#xef;que. N&#xe9;anmoins, de plus en plus d'arguments militent en faveur de l'approche non pharmacologique, au point que celle-ci doit d&#xe9;sormais &#xea;tre consid&#xe9;r&#xe9;e comme le traitement de fond du SCPD. Les troubles du comportement sont consid&#xe9;r&#xe9;s comme des r&#xe9;ponses significatives &#xe0; des besoins insatisfaits par la prise en charge th&#xe9;rapeutique. Comme l'&#xe9;volution et l'impact du SCPD varient selon les patients, les mesures &#xe0; prendre doivent &#xea;tre examin&#xe9;es, choisies, appliqu&#xe9;es et &#xe9;valu&#xe9;es de fa&#xe7;on individuelle. Celles-ci comprennent: le soutien familial et l'&#xe9;ducation, la psychoth&#xe9;rapie, l'orientation par rapport &#xe0; la r&#xe9;alit&#xe9;, la th&#xe9;rapie par validation, l'&#xe9;vocation de la vie ant&#xe9;rieure et des r&#xe9;miniscences, les th&#xe9;rapies comportementales, les activit&#xe9;s th&#xe9;rapeutiques et l'art-th&#xe9;rapie, l'am&#xe9;nagement de l'environnement (y compris des &#xe9;quipements qui ne doivent plus recourir aux entraves physiques), le d&#xe9;veloppement d'unit&#xe9;s de soins intensifs du comportement, et l'adaptation du lieu de travail, sans oublier les mesures visant &#xe0; faciliter la prise en charge continue du stress des professionnels de sant&#xe9;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">behavioral and psychological symptoms of dementia</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">nonpharmacological treatment</Keyword><Keyword MajorTopicYN="N">pharmacological treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22034243</ArticleId><ArticleId IdType="pmc">PMC3181597</ArticleId><ArticleId IdType="doi">10.31887/DCNS.2000.2.2/jmintzer</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blume L., Persely N., Mintzer J. The Prevalence of Dementia: The Confusion of Numbers. Am J Alzheimer Care Relat Disord Res. 1992;May/June:3&#x2013;18.</Citation></Reference><Reference><Citation>Eisdorfer C., Cohen D., Paveza GJ., et al. An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's Disease. AmJ Psychiatry. 1992;140:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734738</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association. 1994:84.</Citation></Reference><Reference><Citation>American Psychiatric Association. . Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association. 1994:85&#x2013;87.</Citation></Reference><Reference><Citation>Reisberg B., Auer SR., Monteiro IM. Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Rating Scale. Int Psychogeriatr. 1996;8(suppl 3):301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH., Todd PA., Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist. 1986;26:260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">3721233</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association. 1994</Citation></Reference><Reference><Citation>Cohen-Mansfield J., Billing N. Agitated behaviors in the elderly: 1 . A conceptual review. J Am Geriatr Soc. 1986;34:711&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J., Marx MS., Rosenthal AS. A description of agitation in a nursing home. J Gerontol Med Sci. 1989;44:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel, Sl., guest ed. Int Psychogeriatr. 1996;8(suppl 3):215&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI. Introduction, New focus on behavioral and psychological signs and symptoms of dementia. Int Psychogeriatr. 1996;8(suppl 3):215&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel, SI., Silva JC., Cohen G., et al. Consensus Statement: Behavioral and Psychological Signs and Symptoms of Dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(suppl 3):497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS., Moossy J., Marinez AJ., et al. Neuropathological and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko, GS. Etiology: clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia. Int Psychogeriatr. 1996;8(suppl3):219&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154567</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV. Behavioral disturbances of dementia: practical and conceptual issues, int Psychogeriatr. 1996;8(suppl 3):281&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirmiran M., Swaab DF., Kok JH., et al. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. In: Swaab DF, Hofman MA, Mirmiran M, Ravid R, Van Leeuwen FW, eds. . Progress in Brain Research. Amsterdam, The Netherlands: Elsevier. 1992:151&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">1480747</ArticleId></ArticleIdList></Reference><Reference><Citation>Swabb DF., Fliers E., Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985;342:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">4041816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubekno GS., Moossy J., Marinez AJ., et al. Neuropathological and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottfries CG., Frederiksen SO., Heilig M. Neuropeptides in Alzheimer's disease. Eur Neuropsychopharmacol. 1995;5:491&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">8998402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P., Gaile SE., Castelli NA., Porsteinsson AP. Treatment of agitation in dementia. New Dir Ment Health Serv. 1997;76:109&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanford Fl., ed. Behavioral and Psychological Symptoms of Dementia. International Psychogeriatric Association Educational Pack. Macclesfield, UK: Gardiner-Caldwell Communications. 1998</Citation></Reference><Reference><Citation>Viteollo MV., Prniz PN., Williams DE., et al. Sleep disturbances in patients with mild-stage Alzheimer's disease. J Gerontol. 1990;45:M131&#x2013;M138.</Citation><ArticleIdList><ArticleId IdType="pubmed">2365965</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppe G., Sandholzer H., Staedt J., et al. Sleep disturbance in demented elderly: treatment in ambulatory care. Sleep. 1995;18:844&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">8746390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebok GW., Rovner BW., Folstein MR. Sleep disturbance in Alzheimer's disease: relationship to behavioral problems. Aging. 1991;3:193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">1911909</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CF., Hoch CC., Stack J., Campbell D. The nature and management of sleep/wake disturbances in Alzheimer's dementia. Psychopharmacol Bull. 1988;24:43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">3290948</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting W., Kwa IH., Eikelenboom P., et al. Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry. 1990;27:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">2322616</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire MH., Rabins PV. Mood disorders. In: Coffey CE, Cummings JL, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press. 1994;chap 12:246&#x2013;260.</Citation></Reference><Reference><Citation>Greenwald BS., Kramer-Ginsberg E., Marin DB., et al. Dementia with coexistent major depression. Ami J Psychiatry. 1989;146:1472&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">2817121</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS., Abrams RC., Young RC., et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T., Alterman IS., Yount D., et al. A new scale for the assessment of depressed mood in demented patients. Am J Psychiatry. 1988;145:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">3394879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS. Clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia. Int Psychogeriatr. 1996;8 (suppl3):219&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemerinski E., Petracca G., Manes F., Leiguarda R., Starkstein SE. Prevalence and correlates of anxiety in Alzheimer's disease. Depress Anxiety. 1998;7:166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">9706453</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS., Silver JM., Kahn DA., et al. A Special Report: The Expert Consensus Guideline Series/Treatment of Agitation in Older Persons with Dementia. Postgrad Med. 1998 Apr;:1&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP., Marder K., Michaels KS., et al. A randomized, placebocontrolled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV., Lacro JP., Bailey A., et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10366172</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR., Jeste DV., Mintzer JE., et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP., Rasmussen A., Bocksberger JP., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS., Clark WS., Gannon K., et al. Olanzapine in the treatment of psychosis and behavioral disturbances assocaited with Alzheimer's disease. American Psychiatric Association Meeting, Washington DC, May 15-20, 1999. Poster NR562</Citation></Reference><Reference><Citation>Knopman D., Schneider LS., Davis K., et al. Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality. The Tacrine Study Group. Neurology. 1996;47:166&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710072</ArticleId></ArticleIdList></Reference><Reference><Citation>Thai LJ., Ferguson JM., Mintzer JE., et al. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999;52:1146&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10214735</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL., Gorman DG., Shapiro J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993;33:536&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P. Treatment of agitation in dementia. J Clin Psychiatry. 1999;60(suppl 18):11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10335667</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark WS., Street J., Sanger T., et al. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease. 12th Congress of the European College of Neuropsychopharmacology, London, UK, September 21-25, 1999. Poster</Citation></Reference><Reference><Citation>Ancoli-lsrael S., Kripke DF. Now I lay me down to sleep: the problem of sleep fragmentation in elderly and demented residents of nursing homes. Bull CiinNeurosci. 1989;1154:127&#x2013;132.</Citation></Reference><Reference><Citation>Satlin A., Volicer L., Ross V., et al. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry. 1992;149:1028&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">1353313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell BB., Ancoli-lsrael S., Gevirtz R. Effect of bright light treatment on agitated behavior in institutionalized elderly subjects. Psychiatr Res. 1995;57:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7568561</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Someren EJW., Kessler A., Mirmiran M., et al. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry. 1997;41:955&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110101</ArticleId></ArticleIdList></Reference><Reference><Citation>Colenda CC., Cohen W., McCall WV., et al. Phototherapy for patients with Alzheimer disease with disturbed sleep patterns: results of a communitybased pilot study. Alzheimer Dis Assoc Disord. 1997;11:175&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305504</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovici A., Tariot PN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol. 1988;1:110&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">3252879</ArticleId></ArticleIdList></Reference><Reference><Citation>Risse SC., Barnes R. Pharmacological treatment of agitation associated with dementia. J Am Geriatr Soc. 1986;34:368&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">2870097</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister TW. Carbamazepine in mixed frontal lobe and psychiatric disorders. J Clin Psychiatry. 1985;46:393&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">4030704</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovici A., Tariot PN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol. 1988;1:110&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">3252879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleason RP., Schneider LS. Carbamazepine treatment for agitation in Alzheimer's out-patients refractory to neuroleptics. J Clin Psychiatry. 1990;51:115&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">1968457</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics. 1987;28:579&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">3432521</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol. 1988;1:21&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">3252875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers CA., Bain J., Rosbottom R., et al. Carbamazepine in senile dementia and in overactivity: a placebo-controlled double-blind trial. IPCS Med Sci. 1982;10:505&#x2013;506.</Citation></Reference><Reference><Citation>Tariot PN., Erb R., Leibovici A., et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">7963202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott AD., McElroy SL., Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Neurol. 1995;7:314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">7580190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellow AM., Solano-Lopez C., Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol. 1993;6:205&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">8251047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS., Pollock VE., Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS., Sobin PB. Non-neuroleptic treatement of behavorial symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacol Bull. 1992;28:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">1351687</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal A. Pharmacologic treatment of behavioral symptoms of Alzheimer's dementia - a review and a possible strategy. Clin Gerontol. 1995;16:3&#x2013;16.</Citation></Reference><Reference><Citation>Saver JL., Salloway SP., Devinsky O., et al. Neuropsychiatry of aggression. In: Fogel BS, Schiffer RB, eds. Neuropsychiatry. Baltimore, Md: Williams &amp; Wilkins. 1996:523&#x2013;548.</Citation></Reference><Reference><Citation>Freud S. On Psychotherapy. In: Collected Papers, Vol 1. London, UK: Hogarth Press. 1924:249&#x2013;263.</Citation></Reference><Reference><Citation>Teri L., Logsdon RG. The future of psychotherapy with older adults. Psychotherapy. 1992;29:81&#x2013;87.</Citation></Reference><Reference><Citation>Engle-Friedman M., Bootzin RR. Insomnia as a problem for the elderly. In: Wisocki PA, ed. Handbook of Clinical Behavioral Therapy with the Elderly Client. New York, NY: Plenum. 1991:273&#x2013;298.</Citation></Reference><Reference><Citation>Fisher JE., Carstensen LL. Behavior management of the dementias. Clin Psychol Rev. 1990;10:611&#x2013;629.</Citation></Reference><Reference><Citation>Hersen M., van Hasselt VB. Behavioral assessment and treatment of anxiety in the elderly. Clin Psychol Rev. 1992;12:619&#x2013;640.</Citation></Reference><Reference><Citation>Thornton S., Brotchie J. Reminiscence: a critical review of the empirical literature. Br J Clin Psychol. 1987;26:93&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">3555663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J., Billing N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986;34:711&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch LH., Rovner BW. Agitation and other non-cognitive abnormalities in Alzheimer's disease. Psychiatr Clin North Am. 1991;14:341&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">1676506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlin N., Mullan JT., Semple SJ., Skaff MM. Caregiving and the stress process: an overview of concepts and their measures. Gerontologist. 1990;30:583&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">2276631</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz R., Visintainer R., Williamson GM. Psychiatric and physical morbidity effects of caregiving. J Gerontol Psychol Sci. 1990;45:181&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">2144310</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz R., O'Brien A., Bookwala J., et al. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist. 1995;35:771&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH., Teri L., Thompson LW., Gallagher D. Interventions and services for family caregivers; Depression and its treatment in the elderly. Ann Rev Gerontol Geriatr. Aging. 1991; 1985;11; 348:241, 14&#x2013;265.</Citation></Reference><Reference><Citation>Greene VL., Monahan DJ. The effect of a support and educational program on stress and burden among family caregivers to frail elderly persons. Gerontologist. 1989;29:472&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">2521105</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery JV., Karner TX. Strategies for the Future. . White Paper for Respite Care Issues Forum. Chicago, III: Alzheimer's Association; 1996:10&#x2013;13.</Citation></Reference><Reference><Citation>Thompson LW., Gallagher D. Efficacy of psychotherapy in the treatment of late-life depression. Adv Behav Res Ther. 1984;6:127&#x2013;139.</Citation></Reference><Reference><Citation>Thompson LW., Gallagher D. Psychotherapy for late-life depression. Generations. 1986;10:38&#x2013;41.</Citation></Reference><Reference><Citation>Thompson LW., Gallagher D., Breckenridge JS. Comparative effectiveness of psychotherapies for depressed elders. J Consult Clin Psychol. 1987;55:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">3597953</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LW., Gallagher-Thompson D., Hanser S., et al. Treatment of late-life depression with cognitive/behavioral therapy or desipramine. Poster presented at the annual meeting of the American Psychological Association, San Francisco, Cal; August 1991</Citation></Reference><Reference><Citation>Feil N. The Validation Breakthrough. Baltimore, Md: Health Professionals Press Inc. 1993</Citation></Reference><Reference><Citation>Butler RN. The life review: an interpretation of reminiscence in the aged. Psychiatry. 1963;26:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">14017386</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L., McCurry SM. Psychological therapies. In: Coffey CE, Cummings JL, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press. 1994:662&#x2013;682.</Citation></Reference><Reference><Citation>Bennett SL., Maas F. The effect of music-based life review on the life satisfaction and integrity of elderly people. Br J Occup Ther. 1988;51:433&#x2013;436.</Citation></Reference><Reference><Citation>Berghorn FJ., Schafer DE. Reminiscence intervention in nursing homes: what and who changes? Int J Aging Hum Dev. 1987;24:113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">3557649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fielden MA. Reminiscence as a therapeutic intervention with sheltered housing residents: a comparative study. Br J Soc Work. 1990;20:21&#x2013;44.</Citation></Reference><Reference><Citation>Lappe JM. Reminiscing: the life review therapy. J Gerontol Nurs. 1987;13:12&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">3646281</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt LM., Wong PT. A taxonomy of reminiscence and therapeutic implications. J Gerontol Soc Work. 1991;16:37&#x2013;57.</Citation></Reference><Reference><Citation>Youssef FA. The impact of group reminiscence counseling on a depressed elderly population. Nurse Pract. 1990;15:32,35&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury N. Problems of elderly people. In: Dryden W, Rentoul R, eds. Adult Clinical Problems: A Cognitive Behavioral Approach. London, UK: Routledge. 1991:203&#x2013;231.</Citation></Reference><Reference><Citation>Norris A. Reminiscence With Elderly People.London, UK: Winslow Press; 1986</Citation></Reference><Reference><Citation>Goldwasser AN., Auerbach SM., Harkins SW. Cognitive, affective, and behavioral effects of reminiscence group therapy on demented elderly. Int J Aging Hum Dev. 1987;25:209&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">3429043</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn NJ. The music therapy assessment tool in Alzheimer's patients. J Gerontol Nurs. 1992;18:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1740613</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J., Werner P., Marx MS. Screaming in nursing home residents. J Am Geriatr Soc. 1990;38:785&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">2370397</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS., Sawyer-DeMaris S. Practical approaches to managing behavioral problems in dementia patients. Geriatrics. 1990;45:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">1969376</ArticleId></ArticleIdList></Reference><Reference><Citation>Whall AL., Gillis GL., Yankou D., et al. Disruptive behavior in elderly nursing home staff. J Gerontol Nurs. 1992;18:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">1479153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunderson JG. Defining the therapeutic processes in psychiatric milieus. Psychiatry. 1978;41:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">715093</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisdorfer C., Cohen D., Paveza GJ., et al. An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's disease. Am J Psychiatry. 1992;140:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734738</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume L., Persely N., Mintzer J. The prevalence of dementia: the confusion of numbers. numbers. Am J Alzheimer Care Relat Disord Res. 1992 May-Jun;:3&#x2013;18.</Citation></Reference><Reference><Citation>Mintzer JE., Lewis L., Pennypaker L., et al. Behavioral intensive care unit (BICU): a new concept in the management of acute agitated behavior in elderly demented patients. Gerontologist. 1993;33:801&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairman J. Watchful vigilance: nursing care, technology, and the development of intensive care units. Nurs Res. 1992;41:56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738618</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragsted L. Outcome from intensive care. A five-year study of 1,308 patients. Dan Med Bull. 1991;38:365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">1914535</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein The effect of brain damage on the personality. Psychiatry. 1952;15:245&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12983441</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle N. The use of physical restraints in nursing home: pre- and postNursing Home Reform Act. J Health Soc Policy. 1998;9:71&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10174385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lach HW., Reed AT., Arfken CL., et al. Falls in the elderly: reliability of a classification system. J Am Geriatr Soc. 1991;39:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">1991951</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LK., Strumpf NE. Myths about elder restraint. Image J Nurs Sch. 1990;22:124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">2365389</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakeslee JA., Goldman BD., Papougenis D., Torell CA. Making the transition to restraint-free care. J Gerontol Nurs. 1991;17:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1902243</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper, CM., Lyles YM. Physiology and complications of bed rest. J Am Geriatr Soc. 1986;36:1047&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">3049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MB. Iatrogenic and nursigenic effects of prolonged mobilization of the ill aged. J Am Geriatr Soc. 1975;23:360&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">1151033</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery JV., Karner TX. Strategies for the Future. Wihite Paper for Respite Care Issues Forum. Chicago, III: Alzheimer's Association. 1996:10&#x2013;13.</Citation></Reference><Reference><Citation>Lach HW. Use of physical restraints and options. In: Szwabo PA, Grossberg GT, eds. Problem Behaviors in Long-term Care. New York, NY: Springer Publishing Company. 1993:176&#x2013;187.</Citation></Reference><Reference><Citation>Office of Technology Assessment. Special Care Units for Persons With Dementia. Washington, DC: Congress of the United States, Office of Technology Assessment. 1992</Citation></Reference><Reference><Citation>Hare J., Pratt CC. Burnout: differences between professional and paraprofessional nursing staff in acute and long-term care health facilities. J Appl Gerontol. 1988;7:60&#x2013;72.</Citation></Reference><Reference><Citation>Alzheimer's Association. Alzheimer special care in nursing homes: is it really special? A survey of families and professional advocates. Chicago, III: Alzheimer's Association; 1994 Jul</Citation></Reference><Reference><Citation>Heine C. Burnout among nursing home personnel. J Gerontol Nurs. 1986;12:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">3633940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM., Cummings JL. Metrifonate: update on a newantidementia agent. J Clin Psychiatry. 1999;60:776&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">10584768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman KA. Day care for persons with dementia: The impact of the physical environment on staff stress and quality care. Gerontologist. 1989;29:557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">2521118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman KA. Staff stress and treatment of clients in Alzheimer's care: a comparison of medical and nonmedical day care programs. J Aging Studies. 1990;4:61&#x2013;79.</Citation></Reference><Reference><Citation>Maslach C. Burnout-The Cost of Caring. New York.NY: Prentice-Hall. 1982</Citation></Reference><Reference><Citation>Solomon K., Vickers R. Attitudes of health care workers toward old people. J Am Geriatr Soc. 1979;27:186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">429739</ArticleId></ArticleIdList></Reference><Reference><Citation>Szwabob PA., Stein AL. Professional caregiver stress in long term care. In: Szwabob PA, Grossberg GT, eds. Problem Behaviors in Long-Term Care: Recognition, Diagnosis, and Treatment. New York, NY: Springer. 1993</Citation></Reference><Reference><Citation>Benson H. The Relaxation Response. New York, NY: William Morrow. 1975</Citation></Reference><Reference><Citation>Fields HL., Basbaum AI. Endogenous pain control mechanisms. In: Wall PD, Melzack R, eds. Textbook of Pain. Edinburgh, UK: Churchill Livingstone. 1989:206&#x2013;217.</Citation></Reference><Reference><Citation>Moos RH., Schaefer JA. Evaluating health care work settings: a holistic conceptual framework. Psychol Health. 1987;1:97&#x2013;122.</Citation></Reference><Reference><Citation>Lyman K., Pynoos J., Cohen E. Occupational stress and workplace design: evaluating the physical environment of Alzheimer's day care</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10822438</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Incidence of and risk factors for hallucinations and delusions in patients with probable AD.</ArticleTitle><Pagination><StartPage>1965</StartPage><EndPage>1971</EndPage><MedlinePgn>1965-71</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the incidence of and risk factors for hallucinations and delusions associated with patients clinically diagnosed with probable AD.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Estimates of the incidence of psychosis in AD range widely from 10% to 75%. The risk factors for psychosis of AD are not known, although multiple studies indicate that AD patients with psychosis demonstrate greater cognitive and functional impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors conducted psychiatric evaluations of 329 patients with probable AD from the University of California at San Diego Alzheimer's Disease Research Center to determine the incidence of hallucinations and delusions. They examined data from annual clinical and neuropsychological evaluations to determine whether there were specific risk factors for the development of hallucinations and delusions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using Cox survival analyses, the cumulative incidence of hallucinations and delusions was 20.1% at 1 year, 36.1% at 2, 49.5% at 3, and 51.3% at 4 years. Parkinsonian gait, bradyphrenia, exaggerated general cognitive decline, and exaggerated semantic memory decline were significant predictors. Age, education, and gender were not significant predictors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The authors found a relatively high incidence of hallucinations and delusions in patients diagnosed with probable AD and suggest that specific neurologic signs, cognitive abilities, and accelerated decline may be predictive markers for their occurrence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paulsen</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, University of Iowa, Iowa City 52242-1057, USA. jane-paulsen@uiowa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Weisstein-Jenkins</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hofstetter</LastName><ForeName>C R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05561</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12963</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2000 Oct 24;55(8):1240-1. doi: 10.1212/wnl.55.8.1240</RefSource><PMID Version="1">11071517</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.10.1965</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10822339</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-4184</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Do susceptibility loci contribute to the expression of more than one mental disorder? A view from the genetics of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>136</EndPage><MedlinePgn>131-6</MedlinePgn></Pagination><Abstract><AbstractText>The susceptibility of developing most major psychiatric disorders is determined in part by contributions from risk alleles at multiple genetic loci. The central aim of this article is to highlight evidence from studies of neurodegenerative disorders suggesting that some of these alleles are shared by more than one psychiatric disorder, and to explore mechanisms that may underly these pleiotropic effects. The identification of constellations of susceptibility alleles associated with particular mental disorders will provide opportunities for new insights into the molecular and cellular pathophysiology of these disorders, and will have a major impact on psychiatric research and clinical care. This approach to reducing the variance in etiopathogenesis is also likely to be important for achieving the optimal use of available treatments (maximizing effectiveness and minimizing side effects), and for the discovery of novel medications or other interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zubenko</LastName><ForeName>G S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH/AG47346</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH45968</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10822339</ArticleId><ArticleId IdType="doi">10.1038/sj.mp.4000713</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10814772</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Depression in the carers of dementia sufferers: a comparison of the carers of patients suffering from dementia with Lewy bodies and the carers of patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>61</StartPage><EndPage>65</EndPage><MedlinePgn>61-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depression has not previously been studied in the carers of patients suffering from dementia with Lewy Bodies (DLB).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Twenty-five DLB carers were matched with 75 AD carers, according to carer characteristics. A standardised assessment incorporated measures of cognition, depression, psychosis and behavioural disturbance. DLB (consensus criteria), and AD (NINCDS ADRDA criteria) were diagnosed using operationalised clinical criteria. Carer depression was diagnosed using the Research Diagnostic Criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall frequency of depression was similar in DLB and AD carers (28% vs. 31%). DLB carers were significantly more likely to experience a major depressive disorder (3/25 - 12% vs. 0/75 - 0% chi(2)=9.3, P=0.002, df 1), although the numbers were small. The severity of behavioural disturbance was associated with carer depression in the DLB carers and in the total sample.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The severity of behavioural disturbance was significantly associated with depression in DLB carers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lowery</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for the Health of the Elderly, Newcastle, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mynt</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Aisbett</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10814772</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(99)00123-8</ArticleId><ArticleId IdType="pii">S0165-0327(99)00123-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10811243</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61 Suppl 8</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Side effects of antipsychotics in the elderly.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>51</EndPage><MedlinePgn>43-9; discussion 50-1</MedlinePgn></Pagination><Abstract><AbstractText>Side effects of antipsychotic medications are particularly problematic in elderly patients, who experience many age-related changes that may exacerbate medication side effects. Side effects of particular concern in the elderly include anticholinergic reactions, parkinsonian events, tardive dyskinesia, orthostatic hypotension, cardiac conduction disturbances, reduced bone mineral density, sedation, and cognitive slowing. In addition, elderly patients with schizophrenia often have comorbid medical illnesses-such as cardiovascular disease and dementia of the Alzheimer's type-and are thus likely to be taking multiple medications. The effects of polypharmacy must be carefully considered. Patients, caregivers, and family often have different perspectives on side effects. This article addresses the side effects of the currently available antipsychotic medications in light of these concerns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masand</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, State University of New York, Syracuse 13210, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009459" MajorTopicYN="N">Neuroleptic Malignant Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10811243</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10802783</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Predictors of progression in patients with AD and Lewy bodies.</ArticleTitle><Pagination><StartPage>1774</StartPage><EndPage>1779</EndPage><MedlinePgn>1774-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the differences in the pattern of progression between AD and AD with Lewy bodies (AD+LB).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors examined predictors of functional and cognitive disability, institutionalization, and death, as well as time to the development of psychosis (e.g., delusions, hallucinations), extrapyramidal signs (EPS), diurnal hypersomnia, and depression in 185 patients with definite AD and 60 with autopsy-confirmed AD+LB. In addition, they analyzed a selected group of patients who did not have comorbid systemic or CNS disease that may have affected progression of the disease (AD = 98 versus AD+LB = 44). The mean follow-up was 58.91 +/- 35.2 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All cases: Patients with AD+LB had faster time to the development of EPS and diurnal hypersomnia, but not to the development of psychosis or depression. The rate of cognitive and functional decline, time to institutionalization, and physical survival was not different between AD+LB and AD. Selected cases: Patients with AD+LB developed earlier EPS and diurnal hypersomnia than AD patients, and there was a trend to develop earlier major depression, but no differences were noted in time to psychosis. Patients with AD+LB had a faster time to institutionalization than those with AD. The rate of cognitive and functional decline and physical survival was not different between AD+LB and AD in these selected cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with AD+LB can develop EPS and diurnal hypersomnia earlier and have faster time to institutionalization than those with AD alone, but cognitive and functional decline and physical survival are similar between these two entities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer's Disease Research Center, University of Pittsburgh School of Medicine, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-MH-01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007326" MajorTopicYN="N">Institutionalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10802783</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.9.1774</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10785583</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.</ArticleTitle><Pagination><StartPage>249</StartPage><EndPage>259</EndPage><MedlinePgn>249-59</MedlinePgn></Pagination><Abstract><AbstractText>Xanomeline is an M(1)/M(4) preferring muscarinic receptor agonist which decreased psychotic behaviors in patients with Alzheimer's disease, suggesting that xanomeline might be useful in the treatment of psychotic symptoms in patients with schizophrenia. The purpose of the present studies was, therefore, to compare the pharmacologic profile of xanomeline with that of known antipsychotic drugs. Electrophysiologically, xanomeline, after both acute and chronic administration in rats, inhibited A10 but not A9 dopamine cells in a manner which was blocked by the muscarinic receptor antagonist scopolamine. Behaviorally, xanomeline, like haloperidol, clozapine and olanzapine, blocked dopamine agonist-induced turning in unilateral 6-hydroxydopamine-lesioned rats, as well as apomorphine-induced climbing in mice. However, unlike the dopamine antagonist antipsychotic haloperidol, xanomeline did not produce catalepsy in rats. Moreover, xanomeline, like haloperidol, clozapine and olanzapine, inhibited conditioned avoidance responding in rats, an effect which also was blocked by scopolamine. The present results thus demonstrate that xanomeline has a pharmacologic profile which is similar to that of the atypical antipsychotics clozapine and olanzapine, thus indicating that xanomeline has the potential to be a novel approach in the treatment of psychotic symptoms in patients with schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. H.Shannon@Lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>F P</ForeName><Initials>FP</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Swedberg</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Jeppesen</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sheardown</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Sauerberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fink-Jensen</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018679">Cholinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>9ORI6L73CJ</RegistryNumber><NameOfSubstance UI="C075257">xanomeline</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018679" MajorTopicYN="N">Cholinergic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011950" MajorTopicYN="N">Receptors, Cholinergic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013830" MajorTopicYN="N">Thiadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10785583</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(99)00138-3</ArticleId><ArticleId IdType="pii">S0920-9964(99)00138-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10780626</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0894-878X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuropsychiatry, neuropsychology, and behavioral neurology</Title><ISOAbbreviation>Neuropsychiatry Neuropsychol Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>88</EndPage><MedlinePgn>83-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to evaluate symptoms associated with impaired insight in patients with Alzheimer disease (AD).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although unawareness of deficits is common in AD, the relation of awareness to psychiatric and behavioral disturbances has not been extensively studied.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a cross-sectional investigation of 91 patients with probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. Awareness of cognitive and functional deficits was measured with the Inaccurate Insight item from the Neurobehavioral Rating Scale. Psychiatric and behavioral symptoms were measured using factor scores and individual items from the Neurobehavioral Rating Scale. Global cognitive deficits were measured using the Mini-Mental State Examination (MMSE).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Stepwise regression analysis showed that insight was associated with MMSE score, depression/anxiety factor score, and agitation/disinhibition factor score. Variables not associated with awareness of deficits included patient age, behavioral retardation factor score, verbal output disturbance factor score, and psychosis factor score. Post hoc analyses showed a positive relation (i.e., greater insight, more symptomatology) between deficit awareness and symptoms of depressed mood and anxiety. There was a negative relation (i.e., greater insight, less symptomatology) between insight and symptoms of hostility, agitation, inattention, and tension. In a follow-up stepwise regression analysis, increased deficit awareness was associated with a higher MMSE score, greater depressed mood, and decreased agitation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that patients with AD may experience symptoms of depressed mood in relation to increased awareness of decrements in functioning. The data also indicate that patients with poor insight demonstrate greater agitated behavior. Consistent with previous research, impaired insight was higher in the later stages of the illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles School of Medicine, and Veterans Affairs Medical Center, Greater Los Angeles Healthcare System, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH00910</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH56031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychiatry Neuropsychol Behav Neurol</MedlineTA><NlmUniqueID>8811108</NlmUniqueID><ISSNLinking>0894-878X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015141" MajorTopicYN="N" Type="Geographic">Los Angeles</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10780626</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10771760</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1592-7830</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Giornale italiano di medicina del lavoro ed ergonomia</Title><ISOAbbreviation>G Ital Med Lav Ergon</ISOAbbreviation></Journal><ArticleTitle>[Occupational poisoning with psychiatric manifestations].</ArticleTitle><Pagination><StartPage>52</StartPage><EndPage>63</EndPage><MedlinePgn>52-61; discussion 62-3</MedlinePgn></Pagination><Abstract><AbstractText>Numerous occupational intoxications (acute, chronic and their sequelae) may affect the central nervous system and result in a wide variety of neuropsychiatric effects, ranging from subtle behavioural disturbances to overt psychosis. Chemicals causing such manifestations include many metals and organometals (Hg, Mn, Pb, Al, Sn), pesticides (organophosphates), compounds utilised in the industrial setting as solvents or intermediates (carbon disulfide, hydrocarbons and their halogenated derivatives), and combustion products (carbon monoxide). Some types of toxic insults may not be reflected in any clinical manifestation. However, this type of damage may render the brain more vulnerable to additional insult or accelerate physiological loss of neurones with ageing. Thus, occupational exposures to chemicals (Al, Pb, organic solvents) might be involved in the causation of neurodegenerative diseases--such as Alzheimer's disease--which are usually labelled as "idiopathic". A careful occupational anamnesis is crucial to diagnose work-related psychiatric manifestations and--consequently--to interrupt the toxic exposure, to start therapy, and to promote insurance compensation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Candura</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Dipartimento di Medicina Preventiva, Universit&#xe0; degli Studi di Pavia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butera</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gandini</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tagliani</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fasola</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Manzo</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>ita</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Intossicazioni professionali con manifestazioni psichiatriche.</VernacularTitle></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>G Ital Med Lav Ergon</MedlineTA><NlmUniqueID>9712708</NlmUniqueID><ISSNLinking>1592-7830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007306">Insecticides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>7440-31-5</RegistryNumber><NameOfSubstance UI="D014001">Tin</NameOfSubstance></Chemical><Chemical><RegistryNumber>CPD4NFA903</RegistryNumber><NameOfSubstance UI="D000535">Aluminum</NameOfSubstance></Chemical><Chemical><RegistryNumber>S54S8B99E8</RegistryNumber><NameOfSubstance UI="D002246">Carbon Disulfide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000535" MajorTopicYN="N">Aluminum</DescriptorName><QualifierName UI="Q000506" MajorTopicYN="N">poisoning</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002246" MajorTopicYN="N">Carbon Disulfide</DescriptorName><QualifierName UI="Q000506" MajorTopicYN="N">poisoning</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002249" MajorTopicYN="N">Carbon Monoxide Poisoning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007306" MajorTopicYN="N">Insecticides</DescriptorName><QualifierName UI="Q000506" MajorTopicYN="N">poisoning</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007855" MajorTopicYN="N">Lead Poisoning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020149" MajorTopicYN="N">Manganese Poisoning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008630" MajorTopicYN="N">Mercury Poisoning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009784" MajorTopicYN="N">Occupational Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014001" MajorTopicYN="N">Tin</DescriptorName><QualifierName UI="Q000506" MajorTopicYN="N">poisoning</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>134</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10771760</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10739328</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61 Suppl 4</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tardive dyskinesia in older patients.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>32</EndPage><MedlinePgn>27-32</MedlinePgn></Pagination><Abstract><AbstractText>Neuroleptic-induced tardive dyskinesia, which often appears in middle-aged and older adults early in the course of treatment with low doses of conventional antipsychotics, is 5 to 6 times more prevalent in elderly than in younger patients. In addition to age, other risk factors for tardive dyskinesia include early extrapyramidal symptoms (EPS), cumulative amounts of neuroleptics, duration of neuroleptic treatment, and history of alcohol abuse and/or dependence. The atypical antipsychotics, which have a low liability for EPS, are likely to also have low potential for tardive dyskinesia, despite the paucity of controlled studies. Starting and maintenance doses of the atypical antipsychotics should generally be lower in older than in younger adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, USA. djeste@ucsd.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10739328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10730061</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0213-4853</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurologia (Barcelona, Spain)</Title><ISOAbbreviation>Neurologia</ISOAbbreviation></Journal><ArticleTitle>[Psychotic symptoms and Alzheimer's disease].</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>14</EndPage><MedlinePgn>8-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotic symptoms appear during the course of Alzheimer's disease, but their frequency and intensity vary according to different studies and their nature remains unsettled.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To study the frequency and intensity of psychotic symptoms in two transversal series of patients with Alzheimer's disease and analyze its relationship with the duration of the disease and severity of cognitive impairment.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This study has been carried out in patients suffering from probable Alzheimer's disease (NINDS-ADRDA criteria). The stage of the disease was determined according to FAST, and the intensity of cognitive impairment in Mini Mental State Examination was classified as mild, moderate or severe. Frequency and intensity of psychotic symptoms (delusions, hallucinations and misidentifications) were determined by means of semistructured interviews (BEHAVE-AD 78 patients and CUSPAD 69 patients). The results obtained in these three groups of patients were compared through ANOVA variance analysis and mean contrast. Variance and covariance analysis were done to determine the relationship between psychotic symptoms and other variables (degree of cognitive impairment, length of evolution and stage of the disease). For this purpose, the patients with Alzheimer's disease but without psychotic symptoms were considered as control and compared to patients with psychotic symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nearly half the patients had psychotic symptoms. Delusions appeared earlier and were more frequent than hallucinations and misinterpretations. The more severe was the cognitive impairment, the more frequent and intense were psychotic symptoms, but the difference was significant only in cases with severe cognitive impairment. Hallucinations appeared mainly in patients with advanced dementia and were related firstly with the intensity of functional and cognitive impairment and secondly with the duration of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mild psychotic symptoms, especially delusions, appear early during the course of Alzheimer's disease. The frequency and intensity of these symptoms increase in parallel with the functional and cognitive impairments caused by the disease. Hallucinations, which appear mainly when the dementia is severe, can be considered as an evolutive marker of the process. Psychotic symptoms differ from those occurring in other disorders, either neurologic or psychiatric in nature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alberca</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital Universitario Virgen del Roc&#xed;o, Sevilla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-N&#xe9;ciga</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ntomas psic&#xf3;ticos y enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurologia</MedlineTA><NlmUniqueID>9005460</NlmUniqueID><ISSNLinking>0213-4853</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10730061</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10696656</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0210-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>9</Issue><PubDate><MedlineDate>1999 Nov 1-15</MedlineDate></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Treatment for non-cognitive symptoms in Alzheimer's disease].</ArticleTitle><Pagination><StartPage>819</StartPage><EndPage>824</EndPage><MedlinePgn>819-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To review the classical treatment for non cognitive symptoms in Alzheimer's disease and to estimate the possible future contributions.</AbstractText><AbstractText Label="DEVELOPMENT" NlmCategory="METHODS">The non cognitive symptoms, with a high frequency in dementia, mean a larger clinical severity, an increment of institutionalization and a larger carer's emotional burden. Several treatment frequently used has been reviewed (antipsychotic, antidepressant, antianxiety, anticonvulsive...) and the response for some of this symptoms is relatively narrow and side effects are frequent and intense. New drugs, as cholinesterase inhibitors and cholinergic agonist, that have demonstrated their efficacy for the cognitive symptoms, seem to be also effective for non cognitive ones.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The relative low effectivity of classical treatment and the frequency and intensity of side effects open new possibilities to cholinesterase inhibitors in the treatment of non cognitive symptoms in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilalta-Franch</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de Demencias, Hospital Santa Caterina, Instituto Asistencia Sanitaria, Girona, Espa&#xf1;a. jvilaltaf@intersep.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Pousa</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Llin&#xe0;s-Regl&#xe0;</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Tratamiento de los s&#xed;ntomas no cognitivos en la enfermedad de Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018679">Cholinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018679" MajorTopicYN="N">Cholinergic Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>93</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10696656</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10678510</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>34</StartPage><EndPage>39</EndPage><MedlinePgn>34-9</MedlinePgn></Pagination><Abstract><AbstractText>Neurobehavioral disturbances often coexist with extrapyramidal signs (EPS) in patients with Alzheimer's disease (AD). In the present study, we examined the relationships between delusions and hallucinations and EPS by using standard observer ratings and sensitive electromyographic (EMG) measures in 52 patients with probable AD. On the basis of observer ratings, 36.5% of the patients exhibited psychotic features and 63.5% exhibited parkinsonism. Severity of clinically rated parkinsonism and the EMG measure of bradykinesia were significantly correlated with severity of neurobehavioral disturbances in this sample. The association between parkinsonism and delusions and hallucinations suggests a subcortical mechanism in the etiopathology of psychosis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caligiuri</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla 92053, USA. mcaligiuri@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peavy</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG14291</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10678510</ArticleId><ArticleId IdType="doi">10.1176/jnp.12.1.34</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10679840</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>107</EndPage><MedlinePgn>99-107</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to examine the frequency of delusions and hallucinations in patients with Alzheimer's disease (AD) and to investigate factors associated with each or the combination of the two.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a cross-sectional, case-control study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Neuropsychiatry and Memory Group, The Johns Hopkins University, USA.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Three hundred and forty-two community-residing patients with probable AD according to NINCDS/ADRDA criteria were included in the study.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Patients were assessed clinically for the presence of psychotic symptoms using the DSM-IV glossary definitions. The patients were also rated on standardized measures of cognitive impairment, depression, extrapyramidal symptoms, functional impairment and general health.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-five (22%) AD patients had delusions only, nine (3%) had hallucinations only and 30 (9%) had both delusions and hallucinations. Hallucinations were associated with less education, African-American race, more severe dementia, longer duration of illness, falls and use of anxiolytics. Delusions were associated with older age, depression, aggression, poor general health and use of antihypertensives. Patients with both delusions and hallucinations were similar to the patients with delusions only.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms the high prevalence of psychotic symptoms in AD patients encountered in clinical practice and suggests that individual psychotic symptoms have different associations.</AbstractText><CopyrightInformation>Copyright 2000 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bassiony</LastName><ForeName>M M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Zagazig University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rosenblatt</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015142" MajorTopicYN="N" Type="Geographic">Baltimore</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10679840</ArticleId><ArticleId IdType="doi">10.1002/(sici)1099-1166(200002)15:2&lt;99::aid-gps82&gt;3.0.co;2-5</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1099-1166(200002)15:2&lt;99::AID-GPS82&gt;3.0.CO;2-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10654102</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>249 Suppl 3</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The Lewy body variant of Alzheimer's disease: clinical, pathophysiological and conceptual issues.</ArticleTitle><Pagination><StartPage>64</StartPage><EndPage>67</EndPage><MedlinePgn>64-7</MedlinePgn></Pagination><Abstract><AbstractText>In 1923, Friedrich H. Lewy described dementia with Lewy bodies in a large proportion of his patients with paralysis agitans which had co-incident plaques and neurofibrillary tangles. The potential contribution of Lewy bodies to a dementia syndrome with fluctuating course, visual hallucinations, Parkinsonian features and neuroleptic hypersensitivity was rediscovered many decades later. The comorbidity of Alzheimer's and Parkinson's disease is not uncommon as both diseases show an exponential increase with advancing age and their coincidence is of great clinical importance. The combination of a cholinergic deficit--which is particularly severe due to the double pathology targeting the basal nucleus of Meynert--and a dopaminergic deficit requires cholinergic and cautious dopaminergic treatment. Excessive dopamine (L-dopa), antidopaminergic (neuroleptic) or anticholinergic treatment (anti-Parkinson or neuroleptic medication) may further complicate the condition, worsen extrapyramidal, psychotic or cognitive disturbances and even lead to a neuroleptic malignant syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>F&#xf6;rstl</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technical University Munich, Klinikum rechts der Isar, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018679">Cholinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002796" MajorTopicYN="N">Choline Deficiency</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018679" MajorTopicYN="N">Cholinergic Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>35</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10654102</ArticleId><ArticleId IdType="doi">10.1007/pl00014176</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10648299</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depressive symptoms in Alzheimer's disease. An examination among community-dwelling Cuban American patients.</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>91</EndPage><MedlinePgn>84-91</MedlinePgn></Pagination><Abstract><AbstractText>The authors examined the prevalence and clinical correlates of mood disturbance in 96 Cuban American (CA) Alzheimer's disease (AD) patients. Depression (Cornell Scale for Depression in Dementia score &gt; or = 7) was evident in 39.6% of the participants and showed associations with comorbid psychosis, lower education, and decreased length of residence in the United States, a measure of acculturation. Mood disturbance was not related to age, gender, marital status, cognitive dysfunction, functional impairment, history of significant alcohol use, or coexisting medical conditions. The results of this investigation suggest that signs and symptoms of depression are common neuropsychiatric disturbances in CA AD patients residing in the community.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>W W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Bravo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Aguero</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069" MajorTopicYN="N">Acculturation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10648299</ArticleId><ArticleId IdType="doi">10.1097/00019442-200002000-00011</ArticleId><ArticleId IdType="pii">S1064-7481(12)61002-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10648292</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1064-7481</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Season>Winter</Season></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>34</EndPage><MedlinePgn>29-34</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Finkel</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH0436955</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH45131</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH49671</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Geriatr Psychiatry. 2001 Spring;9(2):180-1.</RefSource><PMID Version="1">11316622</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId><ArticleId IdType="doi">10.1097/00019442-200002000-00004</ArticleId><ArticleId IdType="pii">S1064-7481(12)60995-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10637938</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>155 Suppl 4</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms, aggression and restlessness in dementia.</ArticleTitle><Pagination><StartPage>S44</StartPage><EndPage>S52</EndPage><MedlinePgn>S44-52</MedlinePgn></Pagination><Abstract><AbstractText>The current article reviews the literature pertaining to psychosis, aggression and restlessness in dementia sufferers examining frequency, course and associations as well as treatment considerations. All of these problems are highly prevalent, with a high impact upon dementia sufferers and their carers. Although there has been an expansion in this literature over the last few years there are still very few studies describing the natural course of behavioural and psychological symptoms in dementia (BPSD) and a paucity of data relating to non-Alzheimer dementias. Several large treatment studies have recently been completed, but there are still very few double blind controlled trials focusing upon BPSD in particular respect to non-pharmacological interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Neurochemical Pathology Unit, Newcastle General Hospital, Newcastle upon Tyne, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ayre</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10637938</ArticleId><ArticleId IdType="pii">80367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10622673</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0893-0341</ISSN><JournalIssue CitedMedium="Print"><Volume>13 Suppl 2</Volume><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>The interrelations between psychosis, behavioral disturbance, and depression in Alzheimer disease.</ArticleTitle><Pagination><StartPage>S3</StartPage><EndPage>S8</EndPage><MedlinePgn>S3-8</MedlinePgn></Pagination><Abstract><AbstractText>Behavioral changes are common in Alzheimer disease (AD), and heterogeneous in their presentation. Subtle personality changes tend to occur early; these include apathy, irritability and inability to pay attention. Later agitation, aggression and disinhibited behaviors may appear. We have utilized the Columbia University Scale for Psychopathology in Alzheimer's Disease to monitor a number of behavioral symptoms in 235 patients with early probable AD. Markov analyses were used to predict the probability of developing or retaining a given symptom at 6-month follow-up. The results show that the symptoms of psychopathology in AD fluctuate with time. Agitation was both the most frequent and persistent symptom, while paranoid delusions and hallucinations were less persistent. Most behavioral disturbances, except paranoid delusions, were associated with greater cognitive impairment. There was no association between depressive features and either cognitive or functional impairment. These results have important implications for the optimal treatment of the psychopathological symptoms of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>College of Physicians &amp; Surgeons of Columbia University, New York, New York 10032, USA. dpd3@columbia.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH44176</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH50038</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10622673</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10619207</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A descriptive study of first presentation psychosis in old age.</ArticleTitle><Pagination><StartPage>814</StartPage><EndPage>824</EndPage><MedlinePgn>814-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This report describes the characteristics of a sample of elderly subjects presenting with their first episode of psychosis in old age.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty-six (38 females and eight males) patients were assessed on a variety of cognitive, psychopathological and personality measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Female preponderance, social isolation and early cognitive deficits were findings of this study which have been replicated by other studies of late-onset psychosis. In contrast, hearing loss was not overly represented in this sample. Personality style differed significantly from accepted norms of adult personality traits, with lower scores for dimensional ratings of neuroticism, extraversion and openness to change.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The descriptive findings in this study suggest that psychosocial factors require further investigation in patients presenting with late-onset psychosis. Comparison with younger first-onset psychotic subjects will be the subject of a later report.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassett</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Melbourne, NWHCN Aged Persons Mental Health Program, St Albans, Victoria, Australia. anne.hassett@nwhcn.org.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10619207</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1614.1999.00651.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10616870</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Behavior Rating Scale for Dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>223</EndPage><MedlinePgn>211-23</MedlinePgn></Pagination><Abstract><AbstractText>We studied 555 Alzheimer's disease patients on the Behavior Rating Scale for Dementia (BRSD), which uses informant interviews to measure behavioral pathology in demented patients. For the 45 items, ratings of present ranged from 5% to 66% of the subjects, with 39 rated present in at least 10%. Twenty-nine items were significantly correlated with dementia severity. The mean number of items present per subject was 13.5; only two subjects had none rated present. Factor analysis identified six factors common to mildly and moderately demented subjects. Six subscales were developed: Depressive Symptoms, Inertia, Vegetative Symptoms, Irritability/Aggression, Behavioral Dysregulation, and Psychotic Symptoms. Interitem consistency was high for three subscales (alpha's from .75 to .80) and moderate for three (alpha's from .48 to .56). Four subscale scores and total scores were significantly but weakly correlated with dementia severity. Detailed results and test instructions are presented in the BRSD manual, available from The Consortium to Establish a Registry for Alzheimer's Disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>P N</ForeName><Initials>PN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10616870</ArticleId><ArticleId IdType="doi">10.1177/089198879901200408</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10609098</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>25 Spec No 5</Volume><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Clinical and paraclinical diagnosis in psychiatry].</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>22</EndPage><MedlinePgn>19-21; discussion 22</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease patient can be addressed sometimes in psychiatry. At the early stage of the disease, the reason can be depressive symptoms or paranoiac reactions. Later, agitation associated with psychotic symptoms is the principal reason of hospitalization in psychiatry. The knowledge of the management of dementia has dramatically progressed, by example, antidepressant agents are not used as a diagnostic method. Psychiatric and behavioral assessment, neuropsychological tests, assessment of activities of daily life are very useful during the first consultation. Before the second consultation with the neuropsychological assessment, the stop of negative treatment, the treatment of depressive mood and the CT-scan must be realized. When the patient is hospitalized for agitation, the global assessment must be conducted after the hospitalization during consultation or day-hospital. Now, the psychiatrist must treat not only behavioral signs but specifically the disease too.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lebert</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire, Centre de la M&#xe9;moire, H&#xf4;pital Roger-Salengro, Lille.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Le diagnostic clinique et paraclinique en psychiatrie.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="Y">Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>12</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10609098</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10588415</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>12</Issue><PubDate><Year>1999</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications.</ArticleTitle><Pagination><StartPage>1983</StartPage><EndPage>1985</EndPage><MedlinePgn>1983-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Studies suggest a link between visual acuity and visual hallucinations in dementia, but links with specific eye pathologies have not been evaluated.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fifty patients (20 with visual hallucinations, 30 without) with probable Alzheimer's disease had an evaluation of psychotic symptoms. Visual acuity was measured before and after refractions, and ophthalmological examinations included standardized assessments for cataracts and macular degeneration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Impaired visual acuity and the severity of cognitive impairments were significantly associated with visual hallucinations. No patients with normal acuity (6/5 or 6/6 on the Snellen chart) experienced these symptoms. Impaired acuity improved with refraction in 60% (N = 12) of the patients with visual hallucinations. Of specific eye pathologies, only cataracts were significantly associated with visual hallucinations. Descriptive follow-up information suggests that an optician's assessment for glasses improves outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Glasses and cataract surgery need evaluation as prophylactic or adjunctive treatments for visual hallucinations in patients with probable Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>F M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Royal Victoria Infirmary, Newcastle, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2000 Dec;157(12):2062. doi: 10.1176/appi.ajp.157.12.2062</RefSource><PMID Version="1">11097994</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002386" MajorTopicYN="N">Cataract</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002387" MajorTopicYN="N">Cataract Extraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="N">Eye Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005139" MajorTopicYN="N">Eyeglasses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009907" MajorTopicYN="N">Optometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="Y">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="Y">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10588415</ArticleId><ArticleId IdType="doi">10.1176/ajp.156.12.1983</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10579599</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>187</Volume><Issue>11</Issue><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Wandering and associated factors in psychiatric inpatients with dementia of Alzheimer's type in Taiwan: clinical implications for management.</ArticleTitle><Pagination><StartPage>695</StartPage><EndPage>697</EndPage><MedlinePgn>695-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans General Hospital-Taipei, National Yang-Ming University, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002194" MajorTopicYN="N">Capgras Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10579599</ArticleId><ArticleId IdType="doi">10.1097/00005053-199911000-00008</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10565707</PMID><DateCompleted><Year>1999</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1079-2082</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>21</Issue><PubDate><Year>1999</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</Title><ISOAbbreviation>Am J Health Syst Pharm</ISOAbbreviation></Journal><ArticleTitle>Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>2245</StartPage><EndPage>2246</EndPage><MedlinePgn>2245-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolfgang</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Health Syst Pharm</MedlineTA><NlmUniqueID>9503023</NlmUniqueID><ISSNLinking>1079-2082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10565707</ArticleId><ArticleId IdType="doi">10.1093/ajhp/56.21.2245</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10533417</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2008</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0029-2001</ISSN><JournalIssue CitedMedium="Print"><Volume>119</Volume><Issue>22</Issue><PubDate><Year>1999</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</Title><ISOAbbreviation>Tidsskr Nor Laegeforen</ISOAbbreviation></Journal><ArticleTitle>[Twin studies in psychiatry].</ArticleTitle><Pagination><StartPage>3322</StartPage><EndPage>3328</EndPage><MedlinePgn>3322-8</MedlinePgn></Pagination><Abstract><AbstractText>Twin research in medicine and psychology has blossomed during the last decades. A brief presentation of twin research methods is given, followed by a review of psychiatric studies, particularly Norwegian ones. The Nordic investigations are of great importance because many of these studies have been able to avoid shortcomings in sampling by linking national twin registers to disease registers. This procedure is of consequence for the estimation of heritability. Twin research shows that the genetic contribution to Alzheimer's disease, manic-depressive (bipolar) disorder, schizophrenia and childhood autism is relatively strong, whereas genetic factors play a minor role in common depressions, anxiety and somatoform disorders, and alcohol abuse. Since the concordance rates are far from 100 percent in most of these illnesses, environmental factors must also be important.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kringlen</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Psykiatrisk institutt, Universitetet i Oslo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>nor</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList><VernacularTitle>Tvillingstudier i psykiatrien.</VernacularTitle></Article><MedlineJournalInfo><Country>Norway</Country><MedlineTA>Tidsskr Nor Laegeforen</MedlineTA><NlmUniqueID>0413423</NlmUniqueID><ISSNLinking>0029-2001</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>65</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10533417</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10520944</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>10</Issue><PubDate><Year>1999</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.</ArticleTitle><Pagination><StartPage>1266</StartPage><EndPage>1272</EndPage><MedlinePgn>1266-72</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the use of psychiatric medication and the presence of abnormal behaviors affects the progression of Alzheimer disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional with longitudinal follow-up and the likelihood of arriving at 4 end points: (1) Mini-Mental State Examination score of 9 or lower; (2) Blessed Dementia Rating Scale score of 15 or higher for activities of daily living; (3) nursing home admission; and (4) death, evaluated using a proportional hazard model with 9 variables: psychosis, insomnia, wandering, aggression, psychomotor agitation, depression, and use of antidepressants, antipsychotic agents, or sedatives/hypnotics.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Multidisciplinary dementia research clinic.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">We examined baseline and follow-up behavioral symptoms and the use of psychiatric medication in 179 mildly to moderately impaired patients with probable Alzheimer disease participating in a longitudinal study of dementia. Patients were observed from 2.4 to 172 months (mean duration +/- SD, 49.5+/-27.4 months).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine patients (5%) were taking sedatives/ hypnotics; 16 (9%), antipsychotic agents; and 22 (12%), antidepressants at study entry. Patients taking antipsychotic agents had lower Mini-Mental State Examination scores and higher Blessed Dementia Rating Scale scores for activities of daily living than patients not taking any medication. Using proportional hazard analysis with time-dependent covariates for individual psychiatric symptoms and medications, we found that the development of psychosis was associated with functional decline (time to Blessed Dementia Rating Scale score of &gt; or =15), institutionalization, aggression, and agitation with functional decline after adjusting for age at study entry, education, Mini-Mental State Examination scores, and Blessed Dementia Rating Scale scores. Use of antipsychotic medication was associated with functional decline, and sedatives/hypnotics with death. Neither the presence of psychiatric symptoms nor use of medication was associated with rate of cognitive decline (time to Mini-Mental State Examination score of &lt; or =9).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings indicate that the use of antipsychotic agents and sedatives can affect the natural course of Alzheimer disease. Psychosis, agitation, and aggression are important predictors of outcome, even when the effects of medication to treat them is taken into account.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, University of Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Boller</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 03705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-MH01077</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008950" MajorTopicYN="N">MMPI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId><ArticleId IdType="doi">10.1001/archneur.56.10.1266</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10509375</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>1999</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Candidate neuroanatomic substrates of psychosis in old-aged depression.</ArticleTitle><Pagination><StartPage>793</StartPage><EndPage>807</EndPage><MedlinePgn>793-807</MedlinePgn></Pagination><Abstract><AbstractText>1. The authors investigated the candidate neuroanatomic substrates underlying delusional thought disorder in old-aged depressed patients by using magnetic resonance imaging (MRI), and examined the relationship between volumes for individual brain structures and clinical correlates of particular relevance to depression: executive cognitive impairment and global severity of depression. 2. MR morphometry was performed on nineteen deluded depressed patients and 26 non-deluded depressed patients, all older than 55 years of age. Subjects were administered a neuropsychological test battery and measures of depression. 3. The absolute volume of prefrontal cortex (PFC) was smaller in the deluded depressed group than in non-deluded depressed group (131.79 +/- 37.26 ml vs. 152.65 +/- 26.13 ml, p = 0.03); a difference that was statistically significant even after adjusting for the effect of whole brain volume (p = 0.01). No group differences were observed in the volumes of the basal ganglia, the temporal lobes, the superior temporal gyri, the amygdala-hippocampal complex, the lateral ventricles, or whole brain. The relative volume of PFC correlated inversely and significantly with the index of Wisconsin Card Sorting Test (WCST) performance (r = -0.76, p &lt; 0.01) in depressed patients. 4. PFC may be one of the candidate neuroanatomic substrates underlying delusional thought disorder in old-aged depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>D K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Samsung Medical Center, College of Medicine, Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>S W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Paik</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10509375</ArticleId><ArticleId IdType="doi">10.1016/s0278-5846(99)00041-x</ArticleId><ArticleId IdType="pii">S027858469900041X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10441846</PMID><DateCompleted><Year>1999</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>7</Issue><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[The role of endogenous and exogenous factors in the development of psychoses in organic dementias in later life].</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>20</EndPage><MedlinePgn>16-20</MedlinePgn></Pagination><Abstract><AbstractText>Influence of different exogenic and endogenic factors (including the very organic process) as analyzed in 231 patients of psychiatric hospital with organic dementia: vascular (VD)--57 cases, senile dementia of Alzheimer's type (SDAT)--29 individuals, dementia conditioned by a combination of vascular and senile-atrophic processes (VD/SDAT)--37 patients, Alzheimer's disease (70 patients) and Pick's disease (38 cases). 160 patients (the study group) had psychotic disorders, 71 patients (the control group) hadn't such disorders. The most frequent (98.2%) and the most various psychotic syndromes (especially delirium and hallucination syndromes) were observed in VD, SDAT and VD/SDAT. A rate of organic process progression was less in patients of the study group as compared with a control one. Prevalence in the study group of cases with endogenic-constitutional predisposition to psychoses development was significant. The role of the other exocerebral factors in origin of psychoses was not so pronounced; among them psychogenias were rather significant, their frequency was 4 times higher in the study group than in the control one. The relationship of psychotic syndromes with origin, stage and progression rate of dementia might indicate a leading role of the organic process in their genesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Budza</LastName><ForeName>V G</ForeName><Initials>VG</Initials></Author><Author ValidYN="Y"><LastName>Medvedev</LastName><ForeName>V A</ForeName><Initials>VA</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Rol' &#xe9;ndogennykh i &#xe9;kzogennykh faktorov v razvitii psikhozov pri organicheskikh dementsiiakh pozdnego vozrasta.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013597" MajorTopicYN="N">Systems Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10441846</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10440009</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Risperidone treatment of behavioral disturbances in outpatients with dementia.</ArticleTitle><Pagination><StartPage>336</StartPage><EndPage>342</EndPage><MedlinePgn>336-42</MedlinePgn></Pagination><Abstract><AbstractText>The authors retrospectively assessed the effectiveness and side effects of risperidone used to treat behavioral disturbances in elderly outpatients with dementia. In 41 patients treated with risperidone 1.8 +/- 1.4 mg/day, there was complete suppression of the target symptom in 15%, partial response in 41%, and no response in 44%. Risperidone appeared equally effective in treating agitation and psychosis. New or worsening extrapyramidal side effects (EPS) occurred in 32%, associated with longer duration of treatment and possibly with concomitant use of serotonergic anti-depressants. Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>S N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Lee-Cherry</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00793</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10440009</ArticleId><ArticleId IdType="doi">10.1176/jnp.11.3.336</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10431061</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1139-9287</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Actas espanolas de psiquiatria</Title><ISOAbbreviation>Actas Esp Psiquiatr</ISOAbbreviation></Journal><ArticleTitle>[Risperidone in the treatment of psychotic, affective and behavioral symptoms associated to Alzheimer's disease].</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>190</EndPage><MedlinePgn>185-90</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">A total of 235 patients with diagnoses of Alzheimer's dementia together with psychotic and/or affective symptomatology, as well as behavioral disturbances was included in an open label postmarketing surveillance study. The study objectives were to asses: 1) risperidone efficiency in psychotic and affective symptomatology and behavioral disturbances; 2) risperidone influence in the patient's performance, 3) dosage range at which efficiency is observed; and 4) safety in this group of patients. Patients were observed during a six month period. Risperidone was used at a mean dosage of 1.23 +/- 0.86 mg daily (range: 0.5-4.5 mg daily).</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Risperidone was assessed by the Clinical Global Impression (CGI), Geriatric Depression Scale (GDS), Neuropsychiatric Inventory (NPI), Clinical Deterioration Rating (CDR), UKU subscale for neurological side effects and spontaneous reports. Patients were evaluated at baseline, 15 days and months 1, 2, 4 and 6. Sixteen patients (6.8%) were excluded from the statistical analysis due to protocol violation. Fifty four patients (24.7%) dropped out.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Risperidone produced a significant improvement in the mean total scores of CGI, NPI, GDS (patient's satisfaction, hope.) and CDR (judgment and problem solving, community affairs, hobbies.) scales. Extrapyramidal symptoms improved from day 15 onwards in patients who had received antipsychotic treatment previously; in naive treated patients these symptoms did not change during the study period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Risperidone was well tolerated. Only 6 (2. 7%) discontinued treatment due to adverse events. Ninety seven percent of the patients did not suffer any adverse event; the resting 2.7% suffered one or more side effects: sedation (1.4%), constipation (0.5%) and vomiting (0.5%) among others.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barcia</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Psiquiatr&#xed;a, Hospital General Universitario, Murcia, 30003, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Herraiz</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mor&#xed;&#xf1;igo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Roca</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Risperidona en el tratamiento de los s&#xed;ntomas psic&#xf3;ticos, afectivos y rastornos de la conducta asociados a demencia tipo Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Esp Psiquiatr</MedlineTA><NlmUniqueID>100886502</NlmUniqueID><ISSNLinking>1139-9287</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001480" MajorTopicYN="N">Basal Ganglia Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10431061</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10420439</PMID><DateCompleted><Year>1999</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0926-5287</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Reproduction, nutrition, development</Title><ISOAbbreviation>Reprod Nutr Dev</ISOAbbreviation></Journal><ArticleTitle>Melatonin and clinical application.</ArticleTitle><Pagination><StartPage>367</StartPage><EndPage>382</EndPage><MedlinePgn>367-82</MedlinePgn></Pagination><Abstract><AbstractText>A review of the different publications dealing with melatonin in humans shows that this field has been very active in the last few years. Normative melatonin values have been defined. Various relationships between melatonin and other traits have been studied, such as sleep, circadian rhythm, surgical stress and anaesthesia. Age-related melatonin studies and melatonin during depression and other psychiatric disorders have been reviewed. Finally, some studies have been performed to use melatonin as a medication for sleep disturbance in depression, for jet-lag and as a skin protector for ultraviolet light.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wetterberg</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. Lennart.Wetterberg@rito.no</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Reprod Nutr Dev</MedlineTA><NlmUniqueID>8913069</NlmUniqueID><ISSNLinking>0926-5287</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044094">Receptors, Melatonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013473">Sunscreening Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>109210-52-8</RegistryNumber><NameOfSubstance UI="C052611">1-acetyl-1,2,3,3a,8,8a-hexahydro-8a-hydroxy-5-methoxypyrrolo(2,3-b)indole</NameOfSubstance></Chemical><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000014" MajorTopicYN="N">Abnormalities, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002114" MajorTopicYN="N">Calcinosis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017440" MajorTopicYN="N">Photoperiod</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010870" MajorTopicYN="N">Pineal Gland</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044094" MajorTopicYN="N">Receptors, Melatonin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013473" MajorTopicYN="N">Sunscreening Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>70</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10420439</ArticleId><ArticleId IdType="doi">10.1051/rnd:19990309</ArticleId><ArticleId IdType="pii">S092652879980063X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10398356</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine in dementia with Lewy bodies: a clinical study.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>466</EndPage><MedlinePgn>459-66</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Dementia with Lewy bodies (DLB) is now a well-recognized form of dementia in which psychosis and behavioural disturbance are common. Treatment with conventional neuroleptics is often very poorly tolerated. Olanzapine, a newly introduced atypical neuroleptic which binds to multiple receptor types with relatively low affinity for D2 receptors, may be a useful treatment option in DLB.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The Behavioural Pathology in Alzheimer's Disease Rating Scale, The Neuropsychiatric Inventory, Unified Parkinson's Disease Rating Scale and The Webster Disability Scale.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We present the results of eight DLB patients with associated psychotic and behavioural difficulties. All patients were given olanzapine 2.5-7.5 mg. Their psychotic phenomena and behavioural and extrapyramidal symptoms were monitored at 2-weekly intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three out of the eight patients could not tolerate olanzapine even at the lowest available dose. Two patients had clear improvement in psychotic and behavioural symptoms. Three patients were able to tolerate olanzapine but gained only minimal benefit.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Olanzapine at the doses used conferred little advantage over conventional neuroleptics and should only be given with great caution to patients with DLB. The utility of smaller doses deserves further evaluation.</AbstractText><CopyrightInformation>Copyright 1999 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>University College London Medical School, Essex and Herts Community NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grace</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Overshot</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Satarasinghe</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Swan</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Katona</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075202" MajorTopicYN="N">Contraindications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10398356</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1099-1166(199906)14:6&lt;459::AID-GPS957&gt;3.0.CO;2-R</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10398349</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6230</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prevalence and correlates of Capgras syndrome in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>415</StartPage><EndPage>420</EndPage><MedlinePgn>415-20</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study examined the prevalence and clinical correlates of Capgras syndrome (CS) in Alzheimer's disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study of elderly patients evaluated at an outpatient memory disorders clinic classified according to the presence or absence of CS.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">One hundred and fifty-one consecutive patients diagnosed with probable (N=110) or possible (N=48) Alzheimer's disease (AD) utilizing NINCDS-ADRDA diagnostic criteria.</AbstractText><AbstractText Label="MATERIALS" NlmCategory="METHODS">The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), Mini-Mental State Examination (MMSE) and Blessed Dementia Scale (BDS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CS was observed in 10% of the sample (N=16). Associated factors included other delusions, lower MMSE scores and higher BDS scores. The relation between CS and both cognitive and functional status remained significant after controlling for other delusions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CS was prevalent in approximately 10% of our community-dwelling AD sample. This syndrome was more common at the later stages of the illness and showed relations with increased functional impairment and other psychotic symptomatology.</AbstractText><CopyrightInformation>Copyright 1999 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>D G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center and the University of Miami School of Medicine, Miami Beach, FL 33140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>W W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002194" MajorTopicYN="N">Capgras Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10398349</ArticleId><ArticleId IdType="doi">10.1002/(sici)1099-1166(199906)14:6&lt;415::aid-gps929&gt;3.0.co;2-3</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1099-1166(199906)14:6&lt;415::AID-GPS929&gt;3.0.CO;2-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>